 Induction_NN of_IN NF-KB_NN during_IN monocyte_NN differentiation_NN by_IN HIV_NN type_NN 1_CD infection_NN ._.
 The_DT production_NN of_IN human_JJ immunodeficiency_NN virus_NN type_NN 1_CD (_( HIV-1_NN )_) progeny_NN was_VBD followed_VBN in_IN the_DT U937_NN promonocytic_JJ cell_NN line_NN after_IN stimulation_NN either_CC with_IN retinoic_JJ acid_NN or_CC PMA_NN ,_, and_CC in_IN purified_VBN human_JJ monocytes_NNS and_CC macrophages_NNS ._.
 Electrophoretic_JJ mobility_NN shift_NN assays_NNS and_CC Southwestern_NN blotting_NN experiments_NNS were_VBD used_VBN to_TO detect_VB the_DT binding_NN of_IN cellular_JJ transactivation_NN factor_NN NF-KB_NN to_TO the_DT double_JJ repeat-KB_JJ|NN enhancer_NN sequence_NN located_JJ in_IN the_DT long_JJ terminal_JJ repeat_NN ._.
 PMA_NN treatment_NN ,_, and_CC not_RB retinoic_JJ acid_NN treatment_NN of_IN the_DT U937_NN cells_NNS acts_VBZ in_IN inducing_VBG NF-KB_NN expression_NN in_IN the_DT nuclei_NNS ._.
 In_IN nuclear_JJ extracts_NNS from_IN monocytes_NNS or_CC macrophages_NNS ,_, induction_NN of_IN NF-KB_NN occurred_VBD only_RB if_IN the_DT cells_NNS were_VBD previously_RB infected_VBN with_IN HIV-1_NN ._.
 When_WRB U937_NN cells_NNS were_VBD infected_VBN with_IN HIV-1_NN ,_, no_DT induction_NN of_IN NF-KB_NN factor_NN was_VBD detected_VBN ,_, whereas_IN high_JJ level_NN of_IN progeny_NN virions_NNS was_VBD produced_VBN ,_, suggesting_VBG that_IN this_DT factor_NN was_VBD not_RB required_VBN for_IN viral_JJ replication_NN ._.
 These_DT results_NNS indicate_VBP that_IN in_IN monocytic_JJ cell_NN lineage_NN ,_, HIV-1_NN could_MD mimic_VB some_DT differentiation/activation_JJ stimuli_NNS allowing_VBG nuclear_JJ NF-KB_NN expression_NN ._.
 Positive_JJ and_CC negative_JJ regulation_NN of_IN immunoglobulin_NN gene_NN expression_NN by_IN a_DT novel_JJ B-cell-specific_JJ enhancer_NN element_NN ._.
 A_DT new_JJ B-cell-specific_JJ enhancer_NN element_NN has_VBZ been_VBN identified_VBN 3'_JJ of_IN E4_NN and_CC the_DT octamerlike_JJ motifs_NNS in_IN the_DT human_JJ immunoglobulin_NN heavy-chain_NN gene_NN enhancer_NN ._.
 Tandem_JJ copies_NNS of_IN this_DT 67-bp_JJ MnlI-AluI_NN fragment_NN ,_, when_WRB fused_VBN to_TO the_DT chloramphenicol_JJ acetyltransferase_NN gene_NN driven_VBN by_IN the_DT conalbumin_JJ promoter_NN ,_, stimulated_VBD transcription_NN in_IN B_NN cells_NNS but_CC not_RB in_IN Jurkat_NN T_NN cells_NNS or_CC HeLa_NN cells_NNS ._.
 Footprinting_NN analysis_NN revealed_VBD that_IN the_DT identical_JJ sequence_NN CCGAAACTGAAAAGG_NN ,_, designated_VBN E6_NN ,_, was_VBD protected_VBN by_IN nuclear_JJ extracts_NNS from_IN B_NN cells_NNS ,_, T_NN cells_NNS ,_, or_CC HeLa_NN cells_NNS ._.
 Gel_NN mobility_NN shift_NN assays_NNS using_VBG a_DT synthetic_JJ E6_NN motif_NN detected_VBD a_DT B-cell-specific_JJ complex_NN in_IN addition_NN to_TO a_DT ubiquitous_JJ band_NN found_VBN also_RB in_IN T_NN cells_NNS and_CC HeLa_NN cells_NNS ._.
 In_IN agreement_NN with_IN the_DT results_NNS of_IN gel_NN retardation_NN assays_NNS ,_, tandem_JJ copies_NNS of_IN the_DT E6_NN motif_NN stimulated_VBD transcription_NN in_IN ARH77_NN and_CC Raji_NN cells_NNS but_CC not_RB in_IN Jurkat_NN or_CC HeLa_NN cells_NNS ._.
 Furthermore_RB ,_, a_DT mutant_JJ E6_NN motif_NN lost_VBD both_CC in_FW vitro_FW binding_NN activity_NN and_CC in_FW vivo_FW enhancer_NN activity_NN ._.
 In_IN striking_JJ contrast_NN to_TO the_DT mouse_NN Ig_NN heavy-chain_JJ enhancer_NN ,_, in_IN which_WDT the_DT octamer_NN motif_NN acts_VBZ as_IN a_DT B-cell-specific_JJ enhancer_NN element_NN ,_, the_DT human_JJ enhancer_NN contains_VBZ an_DT octamerlike_JJ sequence_NN with_IN one_CD base_NN substitution_NN which_WDT bound_VBD octamer-binding_JJ proteins_NNS with_IN only_RB very_RB low_JJ affinity_NN and_CC showed_VBD no_DT enhancer_NN activity_NN of_IN its_PRP$ own_JJ ._.
 Interestingly_RB ,_, the_DT MnlI-AluI_NN fragment_NN could_MD suppress_VB the_DT basal-level_JJ activity_NN of_IN the_DT conalbumin_JJ promoter_NN in_IN both_CC Jurkat_NN and_CC HeLa_NN cells_NNS ._.
 Moreover_RB ,_, simian_JJ virus_NN 40_CD enhancer_NN activity_NN was_VBD blocked_VBN by_IN the_DT MnlI-AluI_NN fragment_NN in_IN HeLa_NN cells_NNS but_CC not_RB in_IN B_NN cells_NNS ._.
 Thus_RB ,_, the_DT novel_JJ enhancer_NN element_NN identified_VBN in_IN this_DT study_NN is_VBZ probably_RB a_DT target_NN site_NN for_IN both_CC positive_JJ and_CC negative_JJ factors_NNS ._.
 The_DT NF_NN kappa_NN B_NN independent_JJ cis-acting_JJ sequences_NNS in_IN HIV-1_NN LTR_NN responsive_NN to_TO T-cell_NN activation_NN ._.
 The_DT rate_NN of_IN transcription_NN initiation_NN directed_VBN by_IN the_DT long_JJ terminal_JJ repeat_NN (_( LTR_NN )_) of_IN HIV-1_NN increases_VBZ in_IN response_NN to_TO mitogenic_JJ stimuli_NNS of_IN T_NN cells_NNS ._.
 Here_RB we_PRP show_VBP that_IN the_DT response_NN of_IN the_DT HIV-1_NN LTR_NN may_MD be_VB governed_VBN by_IN two_CD independent_JJ sequences_NNS located_JJ 5'_JJ to_TO the_DT site_NN of_IN transcription_NN initiation_NN sequences_NNS that_WDT bind_VBP either_CC NFAT-1_NN or_CC NF_NN kappa_NN B_NN ._.
 The_DT rate_NN of_IN LTR-directed_JJ gene_NN expression_NN increased_VBD in_IN response_NN to_TO treatment_NN with_IN either_CC a_DT phorbol_NN ester_NN or_CC tumor_NN necrosis_NN factor_NN alpha_NN if_IN either_CC the_DT NFAT-1_NN or_CC NF_NN kappa_NN B_NN binding_NN sites_NNS were_VBD deleted_VBN ,_, but_CC failed_VBD to_TO respond_VB to_TO these_DT mitogenic_JJ stimuli_NNS if_IN both_DT sequences_NNS were_VBD absent_JJ ._.
 The_DT HIV-1_NN mutant_JJ virus_NN containing_VBG both_CC NF_NN kappa_NN B_NN and_CC NFAT-1_NN deletion_NN was_VBD able_JJ to_TO replicate_VB although_IN at_IN a_DT much_JJ decreased_VBN growth_NN rate_NN ,_, while_IN the_DT deletion_NN of_IN NFAT-1_NN alone_RB increased_VBD the_DT viral_JJ growth_NN rate_NN in_IN Jurkat_NN cells_NNS ._.
 Neither_CC deletion_NN of_IN NF_NN kappa_NN B_NN nor_CC deletion_NN of_IN NFAT-1_NN decreased_VBD activation_NN of_IN viral_JJ replication_NN by_IN phorbol_NN ester_NN ._.
 Specific_JJ depletion_NN of_IN the_DT B-cell_NN population_NN induced_VBN by_IN aberrant_JJ expression_NN of_IN human_JJ interferon_NN regulatory_JJ factor_NN 1_CD gene_NN in_IN transgenic_JJ mice_NNS ._.
 Interferons_NNS (_( IFNs_NNS )_) are_VBP well_RB known_VBN both_CC as_IN antiviral_JJ proteins_NNS and_CC as_IN potent_JJ regulators_NNS of_IN cell_NN growth_NN and_CC differentiation_NN ._.
 In_IN fact_NN ,_, IFNs_NNS inhibit_VBP growth_NN of_IN various_JJ normal_JJ and_CC transformed_VBN cell_NN types_NNS ._.
 Previously_RB ,_, a_DT nuclear_JJ factor_NN ,_, IRF-1_NN (_( interferon_NN regulatory_JJ factor_NN 1_CD )_) ,_, which_WDT binds_VBZ to_TO type_NN I_CD IFN_NN and_CC some_DT IFN-inducible_JJ gene_NN promoters_NNS ,_, was_VBD identified_VBN and_CC cloned_VBN ._.
 Since_IN the_DT IRF-1_NN gene_NN is_VBZ both_CC virus_NN and_CC IFN_NN inducible_JJ ,_, an_DT intriguing_JJ issue_NN is_VBZ raised_VBN as_IN to_TO whether_IN the_DT IRF-1_NN gene_NN is_VBZ functioning_VBG in_IN IFN-mediated_JJ regulation_NN of_IN cell_NN growth_NN and_CC differentiation_NN ._.
 In_IN this_DT study_NN ,_, we_PRP generated_VBD transgenic_JJ mice_NNS carrying_VBG the_DT human_JJ IRF-1_NN gene_NN linked_VBN to_TO the_DT human_JJ immunoglobulin_NN heavy-chain_JJ enhancer_NN ._.
 In_IN the_DT transgenic_JJ mice_NNS ,_, all_PDT the_DT lymphoid_JJ tissues_NNS examined_VBN showed_VBD a_DT dramatic_JJ reduction_NN in_IN the_DT number_NN of_IN B_NN lymphocytes_NNS (_( B_NN cells_NNS )_) ._.
 Preparation_NN and_CC analysis_NN of_IN bone_NN marrow_NN cells_NNS from_IN the_DT chimeric_JJ mice_NNS indicated_VBD that_IN the_DT bone_NN marrow_NN is_VBZ the_DT effective_JJ site_NN for_IN specific_JJ depletion_NN of_IN the_DT B-cell_NN population_NN ._.
 In_IN fact_NN ,_, transgenic_JJ bone_NN marrow_NN cells_NNS cocultured_VBN with_IN a_DT bone_NN marrow-derived_JJ stromal_JJ cell_NN line_NN revealed_VBD an_DT altered_JJ B-cell_NN maturation_NN pattern_NN ._.
 Identification_NN and_CC cloning_NN of_IN TCF-1_NN ,_, a_DT T_NN lymphocyte-specific_JJ transcription_NN factor_NN containing_VBG a_DT sequence-specific_JJ HMG_NN box_NN ._.
 CD3-epsilon_NN expression_NN is_VBZ controlled_VBN by_IN a_DT downstream_JJ T_NN lymphocyte-specific_JJ enhancer_NN element_NN ._.
 We_PRP report_VBP the_DT identification_NN of_IN a_DT T_NN cell-specific_JJ transcription_NN factor_NN ,_, TCF-1_NN ,_, binding_VBG to_TO this_DT element_NN ._.
 The_DT multimerized_JJ recognition_NN motif_NN of_IN TCF-1_NN constituted_VBD a_DT T_NN cell-specific_JJ enhancer_NN ._.
 Subsequent_JJ cloning_NN of_IN TCF-1_NN identified_VBD three_CD splice_NN alternatives_NNS ._.
 TCF-1_NN contained_VBD a_DT single_JJ DNA-binding_JJ HMG_NN box_NN most_RBS closely_RB related_JJ to_TO similar_JJ boxes_NNS in_IN the_DT putative_JJ mammalian_JJ sex-determining_JJ gene_NN SRY_NN and_CC in_IN the_DT Schizosaccharomyces_FW pombe_FW Mc_NN mating_NN type_NN gene_NN ._.
 TCF-1_NN mRNA_NN was_VBD expressed_VBN uniquely_RB in_IN T_NN lymphocytes_NNS ._.
 Upon_IN cotransfection_NN into_IN non-T_JJ cells_NNS ,_, TCF-1_NN could_MD transactivate_VB through_IN its_PRP$ cognate_JJ motif_NN ._.
 These_DT results_NNS identify_VBP TCF-1_NN as_IN a_DT T_NN cell-specific_JJ transcription_NN factor_NN ,_, which_WDT might_MD play_VB a_DT role_NN in_IN the_DT establishment_NN of_IN the_DT mature_JJ T_NN cell_NN phenotype_NN ._.
 Nuclear_JJ factor_NN kappa_NN B_NN activates_VBZ proenkephalin_NN transcription_NN in_IN T_NN lymphocytes_NNS ._.
 Upon_IN activation_NN ,_, T_NN lymphocytes_NNS accumulate_VBP high_JJ levels_NNS of_IN the_DT neuropeptide_NN enkephalin_NN which_WDT correlate_VBP with_IN high_JJ levels_NNS of_IN proenkephalin_NN mRNA_NN in_IN the_DT cells_NNS ._.
 Here_RB we_PRP investigated_VBD the_DT transcriptional_JJ basis_NN for_IN these_DT changes_NNS ._.
 The_DT proenkephalin_NN promoter_NN contains_VBZ a_DT sequence_NN GGGGACGTCCCC_NN ,_, named_VBN B2_NN ,_, which_WDT is_VBZ similar_JJ to_TO the_DT kappa_NN B_NN sequence_NN GGGGACTTTCC_NN ,_, the_DT binding_VBG site_NN of_IN the_DT transcription_NN factor_NN nuclear_JJ factor_NN (_( NF_NN )_) -kappa_NN B_NN ._.
 Activation_NN of_IN T_NN lymphocytes_NNS induces_VBZ an_DT NF-kappa_NN B-like_JJ binding_NN activity_NN to_TO the_DT B2_NN site_NN ,_, concomitant_JJ with_IN activation_NN of_IN the_DT proenkephalin_NN promoter_NN ._.
 Mutations_NNS at_IN the_DT B2_NN site_NN abolish_VBP this_DT transcriptional_JJ activation_NN ._.
 The_DT purified_VBN homodimer_NN (_( two_CD p50s_NNS )_) of_IN the_DT DNA-binding_JJ subunit_NN of_IN NF-kappa_NN B_NN binds_VBZ the_DT B2_NN site_NN of_IN proenkephalin_NN relatively_RB better_JJR than_IN does_VBZ the_DT heterotetramer_NN (_( two_CD p65s_NNS plus_CC two_CD p50s_NNS )_) form_NN of_IN the_DT factor_NN ._.
 Thus_RB ,_, it_PRP appears_VBZ that_IN the_DT T-cell-specific_JJ activation_NN of_IN the_DT proenkephalin_NN promoter_NN is_VBZ mediated_VBN by_IN NF-kappa_NN B_NN ._.
 However_RB ,_, as_IN NF-kappa_NN B_NN is_VBZ ubiquitous_JJ and_CC the_DT transcriptional_JJ activation_NN through_IN the_DT B2_NN site_NN is_VBZ T_NN cell_NN specific_JJ ,_, yet_RB another_DT T-cell-specific_JJ factor_NN which_WDT synergizes_VBZ with_IN NF-kappa_NN B_NN should_MD be_VB considered_VBN ._.
 Expression_NN of_IN c-jun_NN ,_, jun_NN B_NN and_CC jun_NN D_NN proto-oncogenes_NNS in_IN human_JJ peripheral-blood_JJ granulocytes_NNS ._.
 We_PRP have_VBP found_VBN that_IN purified_VBN human_JJ peripheral-blood_JJ granulocytes_NNS express_VBP constitutively_RB significant_JJ levels_NNS of_IN proto-oncogenes_NNS c-jun_NN ,_, jun_NN B_NN and_CC jun_NN D_NN mRNA_NN ._.
 Upon_IN functional_JJ activation_NN of_IN granulocytes_NNS by_IN 4_CD beta-phorbol_NN 12-myristate_NN 13-acetate_NN (_( PMA_NN )_) ,_, the_DT levels_NNS of_IN c-jun_NN ,_, jun_NN B_NN and_CC jun_NN D_NN transcripts_NNS were_VBD increased_VBN ._.
 The_DT three_CD jun_NN genes_NNS showed_VBD a_DT similar_JJ time_NN course_NN in_IN their_PRP$ induction_NN by_IN PMA_NN ,_, maximal_JJ mRNA_NN levels_NNS being_VBG reached_VBN after_IN 60_CD min_NN of_IN induction_NN ._.
 These_DT results_NNS suggest_VBP that_IN expression_NN of_IN c-jun_NN ,_, jun_NN B_NN and_CC jun_NN D_NN genes_NNS might_MD be_VB involved_VBN in_IN terminal_JJ granulocyte_NN differentiation_NN or_CC in_IN regulating_VBG granulocyte_NN functionality_NN ._.
 Platelet-activating_JJ factor_NN induces_VBZ phospholipid_JJ turnover_NN ,_, calcium_NN flux_NN ,_, arachidonic_JJ acid_NN liberation_NN ,_, eicosanoid_NN generation_NN ,_, and_CC oncogene_JJ expression_NN in_IN a_DT human_JJ B_NN cell_NN line_NN ._.
 Platelet-activating_JJ factor_NN is_VBZ a_DT potent_JJ mediator_NN of_IN the_DT inflammatory_JJ response_NN ._.
 Studies_NNS of_IN the_DT actions_NNS of_IN platelet-activating_JJ factor_NN have_VBP centered_VBN mainly_RB around_IN neutrophils_NNS ,_, monocytes_NNS ,_, and_CC platelets_NNS ._.
 In_IN this_DT report_NN we_PRP begin_VBP to_TO uncover_VB the_DT influence_NN of_IN platelet-activating_NN factor_NN on_IN B_NN lymphocytes_NNS ._.
 Employing_VBG the_DT EBV-transformed_JJ human_JJ B_NN cell_NN line_NN SKW6.4_NN ,_, we_PRP demonstrate_VBP that_IN platelet-activating_JJ factor_NN significantly_RB alters_VBZ membrane_NN phospholipid_JJ metabolism_NN indicated_VBN by_IN the_DT incorporation_NN of_IN 32P_NN into_IN phosphatidylcholine_NN ,_, phosphatidylinositol_NN ,_, and_CC phosphatidic_JJ acid_NN but_CC not_RB significantly_RB into_IN phosphatidylethanolamine_NN at_IN concentrations_NNS ranging_VBG from_IN 10(-9)_CD to_TO 10(-6)_CD M_NN ._.
 The_DT inactive_JJ precursor_NN ,_, lyso-platelet-activating_JJ factor_NN ,_, at_IN a_DT concentration_NN as_RB high_JJ as_IN 10(-7)_CD M_NN had_VBD no_DT effect_NN on_IN any_DT of_IN the_DT membrane_NN phospholipids_NNS ._.
 We_PRP also_RB show_VBP that_IN platelet-activating_JJ factor_NN from_IN 10(-12)_CD to_TO 10(-6)_CD M_NN induced_VBD rapid_JJ and_CC significant_JJ elevation_NN in_IN intracellular_JJ calcium_NN levels_NNS ,_, whereas_IN lyso-platelet-activating_JJ factor_NN was_VBD again_RB ineffective_JJ ._.
 We_PRP further_RB demonstrate_VBP the_DT impact_NN of_IN platelet-activating_JJ factor_NN binding_VBG to_TO B_NN cells_NNS by_IN measuring_VBG platelet-activating_JJ factor_NN induced_JJ arachidonic_JJ acid_NN release_NN and_CC 5-hydroxyeicosatetraenoic_JJ acid_NN production_NN ._.
 Moreover_RB ,_, platelet-activating_JJ factor_NN was_VBD capable_JJ of_IN inducing_VBG transcription_NN of_IN the_DT nuclear_JJ proto-oncogenes_NNS c-fos_NN and_CC c-jun_NN ._.
 Finally_RB we_PRP explored_VBD the_DT possible_JJ role_NN of_IN 5-hydroxyeicosatetraenoic_JJ acid_NN as_IN a_DT regulator_NN of_IN arachidonic_JJ acid_NN liberation_NN demonstrating_VBG that_IN endogenous_JJ 5-lipoxygenase_NN activity_NN modulates_VBZ platelet-activating_JJ factor_NN induced_JJ arachidonic_JJ acid_NN release_NN perhaps_RB acting_VBG at_IN the_DT level_NN of_IN phospholipase_NN A2_NN ._.
 In_IN summary_NN ,_, platelet-activating_JJ factor_NN is_VBZ shown_VBN here_RB to_TO have_VB a_DT direct_JJ and_CC profound_JJ effect_NN on_IN a_DT pure_JJ B_NN cell_NN line_NN ._.
 A_DT novel_JJ HIV-1_NN isolate_JJ containing_VBG alterations_NNS affecting_VBG the_DT NF-kappa_NN B_NN element_NN ._.
 Three_CD molecular_JJ clones_NNS of_IN HIV-1_NN ,_, derived_VBN from_IN a_DT single_JJ isolate_NN (_( AL1_NN )_) ,_, exhibited_VBD distinct_JJ replicative_JJ and_CC cytopathic_JJ properties_NNS during_IN propagation_NN in_IN a_DT human_JJ T_NN cell_NN line_NN ._.
 The_DT phenotypic_JJ differences_NNS observed_VBN were_VBD attributable_JJ ,_, in_IN large_JJ part_NN ,_, to_TO changes_NNS affecting_VBG the_DT viral_JJ LTR_NN ._.
 Nucleotide_NN sequence_NN and_CC PCR_NN analyses_NNS demonstrated_VBD the_DT presence_NN of_IN novel_JJ duplications_NNS or_CC deletions_NNS involving_VBG the_DT NF-kappa_NN B_NN motif_NN ._.
 These_DT changes_NNS in_IN the_DT enhancer_NN element_NN were_VBD identified_VBN in_IN the_DT original_JJ AL1_NN virus_NN stock_NN ._.
 Subcloning_NN of_IN the_DT variant_JJ NF-kappa_NN B_NN segments_NNS into_IN LTR-driven_JJ CAT_NN expression_NN vectors_NNS confirmed_VBD a_DT correlation_NN between_IN promoter_JJ activity_NN and_CC replicative/cytopathic_JJ capacity_NN ._.
 1,25-Dihydroxyvitamin_NN D3_NN receptor_NN RNA_NN :_: expression_NN in_IN hematopoietic_JJ cells_NNS ._.
 1,25-Dihydroxyvitamin_NN D3_NN (_( 1,25(OH)2D3_NN )_) induces_VBZ differentiation_NN and_CC inhibits_VBZ proliferation_NN of_IN myeloid_JJ leukemic_JJ cells_NNS from_IN various_JJ lines_NNS and_CC patients_NNS ;_: these_DT effects_NNS are_VBP probably_RB mediated_VBN through_IN the_DT 1,25(OH)2D3_NN receptor_NN ._.
 Little_JJ is_VBZ known_VBN of_IN expression_NN of_IN 1,25(OH)2D3_NN receptor_NN RNA_NN in_IN hematopoietic_JJ cells_NNS ._.
 We_PRP examined_VBD the_DT expression_NN and_CC modulation_NN of_IN expression_NN of_IN 1,25(OH)2D3_NN receptor_NN RNA_NN in_IN various_JJ proliferating_VBG and_CC nonproliferating_JJ hematopoietic_JJ cells_NNS ._.
 Constitutive_JJ expression_NN of_IN 1,25(OH)2D3_NN receptor_NN RNA_NN was_VBD detected_VBN in_IN various_JJ kinds_NNS of_IN hematopoietic_JJ cells_NNS ,_, including_VBG macrophages_NNS and_CC activated_VBN T_NN lymphocytes_NNS ,_, as_RB well_RB as_IN in_IN cell_NN lines_NNS KG-1_NN (_( myeloblasts_NNS )_) ,_, HL-60_NN (_( promyelocytes_NNS )_) ,_, ML-3_NN (_( myelomonoblasts_NNS )_) ,_, U937_NN ,_, THP-1_NN (_( monoblasts_NNS )_) ,_, K562_NN (_( erythroblasts_NNS )_) ,_, and_CC S-LB1_NN (_( HTLV-1-transfected_JJ T_NN lymphocytes_NNS )_) ._.
 Receptor_NN transcripts_NNS were_VBD 4.6_CD kilobases_NNS (_( kb_NN )_) ,_, and_CC no_DT variant_JJ sizes_NNS were_VBD observed_VBN ._.
 All_DT cell_NN lines_NNS examined_VBN in_IN this_DT group_NN also_RB expressed_VBD 1,25(OH)2D3_NN receptors_NNS ._.
 Most_JJS B_NN lymphocyte_NN lines_NNS expressed_VBD negligible_JJ levels_NNS of_IN 1,25(OH)2D3_NN receptor_NN RNA_NN and_CC protein_NN ;_: however_RB ;_: analysis_NN of_IN a_DT lymphoid/myeloid_JJ somatic_JJ hybrid_NN suggested_VBD that_IN suppression_NN of_IN expression_NN of_IN 1,25(OH)2D3_NN receptor_NN RNA_NN in_IN B_NN lymphocytes_NNS may_MD be_VB a_DT dominant_JJ characteristic_NN ._.
 HL-60_NN cells_NNS were_VBD cultured_VBN with_IN 10(-7)_CD mol/L_NN 1,25(OH)2D3_NN for_IN 24_CD to_TO 72_CD hours_NNS ,_, and_CC levels_NNS of_IN expression_NN of_IN 1,25(OH)2D3_NN receptor_NN and_CC its_PRP$ RNA_NN were_VBD examined_VBN ._.
 Levels_NNS of_IN RNA_NN coding_NN for_IN the_DT receptor_NN were_VBD not_RB modulated_VBN by_IN exposure_NN to_TO high_JJ levels_NNS of_IN ligand_NN ._.
 Levels_NNS of_IN occupied_VBN 1,25(OH)2D3_NN receptor_NN protein_NN increased_VBD in_IN these_DT HL-60_NN cells_NNS ;_: but_CC the_DT total_JJ number_NN of_IN 1,25(OH)2D3_NN receptors_NNS decreased_VBD about_RB 50_CD %_NN at_IN 24_CD hours_NNS and_CC returned_VBD toward_IN normal_JJ at_IN 72_CD hours_NNS ._.
 Steady-state_JJ levels_NNS of_IN 1,25(OH)2D3_NN receptor_NN RNA_NN were_VBD not_RB affected_VBN by_IN terminal_JJ differentiation_NN of_IN HL-60_NN toward_IN either_CC granulocytes_NNS or_CC macrophages_NNS ._.
 Nondividing_JJ macrophages_NNS from_IN normal_JJ individuals_NNS also_RB expressed_VBD 1,25(OH)2D3_NN receptor_NN RNA_NN ._.
 In_IN contrast_NN ,_, nondividing_JJ peripheral_JJ blood_NN lymphocytes_NNS from_IN normal_JJ individuals_NNS did_VBD not_RB express_VB 1,25(OH)2D3_NN receptor_NN RNA_NN ;_: with_IN stimulation_NN of_IN proliferation_NN of_IN these_DT cells_NNS ,_, accumulation_NN of_IN 1,25(OH)2D3_NN receptor_NN RNA_NN increased_VBD markedly_RB ._.
 Half-life_NN (_( t1/2_NN )_) of_IN 1,25(OH)2D3_NN receptor_NN RNA_NN in_IN T_NN lymphocytes_NNS was_VBD short_JJ (_( 1_CD hour_NN )_) as_IN determined_VBN by_IN measuring_VBG decay_NN of_IN the_DT message_NN after_IN addition_NN of_IN actinomycin_NN D_NN ._.
 Consistent_JJ with_IN this_DT short_JJ t1/2_NN ,_, accumulation_NN of_IN 1,25(OH)2D3_NN receptor_NN RNA_NN increased_VBD in_IN cells_NNS as_IN their_PRP$ protein_NN synthesis_NN was_VBD inhibited_VBN ._.
 Further_JJ studies_NNS are_VBP required_VBN to_TO understand_VB the_DT physiologic_JJ role_NN of_IN 1,25(OH)2D3_NN receptors_NNS in_IN myeloid_JJ cells_NNS and_CC proliferating_VBG T_NN lymphocytes_NNS ._.
 Kappa_NN B_NN binding_NN proteins_NNS are_VBP constitutively_RB expressed_VBN in_IN an_DT IL-2_NN autocrine_NN human_JJ T_NN cell_NN line_NN ._.
 The_DT IL-2_NN and_CC the_DT IL-2-R_NN alpha_NN genes_NNS are_VBP both_DT expressed_VBN transiently_RB in_IN normal_JJ T_NN lymphocytes_NNS after_IN Ag_NN or_CC mitogen_NN activation_NN ._.
 In_IN contrast_NN ,_, the_DT human_JJ T_NN cell_NN line_NN ,_, IARC_NN 301_CD ,_, expresses_VBZ these_DT two_CD genes_NNS constitutively_RB and_CC we_PRP have_VBP previously_RB demonstrated_VBN that_IN its_PRP$ growth_NN depends_VBZ on_IN the_DT autocrine_JJ production_NN of_IN this_DT T_NN cell_NN growth_NN factor_NN and_CC high_JJ affinity_NN IL-2R_NN ._.
 To_TO dissect_VB the_DT molecular_JJ basis_NN for_IN the_DT unusual_JJ persistent_JJ expression_NN of_IN the_DT IL-2_NN and_CC IL-2-R_NN alpha_NN genes_NNS in_IN these_DT IARC_NN 301_CD T_NN cells_NNS ,_, we_PRP have_VBP analyzed_VBN the_DT interactions_NNS of_IN constitutively_RB expressed_VBN nuclear_JJ proteins_NNS with_IN the_DT 5'_JJ flanking_JJ regions_NNS of_IN the_DT IL-2_NN and_CC IL-2-R_NN alpha_NN genes_NNS using_VBG both_DT DNase_NN I_CD footprinting_NN and_CC gel_NN retardation_NN techniques_NNS ._.
 We_PRP have_VBP found_VBN that_IN a_DT region_NN in_IN both_DT genes_NNS (_( -276_CD to_TO -250_CD for_IN IL-2-R_NN alpha_NN and_CC -203_CD to_TO -183_CD for_IN IL-2_NN )_) ,_, which_WDT corresponds_VBZ to_TO a_DT kappa_NN B_NN enhancer_NN element_NN ,_, is_VBZ specifically_RB protected_VBN by_IN nuclear_JJ proteins_NNS from_IN IARC_NN 301_CD ._.
 In_IN agreement_NN with_IN this_DT finding_NN ,_, both_CC the_DT IL-2_NN and_CC IL-2-R_NN alpha_NN promoters_NNS are_VBP active_JJ in_IN transient_JJ transfection_NN assays_NNS in_IN IARC_NN 301_CD cells_NNS ._.
 In_IN contrast_NN ,_, mutation_NN of_IN the_DT kappa_NN B_NN enhancer_NN results_VBZ in_IN markedly_RB attenuated_VBN activities_NNS of_IN both_DT promoters_NNS ._.
 Two_CD proteins_NNS binding_VBG the_DT kappa_NN B_NN sequence_NN ,_, NF-kappa_NN B_NN and_CC KBF1_NN ,_, are_VBP constitutively_RB expressed_VBN in_IN IARC_NN 301_CD nuclei_NNS and_CC induced_VBN by_IN PMA_NN and_CC PHA_NN in_IN Jurkat_NN ._.
 They_PRP bind_VBP to_TO the_DT kappa_NN B_NN motifs_NNS with_IN different_JJ relative_JJ affinities_NNS that_WDT may_MD reflect_VB their_PRP$ different_JJ contribution_NN in_IN the_DT expression_NN of_IN various_JJ promoters_NNS ._.
 The_DT functional_JJ domains_NNS of_IN the_DT murine_JJ Thy-1_NN gene_NN promoter_NN ._.
 The_DT Thy-1_NN gene_NN promoter_NN resembles_VBZ a_DT "_[[DQS]] housekeeping_JJ "_[[DQE]] promoter_NN in_IN that_IN it_PRP is_VBZ located_JJ within_IN a_DT methylation-free_JJ island_NN ,_, lacks_VBZ a_DT canonical_JJ TATA_NN box_NN ,_, and_CC displays_VBZ heterogeneity_NN in_IN the_DT 5'-end_JJ termini_NNS of_IN the_DT mRNA_NN ._.
 Using_VBG transgenic_JJ mice_NNS ,_, we_PRP show_VBP that_IN this_DT promoter_NN does_VBZ not_RB confer_VB any_DT tissue_NN specificity_NN and_CC is_VBZ active_JJ only_RB in_IN a_DT position-dependent_JJ manner_NN ._.
 It_PRP can_MD only_RB be_VB activated_VBN in_IN a_DT tissue-specific_JJ manner_NN by_IN elements_NNS that_WDT lie_VBP downstream_RB of_IN the_DT initiation_NN site_NN ._.
 We_PRP have_VBP analyzed_VBN the_DT functional_JJ domains_NNS of_IN the_DT minimal_JJ Thy-1_NN promoter_NN and_CC show_VB that_IN the_DT dominant_JJ promoter_NN elements_NNS consist_VBP of_IN multiple_JJ binding_VBG sites_NNS for_IN the_DT transcription_NN factor_NN Sp1_NN ,_, an_DT inverted_JJ CCAAT_NN box_NN ,_, and_CC sequences_VBZ proximal_JJ to_TO the_DT transcription_NN start_NN site_NN ._.
 DNase_NN I_CD and_CC gel_NN mobility_NN shift_NN assays_NNS show_VBP the_DT binding_NN of_IN a_DT number_NN of_IN nuclear_JJ factors_NNS to_TO these_DT elements_NNS ,_, including_VBG Sp1_NN and_CC CP1_NN ._.
 Our_PRP$ results_NNS show_VBP that_IN the_DT structure_NN of_IN this_DT promoter_NN only_RB permits_VBZ productive_JJ interactions_NNS of_IN the_DT two_CD transcription_NN factors_NNS Sp1_NN and_CC CP1_NN with_IN the_DT basal_JJ transcription_NN machinery_NN in_IN the_DT presence_NN of_IN enhancer_NN sequences_NNS ._.
 Comparison_NN of_IN constitutive_JJ and_CC inducible_JJ transcriptional_JJ enhancement_NN mediated_VBN by_IN kappa_NN B-related_JJ sequences_NNS :_: modulation_NN of_IN activity_NN in_IN B_NN cells_NNS by_IN human_JJ T-cell_NN leukemia_NN virus_NN type_NN I_CD tax_NN gene_NN ._.
 The_DT kappa_NN B_NN sequence_NN (_( GGGACTTTCC_NN )_) binds_VBZ a_DT factor_NN ,_, NF-kappa_NN B_NN ,_, that_WDT is_VBZ constitutively_RB found_VBN in_IN its_PRP$ functional_JJ ,_, DNA_NN binding_NN form_NN only_RB in_IN B_NN lymphocytes_NNS ._.
 A_DT factor_NN with_IN apparently_RB indistinguishable_JJ sequence_NN specificity_NN can_MD be_VB induced_VBN in_IN many_JJ other_JJ cell_NN types_NNS ,_, where_WRB it_PRP is_VBZ used_VBN to_TO regulate_VB inducible_JJ gene_NN expression_NN ._.
 For_IN example_NN ,_, kappa_NN B-related_JJ sequences_NNS have_VBP been_VBN shown_VBN to_TO be_VB important_JJ for_IN the_DT transcription_NN of_IN a_DT few_JJ inducible_JJ genes_NNS ,_, such_JJ as_IN the_DT interleukin_NN 2_CD receptor_NN alpha-chain_NN gene_NN and_CC the_DT beta-interferon_NN gene_NN ._.
 However_RB ,_, these_DT genes_NNS are_VBP not_RB constitutively_RB active_JJ in_IN B_NN lymphocytes_NNS ,_, suggesting_VBG that_IN other_JJ regulatory_JJ mechanisms_NNS must_MD play_VB a_DT role_NN in_IN determining_VBG the_DT patterns_NNS of_IN expression_NN ._.
 We_PRP have_VBP investigated_VBN the_DT constitutive_JJ and_CC inducible_JJ transcriptional_JJ activity_NN mediated_VBN by_IN five_CD kappa_NN B-related_JJ sequence_NN elements_NNS in_IN two_CD different_JJ cell_NN types_NNS ._.
 We_PRP show_VBP that_IN in_IN S194_NN plasma_NN cells_NNS the_DT activity_NN of_IN each_DT element_NN correlates_VBZ well_RB with_IN the_DT relative_JJ affinity_NN of_IN B-cell-derived_JJ NF-kappa_NN B_NN for_IN that_DT element_NN ._.
 This_DT leads_VBZ to_TO significantly_RB lower_RBR transcription_NN enhancement_NN by_IN sites_NNS derived_VBN from_IN the_DT interleukin_NN 2_CD receptor_NN or_CC T-cell_NN receptor_NN genes_NNS in_IN S194_NN cells_NNS ._.
 However_RB ,_, in_IN either_CC EL-4_NN (_( T_NN )_) cells_NNS or_CC S194_NN cells_NNS ,_, both_DT lower-affinity_JJ sites_NNS can_MD be_VB significantly_RB induced_VBN by_IN the_DT tax_NN gene_NN product_NN of_IN human_JJ T-cell_NN leukemia_NN virus_NN type_NN I_CD ,_, showing_VBG that_IN NF-kappa_NN B_NN activity_NN can_MD be_VB modulated_VBN even_RB in_IN a_DT B-cell_NN line_NN that_WDT constitutively_RB expresses_VBZ this_DT
 Isolation_NN of_IN a_DT rel-related_JJ human_JJ cDNA_NN that_WDT potentially_RB encodes_VBZ the_DT 65-kD_JJ subunit_NN of_IN NF-kappa_NN B_NN (_( published_VBN erratum_NN appears_VBZ in_IN Science_NNP 1991_CD Oct_NNP 4_CD ;_: 254_CD (_( 5028_CD )_) :_: 11_CD )_)
 A_DT DNA_NN probe_NN that_WDT spanned_VBD a_DT domain_NN conserved_VBN among_IN the_DT proto-oncogene_NN c-rel_NN ,_, the_DT Drosophila_NN morphogen_NN dorsal_NN ,_, and_CC the_DT p50_NN DNA_NN binding_NN subunit_NN of_IN NF-kappa_NN B_NN was_VBD generated_VBN from_IN Jurkat_NN T_NN cell_NN complementary_JJ DNA_NN with_IN the_DT polymerase_NN chain_NN reaction_NN (_( PCR_NN )_) and_CC degenerate_JJ oligonucleotides_NNS ._.
 This_DT probe_NN was_VBD used_VBN to_TO identify_VB a_DT rel-related_JJ complementary_JJ DNA_NN that_WDT hybridized_VBD to_TO a_DT 2.6-kilobase_JJ messenger_NN RNA_NN present_JJ in_IN human_JJ T_NN and_CC B_NN lymphocytes_NNS ._.
 In_FW vitro_FW transcription_NN and_CC translation_NN of_IN the_DT complementary_JJ DNA_NN resulted_VBD in_IN the_DT synthesis_NN of_IN a_DT protein_NN with_IN an_DT apparent_JJ molecular_JJ size_NN of_IN 65_CD kilodaltons_NNS (_( kD_NN )_) ._.
 The_DT translated_VBN protein_NN showed_VBD weak_JJ DNA_NN binding_NN with_IN a_DT specificity_NN for_IN the_DT kappa_NN B_NN binding_VBG motif_NN ._.
 This_DT protein-DNA_JJ complex_JJ comigrated_VBN with_IN the_DT complex_NN obtained_VBN with_IN the_DT purified_VBN human_JJ p65_NN NF-kappa_NN B_NN subunit_NN and_CC binding_NN was_VBD inhibited_VBN by_IN I_NN kappa_NN B-alpha_NN and_CC -beta_NN proteins_NNS ._.
 In_IN addition_NN ,_, the_DT 65-kD_JJ protein_NN associated_VBN with_IN the_DT p50_NN subunit_NN of_IN NF-kappa_NN B_NN and_CC the_DT kappa_NN B_NN probe_NN to_TO form_VB a_DT complex_NN with_IN the_DT same_JJ electrophoretic_JJ mobility_NN as_IN the_DT NF-kappa_NN B-DNA_JJ complex_NN ._.
 Therefore_RB the_DT rel-related_JJ 65-kD_JJ protein_NN may_MD represent_VB the_DT p65_NN subunit_NN of_IN the_DT active_JJ NF-kappa_NN B_NN transcription_NN factor_NN complex_NN ._.
 Lymphocyte_NN glucocorticoid_NN receptor_NN number_NN in_IN posttraumatic_JJ stress_NN disorder_NN ._.
 OBJECTIVE_NN :_: The_DT authors_NNS '_POS objective_NN was_VBD to_TO investigate_VB the_DT possibility_NN that_IN glucocorticoid_NN receptor_NN changes_NNS may_MD be_VB involved_VBN in_IN the_DT dysregulation_NN of_IN the_DT hypothalamic-pituitary-adrenal_JJ (_( HPA_JJ )_) axis_NN in_IN posttraumatic_JJ stress_NN disorder_NN (_( PTSD_NN )_) ._.
 METHOD_NN :_: They_PRP measured_VBD the_DT number_NN of_IN lymphocyte_NN cytosolic_JJ glucocorticoid_NN receptors_NNS and_CC plasma_NN cortisol_NN concentrations_NNS in_IN 15_CD consecutively_RB admitted_VBN male_JJ combat_NN Vietnam_NN veterans_NNS with_IN PTSD_NN and_CC in_IN a_DT normal_JJ comparison_NN group_NN of_IN 11_CD subjects_NNS ._.
 RESULTS_NNS :_: Both_CC the_DT patients_NNS and_CC the_DT normal_JJ comparison_NN subjects_NNS showed_VBD a_DT morning-to-afternoon_JJ decline_NN in_IN glucocorticoid_NN receptor_NN concentrations_NNS ,_, paralleling_VBG the_DT normal_JJ diurnal_JJ decline_NN in_IN cortisol_NN levels_NNS ._.
 The_DT number_NN of_IN glucocorticoid_NN receptors_NNS was_VBD 63_CD %_NN greater_JJR in_IN the_DT morning_NN and_CC 26_CD %_NN greater_JJR in_IN the_DT afternoon_NN in_IN the_DT patients_NNS with_IN PTSD_NN than_IN in_IN the_DT normal_JJ subjects_NNS ._.
 No_DT group_NN differences_NNS in_IN cortisol_NN levels_NNS were_VBD observed_VBN ,_, nor_CC were_VBD glucocorticoid_NN receptor_NN number_NN and_CC cortisol_NN levels_NNS correlated_VBD ._.
 The_DT number_NN of_IN morning_NN glucocorticoid_NN receptors_NNS was_VBD positively_RB correlated_VBN with_IN symptoms_NNS of_IN PTSD_NN and_CC anxiety_NN ._.
 CONCLUSIONS_NNS :_: These_DT results_NNS provide_VBP further_JJ evidence_NN for_IN a_DT dysregulation_NN of_IN the_DT HPA_JJ axis_NN in_IN PTSD_NN ._.
 The_DT finding_NN that_IN patients_NNS with_IN PTSD_NN had_VBD a_DT substantially_RB greater_JJR number_NN of_IN lymphocyte_NN glucocorticoid_NN receptors_NNS than_IN normal_JJ comparison_NN subjects_NNS is_VBZ consistent_JJ with_IN the_DT authors_NNS '_POS previous_JJ observations_NNS of_IN low_JJ 24-hour_JJ urinary_JJ cortisol_NN excretion_NN in_IN subjects_NNS with_IN PTSD_NN ._.
 Furthermore_RB ,_, the_DT receptor_NN changes_NNS observed_VBN are_VBP opposite_JJ of_IN those_DT reported_VBN in_IN major_JJ depressive_JJ disorder_NN ._.
 The_DT present_JJ data_NNS ,_, along_IN with_IN other_JJ findings_NNS of_IN HPA_JJ abnormalities_NNS in_IN PTSD_NN ,_, support_VBP the_DT possibility_NN of_IN a_DT greater_JJR negative_JJ feedback_NN sensitivity_NN at_IN one_CD or_CC more_JJR levels_NNS of_IN the_DT HPA_JJ axis_NN ._.
 A_DT thymus-specific_JJ member_NN of_IN the_DT HMG_NN protein_NN family_NN regulates_VBZ the_DT human_JJ T_NN cell_NN receptor_NN C_NN alpha_NN enhancer_NN ._.
 The_DT human_JJ T_NN cell-specific_JJ transcription_NN factor_NN TCF-1_NN alpha_NN plays_VBZ a_DT key_JJ role_NN in_IN the_DT tissue-specific_JJ activation_NN of_IN the_DT T_NN cell_NN receptor_NN (_( TCR_NN )_) C_NN alpha_NN enhancer_NN and_CC binds_VBZ to_TO pyrimidine-rich_JJ elements_NNS (_( 5'-PyCTTTG-3'_NN )_) present_JJ in_IN a_DT variety_NN of_IN other_JJ T_NN cell-specific_JJ control_NN regions_NNS ._.
 Using_VBG amino_NN acid_NN sequence_NN information_NN derived_VBN from_IN the_DT DNA_NN affinity-purified_JJ protein_NN ,_, we_PRP have_VBP now_RB isolated_VBN cDNA_NN clones_NNS encoding_VBG TCF-1_NN alpha_NN ._.
 The_DT TCF-1_NN alpha_NN cDNA_NN contains_VBZ a_DT single_JJ 68-amino-acid_JJ domain_NN that_WDT is_VBZ homologous_JJ to_TO a_DT region_NN conserved_VBN among_IN high-mobility_JJ group_NN (_( HMG_NN )_) and_CC nonhistone_JJ chromosomal_JJ proteins_NNS ._.
 Expression_NN of_IN full-length_JJ and_CC mutant_JJ cDNA_NN clones_NNS in_IN bacteria_NNS reveal_VBP that_IN the_DT single_JJ HMG_NN motif_NN ,_, which_WDT is_VBZ predicted_VBN to_TO contain_VB two_CD extended_VBN alpha-helical_JJ segments_NNS ,_, is_VBZ sufficient_JJ to_TO direct_VB the_DT sequence-specific_JJ binding_NN of_IN TCF-1_NN alpha_NN to_TO DNA_NN ._.
 Northern_NN blot_NN experiments_NNS demonstrate_VBP further_RBR that_IN TCF-1_NN alpha_NN mRNA_NN is_VBZ highly_RB tissue_NN specific_JJ ,_, found_VBN primarily_RB in_IN the_DT thymus_NN or_CC T_NN cell_NN lines_NNS ._.
 The_DT immature_JJ CEM_NN T_NN cell_NN line_NN expresses_VBZ relatively_RB low_JJ levels_NNS of_IN TCF-1_NN alpha_NN mRNA_NN ,_, which_WDT are_VBP increased_VBN upon_IN activation_NN of_IN these_DT cells_NNS by_IN phorbol_NN esters_NNS ._.
 Interestingly_RB ,_, the_DT cloned_VBN TCF-1_NN alpha_NN protein_NN is_VBZ a_DT potent_JJ transcriptional_JJ activator_NN of_IN the_DT human_JJ TCR_NN alpha_NN enhancer_NN in_IN nonlymphoid_JJ cell_NN lines_NNS ,_, whereas_IN the_DT activity_NN of_IN the_DT endogenous_JJ protein_NN in_IN T_NN cell_NN lines_NNS is_VBZ strongly_RB dependent_JJ on_IN an_DT additional_JJ T_NN cell-specific_JJ protein_NN that_WDT interacts_VBZ with_IN the_DT core_NN enhancer_NN ._.
 TCF-1_NN alpha_NN is_VBZ currently_RB unique_JJ among_IN the_DT newly_RB emerging_VBG family_NN of_IN DNA-binding_JJ regulatory_JJ proteins_NNS that_WDT share_VBP the_DT HMG_NN motif_NN in_IN that_IN it_PRP is_VBZ a_DT highly_RB tissue-specific_JJ RNA_NN polymerase_NN II_CD transcription_NN factor_NN ._.
 Immune_JJ response_NN of_IN peripheral_JJ blood_NN mononuclear_JJ cells_NNS to_TO HBx-antigen_NN of_IN hepatitis_NN B_NN virus_NN ._.
 The_DT hepatitis_NN B_NN virus_NN genome_NN encodes_VBZ a_DT transcriptional_JJ transactivator_NN protein_NN designated_VBN HBxAg_NN ._.
 We_PRP have_VBP investigated_VBN whether_IN this_DT antigen_NN is_VBZ a_DT target_NN structure_NN for_IN human_JJ T-lymphocytes_NNS ._.
 Using_VBG recombinant_JJ HBxAg_NN protein_NN ,_, we_PRP found_VBD HBxAg-specific_JJ stimulation_NN of_IN peripheral_JJ blood_NN mononuclear_JJ cells_NNS in_IN patients_NNS with_IN acute_JJ hepatitis_NN B_NN virus_NN infection_NN (_( 6_CD of_IN 6_CD )_) and_CC chronic_JJ hepatitis_NN B_NN virus_NN infection_NN (_( 6_CD of_IN 17_CD )_) but_CC not_RB in_IN healthy_JJ individuals_NNS ._.
 With_IN HBxAg-specific_JJ synthetic_JJ polypeptides_NNS ,_, several_JJ T-cell_NN epitopes_NNS were_VBD identified_VBN ._.
 Most_JJS were_VBD located_JJ in_IN the_DT carboxyterminal_JJ half_NN of_IN the_DT HBxAg_NN protein_NN ._.
 Five_CD T-cell_NN clones_NNS specific_JJ for_IN a_DT T-cell_NN epitope_NN located_JJ at_IN the_DT carboxyterminal_JJ region_NN of_IN HBxAg_NN were_VBD established_VBN and_CC found_VBN to_TO belong_VB to_TO the_DT CD2/CD4-positive_JJ ,_, CD8-negative_JJ subtype_NN ._.
 These_DT data_NNS establish_VBP for_IN the_DT first_JJ time_NN HBxAg_NN as_IN an_DT antigen_NN in_IN the_DT cellular_JJ immune_JJ response_NN ._.
 A_DT study_NN on_IN the_DT circadian_JJ rhythm_NN of_IN glucocorticoid_NN receptor_NN ._.
 Circadian_JJ rhythm_NN in_IN glucocorticoid_NN receptor_NN (_( GR_NN )_) was_VBD studied_VBN in_IN the_DT rat_NN liver_NN and_CC human_JJ peripheral_JJ leukocytes_NNS ._.
 For_IN rats_NNS exposed_VBN to_TO a_DT natural_JJ environmental_JJ photic_JJ cycle_NN or_CC a_DT 12L_NN :_: 12D_NN artificial_JJ light_NN regime_NN ,_, peak_JJ values_NNS of_IN hepatic_JJ GR_NN were_VBD detected_VBN between_IN 23:00_CD and_CC 02:00_CD h_NN ._.
 Except_IN for_IN a_DT 4-hour_JJ advancement_NN of_IN the_DT peak_NN ,_, a_DT similar_JJ circadian_JJ rhythm_NN of_IN hepatic_JJ GR_NN was_VBD detected_VBN in_IN rats_NNS reared_VBN under_IN a_DT reversed_VBN lighting_NN regimen_NNS (_( 12D_NN :_: 12L_NN ;_: lights_NNS on_IN between_IN 18:30_CD and_CC 06:30_CD h_NN )_) ._.
 In_IN human_JJ leukocytes_NNS ,_, the_DT peak_JJ value_NN of_IN GR_NN was_VBD found_VBN to_TO parallel_VB that_DT of_IN plasma_NN cortisol_NN with_IN high_JJ and_CC low_JJ values_NNS detected_VBN at_IN 04:00-08:00_CD h_NN and_CC 23:00-24:00_CD h_NN ,_, respectively_RB ._.
 In_IN patients_NNS suffering_VBG from_IN Cushing_NN 's_POS syndrome_NN ,_, the_DT circadian_JJ rhythm_NN of_IN plasma_NN cortisol_NN either_CC disappeared_VBD or_CC was_VBD inverted_VBN while_IN that_DT of_IN GR_NN did_VBD not_RB significantly_RB deviate_VB from_IN the_DT normal_JJ subjects_NNS ._.
 For_IN apoplexic_JJ patients_NNS with_IN lesions_NNS localized_JJ to_TO the_DT base_NN of_IN the_DT brain_NN as_IN indicated_VBN by_IN computerized_VBN tomography_NN ,_, the_DT diurnal_JJ variation_NN of_IN GR_NN was_VBD abolished_VBN ._.
 Conversely_RB ,_, diurnal_JJ rhythmicity_NN persisted_VBD in_IN apoplexy_NN patients_NNS whose_WP$ lesions_NNS were_VBD in_IN the_DT cerebral_JJ cortex_NN ._.
 Thus_RB ,_, we_PRP postulated_VBD that_IN the_DT circadian_JJ modification_NN of_IN GR_NN was_VBD independent_JJ of_IN the_DT diurnal_JJ fluctuations_NNS in_IN plasma_NN cortisol_NN level_NN or_CC the_DT circadian_JJ variations_NNS in_IN environmental_JJ lighting_NN and_CC that_IN the_DT rhythmicity_NN might_MD be_VB regulated_VBN by_IN the_DT '_[[DQS]] circadian_JJ pacemaker_NN '_[[DQE]] located_JJ in_IN the_DT human_JJ basal_JJ brain_NN ._.
 These_DT diurnal_JJ variations_NNS in_IN GR_NN might_MD serve_VB to_TO coordinate_VB the_DT reactivity_NN of_IN the_DT target_NN cells_NNS to_TO cortisol_NN because_IN the_DT diurnal_JJ rhythms_NNS of_IN a_DT GR-mediated_JJ response_NN ,_, the_DT fractional_JJ inhibition_NN of_IN chemotactic_JJ migration_NN rate_NN of_IN polymorphonuclear_JJ leukocytes_NNS by_IN cortisol_NN ,_, were_VBD found_VBN to_TO be_VB synchronous_JJ with_IN those_DT of_IN GR_NN ._.
 Multiple_JJ Oct2_NN isoforms_NNS are_VBP generated_VBN by_IN alternative_JJ splicing_NN ._.
 The_DT interaction_NN of_IN the_DT Oct2_NN transcription_NN factor_NN with_IN the_DT cognate_JJ octamer_NN motif_NN ATGCAAAT_NN is_VBZ a_DT critical_JJ determinant_NN of_IN the_DT lymphoid-specific_JJ expression_NN of_IN immunoglobulin_NN genes_NNS ._.
 Ectopic_JJ expression_NN of_IN cloned_VBN Oct2_NN cDNA_NN was_VBD shown_VBN to_TO be_VB sufficient_JJ to_TO reconstitute_VB at_IN least_JJS some_DT aspects_NNS of_IN this_DT regulation_NN in_IN non-lymphoid_JJ cells_NNS ._.
 We_PRP describe_VBP the_DT isolation_NN and_CC characterization_NN of_IN multiple_JJ cDNAs_NNS encoding_VBG mouse_NN Oct2_NN from_IN a_DT mature_JJ B-cell_NN line_NN and_CC we_PRP show_VBP that_IN a_DT variety_NN of_IN isoforms_NNS of_IN this_DT transcription_NN factor_NN is_VBZ generated_VBN from_IN a_DT single_JJ gene_NN by_IN an_DT alternative_JJ splicing_NN mechanism_NN ._.
 All_PDT the_DT isoforms_NNS retain_VBP the_DT previously_RB characterized_VBN POU-domain_NN and_CC are_VBP therefore_RB able_JJ to_TO bind_VB to_TO the_DT octamer_NN motif_NN ._.
 Different_JJ amounts_NNS of_IN the_DT various_JJ isoforms_NNS are_VBP present_JJ within_IN the_DT same_JJ B-cell_NN regardless_RB of_IN the_DT developmental_JJ stage_NN of_IN B-cell_NN differentiation_NN and_CC at_IN least_JJS some_DT of_IN the_DT isoforms_NNS are_VBP conserved_VBN between_IN mouse_NN and_CC humans_NNS ._.
 In_IN cotransfection_NN experiments_NNS we_PRP show_VBP that_IN all_PDT the_DT isoforms_NNS are_VBP able_JJ to_TO activate_VB an_DT octamer_NN containing_VBG promoter_NN element_NN in_IN fibroblasts_NNS revealing_VBG an_DT unexpected_JJ functional_JJ redundancy_NN ._.
 Finally_RB ,_, we_PRP show_VBP that_IN one_CD of_IN the_DT isoforms_NNS encodes_VBZ the_DT previously_RB described_VBN lymphoid-specific_JJ Oct2B_NN protein_NN which_WDT has_VBZ been_VBN suggested_VBN to_TO be_VB involved_VBN in_IN the_DT function_NN of_IN the_DT octamer_NN motif_NN in_IN the_DT context_NN of_IN the_DT immunoglobulin_NN heavy-chain_NN (_( IgH_NN )_) enhancer_NN ._.
 Murine_JJ and_CC human_JJ T-lymphocyte_NN GATA-3_NN factors_NNS mediate_VBP transcription_NN through_IN a_DT cis-regulatory_JJ element_NN within_IN the_DT human_JJ T-cell_NN receptor_NN delta_NN gene_NN enhancer_NN ._.
 A_DT family_NN of_IN transcriptional_JJ activators_NNS has_VBZ recently_RB been_VBN identified_VBN in_IN chickens_NNS ;_: these_DT transcriptional_JJ activators_NNS recognize_VBP a_DT common_JJ consensus_NN motif_NN (_( WGATAR_NN )_) through_IN a_DT conserved_VBN C4_NN zinc_NN finger_NN DNA-binding_JJ domain_NN ._.
 One_CD of_IN the_DT members_NNS of_IN this_DT multigene_JJ family_NN ,_, cGATA-3_NN ,_, is_VBZ most_RBS abundantly_RB expressed_VBN in_IN the_DT T-lymphocyte_NN cell_NN lineage_NN ._.
 Analysis_NN of_IN human_JJ and_CC murine_JJ GATA-3_NN factors_NNS shows_VBZ a_DT striking_JJ degree_NN of_IN amino_NN acid_NN sequence_NN identity_NN and_CC similar_JJ patterns_NNS of_IN tissue_NN specificity_NN of_IN expression_NN in_IN these_DT three_CD organisms_NNS ._.
 The_DT murine_JJ and_CC human_JJ factors_NNS are_VBP abundantly_RB expressed_VBN in_IN a_DT variety_NN of_IN human_JJ and_CC murine_JJ T-cell_NN lines_NNS and_CC can_MD activate_VB transcription_NN through_IN a_DT tissue-specific_JJ GATA-binding_JJ site_NN identified_VBN within_IN the_DT human_JJ T-cell_NN receptor_NN delta_NN gene_NN enhancer_NN ._.
 We_PRP infer_VBP that_IN the_DT murine_JJ and_CC human_JJ GATA-3_NN proteins_NNS play_VBP a_DT central_JJ and_CC highly_RB conserved_VBN role_NN in_IN vertebrate_NN T-cell-specific_JJ transcriptional_JJ regulation_NN ._.
 Processing_NN of_IN the_DT precursor_NN of_IN NF-kappa_NN B_NN by_IN the_DT HIV-1_NN protease_NN during_IN acute_JJ infection_NN ._.
 Transcription_NN of_IN the_DT human_JJ immunodeficiency_NN virus_NN type-1_NN (_( HIV-1_NN )_) genome_NN is_VBZ regulated_VBN in_IN part_NN by_IN cellular_JJ factors_NNS and_CC is_VBZ stimulated_VBN by_IN activation_NN of_IN latently_RB infected_JJ T_NN cells_NNS ._.
 T-cell_NN activation_NN also_RB correlates_VBZ with_IN the_DT induction_NN of_IN the_DT factor_NN NF-kappa_NN B_NN which_WDT binds_VBZ to_TO two_CD adjacent_JJ sites_NNS in_IN the_DT HIV-1_NN long_JJ terminal_JJ repeat_NN ._.
 This_DT factor_NN consists_VBZ of_IN two_CD DNA-binding_JJ subunits_NNS of_IN relative_JJ molecular_JJ mass_NN 50,000_CD (_( 50K_CD )_) associated_VBN with_IN two_CD 65K_CD subunits_NNS ._.
 It_PRP is_VBZ located_JJ in_IN the_DT nucleus_NN in_IN mature_JJ B_NN cells_NNS ,_, but_CC is_VBZ present_JJ in_IN other_JJ cell_NN types_NNS as_IN an_DT inactive_JJ cytoplasmic_JJ complex_NN ._.
 External_JJ stimuli_NNS ,_, including_VBG those_DT that_WDT activate_VBP T_NN cells_NNS ,_, result_VBP in_IN nuclear_JJ translocation_NN of_IN active_JJ NF-kappa_NN B_NN ._.
 The_DT cloning_NN of_IN the_DT complementary_JJ DNA_NN for_IN the_DT 50K_CD subunit_NN helped_VBD to_TO identify_VB an_DT exclusively_RB cytoplasmic_JJ 105K_CD precursor_NN (_( p105_NN )_) (_( V.B._NNP ,_, P.K._NNP and_CC A.I._NNP ,_, manuscript_NN submitted_VBN )_) ._.
 The_DT expression_NN of_IN active_JJ NF-kappa_NN B_NN might_MD therefore_RB also_RB be_VB regulated_VBN by_IN the_DT extent_NN of_IN processing_NN of_IN p105_NN ._.
 Because_IN HIV-1_NN requires_VBZ active_JJ NF-kappa_NN B_NN for_IN efficient_JJ transcription_NN ,_, we_PRP tested_VBD the_DT effect_NN of_IN HIV-1_NN infection_NN on_IN the_DT processing_NN of_IN the_DT human_JJ 105K_CD precursor_NN ._.
 We_PRP show_VBP here_RB that_IN the_DT HIV-1_NN protease_NN can_MD process_VB p105_NN and_CC increases_VBZ levels_NNS of_IN active_JJ nuclear_JJ NF-kappa_NN B_NN complex_NN ._.
 Vitamin_NN D_NN receptor_NN expression_NN in_IN human_JJ lymphocytes_NNS ._.
 Signal_NN requirements_NNS and_CC characterization_NN by_IN western_NN blots_NNS and_CC DNA_NN sequencing_NN ._.
 The_DT signals_NNS controlling_VBG the_DT expression_NN of_IN the_DT receptor_NN protein_NN for_IN 1_CD alpha,25-dihydroxyvitamin_NN D3_NN in_IN normal_JJ human_JJ lymphocytes_NNS and_CC the_DT relationship_NN of_IN this_DT protein_NN to_TO the_DT classical_JJ vitamin_NN D_NN receptor_NN were_VBD examined_VBN ._.
 Lymphocytes_NNS activated_VBN with_IN the_DT OKT3_NN antibody_NN to_TO the_DT T-cell_NN antigen_NN receptor_NN expressed_VBD fewer_JJR binding_VBG sites_NNS as_IN compared_VBN to_TO lymphocytes_NNS that_WDT were_VBD activated_VBN by_IN the_DT polyclonal_JJ activator_NN phytohemagglutinin_NN (_( PHA_NN )_) ._.
 However_RB ,_, combination_NN of_IN OKT3_NN and_CC phorbol_NN myristate_NN acetate_NN produced_VBD a_DT concentration_NN of_IN binding_VBG sites_NNS similar_JJ to_TO the_DT PHA-activated_JJ cells_NNS ._.
 The_DT receptor_NN from_IN OKT3_NN and_CC OKT3_NN +_CC phorbol_NN myristate_NN acetate-activated_JJ lymphocytes_NNS exhibited_VBD decreased_VBN binding_NN to_TO DNA-cellulose_NN compared_VBN to_TO PHA-activated_JJ lymphocytes_NNS ._.
 In_IN lymphocytes_NNS activated_VBN either_CC by_IN PHA_NN or_CC OKT3_NN (_( but_CC not_RB in_IN resting_VBG cells_NNS )_) ,_, a_DT 50-kDa_JJ species_NNS cross-reacting_VBG with_IN a_DT monoclonal_JJ antibody_NN against_IN the_DT intestinal_JJ vitamin_NN D_NN receptor_NN was_VBD detected_VBN ._.
 Finally_RB ,_, RNA_NN from_IN activated_VBN lymphocytes_NNS was_VBD amplified_VBN by_IN polymerase_NN chain_NN reaction_NN using_VBG oligonucleotide_NN primers_NNS flanking_VBG the_DT 196_CD base_NN pair_NN long_JJ region_NN encoding_VBG the_DT DNA-binding_JJ domain_NN of_IN the_DT human_JJ intestinal_JJ receptor_NN ._.
 The_DT amplified_VBN product_NN showed_VBD an_DT identical_JJ nucleotide_NN sequence_NN to_TO the_DT DNA-binding_JJ domain_NN of_IN the_DT human_JJ intestinal_JJ receptor_NN ._.
 These_DT findings_NNS suggest_VBP that_IN expression_NN of_IN the_DT 1,25-(OH)2D3_NN receptor_NN in_IN lymphocytes_NNS is_VBZ triggered_VBN by_IN distinct_JJ and_CC contingent_JJ signals_NNS ,_, and_CC that_IN the_DT protein_NN and_CC the_DT mRNA_NN encoding_VBG it_PRP are_VBP identical_JJ to_TO the_DT classical_JJ vitamin_NN D_NN receptor_NN ._.
 Cloning_NN of_IN murine_JJ TCF-1_NN ,_, a_DT T_NN cell-specific_JJ transcription_NN factor_NN interacting_VBG with_IN functional_JJ motifs_NNS in_IN the_DT CD3-epsilon_NN and_CC T_NN cell_NN receptor_NN alpha_NN enhancers_NNS ._.
 CD3-epsilon_NN gene_NN expression_NN is_VBZ confined_VBN to_TO the_DT T_NN cell_NN lineage_NN ._.
 We_PRP have_VBP recently_RB identified_VBN and_CC cloned_VBN a_DT human_JJ transcription_NN factor_NN ,_, TCF-1_NN ,_, that_WDT binds_VBZ to_TO a_DT functional_JJ element_NN in_IN the_DT T_NN lymphocyte-specific_JJ enhancer_NN of_IN CD3-epsilon_NN ._.
 In_IN a_DT panel_NN of_IN human_JJ cell_NN lines_NNS ,_, TCF-1_NN expression_NN was_VBD restricted_JJ to_TO T_NN lineage_NN cells_NNS ._.
 TCF-1_NN belonged_VBD to_TO a_DT novel_JJ family_NN of_IN genes_NNS that_WDT contain_VBP the_DT so-called_JJ high_JJ mobility_NN group_NN 1_CD (_( HMG_NN )_) box_NN ._.
 Here_RB we_PRP report_VBP the_DT cloning_NN of_IN murine_JJ TCF-1_NN ._.
 Two_CD splice_NN alternatives_NNS were_VBD identified_VBN that_WDT were_VBD not_RB previously_RB observed_VBN in_IN human_JJ TCF-1_NN ._.
 Murine_JJ and_CC human_JJ TCF-1_NN displayed_VBD a_DT 95.5_CD %_NN overall_JJ amino_NN acid_NN homology_NN ._.
 Recombinant_JJ murine_JJ and_CC human_JJ TCF-1_NN recognized_VBD the_DT same_JJ sequence_NN motif_NN in_IN the_DT CD3-epsilon_NN enhancer_NN as_IN judged_VBN by_IN gel_NN retardation_NN and_CC methylation_NN interference_NN assays_NNS ._.
 With_IN the_DT murine_JJ cDNA_NN clones_NNS several_JJ aspects_NNS of_IN TCF-1_NN were_VBD analyzed_VBN ._.
 First_RB ,_, deletion_NN analysis_NN revealed_VBD that_IN a_DT region_NN of_IN TCF-1_NN containing_VBG the_DT HMG_NN box_NN was_VBD sufficient_JJ for_IN sequence-specific_JJ binding_NN ._.
 Second_RB ,_, by_IN high_JJ stringency_NN Northern_NN blotting_NN and_CC in_FW situ_FW hybridization_NN ,_, TCF-1_NN expression_NN was_VBD shown_VBN to_TO be_VB confined_VBN to_TO the_DT thymus_NN and_CC to_TO the_DT T_NN cell_NN areas_NNS of_IN the_DT spleen_NN ._.
 Third_RB ,_, TCF-1_NN bound_VBD specifically_RB to_TO a_DT functional_JJ T_NN cell-specific_JJ element_NN in_IN the_DT T_NN cell_NN receptor_NN alpha_NN (_( TCR-alpha_NN )_) enhancer_NN ._.
 The_DT T_NN lineage-specific_JJ expression_NN and_CC the_DT affinity_NN for_IN functional_JJ motifs_NNS in_IN the_DT TCR-alpha_NN and_CC CD3-epsilon_NN enhancers_NNS imply_VBP an_DT important_JJ role_NN for_IN TCF-1_NN in_IN the_DT establishment_NN of_IN the_DT mature_JJ T_NN cell_NN phenotype_NN ._.
 HIV_NN enhancer_NN activity_NN perpetuated_VBN by_IN NF-kappa_NN B_NN induction_NN on_IN infection_NN of_IN monocytes_NNS (_( see_VB comments_NNS )_)
 Permissiveness_NN to_TO replication_NN of_IN human_JJ immunodeficiency_NN virus_NN (_( HIV_NN )_) differs_VBZ in_IN T_NN lymphocytes_NNS and_CC macrophages_NNS ._.
 In_IN T_NN cells_NNS ,_, HIV_NN transcription_NN is_VBZ poorly_RB detected_VBN in_FW vivo_FW ._.
 Cloned_VBN ,_, normal_JJ T_NN lymphocytes_NNS show_VBP very_RB little_JJ ,_, if_IN any_DT ,_, basal_JJ activity_NN of_IN the_DT HIV_NN enhancer_NN and_CC low_JJ nuclear_JJ expression_NN of_IN NF-kappa_NN B_NN ,_, a_DT potent_JJ transcriptional_JJ activator_NN of_IN the_DT HIV_NN enhancer_NN ._.
 In_IN contrast_NN ,_, fixed_JJ tissue_NN macrophages_NNS express_VBP detectable_JJ HIV_NN proteins_NNS ,_, indicating_VBG permanent_JJ virus_NN transcription_NN ._.
 One_CD explanation_NN for_IN the_DT perpetuation_NN of_IN virus_NN infection_NN in_IN macrophages_NNS could_MD be_VB sustained_JJ nuclear_JJ NF-kappa_NN B_NN expression_NN ._.
 However_RB ,_, the_DT U937_NN monocytic_JJ cell_NN line_NN ,_, which_WDT is_VBZ fully_RB permissive_JJ to_TO HIV_NN replication_NN ,_, is_VBZ known_VBN to_TO express_VB only_RB low_JJ levels_NNS of_IN nuclear_JJ NF-kappa_NN B_NN ._.
 We_PRP show_VBP here_RB that_IN chronic_JJ HIV_VBP infection_NN results_VBZ in_IN both_CC induction_NN of_IN a_DT nuclear_JJ factor_NN with_IN antigenic_JJ properties_NNS indistinguishable_JJ from_IN those_DT of_IN NF-kappa_NN B_NN and_CC permanently_RB increased_VBN HIV_NN enhancer_NN activity_NN ._.
 This_DT phenomenon_NN ,_, which_WDT is_VBZ independent_JJ of_IN tumour_NN necrosis_NN factor_NN ,_, is_VBZ associated_VBN with_IN HIV_NN replication_NN ,_, and_CC is_VBZ thus_RB likely_JJ to_TO explain_VB at_IN least_JJS in_IN part_NN the_DT perpetuation_NN of_IN HIV_NN infection_NN in_IN monocytes_NNS ._.
 Role_NN for_IN the_DT Epstein-Barr_JJ virus_NN nuclear_JJ antigen_NN 2_CD in_IN viral_JJ promoter_NN switching_VBG during_IN initial_JJ stages_NNS of_IN infection_NN ._.
 During_IN latent_JJ Epstein-Barr_JJ virus_NN (_( EBV_NN )_) infection_NN of_IN human_JJ B_NN lymphocytes_NNS ,_, six_CD viral_JJ nuclear_JJ antigen_NN (_( EBNAs_NNS )_) are_VBP expressed_VBN from_IN long_JJ primary_JJ transcripts_NNS by_IN means_NNS of_IN alternative_JJ splicing_NN and_CC alternative_JJ polyadenylylation_NN sites_NNS ._.
 These_DT transcripts_NNS initiate_VBP from_IN one_CD of_IN two_CD promoters_NNS ,_, Cp_NN or_CC Wp_NN ,_, that_WDT function_VBP in_IN a_DT mutually_RB exclusive_JJ fashion_NN ._.
 Wp_NN is_VBZ exclusively_RB utilized_VBN during_IN the_DT initial_JJ stages_NNS of_IN infection_NN of_IN primary_JJ B_NN lymphocytes_NNS ,_, followed_VBN by_IN a_DT switch_NN to_TO Cp_NN usage_NN ._.
 These_DT studies_NNS have_VBP been_VBN extended_VBN to_TO show_VB that_IN (_( i_LS )_) a_DT mutant_JJ EBV_NN strain_NN lacking_VBG the_DT gene_NN encoding_VBG EBNA_NN 2_CD fails_VBZ to_TO switch_VB from_IN Wp_NN to_TO Cp_NN usage_NN in_IN primary_JJ B_NN lymphocytes_NNS ,_, although_IN the_DT virus_NN contains_VBZ a_DT functional_JJ Cp_NN ;_: (_( ii_LS )_) a_DT region_NN from_IN -429_CD to_TO -245_CD base_NN pairs_NNS upstream_JJ of_IN Cp_NN is_VBZ essential_JJ for_IN Cp_NN activity_NN in_IN B_NN lymphocytes_NNS ,_, but_CC only_RB in_IN the_DT context_NN of_IN upstream_JJ and_CC downstream_JJ sequences_NNS ;_: (_( iii_LS )_) this_DT region_NN contains_VBZ an_DT EBNA_NN 2-dependent_JJ enhancer_NN ;_: and_CC (_( iv_LS )_) DNase_NN I_CD protection_NN employing_VBG nuclear_JJ extracts_NNS from_IN B_NN and_CC T_NN lymphocytes_NNS revealed_VBD a_DT B-cell-specific_JJ footprint_NN in_IN the_DT region_NN of_IN the_DT EBNA_NN 2-dependent_JJ enhancer_NN ._.
 These_DT results_NNS support_VBP a_DT model_NN for_IN viral_JJ promoter_NN switching_NN during_IN the_DT initial_JJ stages_NNS of_IN infection_NN in_IN which_WDT Wp_NN activity_NN leads_VBZ to_TO the_DT expression_NN of_IN EBNA_NN 2_CD ,_, followed_VBN by_IN activation_NN of_IN Cp_NN through_IN the_DT EBNA_NN 2-dependent_JJ enhancer_NN ._.
 Glucocorticoid_NN receptor_NN characteristics_NNS in_IN monocytes_NNS of_IN patients_NNS with_IN corticosteroid-resistant_JJ bronchial_JJ asthma_NN ._.
 The_DT mechanism_NN of_IN corticosteroid_NN resistance_NN in_IN bronchial_JJ asthma_NN has_VBZ been_VBN studied_VBN by_IN determining_VBG the_DT rank_NN order_NN of_IN potency_NN for_IN different_JJ corticosteroids_NNS in_IN inhibiting_VBG the_DT generation_NN of_IN a_DT 3_CD kD_NN molecule_NN from_IN peripheral_JJ blood_NN monocytes_NNS isolated_VBN from_IN corticosteroid-sensitive_JJ (_( CS_JJ )_) and_CC corticosteroid-resistant_JJ (_( CR_JJ )_) asthmatic_JJ subjects_NNS ,_, which_WDT augments_VBZ leukotriene_NN B4_NN (_( LTB4_NN )_) generation_NN by_IN human_JJ neutrophils_NNS (_( PMN_NN )_) stimulated_VBN by_IN calcium_NN ionophore_NN ._.
 In_IN addition_NN ,_, binding_VBG studies_NNS with_IN (_( 3H_NN )_) dexamethasone_NN have_VBP been_VBN performed_VBN to_TO determine_VB the_DT dissociation_NN constant_NN (_( Kd_NN )_) and_CC receptor_NN numbers_NNS (_( Ro_NN )_) in_IN the_DT monocytes_NNS of_IN these_DT two_CD groups_NNS of_IN subjects_NNS ._.
 The_DT concentration_NN of_IN corticosteroid_NN producing_VBG 50_CD %_NN inhibition_NN (_( IC50_NN )_) was_VBD 600_CD nM_NN ,_, 70_CD nM_NN ,_, and_CC 0.5_CD nM_NN for_IN hydrocortisone_NN ,_, methylprednisolone_NN ,_, and_CC dexamethasone_NN ,_, respectively_RB ,_, in_IN monocytes_NNS from_IN CS_JJ individuals_NNS ._.
 There_EX was_VBD only_RB weak_JJ inhibition_NN of_IN the_DT generation_NN of_IN enhancing_NN activity_NN by_IN the_DT corticosteroids_NNS in_IN the_DT CR_JJ asthmatic_JJ individuals_NNS ._.
 The_DT dexamethasone_NN Kd_NN was_VBD 2.45_CD +/-_CC 0.58_CD nM_NN (_( mean_NN +/-_CC SEM_NN ,_, n_NN =_JJ 6_CD )_) in_IN the_DT CS_JJ group_NN and_CC 1.6_CD +/-_CC 0.35_CD nM_NN (_( mean_NN +/-_CC SEM_NN ,_, n_NN =_JJ 6_CD )_) in_IN the_DT CR_JJ group_NN of_IN patients_NNS (_( p_NN =_JJ 0.14_CD )_) ._.
 The_DT Ro_NN in_IN the_DT CS_JJ group_NN was_VBD 3,605_CD +/-_CC 984_CD binding_VBG sites_NNS per_IN nucleus_NN (_( mean_NN +/-_CC SEM_NN ,_, n_NN =_JJ 6_CD )_) and_CC 4,757_CD +/-_CC 692_CD binding_VBG sites_NNS per_IN nucleus_NN (_( mean_NN +/-_CC SEM_NN ,_, n_NN =_JJ 6_CD )_) in_IN the_DT CR_JJ group_NN (_( p_NN =_JJ 0.23_CD )_) ._.
 These_DT findings_NNS indicate_VBP that_IN corticosteroid_NN resistance_NN in_IN bronchial_JJ asthma_NN can_MD not_RB be_VB explained_VBN by_IN abnormalities_NNS in_IN corticosteroid_NN receptor_NN characteristics_NNS ._.
 Tissue-specific_JJ expression_NN of_IN the_DT platelet_NN GPIIb_NN gene_NN ._.
 One_CD of_IN the_DT major_JJ objectives_NNS in_IN the_DT study_NN of_IN thrombogenesis_NN is_VBZ to_TO determine_VB the_DT mechanisms_NNS by_IN which_WDT a_DT hematopoietic_JJ progenitor_NN is_VBZ activated_VBN and_CC committed_VBN to_TO the_DT megakaryocytic_JJ lineage_NN ._.
 Recent_JJ development_NN of_IN primary_JJ cultures_NNS of_IN human_JJ megakaryocytes_NNS and_CC the_DT molecular_JJ cloning_NN of_IN genes_NNS that_WDT are_VBP specific_JJ to_TO this_DT lineage_NN offer_VBP the_DT possibility_NN of_IN getting_VBG some_DT insights_NNS into_IN the_DT genetic_JJ mechanisms_NNS that_WDT control_VBP megakaryocytopoiesis_NNS ._.
 One_CD gene_NN of_IN interest_NN is_VBZ the_DT glycoprotein_NN IIb_NN (_( GPIIb_NN )_) gene_NN ;_: GPIIb_NN ,_, the_DT alpha_NN subunit_NN of_IN the_DT platelet_NN cytoadhesin_NN GPIIb-IIIa_NN ,_, is_VBZ produced_VBN in_IN megakaryocytes_NNS at_IN an_DT early_JJ stage_NN of_IN the_DT differentiation_NN ,_, whereas_IN the_DT other_JJ subunit_NN of_IN this_DT complex_NN ,_, GPIIIa_NN ,_, is_VBZ expressed_VBN in_IN other_JJ cells_NNS ._.
 For_IN these_DT reasons_NNS ,_, the_DT 5'-flanking_JJ region_NN of_IN the_DT GPIIb_NN gene_NN was_VBD used_VBN to_TO identify_VB the_DT regions_NNS that_WDT interact_VBP with_IN DNA-binding_JJ nuclear_JJ factors_NNS ._.
 A_DT fragment_NN extending_VBG from_IN -643_CD to_TO +33_CD is_VBZ capable_JJ of_IN controlling_VBG the_DT tissue-specific_JJ expression_NN of_IN the_DT CAT_NN gene_NN in_IN transfection_NN experiments_NNS ._.
 Within_IN this_DT region_NN ,_, we_PRP have_VBP identified_VBN several_JJ sequences_NNS that_WDT are_VBP implicated_VBN in_IN DNA_NN protein_NN interactions_NNS as_IN shown_VBN in_IN DNAse_NN I_NN footprints_NNS and_CC gel_NN mobility_NN shift_NN assays_NNS ._.
 One_CD region_NN ,_, centered_VBN at_IN -54_CD ,_, is_VBZ similar_JJ to_TO a_DT nuclear_JJ factor_NN E1-binding_JJ site_NN ,_, and_CC a_DT region_NN located_JJ at_IN position_NN -233_CD contains_VBZ a_DT CCAAT_NN motif_NN ._.
 Two_CD domains_NNS centered_VBN at_IN positions_NNS -345_CD and_CC -540_CD ,_, respectively_RB ,_, bind_VBP proteins_NNS that_WDT are_VBP present_JJ in_IN megakaryocytic_JJ cells_NNS and_CC nonrelated_JJ cells_NNS as_RB well_RB ._.
 Finally_RB ,_, two_CD other_JJ domains_NNS ,_, located_JJ at_IN positions_NNS -460_CD and_CC -510_CD ,_, interact_VBP with_IN proteins_NNS that_WDT are_VBP only_RB present_JJ in_IN megakaryocytic_JJ cells_NNS ._.
 In_IN addition_NN ,_, deletion_NN of_IN the_DT region_NN containing_VBG these_DT two_CD domains_NNS results_VBZ in_IN a_DT significant_JJ decrease_NN of_IN the_DT promoter_NN activity_NN ._.
 It_PRP is_VBZ very_RB likely_JJ that_IN these_DT domains_NNS bind_VBP megakaryocyte-specific_JJ nuclear_JJ proteins_NNS acting_VBG as_IN positive_JJ transcription_NN factors_NNS ._.
 Inhibition_NN of_IN protein_NN phosphatases_NNS by_IN okadaic_JJ acid_NN induces_VBZ AP1_NN in_IN human_JJ T_NN cells_NNS ._.
 To_TO examine_VB the_DT role_NN of_IN protein_NN phosphatases_NNS in_IN T_NN cell_NN activation_NN ,_, Jurkat_NN cells_NNS were_VBD treated_VBN with_IN okadaic_JJ acid_NN ,_, an_DT inhibitor_NN of_IN type_NN 1_CD and_CC 2A_NN phosphatases_NNS ,_, and_CC nuclear_JJ extracts_NNS were_VBD examined_VBN for_IN the_DT presence_NN of_IN AP1_NN as_IN a_DT measure_NN of_IN early_JJ T_NN cell_NN activation_NN ._.
 Okadaic_JJ acid_NN was_VBD found_VBN to_TO be_VB a_DT potent_JJ inducer_NN of_IN AP1_NN ._.
 In_IN contrast_NN to_TO phorbol_NN esters_NNS such_JJ as_IN phorbol_NN myristate_NN acetate_NN (_( PMA_NN )_) ,_, the_DT induction_NN of_IN AP1_NN by_IN okadaic_JJ acid_NN occurs_VBZ predominantly_RB by_IN transcriptional_JJ activation_NN of_IN the_DT jun_NN and_CC fos_NN family_NN of_IN proto-oncogenes_NNS ._.
 Surprisingly_RB ,_, while_IN the_DT addition_NN of_IN phytohemagglutinin_NN further_RB enhanced_VBD the_DT induction_NN of_IN AP1_NN ,_, the_DT addition_NN of_IN PMA_NN inhibited_VBD it_PRP ._.
 Okadaic_JJ acid_NN treatment_NN was_VBD found_VBN to_TO dramatically_RB increase_VB mRNA_NN transcripts_NNS of_IN the_DT jun_NN family_NN of_IN proto-oncogenes_NNS including_VBG c-jun_NN ,_, junD_NN ,_, and_CC junB_NN and_CC to_TO a_DT lesser_JJR extent_NN the_DT fos_NN family_NN including_VBG c-fos_NN and_CC fra-1_NN ._.
 By_IN comparison_NN ,_, PMA_NN is_VBZ a_DT very_RB inefficient_JJ inducer_NN of_IN the_DT jun_NN gene_NN family_NN in_IN Jurkat_NN cells_NNS ._.
 Similar_JJ to_TO its_PRP$ effect_NN on_IN the_DT induction_NN of_IN AP1_NN by_IN okadaic_JJ acid_NN ,_, PMA_NN inhibits_VBZ the_DT induction_NN of_IN c-jun_NN mRNA_NN by_IN okadaic_JJ acid_NN ._.
 Transfection_NN of_IN c-jun_NN promoter_NN constructs_NNS confirmed_VBD the_DT marked_JJ difference_NN between_IN PMA_NN and_CC okadaic_JJ acid_NN in_IN inducing_VBG c-jun_NN transcription_NN ._.
 The_DT induction_NN of_IN AP1_NN by_IN okadaic_JJ acid_NN suggests_VBZ that_IN protein_NN phosphatases_NNS 1_CD and_CC 2A_NN (_( PP1_NN and_CC PP2A_NN )_) may_MD be_VB involved_VBN in_IN T_NN cell_NN activation_NN as_IN important_JJ negative_JJ regulators_NNS of_IN the_DT transcription_NN factor_NN AP1_NN ._.
 Demonstration_NN of_IN estrogen_NN and_CC progesterone_NN receptors_NNS as_RB well_RB as_IN Ki-67_NN and_CC p-145_NN antigens_NNS in_IN single_JJ tumor_NN cells_NNS from_IN blood_NN and_CC pleural_JJ effusions_NNS using_VBG a_DT slide_NN assay_NN ._.
 We_PRP describe_VBP a_DT slide_NN assay_NN that_WDT allows_VBZ the_DT demonstration_NN of_IN antigens_NNS localized_JJ in_IN the_DT nucleus_NN from_IN isolated_VBN white_JJ blood_NN cells_NNS as_RB well_RB as_IN from_IN single_JJ tumor_NN cells_NNS derived_VBN from_IN malignant_JJ effusions_NNS ._.
 With_IN the_DT antibodies_NNS Ki-67_NN and_CC anti-p-145_NN an_DT increased_VBN rate_NN of_IN nuclear_JJ and_CC nucleolar_JJ staining_NN resulted_VBD in_IN cells_NNS from_IN highly_RB malignant_JJ lymphomas_NNS ._.
 An_DT almost_RB identical_JJ reaction_NN was_VBD obtained_VBN when_WRB tumor_NN cells_NNS from_IN malignant_JJ effusions_NNS were_VBD tested_VBN ._.
 Cells_NNS isolated_VBN from_IN the_DT blood_NN of_IN patients_NNS with_IN leukemic_JJ spread_NN of_IN lymphomas_NNS of_IN low_JJ malignancy_NN yielded_VBD a_DT weak_JJ staining_NN comparable_JJ to_TO that_DT of_IN normal_JJ mesothelial_JJ cells_NNS from_IN non-tumorous_JJ cavity_NN fluids_NNS ._.
 The_DT detection_NN of_IN estrogen_NN and_CC progesterone_NN receptors_NNS (_( ER_NN and_CC PR_NN )_) localized_JJ in_IN the_DT cell_NN nucleus_NN can_MD be_VB achieved_VBN by_IN the_DT same_JJ assay_NN ._.
 The_DT reaction_NN is_VBZ enhanced_VBN by_IN incubation_NN of_IN the_DT tumor_NN cells_NNS for_IN 30_CD min_NN at_IN 37_CD degrees_NNS C_NN prior_RB to_TO fixation_NN ._.
 Pleural_JJ effusions_NNS from_IN 20_CD patients_NNS with_IN breast_NN cancer_NN were_VBD tested_VBN ._.
 ER_NN was_VBD positive_JJ in_IN 13_CD and_CC PR_NN was_VBD positive_JJ in_IN 12_CD of_IN the_DT 20_CD samples_NNS ._.
 In_IN 5_CD cases_NNS there_EX was_VBD a_DT divergent_JJ reaction_NN with_IN ER_NN and_CC PR_NN antibody_NN ._.
 The_DT hormone_NN receptors_NNS of_IN the_DT primary_JJ tumor_NN were_VBD known_VBN in_IN 15_CD (_( ER_NN )_) and_CC 14_CD (_( PR_NN )_) patients_NNS ,_, respectively_RB ._.
 In_IN each_DT cohort_NN there_EX was_VBD only_RB one_CD case_NN with_IN a_DT negative_JJ reaction_NN of_IN the_DT primary_JJ tumor_NN and_CC a_DT positive_JJ reaction_NN with_IN the_DT isolated_VBN tumor_NN cells_NNS from_IN the_DT pleural_JJ effusions_NNS ._.
 These_DT results_NNS indicate_VBP that_IN the_DT demonstration_NN of_IN hormone_NN receptor_NN proteins_NNS in_IN cells_NNS from_IN malignant_JJ effusions_NNS is_VBZ possible_JJ and_CC that_IN there_EX is_VBZ a_DT correlation_NN with_IN the_DT status_NN of_IN the_DT primary_JJ site_NN of_IN cancer_NN ._.
 Transforming_VBG growth_NN factor-beta_NN suppresses_VBZ human_JJ B_NN lymphocyte_NN Ig_NN production_NN by_IN inhibiting_VBG synthesis_NN and_CC the_DT switch_NN from_IN the_DT membrane_NN form_NN to_TO the_DT secreted_JJ form_NN of_IN Ig_NN mRNA_NN ._.
 Transforming_VBG growth_NN factor-beta_NN (_( TGF-beta_NN )_) inhibits_VBZ B_NN cell_NN Ig_NN secretion_NN and_CC reduces_VBZ B_NN cell_NN membrane_NN Ig_NN expression_NN ._.
 The_DT addition_NN of_IN TGF-beta_NN to_TO human_JJ B_NN lymphocyte_NN cultures_NNS stimulated_VBN with_IN Staphylococcus_FW aureus_FW Cowan_NN strain_NN I_NN and_CC IL-2_NN completely_RB inhibited_VBD B_NN cell_NN Ig_NN secretion_NN (_( greater_JJR than_IN 90_CD %_NN )_) and_CC decreased_VBD B_NN cell_NN surface_NN IgM_NN ,_, IgD_NN ,_, kappa_NN L_NN chain_NN ,_, and_CC lambda_NN L_NN chain_NN expression_NN ._.
 In_IN contrast_NN ,_, TGF-beta_NN had_VBD only_RB minimal_JJ effects_NNS on_IN two_CD other_JJ B_NN cell_NN membrane_NN proteins_NNS ,_, HLA-DR_NN and_CC CD20_NN ._.
 Internal_JJ labeling_NN with_IN (35S)methionine_NN and_CC immunoprecipitation_NN with_IN anti-IgM_JJ ,_, anti-kappa_JJ ,_, and_CC anti-lambda_JJ antibodies_NNS revealed_VBD a_DT striking_JJ reduction_NN in_IN kappa_NN L_NN chain_NN in_IN the_DT presence_NN of_IN TGF-beta_NN ._.
 A_DT less_RBR pronounced_JJ reduction_NN in_IN lambda_NN L_NN chain_NN and_CC microH_NN chain_NN was_VBD also_RB noted_VBN ._.
 Northern_NN blot_NN analysis_NN of_IN RNA_NN purified_VBN from_IN B_NN cells_NNS treated_VBN with_IN TGF-beta_NN for_IN varying_VBG time_NN intervals_NNS revealed_VBD a_DT significant_JJ decrease_NN in_IN steady_JJ state_NN kappa_NN and_CC lambda_NN L_NN chain_NN mRNA_NN levels_NNS ._.
 Furthermore_RB ,_, a_DT significant_JJ decrease_NN in_IN the_DT switch_NN from_IN the_DT membrane_NN forms_NNS of_IN mu_NN and_CC gamma_NN to_TO their_PRP$ respective_JJ secreted_JJ forms_NNS was_VBD noted_VBN in_IN the_DT presence_NN of_IN TGF-beta_NN ._.
 Nuclear_JJ run-on_JJ experiments_NNS demonstrated_VBD decreased_VBN transcription_NN of_IN kappa_NN L_NN chain_NN ._.
 The_DT effects_NNS of_IN TGF-beta_NN on_IN two_CD transcriptional_JJ regulatory_JJ factors_NNS ,_, Oct-2_NN and_CC nuclear_JJ factor_NN (_( NF_NN )_) kappa_NN B_NN ,_, known_VBN to_TO be_VB important_JJ in_IN Ig_NN gene_NN transcription_NN were_VBD examined_VBN ._.
 Oct-2_NN mRNA_NN levels_NNS and_CC both_DT Oct-2_NN and_CC NF-kappa_NN B_NN proteins_NNS in_IN nuclear_JJ extracts_NNS were_VBD not_RB altered_VBN by_IN treatment_NN with_IN TGF-beta_NN ._.
 In_IN contrast_NN ,_, levels_NNS of_IN the_DT transcriptional_JJ factor_NN AP-1_NN ,_, which_WDT is_VBZ not_RB known_VBN to_TO be_VB important_JJ in_IN B_NN cell_NN Ig_NN production_NN ,_, were_VBD reduced_VBN by_IN TGF-beta_NN ._.
 These_DT findings_NNS demonstrate_VBP that_IN TGF-beta_NN decreases_VBZ B_NN lymphocyte_NN Ig_NN secretion_NN by_IN inhibiting_VBG the_DT synthesis_NN of_IN Ig_NN mRNA_NN and_CC inhibiting_VBG the_DT switch_NN from_IN the_DT membrane_NN form_NN to_TO the_DT secreted_JJ forms_NNS of_IN mu_NN and_CC gamma_NN mRNA_NN ._.
 The_DT mechanism_NN by_IN which_WDT TGF-beta_NN inhibits_VBZ Ig_NN chain_NN synthesis_NN is_VBZ unclear_JJ although_IN it_PRP does_VBZ not_RB involve_VB inhibition_NN of_IN the_DT binding_NN of_IN NF-kappa_NN B_NN or_CC Oct-2_NN to_TO their_PRP$ respective_JJ target_NN sequences_NNS ._.
 Differentiation-associated_JJ expression_NN of_IN the_DT Epstein-Barr_JJ virus_NN BZLF1_NN transactivator_NN protein_NN in_IN oral_JJ hairy_JJ leukoplakia_NN ._.
 The_DT BZLF1_NN protein_NN of_IN Epstein-Barr_JJ virus_NN (_( EBV_NN )_) is_VBZ a_DT key_JJ immediate-early_JJ protein_NN which_WDT has_VBZ been_VBN shown_VBN to_TO disrupt_VB virus_NN latency_NN in_IN EBV-infected_JJ B_NN cells_NNS ._.
 We_PRP have_VBP generated_VBN a_DT monoclonal_JJ antibody_NN ,_, BZ1_NN ,_, to_TO BZLF1_NN which_WDT reacts_VBZ in_IN immunohistology_NN ,_, immunoblotting_NN ,_, and_CC immunoprecipitation_NN and_CC which_WDT recognizes_VBZ both_CC the_DT active_JJ ,_, dimeric_JJ form_NN and_CC the_DT inactive_JJ ,_, monomeric_JJ form_NN of_IN the_DT protein_NN ._.
 Biopsies_NNS of_IN oral_JJ hairy_JJ leukoplakia_NN ,_, an_DT AIDS-associated_JJ lesion_NN characterized_VBN by_IN high-level_JJ EBV_NN replication_NN ,_, were_VBD examined_VBN by_IN immunohistochemistry_NN using_VBG the_DT BZ1_NN monoclonal_JJ antibody_NN ._.
 A_DT differentiation-associated_JJ pattern_NN of_IN BZLF1_NN expression_NN was_VBD observed_VBN ,_, BZ1_NN reacting_VBG with_IN nuclei_NNS of_IN the_DT upper_JJ spinous_JJ layer_NN of_IN the_DT lesion_NN ._.
 This_DT finding_NN suggests_VBZ that_IN the_DT BZLF1_NN promoter_NN may_MD be_VB regulated_VBN by_IN the_DT degree_NN of_IN squamous_JJ differentiation_NN ._.
 A_DT comparison_NN of_IN in_FW situ_FW hybridization_NN to_TO EBV_NN DNA_NN and_CC viral_JJ capsid_NN antigen_NN staining_VBG with_IN BZ1_NN reactivity_NN suggested_VBD that_IN BZLF1_NN expression_NN precedes_VBZ rampant_JJ virus_NN replication_NN ._.
 The_DT inability_NN to_TO detect_VB EBV_NN in_IN the_DT lower_RBR epithelial_JJ layers_NNS of_IN oral_JJ hairy_JJ leukoplakia_NN raises_VBZ questions_NNS concerning_VBG the_DT nature_NN of_IN EBV_NN latency_NN and_CC persistence_NN in_IN stratified_JJ squamous_JJ epithelium_NN ._.
 Transactivation_NN of_IN the_DT human_JJ immunodeficiency_NN virus_NN promoter_NN by_IN human_JJ herpesvirus_NN 6_CD (_( HHV-6_NN )_) strains_VBZ GS_NN and_CC Z-29_NN in_IN primary_JJ human_JJ T_NN lymphocytes_NNS and_CC identification_NN of_IN transactivating_VBG HHV-6_NN (_( GS_NN )_) gene_NN fragments_NNS ._.
 Human_JJ herpesvirus_NN 6_CD (_( HHV-6_NN )_) can_MD activate_VB the_DT human_JJ immunodeficiency_NN virus_NN (_( HIV_NN )_) promoter_NN and_CC accelerate_VB cytopathic_JJ effects_NNS in_IN HIV-infected_JJ human_JJ T_NN cells_NNS ._.
 This_DT study_NN examines_VBZ the_DT regions_NNS of_IN the_DT HIV_NN promoter_NN required_VBN for_IN HHV-6_NN transactivation_NN in_IN a_DT heterogeneous_JJ population_NN of_IN primary_JJ human_JJ T_NN lymphocytes_NNS with_IN or_CC without_IN antigenic_JJ stimulation_NN ._.
 Two_CD different_JJ strains_NNS of_IN HHV-6_NN ,_, GS_NN and_CC Z29_NN ,_, transactivated_VBD the_DT HIV_NN promoter_NN ._.
 The_DT GS_NN strain_NN transactivated_VBD the_DT promoter_NN in_IN both_CC stimulated_VBN and_CC resting_VBG T_NN cells_NNS ,_, while_IN the_DT Z29_NN strain_NN increased_VBD HIV_NN promoter_NN activity_NN only_RB in_IN stimulated_VBN T_NN cells_NNS ._.
 Three_CD DNA_NN clones_NNS containing_VBG HHV-6_NN (_( GS_NN )_) genomic_JJ fragments_NNS transactivated_VBD the_DT HIV_NN promoter_NN in_IN cotransfected_VBN T_NN cells_NNS ._.
 A_DT 21.4-kb_JJ DNA_NN clone_NN ,_, pZVB70_NN ,_, showed_VBD the_DT highest_JJS transactivating_NN ability_NN ,_, while_IN two_CD other_JJ DNA_NN fragments_NNS ,_, pZVB10_NN (_( 6.2_CD kb_NN )_) and_CC pZVH14_NN (_( 8.7_CD kb_NN )_) ,_, showed_VBD lower_JJR activity_NN ._.
 One_CD of_IN these_DT clones_NNS ,_, pZVH14_NN ,_, activated_VBD the_DT HIV_NN promoter_NN construct_NN containing_VBG a_DT mutation_NN in_IN the_DT NF_NN kappa_NN B_NN site_NN ._.
 However_RB ,_, this_DT mutated_VBN NF_NN kappa_NN B_NN promoter_NN was_VBD not_RB transactivated_VBN during_IN HHV-6_NN (_( GS_NN )_) infection_NN or_CC after_IN cotransfection_NN with_IN pZVB70_NN or_CC pZVB10_NN ._.
 These_DT data_NNS indicate_VBP that_IN the_DT NF_NN kappa_NN B_NN sites_NNS of_IN the_DT HIV_NN promoter_NN are_VBP essential_JJ for_IN its_PRP$ transactivation_NN during_IN HHV-6_NN (_( GS_NN )_) infection_NN ._.
 By_IN increasing_VBG HIV_NN promoter_NN activity_NN in_IN primary_JJ T_NN lymphocytes_NNS ,_, HHV-6_NN may_MD consequently_RB increase_VB HIV_NN replication_NN ,_, leading_VBG to_TO an_DT increase_NN in_IN the_DT cytopathic_JJ effect_NN on_IN coinfected_VBN human_JJ T_NN cells_NNS ._.
 The_DT rhombotin_NN family_NN of_IN cysteine-rich_JJ LIM-domain_JJ oncogenes_NNS :_: distinct_JJ members_NNS are_VBP involved_VBN in_IN T-cell_NN translocations_NNS to_TO human_JJ chromosomes_NNS 11p15_NN and_CC 11p13_NN ._.
 A_DT chromosomal_NN translocation_NN in_IN a_DT T-cell_NN leukemia_NN involving_VBG the_DT short_JJ arm_NN of_IN human_JJ chromosome_NN 11_CD at_IN band_NN 11p15_NN disrupts_VBZ the_DT rhombotin_NN gene_NN ._.
 This_DT gene_NN encodes_VBZ a_DT protein_NN with_IN duplicated_JJ cysteine-rich_JJ regions_NNS called_VBN LIM_NN domains_NNS ,_, which_WDT show_VBP homology_NN to_TO zinc-binding_JJ proteins_NNS and_CC to_TO iron-sulfur_JJ centers_NNS of_IN ferredoxins_NNS ._.
 Two_CD homologues_NNS of_IN the_DT rhombotin_NN gene_NN have_VBP now_RB been_VBN isolated_VBN ._.
 One_CD of_IN these_DT ,_, designated_VBN Rhom-2_NN ,_, is_VBZ located_JJ on_IN human_JJ chromosome_NN 11_CD at_IN band_NN 11p13_NN ,_, where_WRB a_DT cluster_NN of_IN T-cell_NN leukemia-specific_JJ translocations_NNS occur_VBP ;_: all_DT translocation_NN breakpoints_NNS at_IN 11p13_NN are_VBP upstream_JJ of_IN the_DT Rhom-2_NN gene_NN ._.
 Human_JJ and_CC mouse_NN Rhom-2_NN are_VBP highly_RB conserved_VBN and_CC ,_, like_IN rhombotin_NN ,_, encode_VBP two_CD tandem_JJ cysteine-rich_JJ LIM_NN domains_NNS ._.
 Rhom-2_NN mRNA_NN is_VBZ expressed_VBN in_IN early_JJ mouse_NN development_NN in_IN central_JJ nervous_JJ system_NN ,_, lung_NN ,_, kidney_NN ,_, liver_NN ,_, and_CC spleen_NN but_CC only_RB very_RB low_JJ levels_NNS occur_VBP in_IN thymus_NN ._.
 The_DT other_JJ gene_NN ,_, designated_VBN Rhom-3_NN ,_, is_VBZ not_RB on_IN chromosome_NN 11_CD but_CC also_RB retains_VBZ homology_NN to_TO the_DT LIM_NN domain_NN of_IN rhombotin_NN ._.
 Since_IN the_DT Rhom-2_NN gene_NN is_VBZ such_JJ a_DT common_JJ site_NN of_IN chromosomal_JJ damage_NN in_IN T-cell_NN tumors_NNS ,_, the_DT consistency_NN of_IN translocations_NNS near_IN the_DT rhombotin_NN gene_NN was_VBD further_RB examined_VBN ._.
 A_DT second_JJ translocation_NN adjacent_JJ to_TO rhombotin_NN was_VBD found_VBN and_CC at_IN the_DT same_JJ position_NN as_IN in_IN the_DT previous_JJ example_NN ._.
 Therefore_RB ,_, chromosome_NN bands_NNS 11p15_NN (_( rhombotin_NN )_) and_CC 11p13_NN (_( Rhom-2_NN )_) are_VBP consistent_JJ sites_NNS of_IN chromosome_NN translocation_NN in_IN T-cell_NN leukemia_NN ,_, with_IN the_DT 11p15_NN target_NN more_RBR rarely_RB involved_VBN ._.
 The_DT results_NNS define_VBP the_DT rhombotin_NN gene_NN family_NN as_IN a_DT class_NN of_IN T-cell_NN oncogenes_NNS with_IN duplicated_JJ cysteine-rich_JJ LIM_NN domains_NNS ._.
 The_DT human_JJ myelomonocytic_JJ cell_NN line_NN U-937_NN as_IN a_DT model_NN for_IN studying_VBG alterations_NNS in_IN steroid-induced_JJ monokine_NN gene_NN expression_NN :_: marked_JJ enhancement_NN of_IN lipopolysaccharide-stimulated_JJ interleukin-1_NN beta_NN messenger_NN RNA_NN levels_NNS by_IN 1,25-dihydroxyvitamin_NN D3_NN ._.
 The_DT active_JJ metabolite_NN of_IN vitamin_NN D_NN ,_, 1,25-dihydroxyvitamin_NN D3_NN (_( 1,25-(OH)2D3_NN )_) ,_, is_VBZ a_DT potent_JJ regulator_NN of_IN human_JJ monocyte/macrophage_JJ function_NN in_FW vitro_FW ._.
 To_TO establish_VB a_DT model_NN for_IN 1,25-(OH)2D3_NN regulation_NN of_IN human_JJ monocyte_NN monokine_NN synthesis_NN ,_, three_CD human_JJ cell_NN lines_NNS (_( U-937_NN ,_, THP-1_NN ,_, and_CC HL-60_NN )_) were_VBD examined_VBN for_IN :_: 1_LS )_) the_DT presence_NN of_IN functional_JJ 1,25-(OH)2D3_NN receptors_NNS ;_: 2_LS )_) the_DT accumulation_NN of_IN interleukin-1_NN beta_NN (_( IL-1_NN beta_NN )_) mRNA_NN and_CC IL-1_NN beta_NN protein_NN in_IN response_NN to_TO lipopolysaccharide_NN (_( LPS_NN )_) ;_: and_CC 3_LS )_) the_DT regulation_NN of_IN this_DT response_NN by_IN 1,25-(OH)2D3_NN ._.
 All_DT three_CD cell_NN lines_NNS expressed_VBD vitamin_NN D_NN receptor_NN and_CC had_VBD increased_VBN levels_NNS of_IN IL-1_NN beta_NN mRNA_NN in_IN response_NN to_TO LPS_NN ._.
 Preincubation_NN of_IN cells_NNS with_IN 1,25-(OH)2D3_NN augmented_VBD IL-1_NN beta_NN mRNA_NN levels_NNS only_RB in_IN U-937_NN and_CC HL-60_NN cells_NNS ._.
 From_IN these_DT data_NNS ,_, and_CC taking_VBG into_IN consideration_NN their_PRP$ state_NN of_IN differentiation_NN and_CC relative_JJ ease_NN of_IN culture_NN ,_, U-937_NN was_VBD chosen_VBN over_IN HL-60_NN and_CC THP-1_NN as_IN the_DT cell_NN line_NN we_PRP further_RB characterized_VBD ._.
 In_IN U-937_NN cells_NNS ,_, optimum_JJ time_NN and_CC dose_NN of_IN pretreatment_NN with_IN 1,25-(OH)2D3_NN were_VBD determined_VBN to_TO be_VB 12-24_CD h_NN at_IN a_DT receptor_NN saturating_JJ concentration_NN of_IN 1,25-(OH)2D3_NN (_( 10_CD nM_NN )_) ._.
 Preincubation_NN of_IN cells_NNS with_IN 1,25-(OH)2D3_NN had_VBD no_DT effect_NN on_IN the_DT time_NN course_NN of_IN IL-1_NN beta_NN mRNA_NN appearance_NN in_IN response_NN to_TO LPS_NN ._.
 However_RB ,_, exposure_NN of_IN U-937_NN cells_NNS to_TO 1,25-(OH)2D3_NN increased_VBD by_IN 200_CD %_NN the_DT level_NN of_IN IL-1_NN beta_NN mRNA_NN detected_VBD and_CC decreased_VBD by_IN three_CD orders_NNS of_IN magnitude_NN the_DT concentration_NN of_IN LPS_NN required_VBN to_TO achieve_VB steady_JJ state_NN mRNA_NN levels_NNS equivalent_JJ to_TO those_DT observed_VBN in_IN U-937_NN cells_NNS not_RB preincubated_VBN with_IN the_DT hormone.2+o_NN
 Cortivazol_NN mediated_VBD induction_NN of_IN glucocorticoid_NN receptor_NN messenger_NN ribonucleic_JJ acid_NN in_IN wild-type_JJ and_CC dexamethasone-resistant_JJ human_JJ leukemic_NN (_( CEM_NN )_) cells_NNS ._.
 Cortivazol_NN is_VBZ a_DT phenylpyrazolo_JJ glucocorticoid_NN of_IN high_JJ potency_NN and_CC unusual_JJ structure_NN ._.
 In_IN both_CC wild-type_JJ and_CC highly_RB dexamethasone_NN (_( dex_NN )_) -resistant_JJ clones_NNS of_IN the_DT human_JJ leukemic_JJ cell_NN line_NN CEM_NN ,_, exposure_NN to_TO cortivazol_NN leads_VBZ to_TO cell_NN death_NN ._.
 It_PRP has_VBZ been_VBN shown_VBN recently_RB that_IN in_IN wild-type_JJ CEM_NN cells_NNS but_CC not_RB in_IN a_DT dex-resistant_JJ ,_, glucocorticoid_NN receptor_NN (_( GR_NN )_) -defective_JJ clone_NN ICR-27_NN TK-3_NN ,_, dex_NN induces_VBZ GR_NN mRNA_NN ._.
 To_TO test_VB the_DT hypothesis_NN that_IN cortivazol_NN acts_VBZ in_IN dex-resistant_JJ cells_NNS by_IN making_VBG use_NN of_IN the_DT residual_JJ GR_NN found_VBN there_RB ,_, wild-type_JJ and_CC dex-resistant_JJ clones_NNS were_VBD treated_VBN with_IN various_JJ concentrations_NNS of_IN cortivazol_NN and_CC induction_NN of_IN GR_NN mRNA_NN was_VBD studied_VBN ._.
 Cortivazol_NN significantly_RB induced_VBD GR_NN mRNA_NN in_IN the_DT normal_JJ CEM-C7_NN as_RB well_RB as_IN in_IN two_CD classes_NNS of_IN dex-resistant_JJ clones_NNS ,_, although_IN the_DT dex-resistant_JJ clones_NNS needed_VBD at_IN least_JJS 10_CD times_NNS more_JJR cortivazol_NN than_IN the_DT normal_JJ cells_NNS for_IN significant_JJ GR_NN mRNA_NN induction_NN ._.
 Increased_VBN levels_NNS of_IN GR_NN mRNA_NN were_VBD noticed_VBN as_RB early_RB as_IN 3_CD h_NN after_IN treatment_NN ._.
 A_DT general_JJ correlation_NN between_IN induction_NN of_IN GR_NN mRNA_NN and_CC lysis_NN of_IN the_DT normal_JJ and_CC dex-resistant_JJ cells_NNS was_VBD found_VBN ._.
 Positive_JJ induction_NN of_IN GR_NN mRNA_NN might_MD be_VB one_CD of_IN the_DT earliest_JJS crucial_JJ steps_NNS in_IN the_DT lysis_NN of_IN normal_JJ and_CC dex-resistant_JJ CEM_NN cells_NNS ,_, or_CC might_MD serve_VB as_IN a_DT marker_NN for_IN the_DT process_NN ._.
 However_RB ,_, the_DT lysis_NN pathway_NN in_IN the_DT dex-resistant_JJ cells_NNS is_VBZ defective_JJ in_IN that_IN dex-resistant_JJ clones_NNS needed_VBD significantly_RB more_JJR cortivazol_NN than_IN the_DT normal_JJ cells_NNS for_IN lysis_NN of_IN the_DT cells_NNS ._.
 Expression_NN of_IN 1,25(OH)2D3_NN receptors_NNS on_IN alveolar_JJ lymphocytes_NNS from_IN patients_NNS with_IN pulmonary_JJ granulomatous_JJ diseases_NNS ._.
 1,25(OH)2D3_NN is_VBZ known_VBN to_TO be_VB produced_VBN at_IN sites_NNS of_IN granulomatous_JJ reactions_NNS ._.
 In_IN order_NN to_TO characterize_VB the_DT cell_NN types_NNS that_WDT are_VBP targets_NNS for_IN this_DT immunoregulatory_JJ hormone_NN ,_, we_PRP have_VBP evaluated_VBN the_DT expression_NN of_IN 1,25(OH)2D3_NN receptors_NNS on_IN peripheral_JJ blood_NN T-lymphocytes_NNS and_CC those_DT recovered_VBN from_IN the_DT lung_NN by_IN bronchoalveolar_JJ lavage_NN from_IN patients_NNS with_IN pulmonary_JJ granulomatous_JJ diseases_NNS (_( tuberculosis_NN and_CC sarcoidosis_NN )_) and_CC from_IN normal_JJ control_NN subjects_NNS using_VBG combined_JJ autoradiographic_JJ and_CC immunohistochemical_JJ techniques_NNS ._.
 Lavage_NN T-lymphocytes_NNS from_IN patients_NNS with_IN tuberculosis_NN or_CC with_IN sarcoidosis_NN ,_, but_CC not_RB those_DT from_IN normal_JJ control_NN subjects_NNS ,_, expressed_VBD 1,25(OH)2D3_NN receptors_NNS as_IN demonstrated_VBN by_IN binding_NN of_IN (3H)1,25(OH)2D3_NN ,_, which_WDT was_VBD inhibited_VBN by_IN the_DT presence_NN of_IN excess_JJ unlabeled_JJ 1,25(OH)2D3_NN ,_, but_CC not_RB by_IN the_DT presence_NN of_IN unlabeled_JJ 25(OH)D3_NN (_( receptor-positive_JJ lymphocytes_NNS :_: sarcoidosis_NN ,_, 20_CD +/-_CC 12_CD %_NN ;_: tuberculosis_NN ,_, 31_CD +/-_CC 17_CD %_NN )_) ._.
 In_IN contrast_NN ,_, blood_NN lymphocytes_NNS from_IN patients_NNS with_IN granulomatous_JJ diseases_NNS did_VBD not_RB express_VB detectable_JJ 1,25(OH)2D3_NN receptors_NNS ._.
 The_DT percentage_NN of_IN lavage_NN T-lymphocytes_NNS expressing_VBG 1,25(OH)2D3_NN receptors_NNS was_VBD significantly_RB greater_JJR for_IN patients_NNS with_IN tuberculosis_NN presenting_VBG with_IN isolated_VBN hilar_JJ adenopathy_JJ than_IN for_IN patients_NNS with_IN pulmonary_JJ infiltrates_NNS and/or_CC cavities_NNS ._.
 1,25(OH)2D3_NN receptors_NNS were_VBD expressed_VBN to_TO a_DT greater_JJR extent_NN on_IN CD8+_JJ T-lymphocytes_NNS than_IN on_IN CD4+_JJ T-lymphocytes_NNS in_IN sarcoidosis_NN ,_, whereas_IN a_DT greater_JJR proportion_NN of_IN CD4+_JJ than_IN of_IN CD8+_JJ T-lymphocytes_NNS from_IN patients_NNS with_IN tuberculosis_NN were_VBD receptor-positive_JJ ._.
 These_DT findings_NNS support_VBP the_DT conclusion_NN that_IN the_DT interaction_NN of_IN 1,25(OH)2D3_NN with_IN its_PRP$ receptor_NN on_IN T-lymphocytes_NNS may_MD play_VB an_DT important_JJ role_NN in_IN the_DT regulation_NN of_IN granulomatous_JJ reactions_NNS ,_, but_CC because_IN these_DT receptors_NNS are_VBP expressed_VBN on_IN different_JJ lymphocyte_NN populations_NNS ,_, the_DT net_JJ effect_NN of_IN this_DT potent_JJ immunoregulatory_JJ molecule_NN is_VBZ likely_RB different_JJ in_IN sarcoidosis_NN and_CC tuberculosis_NN ._.
 Inhibition_NN of_IN transcription_NN factors_NNS belonging_VBG to_TO the_DT rel/NF-kappa_NN B_NN family_NN by_IN a_DT transdominant_JJ negative_JJ mutant_NN ._.
 The_DT KBF1_NN factor_NN ,_, which_WDT binds_VBZ to_TO the_DT enhancer_NN A_NN located_JJ in_IN the_DT promoter_NN of_IN the_DT mouse_NN MHC_NN class_NN I_CD gene_NN H-2Kb_NN ,_, is_VBZ indistinguishable_JJ from_IN the_DT p50_NN DNA_NN binding_NN subunit_NN of_IN the_DT transcription_NN factor_NN NF-kappa_NN B_NN ,_, which_WDT regulates_VBZ a_DT series_NN of_IN genes_NNS involved_VBN in_IN immune_JJ and_CC inflammatory_JJ responses_NNS ._.
 The_DT KBF1/p50_NN factor_NN binds_VBZ as_IN a_DT homodimer_NN but_CC can_MD also_RB form_VB heterodimers_NNS with_IN the_DT products_NNS of_IN other_JJ members_NNS of_IN the_DT same_JJ family_NN ,_, like_IN the_DT c-rel_NN and_CC v-rel_NN (_( proto_NN )_) oncogenes_NNS ._.
 The_DT dimerization_NN domain_NN of_IN KBF1/p50_NN is_VBZ contained_VBN between_IN amino_NN acids_NNS 201_CD and_CC 367_CD ._.
 A_DT mutant_NN of_IN KBF1/p50_NN (_( delta_NN SP_NN )_) ,_, unable_JJ to_TO bind_VB to_TO DNA_NN but_CC able_JJ to_TO form_VB homo-_JJ or_CC heterodimers_NNS ,_, has_VBZ been_VBN constructed_VBN ._.
 This_DT protein_NN reduces_VBZ or_CC abolishes_VBZ in_FW vitro_FW the_DT DNA_NN binding_NN activity_NN of_IN wild-type_JJ proteins_NNS of_IN the_DT same_JJ family_NN (_( KBF1/p50_NN ,_, c-_NN and_CC v-rel_NN )_) ._.
 This_DT mutant_JJ also_RB functions_NNS in_FW vivo_FW as_IN a_DT trans-acting_JJ dominant_JJ negative_JJ regulator_NN :_: the_DT transcriptional_JJ inducibility_NN of_IN the_DT HIV_NN long_JJ terminal_JJ repeat_NN (_( which_WDT contains_VBZ two_CD potential_JJ NF-kappa_NN B_NN binding_NN sites_NNS )_) by_IN phorbol_NN ester_NN (_( PMA_NN )_) is_VBZ inhibited_VBN when_WRB it_PRP is_VBZ co-transfected_VBN into_IN CD4+_JJ T_NN cells_NNS with_IN the_DT delta_NN SP_NN mutant_NN ._.
 Similarly_RB the_DT basal_JJ as_RB well_RB as_IN TNF_NN or_CC IL1-induced_JJ activity_NN of_IN the_DT MHC_NN class_NN I_CD H-2Kb_NN promoter_NN can_MD be_VB inhibited_VBN by_IN this_DT mutant_NN in_IN two_CD different_JJ cell_NN lines_NNS ._.
 These_DT results_NNS constitute_VBP the_DT first_JJ formal_JJ demonstration_NN that_IN these_DT genes_NNS are_VBP regulated_VBN by_IN members_NNS of_IN the_DT rel/NF-kappa_NN B_NN family_NN ._.
 Human_JJ erythroid_JJ 5-aminolevulinate_NN synthase_NN :_: promoter_NN analysis_NN and_CC identification_NN of_IN an_DT iron-responsive_JJ element_NN in_IN the_DT mRNA_NN ._.
 5-Aminolevulinate_NN synthase_NN (_( ALAS_NN )_) catalyzes_VBZ the_DT first_JJ step_NN of_IN the_DT heme_NN biosynthetic_JJ pathway_NN ._.
 cDNA_NN clones_NNS for_IN the_DT human_JJ erythroid_JJ ALAS_NN isozyme_NN were_VBD isolated_VBN from_IN a_DT fetal_JJ liver_NN library_NN ._.
 It_PRP can_MD be_VB deduced_VBN that_IN the_DT erythroid_JJ ALAS_NN precursor_NN protein_NN has_VBZ a_DT molecular_JJ weight_NN of_IN 64.6_CD kd_NN ,_, and_CC is_VBZ similar_JJ in_IN size_NN to_TO the_DT previously_RB isolated_VBN human_JJ housekeeping_JJ ALAS_NN precursor_NN of_IN molecular_JJ weight_NN 70.6_CD kd_NN ._.
 The_DT mature_JJ mitochondrial_JJ forms_NNS of_IN the_DT erythroid_JJ and_CC housekeeping_JJ ALAS_NN isozymes_NNS are_VBP predicted_VBN to_TO have_VB molecular_JJ weights_NNS of_IN 59.5_CD kd_NN and_CC 64.6_CD kd_NN ,_, respectively_RB ._.
 The_DT two_CD isozymes_NNS show_VBP little_JJ amino_NN acid_NN identity_NN in_IN their_PRP$ N-terminal_JJ signal_NN sequences_NNS but_CC have_VBP considerable_JJ sequence_NN identity_NN in_IN the_DT C-terminal_JJ two-thirds_CD of_IN their_PRP$ proteins_NNS ._.
 An_DT analysis_NN of_IN the_DT immediate_JJ promoter_NN of_IN the_DT human_JJ erythroid_JJ ALAS_NN gene_NN revealed_VBD several_JJ putative_JJ erythroid-specific_JJ cis-acting_JJ elements_NNS including_VBG both_PDT a_DT GATA-1_NN and_CC an_DT NF-E2_NN binding_NN site_NN ._.
 An_DT iron-responsive_JJ element_NN (_( IRE_NN )_) motif_NN has_VBZ been_VBN identified_VBN in_IN the_DT 5'-untranslated_JJ region_NN of_IN the_DT human_JJ erythroid_JJ ALAS_NN mRNA_NN ,_, but_CC is_VBZ not_RB present_JJ in_IN the_DT housekeeping_JJ ALAS_NN mRNA_NN ._.
 Gel_NN retardation_NN experiments_NNS established_VBD that_IN this_DT IRE_NN motif_NN formed_VBD a_DT protein-RNA_JJ complex_NN with_IN cytosolic_JJ extracts_NNS from_IN human_JJ K562_NN cells_NNS and_CC this_DT binding_NN was_VBD strongly_RB competed_VBN with_IN IRE_NN transcripts_NNS from_IN ferritin_NN or_CC transferrin_NN receptor_NN mRNAs_NNS ._.
 A_DT transcript_NN of_IN the_DT ALAS_NN IRE_NN ,_, mutated_VBN in_IN the_DT conserved_VBN loop_NN of_IN the_DT IRE_NN ,_, did_VBD not_RB readily_RB form_VB this_DT protein-RNA_JJ complex_NN ._.
 These_DT results_NNS suggest_VBP that_IN the_DT IRE_NN motif_NN in_IN the_DT ALAS_NN mRNA_NN is_VBZ functional_JJ and_CC imply_VBP that_IN translation_NN of_IN the_DT mRNA_NN is_VBZ controlled_VBN by_IN cellular_JJ iron_NN availability_NN during_IN erythropoiesis_NN ._.
 Human_JJ tumor_NN necrosis_NN factor_NN alpha_NN gene_NN regulation_NN in_IN phorbol_NN ester_NN stimulated_VBD T_NN and_CC B_NN cell_NN lines_NNS ._.
 The_DT minimal_JJ region_NN of_IN the_DT human_JJ tumor_NN necrosis_NN factor_NN alpha_NN (_( TNF-alpha_NN )_) gene_NN promoter_NN necessary_JJ for_IN its_PRP$ transcriptional_JJ induction_NN by_IN phorbol_NN esters_NNS (_( PMA_NN )_) in_IN human_JJ T_NN and_CC B_NN lymphocyte_NN cell_NN lines_NNS has_VBZ been_VBN localized_JJ between_IN -52_CD and_CC +89_CD nucleotides_NNS (_( nt_NN )_) relative_JJ to_TO the_DT gene_NN 's_POS transcriptional_JJ start_NN site_NN ._.
 Comparison_NN of_IN these_DT sequences_NNS to_TO those_DT required_VBN to_TO mediate_VB virus_NN or_CC lipopolysaccharide_NN (_( LPS_NN )_) induction_NN of_IN the_DT gene_NN reveal_VB significant_JJ differences_NNS ,_, and_CC thus_RB ,_, the_DT sequence_NN requirements_NNS for_IN PMA_NN induction_NN are_VBP distinct_JJ from_IN those_DT that_WDT mediate_VBP induction_NN by_IN virus_NN or_CC LPS_NN ._.
 Although_IN three_CD sites_NNS in_IN the_DT TNF-alpha_NN promoter_NN (_( kappa_NN 1_CD ,_, kappa_NN 2_CD ,_, and_CC kappa_NN 3_CD )_) specifically_RB bind_VBP the_DT transcription_NN factor_NN NF-kappa_NN B_NN in_IN lymphoid_JJ nuclear_JJ extracts_NNS ,_, TNF-alpha_NN mRNA_NN induction_NN by_IN PMA_NN does_VBZ not_RB correlate_VB with_IN NF-kappa_NN B_NN binding_NN activities_NNS displayed_VBN by_IN different_JJ T_NN and_CC B_NN cell_NN lines_NNS ._.
 Moreover_RB ,_, kappa_NN 1_CD -_: kappa_NN 3_CD can_MD each_DT be_VB deleted_VBN from_IN the_DT TNF-alpha_NN promoter_NN with_IN little_JJ effect_NN on_IN the_DT gene_NN 's_POS inducibility_NN by_IN PMA_NN ._.
 Therefore_RB ,_, TNF-alpha_NN mRNA_NN induction_NN by_IN PMA_NN ,_, like_IN its_PRP$ induction_NN by_IN virus_NN and_CC LPS_NN ,_, is_VBZ not_RB primarily_RB mediated_VBN by_IN NF-kappa_NN B_NN ,_, but_CC rather_RB is_VBZ mediated_VBN through_IN other_JJ sequences_NNS and_CC protein_NN factors_NNS ._.
 Surprisingly_RB ,_, multimers_NNS of_IN kappa_NN 1_CD -_: kappa_NN 3_CD can_MD confer_VB PMA_NN inducibility_NN on_IN a_DT heterologous_JJ promoter_NN in_IN a_DT B_NN (_( Raji_NN )_) ,_, but_CC not_RB a_DT T_NN (_( HUT78_NN )_) cell_NN line_NN ._.
 However_WRB they_PRP are_VBP not_RB functional_JJ on_IN a_DT truncated_VBN TNF-alpha_NN promoter_NN ,_, indicating_VBG that_IN promoter_NN context_NN and_CC cell_NN type_NN specificity_NN influence_VBP the_DT PMA_NN inducible_JJ function_NN of_IN these_DT NF-kappa_NN B_NN binding_NN sites_NNS ._.
 Towards_IN a_DT molecular_JJ understanding_NN of_IN T-cell_NN differentiation_NN ._.
 Lymphoid_JJ differentiation_NN is_VBZ one_CD of_IN the_DT best_RBS studied_VBN examples_NNS of_IN mammalian_JJ development_NN ._.
 Here_RB Hans_NNP Clevers_NNP and_CC Michael_NNP Owen_NNP describe_VBP how_WRB the_DT cloning_NN of_IN the_DT genes_NNS that_WDT encode_VBP T-cell-specific_JJ membrane_NN proteins_NNS allows_VBZ the_DT identification_NN of_IN transcription_NN factors_NNS that_WDT control_VBP the_DT expression_NN of_IN these_DT T-cell_NN genes_NNS ._.
 Such_JJ transcription_NN factors_NNS play_VBP a_DT key_JJ role_NN in_IN the_DT development_NN of_IN the_DT mature_JJ T-cell_NN phenotype_NN by_IN functioning_VBG as_IN '_[[DQS]] master_JJ regulators_NNS of_IN T-cell_NN differentiation_NN '_[[DQE]] ._.
 Regulation_NN of_IN jun_NN and_CC fos_NN gene_NN expression_NN in_IN human_JJ monocytes_NNS by_IN the_DT macrophage_NN colony-stimulating_JJ factor_NN ._.
 The_DT macrophage_NN colony-stimulating_JJ factor_NN (_( M-CSF_NN )_) is_VBZ required_VBN for_IN the_DT growth_NN and_CC differentiation_NN of_IN mononuclear_JJ phagocytes_NNS ._.
 However_RB ,_, the_DT signaling_NN events_NNS responsible_JJ for_IN these_DT effects_NNS remain_VBP unclear_JJ ._.
 The_DT present_JJ studies_NNS have_VBP examined_VBN the_DT effects_NNS of_IN M-CSF_NN on_IN potential_JJ signaling_NN pathways_NNS involving_VBG expression_NN of_IN the_DT jun_NN and_CC fos_NN early_JJ response_NN genes_NNS ._.
 Low_JJ levels_NNS of_IN c-jun_NN transcripts_NNS were_VBD detectable_JJ in_IN resting_VBG human_JJ peripheral_JJ blood_NN monocytes_NNS ._.
 Treatment_NN of_IN these_DT cells_NNS with_IN 10(3)_CD units/ml_NNS human_JJ recombinant_JJ M-CSF_NN was_VBD associated_VBN with_IN rapid_JJ and_CC transient_JJ increases_NNS in_IN c-jun_NN mRNA_NN levels_NNS ._.
 Nuclear_JJ run-on_JJ assays_NNS and_CC mRNA_NN stability_NN studies_NNS demonstrated_VBD that_IN M-CSF_NN regulates_VBZ c-jun_NN expression_NN by_IN both_CC an_DT increase_NN in_IN transcription_NN rate_NN and_CC a_DT prolongation_NN in_IN the_DT half-life_NN of_IN c-jun_NN transcripts_NNS ._.
 M-CSF_NN treatment_NN was_VBD also_RB associated_VBN with_IN a_DT rapid_JJ induction_NN of_IN the_DT jun-B_NN gene_NN ,_, although_IN expression_NN of_IN this_DT gene_NN was_VBD prolonged_JJ compared_VBN to_TO that_DT of_IN c-jun_NN ._.
 We_PRP further_RB demonstrate_VBP that_IN M-CSF_NN increases_VBZ c-fos_NN mRNA_NN levels_NNS in_IN human_JJ monocytes_NNS through_IN control_NN at_IN both_CC the_DT transcriptional_JJ and_CC posttranscriptional_JJ levels_NNS ._.
 Maximal_JJ induction_NN of_IN the_DT c-fos_NN gene_NN was_VBD followed_VBN by_IN that_DT for_IN the_DT fos-B_NN gene_NN ._.
 Moreover_RB ,_, M-CSF-induced_JJ expression_NN of_IN the_DT fos-related_JJ gene_NN ,_, fra-1_NN ,_, was_VBD delayed_VBN compared_VBN to_TO that_DT for_IN both_DT c-fos_NN and_CC fos-B_NN ._.
 Taken_VBN together_RB ,_, the_DT results_NNS indicate_VBP that_IN M-CSF_NN treatment_NN is_VBZ associated_VBN with_IN differential_JJ activation_NN of_IN multiple_JJ members_NNS of_IN the_DT jun/fos_NN family_NN and_CC that_IN expression_NN of_IN these_DT genes_NNS could_MD contribute_VB to_TO nuclear_JJ signaling_NN mechanisms_NNS that_WDT regulate_VBP a_DT specific_JJ program_NN of_IN monocyte_NN differentiation_NN ._.
 Cloning_NN of_IN a_DT human_JJ homeobox_NN gene_NN that_WDT resembles_VBZ a_DT diverged_JJ Drosophila_NN homeobox_NN gene_NN and_CC is_VBZ expressed_VBN in_IN activated_VBN lymphocytes_NNS ._.
 A_DT new_JJ homeobox_NN gene_NN ,_, HB24_NN ,_, has_VBZ been_VBN isolated_VBN from_IN a_DT human_JJ B-lymphocyte_NN cDNA_NN library_NN ._.
 Northern_JJ|NN blot_NN analysis_NN of_IN polyadenylated_JJ RNA_NN purified_VBN from_IN activated_VBN human_JJ B_NN cells_NNS revealed_VBD a_DT single_JJ mRNA_NN transcript_NN of_IN approximately_RB 2.3_CD kb_NN ._.
 Two_CD cDNA_NN clones_NNS were_VBD sequenced_VBN and_CC provided_VBN 2,250_CD nucleotides_NNS (_( nt_NN )_) of_IN DNA_NN sequence_NN information_NN ._.
 There_EX is_VBZ a_DT single_JJ methionine_NN codon-initiated_JJ open_JJ reading_NN frame_NN of_IN 1,458_CD nt_NN in_IN frame_NN with_IN a_DT homeobox_NN and_CC a_DT CAX_NN repeat_NN ,_, and_CC the_DT open_JJ reading_NN frame_NN is_VBZ predicted_VBN to_TO encode_VB a_DT protein_NN of_IN 51,659_CD daltons_NNS ._.
 When_WRB the_DT homeodomain_NN from_IN HB24_NN was_VBD compared_VBN to_TO known_JJ mammalian_JJ and_CC Drosophila_NN homeodomains_NNS it_PRP was_VBD found_VBN to_TO be_VB only_RB moderately_RB conserved_VBN ,_, but_CC when_WRB it_PRP was_VBD compared_VBN to_TO a_DT highly_RB diverged_JJ Drosophila_FW homeodomain_NN ,_, H2.0_NN ,_, it_PRP was_VBD found_VBN to_TO be_VB 80_CD %_NN identical_JJ ._.
 The_DT HB24_NN mRNA_NN was_VBD absent_JJ or_CC present_JJ at_IN low_JJ levels_NNS in_IN normal_JJ B_NN and_CC T_NN lymphocytes_NNS ;_: however_RB ,_, with_IN the_DT appropriate_JJ activation_NN signal_NN HB24_NN mRNA_NN was_VBD induced_VBN within_IN several_JJ hours_NNS even_RB in_IN the_DT presence_NN of_IN cycloheximide_NN ._.
 Characterization_NN of_IN HB24_NN expression_NN in_IN lymphoid_JJ and_CC select_JJ developing_VBG tissues_NNS was_VBD performed_VBN by_IN in_FW situ_FW hybridization_NN ._.
 Positive_JJ hybridization_NN was_VBD found_VBN in_IN thymus_NN ,_, tonsil_NN ,_, bone_NN marrow_NN ,_, developing_VBG vessels_NNS ,_, and_CC in_IN fetal_JJ brain_NN ._.
 HB24_NN is_VBZ likely_JJ to_TO have_VB an_DT important_JJ role_NN in_IN lymphocytes_NNS as_RB well_RB as_IN in_IN certain_JJ developing_VBG tissues_NNS ._.
 Severe_JJ 5-fluorouracil_NN toxicity_NN secondary_JJ to_TO dihydropyrimidine_NN dehydrogenase_NN deficiency_NN ._.
 A_DT potentially_RB more_RBR common_JJ pharmacogenetic_JJ syndrome_NN ._.
 This_DT study_NN describes_VBZ the_DT inheritance_NN of_IN a_DT defect_NN in_IN pyrimidine_NN catabolism_NN and_CC its_PRP$ association_NN with_IN drug-induced_JJ toxicity_NN in_IN a_DT patient_NN receiving_VBG 5-fluorouracil_NN (_( FUra_NN )_) as_IN adjuvant_JJ chemotherapy_NN for_IN breast_NN carcinoma_NN ._.
 The_DT study_NN population_NN included_VBD the_DT affected_VBN patient_NN (_( proband_NN )_) ,_, nine_CD of_IN her_PRP$ blood_NN relatives_NNS ,_, and_CC seven_CD healthy_JJ volunteers_NNS ._.
 The_DT activity_NN of_IN dihydropyrimidine_NN dehydrogenase_NN (_( DPD_NN )_) ,_, the_DT initial_JJ enzyme_NN of_IN pyrimidine_NN (_( and_CC FUra_NN )_) catabolism_NN ,_, in_IN peripheral_JJ blood_NN mononuclear_JJ cells_NNS was_VBD measured_VBN in_IN each_DT subject_NN by_IN a_DT specific_JJ radiometric_JJ assay_NN using_VBG FUra_NN as_IN the_DT substrate_NN ._.
 The_DT proband_NN had_VBD no_DT detectable_JJ DPD_NN activity_NN ._.
 When_WRB enzyme_NN levels_NNS in_IN the_DT proband_NN and_CC relatives_NNS were_VBD compared_VBN with_IN that_DT in_NN controls_NNS ,_, an_DT autosomal_JJ recessive_JJ pattern_NN of_IN inheritance_NN was_VBD demonstrated_VBN ._.
 This_DT is_VBZ the_DT third_JJ patient_NN with_IN severe_JJ FUra_NN toxicity_NN secondary_JJ to_TO an_DT alteration_NN in_IN pyrimidine_NN catabolism_NN and_CC the_DT second_NN from_IN our_PRP$ clinic_NN population_NN suggesting_VBG that_IN the_DT frequency_NN of_IN this_DT genetic_JJ defect_NN may_MD be_VB greater_JJR than_IN previously_RB thought_VBN ._.
 Monitoring_VBG DPD_NN activity_NN may_MD be_VB important_JJ in_IN the_DT management_NN of_IN patients_NNS experiencing_VBG severe_JJ toxicity_NN secondary_JJ to_TO FUra_NN chemotherapy_NN ._.
 Characterization_NN of_IN an_DT immediate-early_JJ gene_NN induced_VBN in_IN adherent_JJ monocytes_NNS that_WDT encodes_VBZ I_NN kappa_NN B-like_JJ activity_NN ._.
 We_PRP have_VBP cloned_VBN a_DT group_NN of_IN cDNAs_NNS representing_VBG mRNAs_NNS that_WDT are_VBP rapidly_RB induced_VBN following_VBG adherence_NN of_IN human_JJ monocytes_NNS ._.
 One_CD of_IN the_DT induced_VBN transcripts_NNS (_( MAD-3_NN )_) encodes_VBZ a_DT protein_NN of_IN 317_CD amino_NN acids_NNS with_IN one_CD domain_NN containing_VBG five_CD tandem_JJ repeats_NNS of_IN the_DT cdc10/ankyrin_JJ motif_NN ,_, which_WDT is_VBZ 60_CD %_NN similar_JJ (_( 46_CD %_NN identical_JJ )_) to_TO the_DT ankyrin_NN repeat_NN region_NN of_IN the_DT precursor_NN of_IN NF-kappa_NN B/KBF1_NN p50_NN ._.
 The_DT C-terminus_NN has_VBZ a_DT putative_JJ protein_NN kinase_NN C_NN phosphorylation_NN site_NN ._.
 In_FW vitro_FW translated_VBN MAD-3_NN protein_NN was_VBD found_VBN to_TO specifically_RB inhibit_VB the_DT DNA-binding_JJ activity_NN of_IN the_DT p50/p65_NN NF-kappa_NN B_NN complex_NN but_CC not_RB that_DT of_IN the_DT p50/p50_NN KBF1_NN factor_NN or_CC of_IN other_JJ DNA-binding_JJ proteins_NNS ._.
 The_DT MAD-3_NN cDNA_NN encodes_VBZ an_DT I_NN kappa_NN B-like_JJ protein_NN that_WDT is_VBZ likely_JJ to_TO be_VB involved_VBN in_IN regulation_NN of_IN transcriptional_JJ responses_NNS to_TO NF-kappa_NN B_NN ,_, including_VBG adhesion-dependent_JJ pathways_NNS of_IN monocyte_NN activation_NN ._.
 Reactive_JJ oxygen_NN intermediates_NNS as_IN apparently_RB widely_RB used_VBN messengers_NNS in_IN the_DT activation_NN of_IN the_DT NF-kappa_NN B_NN transcription_NN factor_NN and_CC HIV-1_NN ._.
 Hydrogen_NN peroxide_NN and_CC oxygen_NN radicals_NNS are_VBP agents_NNS commonly_RB produced_VBN during_IN inflammatory_JJ processes_NNS ._.
 In_IN this_DT study_NN ,_, we_PRP show_VBP that_IN micromolar_JJ concentrations_NNS of_IN H2O2_NN can_MD induce_VB the_DT expression_NN and_CC replication_NN of_IN HIV-1_NN in_IN a_DT human_JJ T_NN cell_NN line_NN ._.
 The_DT effect_NN is_VBZ mediated_VBN by_IN the_DT NF-kappa_NN B_NN transcription_NN factor_NN which_WDT is_VBZ potently_RB and_CC rapidly_RB activated_VBN by_IN an_DT H2O2_NN treatment_NN of_IN cells_NNS from_IN its_PRP$ inactive_JJ cytoplasmic_JJ form_NN ._.
 N-acetyl-L-cysteine_NN (_( NP_NN )_) ,_, a_DT well_RB characterized_VBN antioxidant_NN which_WDT counteracts_VBZ the_DT effects_NNS of_IN reactive_JJ oxygen_NN intermediates_NNS (_( ROI_NN )_) in_IN living_VBG cells_NNS ,_, prevented_VBD the_DT activation_NN of_IN NF-kappa_NN B_NN by_IN H2O2_NN ._.
 NP_NN and_CC other_JJ thiol_JJ compounds_NNS also_RB blocked_VBD the_DT activation_NN of_IN NF-kappa_NN B_NN by_IN cycloheximide_NN ,_, double-stranded_JJ RNA_NN ,_, calcium_NN ionophore_NN ,_, TNF-alpha_NN ,_, active_JJ phorbol_NN ester_NN ,_, interleukin-1_NN ,_, lipopolysaccharide_NN and_CC lectin_NN ._.
 This_DT suggests_VBZ that_IN diverse_JJ agents_NNS thought_VBN to_TO activate_VB NF-kappa_NN B_NN by_IN distinct_JJ intracellular_JJ pathways_NNS might_MD all_DT act_VB through_IN a_DT common_JJ mechanism_NN involving_VBG the_DT synthesis_NN of_IN ROI_NN ._.
 ROI_NN appear_VBP to_TO serve_VB as_IN messengers_NNS mediating_VBG directly_RB or_CC indirectly_RB the_DT release_NN of_IN the_DT inhibitory_JJ subunit_NN I_NN kappa_NN B_NN from_IN NF-kappa_NN B_NN ._.
 HTLV-1_NN Tax_NN induces_VBZ expression_NN of_IN various_JJ immediate_JJ early_JJ serum_NN responsive_JJ genes_NNS ._.
 Human_JJ T-cell_NN leukemia_NN virus_NN type_NN 1_CD (_( HTLV-1_NN )_) is_VBZ an_DT etiological_JJ agent_NN of_IN adult_JJ T-cell_NN leukemia_NN (_( ATL_NN )_) ._.
 We_PRP showed_VBD here_RB by_IN mobility-shift_NN assay_NN that_IN T-cell_NN lines_NNS transformed_VBN with_IN the_DT virus_NN contained_VBD high_JJ levels_NNS of_IN AP-1_NN activities_NNS ._.
 Consistent_JJ with_IN this_DT result_NN ,_, these_DT cell_NN lines_NNS expressed_VBD increased_VBN levels_NNS of_IN mRNAs_NNS encoding_VBG the_DT AP-1_NN proteins_NNS ,_, c-Fos_NN ,_, Fra-1_NN ,_, c-Jun_NN ,_, JunB_NN ,_, and_CC JunD_NN ._.
 Previously_RB ,_, transcription_NN of_IN the_DT c-fos_NN gene_NN has_VBZ been_VBN reported_VBN to_TO be_VB transactivated_VBN by_IN the_DT viral_JJ transcription_NN factor_NN ,_, Tax1_NN ._.
 By_IN using_VBG the_DT human_JJ T-cell_NN line_NN (_( JPX-9_NN )_) ,_, in_IN which_WDT expression_NN of_IN the_DT Tax1_NN is_VBZ inducible_JJ ,_, we_PRP showed_VBD that_IN expression_NN of_IN mRNAs_NNS for_IN Fra-1_NN ,_, c-Jun_NN ,_, and_CC JunD_NN was_VBD also_RB transactivated_VBN by_IN Tax1_NN ._.
 Moreover_RB ,_, Tax1_NN activated_VBD expression_NN of_IN two_CD other_JJ transcription_NN factors_NNS having_VBG zinc_NN finger_NN motifs_NNS ,_, Egr-1_NN and_CC Egr-2_NN ,_, in_IN the_DT same_JJ cells_NNS ._.
 The_DT Tax1-inducible_JJ transcription_NN factors_NNS identified_VBN here_RB are_VBP encoded_VBN by_IN the_DT members_NNS of_IN immediate_JJ early_JJ genes_NNS under_IN the_DT control_NN of_IN growth_NN signals_NNS ._.
 Thus_RB ,_, Tax1_NN was_VBD suggested_VBN to_TO replace_VB growth_NN signals_NNS ,_, at_IN least_JJS in_IN part_NN ,_, by_IN this_DT mechanism_NN ._.
 Contribution_NN of_IN NF-kappa_NN B_NN and_CC Sp1_NN binding_NN motifs_NNS to_TO the_DT replicative_JJ capacity_NN of_IN human_JJ immunodeficiency_NN virus_NN type_NN 1_CD :_: distinct_JJ patterns_NNS of_IN viral_JJ growth_NN are_VBP determined_VBN by_IN T-cell_NN types_NNS ._.
 Starting_VBG with_IN a_DT replication-incompetent_JJ molecular_JJ clone_NN of_IN human_JJ immunodeficiency_NN virus_NN type_NN 1_CD ,_, lacking_VBG all_PDT the_DT NF-kappa_NN B_NN and_CC Sp1_NN binding_NN sites_NNS present_JJ in_IN the_DT native_JJ long_JJ terminal_JJ repeat_NN (_( LTR_NN )_) ,_, proviruses_NNS containing_VBG reconstructed_VBN LTRs_NNS with_IN individual_JJ or_CC combinations_NNS of_IN NF-kappa_NN B_NN and_CC Sp1_NN elements_NNS were_VBD generated_VBN and_CC evaluated_VBN for_IN their_PRP$ capacity_NN to_TO produce_VB virus_NN progeny_NN following_VBG transfection-cocultivation_NN ._.
 Virus_NN stocks_NNS obtained_VBN from_IN these_DT experiments_NNS exhibited_VBD a_DT continuum_NN of_IN replicative_JJ capacities_NNS in_IN different_JJ human_JJ T-cell_NN types_NNS depending_VBG on_IN which_WDT element_NN (_( s_NNS )_) was_VBD present_JJ in_IN the_DT LTR_NN ._.
 For_IN example_NN ,_, in_IN experiments_NNS involving_VBG proviral_JJ clones_NNS with_IN LTRs_NNS containing_VBG one_CD or_CC two_CD NF-kappa_NN B_NN elements_NNS (_( and_CC no_DT Sp1_NN binding_NN sites_NNS )_) ,_, a_DT hierarchy_NN of_IN cellular_JJ permissivity_NN to_TO virus_NN replication_NN (_( peripheral_JJ blood_NN lymphocytes_NNS =_JJ MT4_NN greater_JJR than_IN H9_NN greater_JJR than_IN CEM_NN greater_JJR than_IN Jurkat_NN )_) was_VBD observed_VBN ._.
 Of_IN note_NN was_VBD the_DT associated_VBN emergence_NN of_IN second-site_JJ LTR_NN revertants_NNS which_WDT involved_VBD an_DT alteration_NN of_IN the_DT TATA_NN box_NN ._.
 These_DT results_NNS suggest_VBP that_IN the_DT human_JJ immunodeficiency_NN virus_NN type_NN 1_CD LTR_NN possesses_VBZ functional_JJ redundancy_NN which_WDT ensures_VBZ virus_NN replication_NN in_IN different_JJ T-cell_NN types_NNS and_CC is_VBZ capable_JJ of_IN changing_VBG depending_VBG on_IN the_DT particular_JJ combination_NN of_IN transcriptional_JJ factors_NNS present_JJ ._.
 Enhancement_NN of_IN human_JJ immunodeficiency_NN virus_NN 1_CD replication_NN in_IN monocytes_NNS by_IN 1,25-dihydroxycholecalciferol_NN ._.
 Human_JJ immunodeficiency_NN virus_NN (_( HIV_NN )_) expression_NN and_CC replication_NN are_VBP under_IN tight_JJ regulatory_JJ control_NN ._.
 We_PRP demonstrate_VBP that_IN 1,25-dihydroxycholecalciferol_NN (_( 1,25-(OH)2D3_NN )_) enhances_VBZ the_DT replication_NN of_IN monocyte-_NN and_CC lymphocyte-tropic_JJ strains_NNS of_IN HIV-1_NN up_IN to_TO 10,000-fold_RB in_IN monocyte_NN cell_NN lines_NNS ,_, peripheral_JJ blood_NN monocytes_NNS ,_, and_CC unfractionated_JJ peripheral_JJ blood_NN mononuclear_JJ cells_NNS ._.
 1,25(OH)2D3_NN is_VBZ therefore_RB one_CD of_IN the_DT most_RBS potent_JJ regulators_NNS of_IN HIV-1_NN replication_NN described_VBN to_TO date_NN ._.
 Precursors_NNS of_IN 1,25(OH)2D3_NN enhance_VBP HIV-1_NN replication_NN in_IN proportion_NN to_TO their_PRP$ affinity_NN for_IN the_DT 1,25(OH)2D3_NN intracellular_JJ receptor_NN ,_, suggesting_VBG that_IN 1,25(OH)2D3_NN influences_VBZ HIV-1_NN replication_NN by_IN mechanisms_NNS involving_VBG this_DT receptor_NN ._.
 These_DT studies_NNS may_MD have_VB important_JJ implications_NNS for_IN the_DT design_NN of_IN effective_JJ therapy_NN of_IN HIV-1_NN infection_NN ._.
 Inhibition_NN of_IN HIV-1_NN replication_NN and_CC NF-kappa_NN B_NN activity_NN by_IN cysteine_NN and_CC cysteine_NN derivatives_NNS ._.
 HIV-1_NN proviral_JJ DNA_NN contains_VBZ two_CD binding_VBG sites_NNS for_IN the_DT transcription_NN factor_NN NF-kappa_NN B_NN ._.
 HIV-1-infected_JJ individuals_NNS have_VBP ,_, on_IN average_NN ,_, abnormally_RB high_JJ levels_NNS of_IN tumour_NN necrosis_NN factor_NN alpha_NN (_( TNF_NN alpha_NN )_) and_CC abnormally_RB low_JJ plasma_NN cysteine_NN levels_NNS ._.
 We_PRP therefore_RB investigated_VBD the_DT effects_NNS of_IN cysteine_NN and_CC related_JJ thiols_NNS on_IN HIV-1_NN replication_NN and_CC NF-kappa_NN B_NN expression_NN ._.
 The_DT experiments_NNS in_IN this_DT report_NN show_VBP that_IN cysteine_NN or_CC N-acetylcysteine_NN (_( NP_NN )_) raise_VBP the_DT intracellular_JJ glutathione_NN (_( GSH_NN )_) level_NN and_CC inhibit_VBP HIV-1_NN replication_NN in_IN persistently_RB infected_JJ Molt-4_NN and_CC U937_NN cells_NNS ._.
 However_RB ,_, inhibition_NN of_IN HIV-1_NN replication_NN appears_VBZ not_RB to_TO be_VB directly_RB correlated_VBN with_IN GSH_NN levels_NNS ._.
 Cysteine_NN and_CC NP_NN also_RB inhibit_VBP NF-kappa_NN B_NN activity_NN as_IN determined_VBN by_IN electrophoretic_JJ mobility_NN shift_NN assays_NNS and_CC chloramphenicol_NN acetyl-transferase_NN (_( CAT_NN )_) gene_NN expression_NN under_IN control_NN of_IN NF-kappa_NN B_NN binding_NN sites_NNS in_IN uninfected_JJ cells_NNS ._.
 This_DT suggests_VBZ that_IN the_DT cysteine_NN deficiency_NN in_IN HIV-1-infected_JJ individuals_NNS may_MD cause_VB an_DT over-expression_NN of_IN NF-kappa_NN B-dependent_JJ genes_NNS and_CC enhance_VB HIV-1_NN replication_NN ._.
 NP_NN may_MD be_VB considered_VBN for_IN the_DT treatment_NN of_IN HIV-1-infected_JJ individuals_NNS ._.
 Glucocorticoid_NN receptors_NNS in_IN systemic_JJ lupus_NN erythematosus_NN ._.
 Glucocorticosteroids_NNS remain_VBP the_DT major_JJ treatment_NN modality_NN for_IN systemic_JJ lupus_NN erythematosus_NN (_( SLE_NN )_) ,_, but_CC their_PRP$ mechanism_NN of_IN action_NN is_VBZ unclear_JJ ._.
 Over_IN the_DT past_JJ decade_NN it_PRP has_VBZ become_VBN clear_JJ that_IN glucocorticosteroid_NN receptors_NNS play_VBP a_DT significant_JJ role_NN in_IN the_DT mechanism_NN of_IN glucocorticosteroid_NN action_NN ._.
 We_PRP studied_VBD glucocorticosteroid_NN receptor_NN density_NN and_CC affinity_NN on_IN peripheral_JJ blood_NN mononuclear_JJ cells_NNS by_IN the_DT glucocorticosteroid_NN binding_NN assay_NN in_IN 33_CD patients_NNS with_IN SLE_NN who_WP had_VBD taken_VBN no_DT glucocorticosteroid_NN for_IN the_DT previous_JJ 6_CD months_NNS and_CC in_IN 32_CD healthy_JJ controls_NNS ._.
 Patients_NNS '_POS disease_NN activity_NN was_VBD measured_VBN by_IN the_DT SLE_NN Disease_NN Activity_NN Index_NN (_( SLEDAI_NN )_) ._.
 Glucocorticosteroid_NN receptors_NNS on_IN leukocytes_NNS of_IN patients_NNS with_IN SLE_NN were_VBD significantly_RB higher_JJR than_IN in_IN healthy_JJ controls_NNS (_( 4419_CD +/-_CC 306_CD vs_CC 3369_CD +/-_CC 196_CD ,_, p_NN less_JJR than_IN 0.005_CD )_) ._.
 The_DT binding_NN affinity_NN was_VBD not_RB different_JJ between_IN patients_NNS and_CC controls_NNS ._.
 There_EX was_VBD no_DT correlation_NN between_IN glucocorticosteroid_NN receptor_NN number_NN and_CC SLE_NN disease_NN activity_NN ._.
 (_( Changes_NNS in_IN leucocytic_JJ estrogen_NN receptor_NN levels_NNS in_IN patients_NNS with_IN gynecomastia_NN )_)
 The_DT number_NN of_IN estrogen_NN receptor_NN (_( ER_NN )_) in_IN human_JJ peripheral_JJ leucocytes_NNS in_IN 13_CD men_NNS with_IN gynecomastia_NNS were_VBD measured_VBN by_IN radioligand_NN binding_NN method_NN ._.
 The_DT results_NNS were_VBD compared_VBN with_IN those_DT of_IN 13_CD sex-_NN and_CC age-matched_JJ healthy_JJ subjects_NNS ._.
 It_PRP was_VBD found_VBN that_IN the_DT number_NN of_IN ER_NN in_IN leucocytes_NNS was_VBD significantly_RB increased_VBN in_IN gynecomastia_NN (_( Rs_NN of_IN leucocytes_NNS were_VBD 1054_CD +/-_CC 254_CD sites/cell_NN )_) ._.
 It_PRP suggested_VBD that_IN increase_NN of_IN ER_NN levels_NNS play_VBP an_DT important_JJ role_NN in_IN the_DT pathogenesis_NN of_IN gynecomastia_NN ._.
 (_( Changes_NNS in_IN levels_NNS of_IN leucocytic_JJ estrogen_NN receptor_NN in_IN patients_NNS with_IN menopausal_JJ type_NN II_CD diabetes_NNS and_CC its_PRP$ significance_NN )_)
 The_DT number_NN of_IN estrogen_NN receptors_NNS (_( ER_NN )_) in_IN human_JJ peripheral_JJ leucocytes_NNS in_IN 12_CD women_NNS with_IN menopausal_JJ type_NN II_CD diabetes_NNS was_VBD measured_VBN with_IN radio-ligand_JJ binding_NN method_NN ._.
 The_DT results_NNS were_VBD compared_VBN with_IN those_DT of_IN 12_CD menopausal_JJ women_NNS without_IN diabetes_NNS and_CC 12_CD normal_JJ women_NNS of_IN childbearing_JJ age_NN ._.
 It_PRP was_VBD found_VBN that_IN the_DT number_NN of_IN ER_NN in_IN the_DT patients_NNS was_VBD significantly_RB decreased_VBN ._.
 Our_PRP$ data_NNS indicate_VBP that_IN decrease_NN of_IN ER_NN level_NN in_IN leukocytes_NNS may_MD be_VB related_JJ to_TO the_DT pathogenesis_NN of_IN type_NN II_CD diabetes_NNS in_IN menopausal_JJ period_NN ._.
 Lymphocyte_NN glucocorticoid_NN receptor_NN binding_NN during_IN depression_NN and_CC after_IN clinical_JJ recovery_NN ._.
 Lymphocyte_NN glucocorticoid_NN receptor_NN binding_NN parameters_NNS were_VBD studied_VBN in_IN 15_CD severely_RB depressed_JJ patients_NNS during_IN depression_NN and_CC after_IN clinical_JJ recovery_NN ,_, and_CC in_IN 15_CD healthy_JJ controls_NNS ._.
 There_EX was_VBD no_DT difference_NN in_IN glucocorticoid_NN receptor_NN number_NN or_CC affinity_NN between_IN depressed_JJ patients_NNS and_CC recovered_JJ or_CC control_NN subjects_NNS ._.
 Afternoon_NN ACTH_NN and_CC cortisol_NN concentrations_NNS did_VBD not_RB differ_VB significantly_RB between_IN the_DT three_CD groups_NNS ._.
 No_DT relationship_NN could_MD be_VB established_VBN between_IN glucocorticoid_NN receptor_NN binding_NN and_CC antidepressant_JJ medication_NN ._.
 These_DT data_NNS support_VBP the_DT view_NN of_IN an_DT impaired_JJ ligand-induced_JJ plasticity_NN of_IN glucocorticoid_NN receptor_NN regulation_NN rather_RB than_IN the_DT hypothesis_NN of_IN decreased_VBN glucocorticoid_NN receptor_NN numbers_NNS during_IN depression_NN ._.
 Nuclear_JJ association_NN of_IN a_DT T-cell_NN transcription_NN factor_NN blocked_VBN by_IN FK-506_NN and_CC cyclosporin_NN A_NN (_( see_VB comments_NNS )_)
 Cyclosporin_NN A_NN and_CC FK506_NN inhibit_VBP T-_NN and_CC B-cell_NN activation_NN and_CC other_JJ processes_NNS essential_JJ to_TO an_DT effective_JJ immune_JJ response_NN ._.
 In_IN T_NN lymphocytes_NNS these_DT drugs_NNS disrupt_VBP an_DT unknown_JJ step_NN in_IN the_DT transmission_NN of_IN signals_NNS from_IN the_DT T-cell_NN antigen_NN receptor_NN to_TO cytokine_NN genes_NNS that_WDT coordinate_VBP the_DT immune_JJ response_NN ._.
 The_DT putative_JJ intracellular_JJ receptors_NNS for_IN FK506_NN and_CC cyclosporin_NN are_VBP cis-trans_JJ prolyl_JJ isomerases_NNS ._.
 Binding_NN of_IN the_DT drug_NN inhibits_VBZ isomerase_NN activity_NN ,_, but_CC studies_NNS with_IN other_JJ prolyl_JJ isomerase_NN inhibitors_NNS and_CC analysis_NN of_IN cyclosporin-resistant_JJ mutants_NNS in_IN yeast_NN suggest_VBP that_IN the_DT effects_NNS of_IN the_DT drug_NN result_VBP from_IN the_DT formation_NN of_IN an_DT inhibitory_JJ complex_NN between_IN the_DT drug_NN and_CC isomerase_NN ,_, and_CC not_RB from_IN inhibition_NN of_IN isomerase_NN activity_NN ._.
 A_DT transcription_NN factor_NN ,_, NF-AT_NN ,_, which_WDT is_VBZ essential_JJ for_IN early_JJ T-cell_NN gene_NN activation_NN ,_, seems_VBZ to_TO be_VB a_DT specific_JJ target_NN of_IN cyclosporin_NN A_NN and_CC FK506_NN action_NN because_IN transcription_NN directed_VBN by_IN this_DT protein_NN is_VBZ blocked_VBN in_IN T_NN cells_NNS treated_VBN with_IN these_DT drugs_NNS ,_, with_IN little_JJ or_CC no_DT effect_NN on_IN other_JJ transcription_NN factors_NNS such_JJ as_IN AP-1_NN and_CC NF-kappa_NN B_NN ._.
 Here_RB we_PRP demonstrate_VBP that_IN NF-AT_NN is_VBZ formed_VBN when_WRB a_DT signal_NN from_IN the_DT antigen_NN receptor_NN induces_VBZ a_DT pre-existing_JJ cytoplasmic_JJ subunit_NN to_TO translocate_VB to_TO the_DT nucleus_NN and_CC combine_VB with_IN a_DT newly_RB synthesized_VBN nuclear_JJ subunit_NN of_IN NF-AT_NN ._.
 FK506_NN and_CC cyclosporin_NN A_NN block_VBP translocation_NN of_IN the_DT cytoplasmic_JJ component_NN without_IN affecting_VBG synthesis_NN of_IN the_DT nuclear_JJ subunit_NN ._.
 Regulation_NN of_IN M-CSF_NN expression_NN by_IN M-CSF_NN :_: role_NN of_IN protein_NN kinase_NN C_NN and_CC transcription_NN factor_NN NF_NN kappa_NN B_NN ._.
 Macrophage-colony-stimulating_JJ factor_NN (_( M-CSF_NN )_) ,_, also_RB referred_VBN to_TO as_IN CSF-1_NN ,_, regulates_VBZ the_DT survival_NN ,_, growth_NN ,_, differentiation_NN and_CC functional_JJ activity_NN of_IN monocytes_NNS by_IN binding_VBG to_TO a_DT single_JJ class_NN of_IN high-affinity_JJ cell_NN surface_NN receptors_NNS ,_, known_VBN to_TO be_VB the_DT product_NN of_IN the_DT c-fms_NN protooncogene_NN ._.
 The_DT detection_NN of_IN both_CC M-CSF_NN and_CC c-fms_NN expression_NN by_IN cells_NNS of_IN the_DT monocyte_NN lineage_NN has_VBZ suggested_VBN that_IN M-CSF_NN may_MD act_VB by_IN an_DT autocrine_JJ mechanism_NN ._.
 Interestingly_RB ,_, it_PRP has_VBZ been_VBN shown_VBN that_IN M-CSF_NN can_MD induce_VB the_DT expression_NN of_IN its_PRP$ own_JJ gene_NN ._.
 Although_IN sensitivity_NN to_TO M-CSF_NN can_MD be_VB modulated_VBN by_IN regulation_NN of_IN receptor_NN expression_NN and_CC function_NN ,_, M-CSF_NN responsiveness_NN is_VBZ largely_RB determined_VBN at_IN a_DT postreceptor_NN level_NN ._.
 To_TO date_NN ,_, little_JJ is_VBZ known_VBN about_IN the_DT intracellular_JJ pathway_NN of_IN M-CSF_NN signal_NN transduction_NN ._.
 We_PRP have_VBP therefore_RB investigated_VBN the_DT changes_NNS in_IN protein_NN kinase_NN C_NN (_( PKC_NN )_) activity_NN upon_IN exposure_NN of_IN monocytes_NNS to_TO M-CSF_NN ._.
 We_PRP show_VBP that_IN M-CSF_NN activates_VBZ and_CC translocates_VBZ PKC_NN ._.
 Inhibition_NN of_IN PKC_NN by_IN the_DT isoquinoline_NN derivative_JJ H7_NN abolishes_VBZ induction_NN of_IN M-CSF_NN by_IN M-CSF_NN ._.
 Furthermore_RB ,_, activation_NN of_IN PKC_NN was_VBD pertussis-toxin-sensitive_JJ and_CC was_VBD associated_VBN with_IN the_DT detection_NN of_IN an_DT NF_NN kappa_NN B_NN protein_NN in_IN nuclear_JJ extracts_NNS of_IN M-CSF-induced_JJ blood_NN monocytes_NNS but_CC not_RB in_IN monocytes_NNS exposed_VBN to_TO medium_NN treatment_NN only_RB ._.
 The_DT results_NNS suggest_VBP that_IN M-CSF_NN induction_NN of_IN M-CSF_NN involves_VBZ G_NN proteins_NNS ,_, PKC_NN and_CC NF_NN kappa_NN B_NN ._.
 NF-kappa_NN B_NN activation_NN by_IN tumor_NN necrosis_NN factor_NN alpha_NN in_IN the_DT Jurkat_NN T_NN cell_NN line_NN is_VBZ independent_JJ of_IN protein_NN kinase_NN A_NN ,_, protein_NN kinase_NN C_NN ,_, and_CC Ca(2+)-regulated_JJ kinases_NNS ._.
 NF-kappa_NN B_NN is_VBZ a_DT DNA-binding_JJ regulatory_JJ factor_NN able_JJ to_TO control_VB transcription_NN of_IN a_DT number_NN of_IN genes_NNS ,_, including_VBG human_JJ immunodeficiency_NN virus_NN (_( HIV_NN )_) genes_NNS ._.
 In_IN T_NN cells_NNS ,_, NF-kappa_NN B_NN is_VBZ activated_VBN upon_IN cellular_JJ treatment_NN by_IN phorbol_NN esters_NNS and_CC the_DT cytokine_NN tumor_NN necrosis_NN factor_NN alpha_NN (_( TNF_NN alpha_NN )_) ._.
 In_IN the_DT present_JJ work_NN ,_, we_PRP investigated_VBD the_DT molecular_JJ events_NNS leading_VBG to_TO NF-kappa_NN B_NN activation_NN by_IN TNF_NN alpha_NN in_IN a_DT human_JJ T_NN cell_NN line_NN (_( Jurkat_NN )_) and_CC its_PRP$ subclone_JJ JCT6_NN ,_, which_WDT presents_VBZ a_DT deficiency_NN in_IN the_DT PKA_NN transduction_NN pathway_NN ._.
 We_PRP found_VBD that_IN in_IN both_DT cell_NN lines_NNS ,_, both_CC phorbol_NN ester_NN and_CC TNF_NN alpha_NN were_VBD able_JJ to_TO activate_VB NF-kappa_NN B_NN ._.
 Phorbol_NN activation_NN was_VBD positively_RB modulated_VBN by_IN Ca2+_NN influx_NN while_IN TNF_NN alpha_NN activation_NN was_VBD not_RB ._.
 Furthermore_RB ,_, while_IN PMA_NN activation_NN was_VBD inhibited_VBN by_IN the_DT PKC_NN inhibitor_NN staurosporin_NN ,_, the_DT TNF_NN alpha_NN effect_NN was_VBD unchanged_JJ ._.
 TNF_NN alpha_NN did_VBD not_RB activate_VB cAMP_NN production_NN and_CC its_PRP$ signal_NN was_VBD not_RB modulated_VBN by_IN cAMP_NN activators_NNS ._.
 Moreover_RB ,_, cAMP_NN activators_NNS did_VBD not_RB activate_VB NF-kappa_NN B_NN in_IN Jurkat_NN cells_NNS ._.
 Thus_RB ,_, TNF_NN alpha-induced_JJ NF-kappa_NN B_NN activation_NN was_VBD found_VBN to_TO be_VB mediated_VBN by_IN none_NN of_IN the_DT major_JJ signal-mediating_JJ kinases_NNS such_JJ as_IN protein_NN kinase_NN C_NN (_( PKC_NN )_) ,_, protein_NN kinase_NN A_NN ,_, or_CC Ca(2+)-regulated_JJ kinases_NNS ._.
 Furthermore_RB ,_, we_PRP found_VBD that_IN cytoplasmic_JJ acidification_NN facilitated_VBD NF-kappa_NN B_NN activation_NN by_IN both_CC TNF_NN alpha_NN and_CC PKC_NN ,_, by_IN a_DT mechanism_NN that_WDT increases_VBZ NF-kappa_NN B/I_NN kappa_NN B_NN dissociation_NN without_IN affecting_VBG the_DT NF-kappa_NN B_NN translocation_NN step_NN ._.
 NF-kappa_NN B_NN activity_NN in_IN T_NN cells_NNS stably_RB expressing_VBG the_DT Tax_NN protein_NN of_IN human_JJ T_NN cell_NN lymphotropic_JJ virus_NN type_NN I_CD ._.
 The_DT effect_NN of_IN constitutive_JJ Tax_NN expression_NN on_IN the_DT interaction_NN of_IN NF-kappa_NN B_NN with_IN its_PRP$ recognition_NN sequence_NN and_CC on_IN NF-kappa_NN B-dependent_JJ gene_NN expression_NN was_VBD examined_VBN in_IN T_NN lymphoid_JJ Jurkat_NN cell_NN lines_NNS (_( 19D_NN and_CC 9J_NN )_) stably_RB transformed_VBN with_IN a_DT Tax_NN expression_NN vector_NN ._.
 Tax_NN expressing_NN T_NN cell_NN lines_NNS contained_VBD a_DT constitutive_JJ level_NN of_IN NF-kappa_NN B_NN binding_NN activity_NN ,_, detectable_JJ by_IN mobility_NN shift_NN assay_NN and_CC uv_NN cross-linking_NN using_VBG a_DT palindromic_JJ NF-kappa_NN B_NN probe_NN homologous_JJ to_TO the_DT interferon_NN beta_NN PRDII_NN site_NN ._.
 In_IN Jurkat_NN and_CC NC2.10_NN induction_NN with_IN phorbol_NN esters_NNS resulted_VBD in_IN the_DT appearance_NN of_IN new_JJ DNA_NN binding_NN proteins_NNS of_IN 85_CD ,_, 75_CD ,_, and_CC 54_CD kDa_NN ,_, whereas_IN in_IN Tax_NN expressing_NN cells_NNS the_DT 85-kDa_JJ protein_NN and_CC a_DT 92-kDa_JJ DNA_NN binding_NN protein_NN were_VBD constitutively_RB induced_VBN ._.
 Expression_NN of_IN Tax_NN protein_NN in_IN 19D_NN and_CC 9J_NN resulted_VBD in_IN transcription_NN of_IN the_DT endogenous_JJ NF-kappa_NN B-dependent_JJ granulocyte-macrophage_JJ colony_NN stimulating_NN factor_NN gene_NN and_CC increased_VBD basal_JJ level_NN expression_NN of_IN transfected_VBN NF-kappa_NN B-regulated_JJ promoters_NNS ._.
 Nonetheless_RB transcription_NN of_IN both_CC the_DT endogenous_JJ and_CC the_DT transfected_VBN gene_NN was_VBD inducible_JJ by_IN PMA_NN treatment_NN ._.
 Tax_NN expression_NN in_IN Jurkat_NN T_NN cells_NNS may_MD alter_VB the_DT stoichiometry_NN of_IN NF-kappa_NN B_NN DNA_NN binding_NN proteins_NNS and_CC thus_RB change_VB the_DT expression_NN of_IN NF-kappa_NN B-regulated_JJ promoters_NNS ._.
 Regulation_NN of_IN glucocorticoid_NN receptors_NNS in_IN human_JJ mononuclear_JJ cells_NNS :_: effects_NNS of_IN glucocorticoid_NN treatment_NN ,_, Cushing_NN 's_POS disease_NN and_CC ketoconazole_NN ._.
 Glucocorticoid_NN receptors_NNS (_( GcR_NN )_) were_VBD determined_VBN by_IN a_DT whole_JJ cell_NN assay_NN in_IN human_JJ mononulear_JJ leukocytes_NNS (_( hMNL_NN )_) from_IN control_NN subjects_NNS ,_, patients_NNS receiving_VBG glucocorticoid_NN therapy_NN for_IN systemic_JJ diseases_NNS and_CC Cushing_NN 's_POS disease_NN patients_NNS with_IN or_CC without_IN ketoconazole_NN therapy_NN ._.
 Prolonged_JJ corticosteroid_NN treatment_NN resulted_VBD in_IN down-regulation_NN of_IN GcR_NN ,_, while_IN the_DT mean_NN level_NN of_IN GcR_NN in_IN Cushing_NN 's_POS disease_NN was_VBD normal_JJ ._.
 In_IN this_DT group_NN ,_, however_RB ,_, receptor_NN levels_NNS and_CC morning_NN plasma_NN cortisol_NN values_NNS showed_VBD a_DT negative_JJ correlation_NN ,_, indicating_VBG a_DT subtle_JJ down-regulatory_JJ effect_NN ._.
 Furthermore_RB ,_, GcR_NN were_VBD unaltered_JJ after_IN these_DT patients_NNS received_VBD ketoconazole_NN ,_, in_IN spite_NN of_IN a_DT marked_JJ reduction_NN in_IN morning_NN plasma_NN cortisol_NN and_CC urinary_JJ free_JJ cortisol_NN ._.
 We_PRP also_RB observed_VBD that_IN ketoconazole_NN was_VBD a_DT weak_JJ competitor_NN of_IN GcR_NN in_IN intact_JJ cells_NNS ,_, although_IN it_PRP significantly_RB inhibited_VBD (3H)_NN dexamethasone_NN binding_NN in_IN cytosolic_JJ preparations_NNS from_IN rat_NN tissues_NNS ._.
 The_DT results_NNS suggested_VBD that_IN GcR_NN in_IN hMNL_NN are_VBP down-regulated_VBN by_IN synthetic_JJ steroids_NNS given_VBN in_FW vivo_FW ,_, but_CC they_PRP showed_VBD very_RB mild_JJ down-regulation_NN in_IN hypercortisolemic_JJ patients_NNS suffering_VBG from_IN Cushing_NN 's_POS disease_NN ._.
 Finally_RB ,_, we_PRP did_VBD not_RB observed_VBN either_CC up-regulation_NN or_CC antagonism_NN of_IN GcR_NN by_IN ketoconazole_NN treatment_NN ,_, at_IN the_DT time_NN that_IN cortisol_NN levels_NNS of_IN patients_NNS with_IN Cushing_NN 's_POS disease_NN were_VBD reduced_VBN ._.
 This_DT indicates_VBZ that_IN the_DT beneficial_JJ effects_NNS of_IN ketoconazole_NN in_IN Cushing_NN 's_POS disease_NN are_VBP due_JJ to_TO adrenal_JJ cortisol_NN suppression_NN and_CC not_RB to_TO interaction_NN with_IN GcR_NN of_IN target_NN cells_NNS ,_, and_CC that_IN the_DT process_NN of_IN GcR_NN regulation_NN in_IN hMNL_NN is_VBZ a_DT complex_JJ phenomenon_NN awaiting_VBG further_RBR elucidation_NN ._.
 Glucocorticoid_NN receptors_NNS in_IN lymphocytes_NNS in_IN anorexia_NN nervosa_NN ._.
 OBJECTIVE_NN :_: The_DT aim_NN was_VBD to_TO explore_VB the_DT down-regulation_NN of_IN the_DT glucocorticoid_NN receptors_NNS during_IN hypercortisolaemia_NN in_IN anorexia_NN nervosa_NN ._.
 DESIGN_NN :_: Urine_NN and_CC plasma_NN samples_NNS were_VBD obtained_VBN for_IN cortisol_NN determination_NN and_CC blood_NN lymphocytes_NNS were_VBD isolated_VBN for_IN receptor_NN binding_NN studies_NNS ._.
 PATIENTS_NNS :_: Sixteen_CD anorexic_JJ patients_NNS ,_, aged_JJ 16-27_CD years_NNS ,_, with_IN a_DT mean_NN +/-_CC SEM_NN body_NN mass_NN index_NN of_IN 14.2_CD +/-_CC 2.0_CD (_( ranging_VBG from_IN 11.1_CD to_TO 17.4_CD )_) ,_, and_CC 15_CD normal_JJ women_NNS were_VBD studied_VBN ._.
 Six_CD patients_NNS were_VBD reinvestigated_VBN after_IN a_DT significant_JJ weight_NN gain_NN ._.
 MEASUREMENTS_NNS :_: The_DT binding_NN capacity_NN and_CC affinity_NN of_IN the_DT glucocorticoid_NN receptors_NNS were_VBD measured_VBN with_IN dexamethasone_NN as_IN ligand_NN on_IN lymphocytes_NNS ._.
 RESULTS_NNS :_: In_IN patients_NNS ,_, both_DT total_JJ and_CC free_JJ plasma_NN cortisol_NN concentrations_NNS were_VBD higher_JJR than_IN in_IN the_DT normal_JJ women_NNS ,_, as_IN was_VBD their_PRP$ urinary_JJ free_JJ cortisol_NN ;_: the_DT number_NN of_IN glucocorticoid_NN receptors_NNS per_IN cell_NN (_( Ro_NN )_) and_CC the_DT binding_NN affinity_NN (_( Kd_NN )_) for_IN dexamethasone_NN were_VBD ,_, however_RB ,_, not_RB significantly_RB different_JJ (_( Ro_NN :_: 7687_CD +/-_CC 1750_CD vs_CC 7347_CD +/-_CC 1285_CD sites/cell_NN ;_: Kd_NN :_: 7.7_CD +/-_CC 2.4_CD vs_CC 7.4_CD +/-_CC 1.7_CD nM_NN at_IN 24_CD degrees_NNS C_NN )_) ._.
 After_IN weight_NN gain_NN (_( 14_CD +/-_CC 2_CD to_TO 16_CD +/-_CC 2_CD kg/m2_NN )_) ,_, receptor_NN numbers_NNS were_VBD 8421_CD +/-_CC 2126_CD (_( pre_JJ|RB )_) and_CC 9011_CD +/-_CC 500_CD (_( post_JJ|RB )_) sites/cell_NN ,_, which_WDT are_VBP not_RB significantly_RB different_JJ (_( P_NN greater_JJR than_IN 0.2_CD )_) ;_: the_DT Kd_NN was_VBD unchanged_JJ (_( 9.3_CD +/-_CC 2.6_CD vs_CC 9.2_CD +/-_CC 2.4_CD nM_NN )_) ._.
 CONCLUSIONS_NNS Hypercortisolaemia_NN does_VBZ not_RB down-regulate_VB the_DT lymphocyte_NN glucocorticoid_NN receptors_NNS in_IN anorexia_NN nervosa_NN and_CC a_DT post-receptor_JJ defect_NN might_MD be_VB involved_VBN in_IN peripheral_JJ tissue_NN resistance_NN to_TO the_DT effects_NNS of_IN glucocorticoid_NN hormones_NNS in_IN undernutrition_NN ._.
 Tumor_NN necrosis_NN factor-alpha_NN mRNA_NN accumulation_NN in_IN human_JJ myelomonocytic_JJ cell_NN lines_NNS ._.
 Role_NN of_IN transcriptional_JJ regulation_NN by_IN DNA_NN sequence_NN motifs_NNS and_CC mRNA_NN stabilization_NN ._.
 The_DT cytokine_NN TNF_NN mediates_VBZ many_JJ of_IN the_DT pathologic_JJ signs_NNS of_IN cachexia_NN ,_, inflammation_NN ,_, and_CC sepsis_NN ._.
 The_DT current_JJ work_NN describes_VBZ the_DT regulation_NN of_IN TNF_NN in_IN human_JJ myelomonocytic_JJ cell_NN lines_NNS after_IN PMA_NN stimulation_NN ._.
 The_DT cell_NN lines_NNS exhibit_VBP a_DT low_JJ level_NN of_IN constitutive_JJ TNF_NN mRNA_NN expression_NN ._.
 Within_IN 2_CD to_TO 4_CD h_NN of_IN PMA_NN exposure_NN ,_, steady_JJ state_NN levels_NNS of_IN TNF_NN mRNA_NN are_VBP markedly_RB elevated_JJ in_IN all_DT myelomonocytic_JJ cell_NN lines_NNS studied_VBN ._.
 This_DT rise_NN is_VBZ due_JJ to_TO increased_VBN mRNA_NN stability_NN ,_, which_WDT increased_VBD by_IN almost_RB twofold_RB ,_, and_CC to_TO an_DT overall_JJ increase_NN in_IN transcription_NN ,_, which_WDT rises_VBZ by_IN more_JJR than_IN sixfold_RB ._.
 At_IN the_DT level_NN of_IN the_DT genomic_JJ TNF_NN gene_NN ,_, a_DT DNase_NN I_CD hypersensitive_JJ site_NN is_VBZ detected_VBN within_IN the_DT TNF_NN promoter_NN between_IN -200_CD to_TO -100_CD bp_NN relative_JJ to_TO the_DT transcription_NN initiation_NN site_NN ._.
 Although_IN absent_JJ in_IN nonexpressing_VBG erythroleukemia_NN cell_NN lines_NNS ,_, the_DT DNase_NN I_CD site_NN is_VBZ present_JJ in_IN uninduced_JJ myelomonocytic_JJ cell_NN lines_NNS and_CC is_VBZ not_RB changed_VBN after_IN PMA_NN induction_NN ._.
 The_DT PMA_NN induction_NN of_IN c-fos_NN mRNA_NN correlated_VBD well_RB with_IN TNF_NN gene_NN induction_NN ;_: expression_NN of_IN genes_NNS encoding_VBG other_JJ proteins_NNS in_IN the_DT AP-1_NN complex_NN (_( junB_NN and_CC junD_NN )_) were_VBD also_RB induced_VBN by_IN PMA_NN ._.
 The_DT nuclear_JJ extracts_NNS from_IN resting_VBG and_CC induced_VBN ML-1_NN cells_NNS contain_VBP proteins_NNS binding_VBG specifically_RB to_TO the_DT AP-1_NN ,_, AP-2_NN ,_, and_CC NF_NN kappa_NN B_NN sequence_NN located_JJ within_IN the_DT TNF_NN promoter_NN ._.
 PMA_NN induction_NN increases_VBZ the_DT level_NN of_IN a_DT number_NN of_IN specific_JJ binding_VBG complexes_NNS relative_JJ to_TO the_DT resting_VBG cells_NNS ._.
 The_DT regulatory_JJ mechanisms_NNS of_IN the_DT human_JJ and_CC murine_JJ TNF_NN genes_NNS are_VBP discussed_VBN ._.
 USF-related_JJ transcription_NN factor_NN ,_, HIV-TF1_NN ,_, stimulates_VBZ transcription_NN of_IN human_JJ immunodeficiency_NN virus-1_NN ._.
 The_DT transcription_NN factor_NN HIV-TF1_NN ,_, which_WDT binds_VBZ to_TO a_DT region_NN about_IN 60_CD bp_NN upstream_JJ from_IN the_DT enhancer_NN of_IN the_DT human_JJ immunodeficiency_NN virus-1_NN (_( HIV-1_NN )_) ,_, was_VBD purified_VBN from_IN human_JJ B_NN cells_NNS ._.
 HIV-TF1_NN had_VBD a_DT molecular_JJ weight_NN of_IN 39,000_CD ._.
 Binding_NN of_IN HIV-TF1_NN to_TO the_DT HIV_NN long_JJ terminal_JJ repeat_NN (_( LTR_NN )_) activated_VBD transcription_NN from_IN the_DT HIV_NN promoter_NN in_FW vitro_FW ._.
 The_DT HIV-TF1-binding_JJ site_NN in_IN HIV_NN LTR_NN was_VBD similar_JJ to_TO the_DT site_NN recognized_VBN by_IN upstream_JJ stimulatory_JJ factor_NN (_( USF_NN )_) in_IN the_DT adenovirus_NN major_JJ late_JJ promoter_NN ._.
 DNA-binding_JJ properties_NNS of_IN HIV-TF1_NN suggested_VBD that_IN HIV-TF1_NN might_MD be_VB identical_JJ or_CC related_JJ to_TO USF_NN ._.
 Interestingly_RB ,_, treatment_NN of_IN purified_VBN HIV-TF1_NN by_IN phosphatase_NN greatly_RB reduced_VBD its_PRP$ DNA-binding_JJ activity_NN ,_, suggesting_VBG that_IN phosphorylation_NN of_IN HIV-TF1_NN was_VBD essential_JJ for_IN DNA_NN binding_NN ._.
 The_DT disruption_NN of_IN HIV-TF1-binding_JJ site_NN induced_VBD a_DT 60_CD %_NN decrease_NN in_IN the_DT level_NN of_IN transcription_NN from_IN the_DT HIV_NN promoter_NN in_FW vivo_FW ._.
 These_DT results_NNS suggest_VBP that_IN HIV-TF1_NN is_VBZ involved_VBN in_IN transcriptional_JJ regulation_NN of_IN HIV-1_NN ._.
 The_DT effect_NN of_IN toremifene_NN therapy_NN on_IN serum_NN immunoglobulin_NN levels_NNS in_IN breast_NN cancer_NN ._.
 Estrogens_NNS and_CC anti-estrogens_NNS enhance_VBP the_DT number_NN of_IN immunoglobulin_NN (_( Ig_NN )_) -secreting_NN cells_NNS in_IN pokeweed_NN mitogen_NN (_( PWM_NN )_) -stimulated_JJ lymphocyte_NN cultures_NNS ._.
 Lymphocytes_NNS from_IN patients_NNS who_WP have_VBP received_VBN anti-estrogen_NN therapy_NN show_VBP similar_JJ enhancement_NN of_IN Ig-secreting_JJ cells_NNS after_IN PWM_NN stimulation_NN ._.
 In_IN this_DT study_NN the_DT effect_NN of_IN anti-estrogen_NN (_( toremifene_NN )_) therapy_NN on_IN serum_NN immunoglobulin_NN (_( IgA_NN ,_, IgM_NN ,_, IgG_NN )_) levels_NNS in_IN breast_NN cancer_NN patients_NNS was_VBD investigated_VBN ._.
 Serum_NN Ig_NN levels_NNS were_VBD followed_VBN up_RB to_TO two_CD years_NNS after_IN or_CC during_IN the_DT therapy_NN ._.
 An_DT unexpected_JJ finding_NN was_VBD that_IN the_DT Ig_NN levels_NNS decreased_VBD during_IN the_DT follow-up_JJ period_NN ._.
 This_DT decrease_NN was_VBD seen_VBN in_IN patients_NNS who_WP responded_VBD to_TO the_DT therapy_NN as_RB well_RB as_IN in_IN those_DT who_WP did_VBD not_RB ._.
 HIV1_NN infection_NN of_IN human_JJ monocytes_NNS and_CC macrophages_NNS promotes_VBZ induction_NN or_CC translocation_NN of_IN NF-KB-related_JJ factors_NNS ._.
 In_IN 1991_CD ,_, we_PRP demonstrated_VBD ,_, using_VBG electrophoretic_JJ mobility_NN shift_NN assays_NNS ,_, that_IN 3_CD different_JJ factors_NNS (_( termed_VBN B1_NN ,_, B2_NN and_CC B3_NN )_) with_IN affinity_NN for_IN the_DT KB-enhancer_JJ|NN target_NN sequence_NN were_VBD specifically_RB detected_VBN in_IN nuclear_JJ extracts_NNS from_IN HIV1-infected_JJ monocytes_NNS and_CC macrophages_NNS ._.
 The_DT B2_NN factor_NN was_VBD induced_VBN in_IN the_DT nuclei_NNS of_IN these_DT cells_NNS only_RB upon_IN HIV1_NN infection_NN ._.
 The_DT B3_NN factor_NN was_VBD only_RB slightly_RB evident_JJ in_IN nuclei_NNS of_IN uninfected_JJ cells_NNS but_CC was_VBD readily_RB detectable_JJ in_IN nuclei_NNS of_IN infected_JJ monocytes_NNS ._.
 Its_PRP$ expression_NN remained_VBD very_RB low_JJ in_IN nuclei_NNS of_IN HIV1-infected_JJ macrophages_NNS ._.
 In_IN this_DT paper_NN ,_, we_PRP demonstrate_VBP that_IN the_DT B2_NN factor_NN is_VBZ expressed_VBN in_IN the_DT cytosol_NN of_IN monocytes_NNS and_CC macrophages_NNS as_IN a_DT DNA-binding_JJ protein_NN ,_, indicating_VBG that_IN it_PRP is_VBZ not_RB associated_VBN with_IN an_DT inhibitor_NN (_( IKB_NN )_) ._.
 This_DT factor_NN remained_VBD clustered_VBN in_IN the_DT cytosol_NN and_CC was_VBD translocated_VBN to_TO the_DT nuclei_NNS only_RB after_IN HIV1_NN infection_NN ._.
 The_DT B3_NN factor_NN is_VBZ detected_VBN in_IN the_DT cytosol_NN only_RB when_WRB cells_NNS are_VBP HIV1-infected_JJ ._.
 The_DT role_NN of_IN HIV1_NN infection_NN in_IN the_DT expression_NN and_CC the_DT translocation_NN of_IN these_DT factors_NNS is_VBZ discussed_VBN ._.
 Induction_NN of_IN NF-kappa_NN B_NN during_IN monocyte_NN differentiation_NN is_VBZ associated_VBN with_IN activation_NN of_IN HIV-gene_JJ expression_NN ._.
 Cells_NNS of_IN the_DT monocyte-macrophage_JJ lineage_NN are_VBP important_JJ targets_NNS of_IN HIV_NN infection_NN ._.
 We_PRP report_VBP here_RB that_IN the_DT phenotypic_JJ differentiation_NN of_IN monocyte_NN cell_NN lines_NNS induced_VBN by_IN phorbol_NN esters_NNS or_CC tumour_NN necrosis_NN factor_NN alpha_NN (_( TNF_NN alpha_NN )_) is_VBZ associated_VBN with_IN expression_NN of_IN nuclear_JJ factor_NN kappa_NN B_NN (_( NF-kappa_NN B_NN )_) ._.
 In_IN parallel_NN with_IN such_JJ differentiation_NN ,_, HIV_NN transcription_NN ,_, monitored_VBN using_VBG an_DT HIV_NN long_JJ terminal_JJ repeat_NN reporter_NN gene_NN construct_NN ,_, is_VBZ activated_VBN in_IN such_JJ cells_NNS under_IN the_DT influence_NN of_IN enhanced_VBN NF-kappa_NN B_NN expression_NN ._.
 Also_RB ,_, in_IN a_DT promonocyte_JJ cell_NN line_NN chronically_RB infected_VBN with_IN HIV_NN ,_, NF-kappa_NN B_NN expression_NN and_CC HIV_NN transcription_NN were_VBD enhanced_VBN on_IN stimulation_NN with_IN phorbol_NN ester_NN or_CC TNF_NN alpha_NN ._.
 Thus_RB ,_, stimulation_NN of_IN monocyte_NN cell_NN lines_NNS by_IN phorbol_NN esters_NNS or_CC TNF_NN alpha_NN induces_VBZ cell_NN differentiation_NN and_CC activates_VBZ HIV_NN transcription_NN ._.
 Such_PDT a_DT process_NN may_MD have_VB fundamental_JJ implications_NNS in_IN AIDS_NN pathogenesis_NN in_FW vivo_FW and_CC may_MD be_VB important_JJ in_IN disease_NN progression_NN induced_VBN by_IN opportunistic_JJ infections_NNS directly_RB or_CC indirectly_RB involving_VBG macrophages_NNS ._.
 A_DT nuclear_JJ factor_NN NF-GM2_NN that_WDT interacts_VBZ with_IN a_DT regulatory_JJ region_NN of_IN the_DT GM-CSF_NN gene_NN essential_JJ for_IN its_PRP$ induction_NN in_IN responses_NNS to_TO T-cell_NN activation_NN :_: purification_NN from_IN human_JJ T-cell_NN leukemia_NN line_NN Jurkat_NN cells_NNS and_CC similarity_NN to_TO NF-kappa_NN B_NN ._.
 Activation_NN of_IN T_NN cells_NNS by_IN antigen_NN ,_, lectin_NN ,_, or_CC a_DT combination_NN of_IN phorbol-12-myristate_NN acetate_NN (_( PMA_NN )_) and_CC calcium_NN ionophore_NN (_( A23187_NN )_) leads_VBZ to_TO the_DT induction_NN of_IN genes_NNS for_IN a_DT set_NN of_IN lymphokines_NNS ,_, including_VBG granulocyte-macrophage_JJ colony-stimulating_JJ factor_NN (_( GM-CSF_NN )_) ._.
 We_PRP demonstrated_VBD in_IN earlier_JJR studies_NNS that_IN the_DT upstream_JJ region_NN of_IN the_DT mouse_NN GM-CSF_NN promoter_NN at_IN positions_NNS between_IN -95_CD and_CC -73_CD is_VBZ essential_JJ for_IN transcriptional_JJ activation_NN in_IN response_NN to_TO PMA/A23187_NN ._.
 This_DT region_NN contains_VBZ two_CD DNA-binding_JJ motifs_NNS ,_, GM2_NN and_CC GC-box_NN ._.
 The_DT GM2_NN sequence_NN (_( GGTAGTTCCC_NN )_) is_VBZ recognized_VBN by_IN an_DT inducible_JJ factor_NN NF-GM2_NN ;_: the_DT other_JJ (_( CCGCCC_NN )_) by_IN constitutive_JJ factors_NNS A1_NN ,_, A2_NN ,_, and_CC B_NN ._.
 To_TO elucidate_VB the_DT mechanism_NN of_IN GM-CSF_NN gene_NN activation_NN ,_, we_PRP have_VBP purified_VBN the_DT inducible_JJ factor_NN NF-GM2_NN from_IN the_DT nuclear_JJ extract_NN of_IN stimulated_VBN Jurkat_NN cells_NNS on_IN the_DT basis_NN of_IN specific_JJ DNA-binding_JJ activity_NN ._.
 The_DT purified_VBN NF-GM2_NN consists_VBZ of_IN 50_CD (_( p50_NN )_) and_CC 65_CD kDa_NN (_( p65_NN )_) polypeptides_NNS and_CC has_VBZ a_DT binding_NN activity_NN specific_JJ for_IN both_CC the_DT GM-CSF_NN and_CC immunoglobulin_NN kappa_NN (_( GGAAAGTCCC_NN )_) enhancers_NNS ._.
 Electrophoretically_RB purified_VBN p50_NN alone_RB can_MD form_VB a_DT protein-DNA_JJ complex_NN ,_, but_CC in_IN the_DT mixture_NN ,_, p50_NN associates_VBZ preferentially_RB with_IN p65_NN to_TO form_VB the_DT NF-GM2_NN complex_NN ._.
 In_IN addition_NN ,_, p65_NN gave_VBD per_FW se_FW ,_, with_IN low_JJ affinity_NN ,_, a_DT protein-DNA_JJ complex_NN that_WDT migrated_VBD more_RBR slowly_RB than_IN native_JJ NF-GM2_NN complex_NN ._.
 Furthermore_RB ,_, an_DT antiserum_NN against_IN KBF1_NN (_( identical_JJ to_TO 50_CD kDa_NN NF-kappa_NN B_NN protein_NN )_) reacted_VBD with_IN the_DT p50_NN of_IN NF-GM2_NN ,_, indicating_VBG that_IN the_DT NF-GM2_NN polypeptide_NN can_MD not_RB be_VB immunologically_RB differentiated_VBN from_IN the_DT 50_CD kDa_NN subunit_NN of_IN NF-kappa_NN B_NN ._.
 The_DT purified_VBN NF-GM2_NN activated_VBD in_FW vitro_FW transcription_NN from_IN the_DT kappa_NN B_NN enhancer_NN ,_, while_IN it_PRP failed_VBD to_TO stimulate_VB transcription_NN from_IN the_DT GM-CSF_NN promoter_NN harboring_VBG the_DT GM2_NN sequence_NN ._.
 This_DT suggests_VBZ that_IN the_DT activation_NN mechanism_NN of_IN the_DT GM-CSF_NN gene_NN through_IN the_DT GM2/GC-box_JJ|NN sequence_NN is_VBZ different_JJ from_IN that_DT of_IN genes_NNS carrying_VBG the_DT kappa_NN B_NN enhancer_NN alone_RB ._.
 Glucocorticoid_NN receptors_NNS in_IN normal_JJ leukocytes_NNS :_: effects_NNS of_IN age_NN ,_, gender_NN ,_, season_NN ,_, and_CC plasma_NN cortisol_NN concentrations_NNS ._.
 We_PRP measured_VBD glucocorticoid_NN receptors_NNS (_( GR_NN )_) in_IN mononuclear_JJ leukocytes_NNS (_( MNL_NN )_) isolated_VBN from_IN peripheral_JJ blood_NN of_IN 145_CD apparently_RB healthy_JJ volunteers_NNS (_( 86_CD men_NNS and_CC 59_CD women_NNS )_) ._.
 An_DT age-related_JJ decrease_NN in_IN the_DT number_NN of_IN GR_NN was_VBD suggested_VBN between_IN subjects_NNS younger_JJR than_IN 20_CD years_NNS and_CC elderly_JJ subjects_NNS ;_: there_EX was_VBD no_DT apparent_JJ seasonal_JJ variation_NN in_IN GR_NN ._.
 Gender_NN difference_NN in_IN the_DT number_NN of_IN GR_NN was_VBD not_RB significant_JJ ,_, although_IN women_NNS showed_VBD slightly_RB fewer_JJR GR_NN ._.
 Eight_CD patients_NNS with_IN dermatomyositis/polymyositis_NN were_VBD examined_VBN to_TO determine_VB whether_IN the_DT number_NN of_IN GR_NN in_IN MNL_NN could_MD be_VB down-regulated_VBN by_IN their_PRP$ cognate_JJ ligands_NNS ._.
 The_DT number_NN of_IN GR_NN in_IN MNL_NN from_IN these_DT patients_NNS was_VBD significantly_RB decreased_VBN one_CD month_NN after_IN the_DT initiation_NN of_IN prednisolone_NN therapy_NN ._.
 However_RB ,_, in_IN normal_JJ subjects_NNS ,_, the_DT GR_NN in_IN MNL_NN did_VBD not_RB demonstrate_VB circadian_JJ variation_NN ,_, in_IN contrast_NN to_TO concentrations_NNS of_IN plasma_NN cortisol_NN ._.
 Anti-CD2_JJ receptor_NN antibodies_NNS activate_VBP the_DT HIV_NN long_JJ terminal_JJ repeat_NN in_IN T_NN lymphocytes_NNS ._.
 The_DT CD2_NN T_NN lymphocyte_NN glycoprotein_NN surface_NN molecule_NN mediates_VBZ both_CC cell_NN to_TO cell_NN adhesion_NN and_CC T_NN cell_NN activation_NN ,_, two_CD processes_NNS that_WDT are_VBP involved_VBN in_IN the_DT spread_NN of_IN HIV_NN infection_NN ._.
 Treatment_NN of_IN chronically_RB HIV-infected_JJ PBMC_NN with_IN anti-CD2_JJ mAb_NN has_VBZ been_VBN shown_VBN to_TO induce_VB the_DT expression_NN of_IN infectious_JJ virus_NN from_IN these_DT cultures_NNS ._.
 In_IN this_DT study_NN we_PRP investigated_VBD the_DT mechanisms_NNS whereby_WRB anti-CD2_JJ antibodies_NNS stimulate_VBP viral_JJ production_NN ._.
 We_PRP demonstrate_VBP that_IN treatment_NN of_IN transiently_RB transfected_VBN T_NN lymphocytes_NNS with_IN anti-CD2_JJ antibodies_NNS results_VBZ in_IN activation_NN of_IN the_DT HIV_NN long_JJ terminal_JJ repeat_NN ._.
 Furthermore_RB ,_, CAT_NN assays_NNS using_VBG mutated_VBN HIV_NN long_JJ terminal_JJ repeat-CAT_NN constructs_NNS and_CC gel_NN shift_NN assays_NNS demonstrate_VBP that_IN this_DT activation_NN is_VBZ dependent_JJ on_IN the_DT NF-kappa_NN B_NN enhancer_NN ._.
 These_DT studies_NNS suggest_VBP that_IN interaction_NN of_IN CD2_NN with_IN its_PRP$ natural_JJ ligand_NN ,_, LFA-3_NN ,_, may_MD play_VB a_DT role_NN in_IN regulation_NN of_IN HIV_NN expression_NN ._.
 Nuclear_JJ transcription_NN factors_NNS that_WDT bind_VBP to_TO elements_NNS of_IN the_DT IL-2_NN promoter_NN ._.
 Induction_NN requirements_NNS in_IN primary_JJ human_JJ T_NN cells_NNS ._.
 Prior_JJ studies_NNS have_VBP identified_VBN several_JJ elements_NNS that_WDT contribute_VBP to_TO the_DT activity_NN of_IN the_DT IL-2_NN promoter_NN in_IN the_DT stimulated_VBN T_NN cell_NN line_NN ,_, Jurkat_NN ._.
 The_DT sites_NNS and_CC their_PRP$ corresponding_JJ nuclear_JJ binding_VBG factors_NNS include_VBP :_: NF-kappa_NN B_NN ,_, AP-1_NN ,_, AP-3_NN ,_, OCT-1_NN ,_, and_CC NF-AT_NN ._.
 The_DT latter_JJ "_[[DQS]] nuclear_JJ factor_NN for_IN activated_VBN T_NN cells_NNS "_[[DQE]] likely_RB contributes_VBZ to_TO the_DT tissue_NN specificity_NN of_IN IL-2_NN gene_NN expression_NN ._.
 Using_VBG electrophoretic_JJ mobility_NN shift_NN assays_NNS ,_, we_PRP have_VBP studied_VBN these_DT transcription_NN factors_NNS in_IN primary_JJ T_NN cells_NNS from_IN human_JJ blood_NN to_TO verify_VB their_PRP$ presence_NN in_IN a_DT physiologic_JJ setting_NN and_CC to_TO identify_VB the_DT signals_NNS that_WDT stimulate_VBP factor_NN activity_NN ._.
 All_DT factors_NNS are_VBP induced_VBN in_IN the_DT nuclei_NNS of_IN T_NN cells_NNS upon_IN activation_NN with_IN mitogens_NNS but_CC not_RB with_IN exogenous_JJ IL-2_NN growth_NN factor_NN ._.
 However_RB ,_, the_DT signaling_NN requirements_NNS and_CC sensitivity_NN to_TO protein_NN synthesis_NN inhibitors_NNS differ_VBP considerably_RB ._.
 Only_RB the_DT activities_NNS for_IN NF-AT_NN and_CC AP-1_NN sites_NNS require_VBP two_CD signals_NNS for_IN optimal_JJ induction_NN ,_, i.e._FW ,_, PMA_NN plus_CC either_CC lectin_NN or_CC antibody_NN to_TO the_DT CD3_NN or_CC CD28_NN surface_NN molecules_NNS ._.
 Other_JJ factors_NNS are_VBP induced_VBN by_IN lectin_NN ,_, antibody_NN ,_, and/or_CC PMA_NN alone_RB ._.
 After_IN appropriate_JJ stimulation_NN ,_, both_CC NF-AT_NN and_CC AP-1_NN are_VBP peculiarly_RB sensitive_JJ to_TO the_DT protein_NN synthesis_NN inhibitor_NN anisomycin_NN ._.
 Our_PRP$ data_NNS correlate_VBP the_DT activity_NN of_IN NF-AT_NN and_CC AP-1_NN in_IN gel_NN shift_NN assays_NNS with_IN the_DT two_CD signals_NNS requirements_NNS for_IN IL-2_NN gene_NN expression_NN ._.
 An_DT erythroid_JJ specific_JJ enhancer_NN upstream_JJ to_TO the_DT gene_NN encoding_VBG the_DT cell-type_JJ specific_JJ transcription_NN factor_NN GATA-1_NN ._.
 The_DT transcription_NN factor_NN GATA-1_NN is_VBZ expressed_VBN in_IN a_DT subset_NN of_IN hemopoietic_JJ cells_NNS ,_, where_WRB it_PRP mediates_VBZ the_DT cell-type_JJ specific_JJ expression_NN of_IN several_JJ genes_NNS ._.
 We_PRP have_VBP cloned_VBN the_DT mouse_NN and_CC human_JJ GATA-1_NN genes_NNS ._.
 A_DT region_NN upstream_JJ to_TO the_DT first_JJ exon_NN ,_, and_CC highly_RB conserved_VBN between_IN mouse_NN and_CC man_NN ,_, acts_VBZ as_IN an_DT erythroid_JJ specific_JJ enhancer_NN in_IN transient_JJ assays_NNS ,_, if_IN linked_VBN to_TO the_DT GATA-1_NN or_CC to_TO the_DT SV40_NN promoter_NN ._.
 The_DT activity_NN of_IN the_DT enhancer_NN is_VBZ almost_RB completely_RB dependent_JJ on_IN the_DT integrity_NN of_IN a_DT dimeric_JJ GATA-1_NN binding_NN site_NN ._.
 Demonstration_NN of_IN a_DT 1,25-dihydroxyvitamin_NN D3-responsive_JJ protein_NN in_IN human_JJ lymphocytes_NNS :_: immunologic_JJ crossreactivity_NN and_CC inverse_JJ regulation_NN with_IN the_DT vitamin_NN D_NN receptor_NN ._.
 Using_VBG Western_NN blot_NN analysis_NN with_IN a_DT monoclonal_JJ antibody_NN recognizing_VBG a_DT 17-amino_NN acid_NN epitope_NN of_IN the_DT 1,25-dihydroxyvitamin_NN D3_NN (_( 1,25(OH)2D3_NN )_) receptor_NN ,_, we_PRP have_VBP detected_VBN two_CD crossreacting_VBG proteins_NNS in_IN activated_VBN normal_JJ human_JJ lymphocytes_NNS ._.
 The_DT smaller_JJR of_IN the_DT two_CD proteins_NNS (_( 50_CD kDa_NN )_) was_VBD indistinguishable_JJ from_IN the_DT classical_JJ 1,25(OH)2D3_NN receptor_NN and_CC ,_, similar_JJ to_TO the_DT classical_JJ 1,25(OH)2D3_NN receptor_NN ,_, was_VBD upregulated_VBN in_IN a_DT dose-dependent_JJ fashion_NN by_IN 1,25(OH)2D3_NN ._.
 The_DT larger_JJR crossreacting_VBG protein_NN exhibited_VBD an_DT electrophoretic_JJ mobility_NN of_IN 80_CD kDa_NN ,_, was_VBD localized_JJ in_IN the_DT cell_NN cytosol_NN ,_, and_CC appeared_VBD to_TO be_VB specific_JJ for_IN activated_VBN lymphocytes_NNS since_IN it_PRP was_VBD not_RB detected_VBN in_IN several_JJ other_JJ human_JJ cells_NNS including_VBG monocytes_NNS ._.
 More_RBR strikingly_RB ,_, the_DT 80-kDa_JJ protein_NN was_VBD downregulated_VBN in_IN a_DT dose-dependent_JJ fashion_NN by_IN 1,25(OH)2D3_NN ;_: this_DT effect_NN was_VBD independent_JJ of_IN the_DT mode_NN of_IN lymphocyte_NN activation_NN and_CC specific_JJ for_IN the_DT 1,25(OH)2D3_NN metabolite_NN of_IN vitamin_NN D3_NN ._.
 However_RB ,_, two_CD potent_JJ immunosuppressive_JJ agents_NNS ,_, glucocorticoids_NNS and_CC cyclosporin_NN A_DT ,_, also_RB inhibited_VBD the_DT 80-kDa_JJ protein_NN ._.
 T-helper-cell_JJ determinants_NNS in_IN protein_NN antigens_NNS are_VBP preferentially_RB located_JJ in_IN cysteine-rich_JJ antigen_NN segments_NNS resistant_JJ to_TO proteolytic_JJ cleavage_NN by_IN cathepsin_NN B_NN ,_, L_NN ,_, and_CC D_NN ._.
 We_PRP report_VBP on_IN a_DT computer_NN algorithm_NN capable_JJ of_IN predicting_VBG the_DT location_NN of_IN T-helper-cell_NN epitopes_NNS in_IN protein_NN antigen_NN (_( Ag_NN )_) by_IN analysing_VBG the_DT Ag_NN amino_NN acid_NN sequence_NN ._.
 The_DT algorithm_NN was_VBD constructed_VBN with_IN the_DT aim_NN of_IN identifying_VBG segments_NNS in_IN Ag_NN which_WDT are_VBP resistant_JJ to_TO proteolytic_JJ degradation_NN by_IN the_DT enzymes_NNS cathepsin_NN B_NN ,_, L_NN ,_, and_CC D_NN ._.
 These_DT are_VBP prominent_JJ enzymes_NNS in_IN the_DT endocytic_JJ pathway_NN through_IN which_WDT soluble_JJ protein_NN Ag_NN enter_VBP APC_NN ,_, and_CC resistant_JJ segments_NNS in_IN Ag_NN may_MD ,_, therefore_RB ,_, be_VB expected_VBN to_TO contain_VB more_JJR T-cell_NN determinants_NNS than_IN susceptible_JJ segments_NNS ._.
 From_IN information_NN available_JJ in_IN the_DT literature_NN on_IN the_DT substrate_JJ specificity_NN of_IN the_DT three_CD enzymes_NNS ,_, it_PRP is_VBZ clear_JJ that_IN a_DT cysteine_NN is_VBZ not_RB accepted_VBN in_IN any_DT of_IN the_DT S2_NN ,_, S1_NN ,_, S1'_NN ,_, and_CC S2'_NN subsites_NNS of_IN cathepsin_NN B_NN and_CC L_NN ,_, and_CC not_RB in_IN the_DT S1_NN and_CC S1'_NN subsites_NNS of_IN cathepsin_NN D_NN ._.
 Moreover_RB ,_, we_PRP have_VBP noticed_VBN that_IN cysteine-containing_JJ T-cell_NN determinants_NNS in_IN a_DT number_NN of_IN protein_NN Ag_NN are_VBP particularly_RB rich_JJ in_IN the_DT amino_NN acids_NNS alanine_NN ,_, glycine_NN ,_, lysine_NN ,_, leucine_NN ,_, serine_NN ,_, threonine_NN ,_, and_CC valine_NN ._.
 By_IN searching_VBG protein_NN Ag_NN for_IN clusters_NNS of_IN amino_NN acids_NNS containing_VBG cysteine_NN and_CC two_CD of_IN the_DT other_JJ amino_NN acids_NNS we_PRP were_VBD able_JJ to_TO predict_VB 17_CD out_IN of_IN 23_CD empirically_RB known_VBN T-cell_NN determinants_NNS in_IN the_DT Ag_NN with_IN a_DT relatively_RB low_JJ number_NN of_IN false_JJ (_( positive_JJ )_) predictions_NNS ._.
 Furthermore_RB ,_, we_PRP present_VBP a_DT new_JJ principle_NN for_IN searching_VBG Ag_NN for_IN potential_JJ amphipatic_JJ alpha-helical_JJ protein_NN segments_NNS ._.
 Such_JJ segments_NNS accord_VBP well_RB with_IN empirically_RB known_JJ T-cell_NN determinants_NNS and_CC our_PRP$ algorithm_NN produces_VBZ a_DT lower_JJR number_NN of_IN false_JJ positive_JJ predictions_NNS than_IN the_DT principle_NN based_VBN on_IN discrete_JJ Fourier_NN transformations_NNS previously_RB described_VBN ._.
 A_DT human_JJ putative_JJ lymphocyte_NN G0/G1_NN switch_NN gene_NN containing_VBG a_DT CpG-rich_JJ island_NN encodes_VBZ a_DT small_JJ basic_JJ protein_NN with_IN the_DT potential_NN to_TO be_VB phosphorylated_VBN ._.
 Genes_NNS actively_RB involved_VBN in_IN the_DT G0/G1_NN switch_NN (_( G0S_NN genes_NNS )_) may_MD be_VB differentially_RB expressed_VBN during_IN the_DT lectin-induced_JJ switch_NN of_IN lymphocytes_NNS from_IN the_DT G0_NN to_TO the_DT G1_NN phases_NNS of_IN the_DT cell_NN cycle_NN ._.
 This_DT paper_NN presents_VBZ studies_NNS of_IN G0S2_NN ,_, a_DT member_NN of_IN a_DT set_NN of_IN putative_JJ G0S_NN genes_NNS ,_, for_IN which_WDT cDNAs_NNS were_VBD cloned_VBN and_CC selected_VBN on_IN the_DT basis_NN of_IN differential_JJ cDNA_NN hybridization_NN ._.
 G0S2_NN mRNA_NN increases_VBZ transiently_RB within_IN 1-2_CD hr_NN of_IN the_DT addition_NN of_IN lectin_NN or_CC cycloheximide_NN to_TO cultured_VBN blood_NN mononuclear_JJ cells_NNS ._.
 Comparison_NN of_IN a_DT nearly_RB full-length_JJ cDNA_NN sequence_NN with_IN the_DT corresponding_JJ genomic_JJ sequence_NN reveals_VBZ one_CD small_JJ intron_NN and_CC an_DT open_JJ reading_NN frame_NN in_IN the_DT second_JJ exon_NN ._.
 The_DT derived_VBN 103-amino-acid_JJ basic_JJ protein_NN has_VBZ two_CD potential_JJ alpha-helical_JJ domains_NNS separated_VBN by_IN a_DT hydrophobic_JJ region_NN with_IN the_DT potential_NN to_TO generate_VB turns_NNS and_CC assume_VB a_DT beta-sheet_JJ conformation_NN ._.
 Consistent_JJ with_IN involvement_NN in_IN the_DT G0/G1_NN switch_NN ,_, the_DT protein_NN contains_VBZ potential_JJ sites_NNS for_IN phosphorylation_NN by_IN protein_NN kinase_NN C_NN and_CC casein_NN kinase_NN II_CD ._.
 The_DT gene_NN contains_VBZ a_DT CpG-rich_JJ island_NN suggesting_VBG expression_NN in_IN the_DT germ_NN line_NN ._.
 An_DT upstream_JJ segment_NN contains_VBZ tandem_JJ dinucleotide_NN repeats_NNS (CT)19/(CA)16_NN ._.
 There_EX is_VBZ a_DT suitably_RB located_JJ TATA_NN box_NN ,_, but_CC potential_JJ sites_NNS for_IN CCAAT-box_NN binding_NN factors_NNS are_VBP far_RB upstream_JJ ,_, embedded_JJ in_IN a_DT 42-nucleotide_JJ repeat_NN element_NN ._.
 Potential_JJ sites_NNS for_IN transcription_NN factors_NNS AP1_NN ,_, AP2_NN ,_, and_CC AP3_NN are_VBP consistent_JJ with_IN rapid_JJ transcriptional_JJ activation_NN in_IN response_NN to_TO inducing_VBG agents_NNS ._.
 Synergism_NN between_IN two_CD distinct_JJ elements_NNS of_IN the_DT HTLV-I_NN enhancer_NN during_IN activation_NN by_IN the_DT trans-activator_NN of_IN HTLV-I_NN ._.
 We_PRP have_VBP conducted_VBN functional_JJ studies_NNS of_IN the_DT enhancer_NN elements_NNS of_IN human_JJ T-cell_NN leukemia_NN virus_NN type_NN I_CD (_( HTLV-I_NN )_) using_VBG the_DT human_JJ T-cell_NN lines_NNS Jurkat_NN and_CC MOLT_NN 4_CD ,_, which_WDT are_VBP negative_JJ for_IN HTLV-I_NN ,_, and_CC MT-2_NN and_CC TL-Mor_NN ,_, which_WDT carry_VBP the_DT proviral_JJ genome_NN of_IN HTLV-I_NN ._.
 Two_CD distinct_JJ elements_NNS have_VBP been_VBN implicated_VBN in_IN function_NN of_IN the_DT HTLV-I_NN enhancer_NN ._.
 One_CD is_VBZ the_DT 21-base-pair_JJ (_( bp_NN )_) core_NN element_NN that_WDT is_VBZ responsible_JJ for_IN trans-activation_NN by_IN the_DT HTLV-I_NN trans-activator_NN p40tax_NN and_CC that_WDT has_VBZ the_DT ability_NN to_TO bind_VB to_TO cyclic-AMP_NN responsive_JJ element_NN binding_NN factor_NN (_( CREB_NN )_) -like_JJ factor_NN (_( s_NNS )_) ._.
 The_DT other_JJ is_VBZ a_DT region_NN interposed_VBN between_IN the_DT 21-bp_JJ elements_NNS ._.
 In_IN this_DT study_NN we_PRP demonstrate_VBP that_IN a_DT subfragment_NN (_( C26_NN )_) in_IN the_DT region_NN between_IN the_DT 21-bp_JJ elements_NNS is_VBZ involved_VBN in_IN trans-activation_NN by_IN p40tax_NN ,_, possibly_RB through_IN binding_NN to_TO an_DT NF-kappa_NN B-like_JJ nuclear_JJ factor_NN or_CC factors_NNS ._.
 Formation_NN of_IN the_DT protein-DNA_JJ complex_NN with_IN the_DT C26_NN subfragment_NN was_VBD positively_RB affected_VBN by_IN p40tax_NN ._.
 The_DT C26_NN element_NN conferred_VBD partial_JJ responsiveness_NN to_TO p40tax_NN when_WRB linked_VBN to_TO one_CD copy_NN of_IN the_DT 21-bp_JJ element_NN that_WDT ,_, by_IN itself_PRP ,_, showed_VBD little_JJ activation_NN in_IN response_NN to_TO p40tax_NN ._.
 However_RB ,_, the_DT C26_NN element_NN alone_RB ,_, even_RB when_WRB repeated_VBN ,_, could_MD not_RB be_VB activated_VBN by_IN p40tax_NN ,_, unlike_IN other_JJ NF-kappa_NN B-binding_JJ elements_NNS ._.
 In_IN contrast_NN ,_, the_DT C26_NN element_NN itself_PRP was_VBD profoundly_RB activated_VBN upon_IN stimulation_NN with_IN 12-O-tetradecanoylphorbol-13-acetate_NN ._.
 These_DT findings_NNS therefore_RB suggest_VBP that_IN the_DT HTLV-I_NN enhancer_NN contains_VBZ multiple_JJ functional_JJ elements_NNS ,_, including_VBG binding_VBG sites_NNS for_IN at_IN least_JJS CREB-_NN and_CC NF-kappa_NN B-like_JJ factors_NNS ,_, which_WDT synergistically_RB cooperate_VBP in_IN activation_NN of_IN the_DT HTLV-I_NN enhancer_NN in_IN response_NN to_TO p40tax_NN ._.
 Our_PRP$ results_NNS also_RB demonstrate_VBP that_IN TPA-dependent_JJ activation_NN of_IN the_DT HTLV-I_NN enhancer_NN may_MD be_VB mediated_VBN through_IN the_DT C26_NN element_NN ._.
 v-erbA_NN overexpression_NN is_VBZ required_VBN to_TO extinguish_VB c-erbA_NN function_NN in_IN erythroid_JJ cell_NN differentiation_NN and_CC regulation_NN of_IN the_DT erbA_NN target_NN gene_NN CAII_NN ._.
 The_DT v-erbA_NN oncoprotein_NN represents_VBZ a_DT retrovirus-transduced_JJ oncogenic_JJ version_NN of_IN the_DT thyroid_NN hormone_NN (_( T3/T4_NN )_) receptor_NN c-erbA_NN (_( type_NN alpha_NN )_) ._.
 It_PRP contributes_VBZ to_TO virus-induced_JJ erythroleukemia_NN by_IN efficiently_RB arresting_VBG differentiation_NN of_IN red_JJ cell_NN progenitors_NNS and_CC by_IN suppressing_VBG transcription_NN of_IN erythrocyte-specific_JJ genes_NNS ._.
 Here_RB ,_, we_PRP show_VBP that_IN v-erbA_NN and_CC c-erbA_NN bind_VBP directly_RB to_TO sequences_NNS within_IN the_DT promoter_NN of_IN the_DT erythrocyte-specific_JJ carbonic_JJ anhydrase_NN II_CD (_( CAII_NN )_) ,_, a_DT gene_NN whose_WP$ transcription_NN is_VBZ efficiently_RB suppressed_VBN by_IN v-erbA_NN ._.
 This_DT erbA-binding_JJ site_NN confers_VBZ thyroid_NN hormone_NN responsiveness_NN to_TO a_DT heterologous_JJ promoter_NN in_IN transient_JJ expression_NN experiments_NNS and_CC is_VBZ a_DT target_NN for_IN efficient_JJ down-regulation_NN of_IN CAII_NN transcription_NN by_IN the_DT v-erbA_NN oncoprotein_NN ._.
 In_IN stably_RB transformed_VBN erythroblasts_NNS coexpressing_VBG the_DT v-erbA_NN oncoprotein_NN and_CC the_DT c-erbA/T3_NN receptor_NN at_IN an_DT approximately_RB equimolar_JJ ratio_NN ,_, c-erbA_NN activity_NN is_VBZ dominant_JJ over_IN v-erbA_NN ._.
 T3_NN efficiently_RB induced_VBD erythroid_JJ differentiation_NN in_IN these_DT cells_NNS ,_, thus_RB overcoming_VBG the_DT v-erbA-mediated_JJ differentiation_NN arrest_NN ._.
 Likewise_RB ,_, T3_NN activated_VBD CAII_NN transcription_NN as_RB well_RB as_IN transient_JJ expression_NN of_IN a_DT T3-responsive_JJ reporter_NN gene_NN containing_VBG the_DT CAII-specific_JJ erbA-binding_JJ site_NN ._.
 The_DT c-erbA-dependent_JJ activation_NN of_IN this_DT CAII_NN reporter_NN construct_NN could_MD only_RB be_VB suppressed_VBN by_IN very_RB high_JJ amounts_NNS of_IN v-erbA_NN ._.
 Our_PRP$ results_NNS suggest_VBP that_IN overexpression_NN of_IN v-erbA_NN is_VBZ required_VBN for_IN its_PRP$ function_NN as_IN an_DT oncoprotein_NN ._.
 Inhibition_NN of_IN phorbol_NN ester-induced_JJ monocytic_JJ differentiation_NN by_IN dexamethasone_NN is_VBZ associated_VBN with_IN down-regulation_NN of_IN c-fos_NN and_CC c-jun_NN (_( AP-1_NN )_) ._.
 Previous_JJ studies_NNS have_VBP shown_VBN that_IN treatment_NN of_IN human_JJ myeloid_JJ leukemia_NN cells_NNS with_IN 12-O-tetradecanoylphorbol-13-acetate_NN (_( TPA_NN )_) is_VBZ associated_VBN with_IN induction_NN of_IN monocytic_JJ differentiation_NN and_CC expression_NN of_IN the_DT c-jun_NN and_CC c-fos_NN early_JJ response_NN genes_NNS ._.
 The_DT present_JJ work_NN demonstrates_VBZ that_IN the_DT glucocorticoid_NN dexamethasone_NN inhibits_VBZ TPA-induced_JJ increases_NNS in_IN c-jun_NN and_CC c-fos_NN mRNA_NN levels_NNS in_IN U-937_NN leukemia_NN cells_NNS ._.
 These_DT findings_NNS were_VBD associated_VBN with_IN a_DT block_NN in_IN appearance_NN of_IN the_DT monocytic_JJ phenotype_NN ,_, including_VBG inhibition_NN of_IN TPA-induced_JJ increases_NNS in_IN lamin_NN A_NN ,_, lamin_NN C_NN ,_, and_CC vimentin_NN transcripts_NNS ._.
 Other_JJ studies_NNS have_VBP demonstrated_VBN that_IN TPA-induced_JJ monocytic_JJ differentiation_NN and_CC expression_NN of_IN the_DT c-jun_NN and_CC c-fos_NN genes_NNS in_IN myeloid_JJ leukemia_NN cells_NNS are_VBP regulated_VBN by_IN protein_NN kinase_NN C_NN (_( PKC_NN )_) ._.
 The_DT finding_NN that_IN dexamethasone_NN has_VBZ no_DT effect_NN on_IN TPA-induced_JJ activation_NN of_IN PKC_NN suggests_VBZ that_IN this_DT glucocorticoid_NN inhibits_VBZ signals_NNS downstream_JJ or_CC parallel_JJ to_TO this_DT enzyme_NN ._.
 Nuclear_JJ run-on_JJ assays_NNS demonstrate_VBP that_IN :_: (_( 1_LS )_) induction_NN of_IN c-jun_NN and_CC c-fos_NN expression_NN by_IN TPA_NN is_VBZ regulated_VBN by_IN transcriptional_JJ mechanisms_NNS ,_, (_( 2_LS )_) TPA-induced_JJ expression_NN of_IN c-jun_NN and_CC c-fos_NN does_VBZ not_RB require_VB protein_NN synthesis_NN ,_, and_CC (_( 3_LS )_) TPA-induced_JJ expression_NN of_IN both_DT genes_NNS is_VBZ inhibited_VBN at_IN the_DT transcriptional_JJ level_NN by_IN dexamethasone_NN ._.
 To_TO further_RB define_VB the_DT effects_NNS of_IN dexamethasone_NN at_IN the_DT molecular_JJ level_NN ,_, we_PRP prepared_VBD a_DT series_NN of_IN deleted_VBN c-jun_NN promoter_NN fragments_NNS linked_VBN to_TO the_DT chloramphenicol_NN acetyltransferase_NN (_( CAT_NN )_) gene_NN ._.
 Increases_NNS in_IN CAT_NN activity_NN during_IN transient_JJ expression_NN of_IN these_DT constructs_NNS in_IN TPA-treated_JJ U-937_NN cells_NNS could_MD be_VB assigned_VBN to_TO the_DT region_NN (_( -97_CD to_TO -20_CD )_) of_IN the_DT promoter_NN that_WDT contains_VBZ the_DT AP-1_NN binding_NN site_NN ._.
 This_DT induction_NN of_IN CAT_NN activity_NN was_VBD sensitive_JJ to_TO dexamethasone_NN ._.
 These_DT findings_NNS suggest_VBP that_IN dexamethasone_NN down-regulates_VBZ TPA-induced_JJ transcription_NN of_IN the_DT c-jun_NN gene_NN during_IN monocytic_JJ differentiation_NN by_IN inhibiting_VBG activation_NN of_IN the_DT AP-1_NN site_NN ._.
 Charybdotoxin-sensitive_JJ ,_, Ca(2+)-dependent_JJ membrane_NN potential_JJ changes_NNS are_VBP not_RB involved_VBN in_IN human_JJ T_NN or_CC B_NN cell_NN activation_NN and_CC proliferation_NN ._.
 The_DT involvement_NN of_IN ion_NN channels_NNS in_IN B_NN and_CC T_NN lymphocyte_NN activation_NN is_VBZ supported_VBN by_IN many_JJ reports_NNS of_IN changes_NNS in_IN ion_NN fluxes_NNS and_CC membrane_NN potential_NN after_IN mitogen_NN binding_NN ._.
 Human_JJ T_NN and_CC B_NN lymphocytes_NNS demonstrate_VBP an_DT early_JJ and_CC transient_JJ hyperpolarization_NN after_IN ligand_JJ binding_NN ._.
 Inasmuch_RB as_IN the_DT change_NN in_IN membrane_NN potential_NN is_VBZ dependent_JJ on_IN elevation_NN of_IN free_JJ cytosolic_JJ calcium_NN ,_, the_DT hyperpolarization_NN is_VBZ presumably_RB through_IN opening_NN of_IN Ca(2+)-stimulated_JJ K+_NN channels_NNS ._.
 We_PRP have_VBP used_VBN charybdotoxin_NN ,_, a_DT known_JJ inhibitor_NN of_IN Ca(2+)-dependent_JJ K+_NN channels_NNS ,_, to_TO study_VB the_DT role_NN of_IN these_DT channels_NNS in_IN lymphocyte_NN activation_NN and_CC mitogenesis_NN ._.
 We_PRP demonstrate_VBP that_IN charybdotoxin_NN inhibits_VBZ the_DT ligand-induced_JJ transient_JJ membrane_NN hyperpolarization_NN in_IN B_NN and_CC T_NN cells_NNS in_IN a_DT dose-dependent_JJ fashion_NN ,_, without_IN affecting_VBG changes_NNS in_IN cytosolic_JJ Ca2+_NN ._.
 However_RB ,_, blockade_NN of_IN the_DT Ca(2+)-activated_JJ K+_NN channel_NN is_VBZ not_RB associated_VBN with_IN changes_NNS in_IN cell-cycle_JJ gene_NN activation_NN ,_, IL-2_NN production_NN ,_, IL-2R_NN expression_NN or_CC B_NN and_CC T_NN cell_NN mitogenesis_NN ._.
 These_DT results_NNS imply_VBP that_IN membrane_NN potential_JJ changes_NNS secondary_JJ to_TO the_DT ligand-dependent_JJ opening_NN of_IN Ca(2+)-activated_JJ K+_NN channels_NNS are_VBP not_RB involved_VBN in_IN B_NN and_CC T_NN lymphocyte_NN activation_NN and_CC mitogenesis_NN ._.
 Evaluation_NN of_IN the_DT role_NN of_IN ligand_NN and_CC thermal_JJ activation_NN of_IN specific_JJ DNA_NN binding_NN by_IN in_FW vitro_FW synthesized_VBN human_JJ glucocorticoid_NN receptor_NN ._.
 We_PRP have_VBP used_VBN a_DT DNA-binding/immunoprecipitation_JJ assay_NN to_TO analyze_VB the_DT capacity_NN of_IN human_JJ glucocorticoid_NN receptor_NN (_( hGR_NN )_) ,_, generated_VBN in_IN rabbit_NN reticulocyte_NN lysates_NNS ,_, to_TO bind_VB DNA_NN ._.
 In_FW vitro_FW translated_VBN hGR_NN was_VBD indistinguishable_JJ from_IN native_JJ hGR_NN ,_, as_IN determined_VBN by_IN migration_NN on_IN sodium_NN dodecyl_NN sulfate-polyacrylamide_JJ gels_NNS ,_, sedimentation_NN on_IN sucrose_NN density_NN gradients_NNS ,_, and_CC reactivity_NN with_IN antipeptide_JJ antibodies_NNS generated_VBN against_IN hGR_NN ._.
 In_IN addition_NN ,_, cell-free_JJ synthesized_VBN hGR_NN was_VBD capable_JJ of_IN specific_JJ binding_NN to_TO glucocorticoid_NN response_NN element_NN (_( GRE_NN )_) -containing_JJ DNA_NN fragments_NNS ._.
 Using_VBG this_DT assay_NN system_NN ,_, we_PRP have_VBP evaluated_VBN the_DT contributions_NNS of_IN ligand_NN binding_NN and_CC heat_NN activation_NN to_TO DNA_NN binding_NN by_IN these_DT glucocorticoid_NN receptors_NNS ._.
 In_FW vitro_FW translated_VBN hGR_NN was_VBD capable_JJ of_IN selective_JJ DNA_NN binding_NN even_RB in_IN the_DT absence_NN of_IN glucocorticoid_NN ._.
 Treatment_NN with_IN dexamethasone_NN or_CC the_DT antiglucocorticoid_JJ RU486_NN had_VBD no_DT additional_JJ effect_NN on_IN the_DT DNA-binding_JJ capacity_NN when_WRB receptor_NN preparations_NNS were_VBD maintained_VBN at_IN 0_CD C_NN (_( no_DT activation_NN )_) ._.
 In_IN contrast_NN ,_, addition_NN of_IN either_CC ligand_NN or_CC antagonist_NN in_IN combination_NN with_IN a_DT heat_NN activation_NN step_NN promoted_VBD DNA_NN binding_NN by_IN approximately_RB 3-fold_RB over_IN that_DT of_IN heat-activated_JJ unliganded_JJ receptors_NNS ._.
 Agonist_NN (_( dexamethasone_NN )_) was_VBD slightly_RB more_JJR effective_JJ in_IN supporting_VBG specific_JJ DNA_NN binding_NN than_IN antagonist_NN (_( RU486_NN )_) ._.
 DNA_NN binding_NN by_IN in_FW vitro_FW synthesized_VBN GR_NN was_VBD blocked_VBN by_IN the_DT addition_NN of_IN sodium_NN molybdate_NN to_TO the_DT receptor_NN preparations_NNS before_IN steroid_NN addition_NN and_CC thermal_JJ activation_NN ._.
 Addition_NN of_IN KCl_NN resulted_VBD in_IN less_RBR DNA_NN binding_NN either_CC due_JJ to_TO blockage_NN of_IN DNA-receptor_JJ complex_NN formation_NN or_CC disruption_NN of_IN the_DT complexes_NNS ._.
 The_DT specificity_NN of_IN DNA_NN binding_NN by_IN cell-free_JJ synthesized_VBN hGR_NN was_VBD analyzed_VBN further_RB by_IN examining_VBG the_DT abilities_NNS of_IN various_JJ DNAs_NNS to_TO compete_VB for_IN binding_VBG to_TO a_DT naturally_RB occurring_VBG GRE_NN found_VBD in_IN the_DT mouse_NN mammary_JJ tumor_NN virus-long_JJ terminal_JJ repeat_NN ._.
 Oligonucleotides_NNS containing_VBG the_DT consensus_NN GRE_NN were_VBD the_DT most_RBS efficient_JJ competitors_NNS ,_, and_CC fragments_NNS containing_VBG regulatory_JJ sequences_NNS from_IN glucocorticoid-repressible_JJ genes_NNS were_VBD somewhat_RB competitive_JJ ,_, whereas_IN single_JJ stranded_JJ oligonucleotides_NNS were_VBD unable_JJ to_TO compete_VB for_IN mouse_NN mammary_JJ tumor_NN virus-long_JJ terminal_JJ repeat_NN DNA_NN binding_NN ,_, except_IN when_WRB competitor_NN was_VBD present_JJ at_IN extremely_RB high_JJ concentrations_NNS ._.
 Together_RB these_DT studies_NNS indicate_VBP that_IN hGR_NN synthesized_VBN in_IN rabbit_NN reticulocyte_NN lysates_NNS displays_VBZ many_JJ of_IN the_DT same_JJ properties_NNS ,_, including_VBG GRE-specific_JJ DNA_NN binding_NN ,_, observed_VBN for_IN glucocorticoid_NN receptor_NN present_JJ in_IN cytosolic_JJ extracts_NNS of_IN mammalian_JJ cells_NNS and_CC tissues_NNS ._.
 Similarities_NNS between_IN the_DT effects_NNS of_IN dexamethasone_NN and_CC RU486_NN suggest_VBP that_IN the_DT antiglucocorticoid_JJ properties_NNS of_IN RU486_NN do_VBP not_RB occur_VB at_IN the_DT level_NN of_IN specific_JJ DNA_NN binding_NN ._.
 One_CD base_NN pair_NN change_NN abolishes_VBZ the_DT T_NN cell-restricted_JJ activity_NN of_IN a_DT kB-like_JJ proto-enhancer_NN element_NN from_IN the_DT interleukin_NN 2_CD promoter_NN ._.
 The_DT inducible_JJ ,_, T_NN cell-specific_JJ enhancers_NNS of_IN murine_JJ and_CC human_JJ Interleukin_NN 2_CD (_( Il-2_NN )_) genes_NNS contain_VBP the_DT kB-like_JJ sequence_NN GGGATTTCACC_NN as_IN an_DT essential_JJ cis-acting_JJ enhancer_NN motif_NN ._.
 When_WRB cloned_VBN in_IN multiple_JJ copies_NNS this_DT so-called_JJ TCEd_NN (_( distal_JJ T_NN cell_NN element_NN )_) acts_VBZ as_IN an_DT inducible_JJ proto-enhancer_NN element_NN in_IN E14_NN T_NN lymphoma_NN cells_NNS ,_, but_CC not_RB in_IN HeLa_NN cells_NNS ._.
 In_IN extracts_NNS of_IN induced_VBN ,_, Il-2_NN secreting_NN El4_NN cells_NNS three_CD individual_JJ protein_NN factors_NNS bind_VBP to_TO TCEd_NN DNA_NN ._.
 The_DT binding_NN of_IN the_DT most_RBS prominent_JJ factor_NN ,_, named_VBN TCF-1_NN (_( T_NN cell_NN factor_NN 1_CD )_) ,_, is_VBZ correlated_VBN with_IN the_DT proto-enhancer_NN activity_NN of_IN TCEd_NN ._.
 TCF-1_NN consists_VBZ of_IN two_CD polypeptides_NNS of_IN about_RB 50_CD kD_NN and_CC 105_CD kD_NN ;_: the_DT former_JJ seems_VBZ to_TO be_VB related_JJ to_TO the_DT 50_CD kD_NN polypeptide_NN of_IN NF-kB_NN ._.
 Purified_VBN NF-kB_NN is_VBZ also_RB able_JJ to_TO bind_VB to_TO the_DT TCEd_NN ,_, but_CC TCF-1_NN binds_VBZ stronger_JJR than_IN NF-kB_NN to_TO TCEd_NN DNA_NN ._.
 The_DT conversion_NN of_IN the_DT TCEd_NN to_TO a_DT '_[[DQS]] perfect_JJ '_[[DQE]] NF-kB_NN binding_NN site_NN leads_VBZ to_TO a_DT tighter_JJR binding_NN of_IN NF-kB_NN to_TO TCEd_NN DNA_NN and_CC ,_, as_IN a_DT functional_JJ consequence_NN ,_, to_TO the_DT activity_NN of_IN the_DT '_[[DQS]] converted_VBN '_[[DQE]] TCEd_NN motifs_NNS in_IN HeLa_NN cells_NNS ._.
 Thus_RB ,_, the_DT substitution_NN of_IN the_DT underlined_VBN A_NN residue_NN to_TO a_DT C_NN within_IN the_DT GGGATTTCACC_NN motif_NN abolishes_VBZ its_PRP$ T_NN cell-restricted_JJ activity_NN and_CC leads_VBZ to_TO its_PRP$ functioning_VBG in_IN both_CC El4_NN cells_NNS and_CC HeLa_NN cells_NNS ._.
 These_DT results_NNS indicate_VBP that_IN lymphocyte-specific_JJ factors_NNS binding_VBG to_TO the_DT TCEd_NN are_VBP involved_VBN in_IN the_DT control_NN of_IN T_NN cell_NN specific-transcription_NN of_IN the_DT Il-2_NN gene_NN ._.
 Negative_JJ regulation_NN of_IN human_JJ immunodeficiency_NN virus_NN type_NN 1_CD expression_NN in_IN monocytes_NNS :_: role_NN of_IN the_DT 65-kDa_JJ plus_CC 50-kDa_JJ NF-kappa_NN B_NN dimer_NN ._.
 Although_IN monocytic_JJ cells_NNS can_MD provide_VB a_DT reservoir_NN for_IN viral_JJ production_NN in_FW vivo_FW ,_, their_PRP$ regulation_NN of_IN human_JJ immunodeficiency_NN virus_NN type_NN 1_CD (_( HIV-1_NN )_) transcription_NN can_MD be_VB either_CC latent_JJ ,_, restricted_JJ ,_, or_CC productive_JJ ._.
 These_DT differences_NNS in_IN gene_NN expression_NN have_VBP not_RB been_VBN molecularly_RB defined_VBN ._.
 In_IN THP-1_NN cells_NNS with_IN restricted_JJ HIV_NN expression_NN ,_, there_EX is_VBZ an_DT absence_NN of_IN DNA-protein_JJ binding_NN complex_NN formation_NN with_IN the_DT HIV-1_NN promoter-enhancer_NN associated_VBN with_IN markedly_RB less_JJR viral_JJ RNA_NN production_NN ._.
 This_DT absence_NN of_IN binding_NN was_VBD localized_JJ to_TO the_DT NF-kappa_NN B_NN region_NN of_IN the_DT HIV-1_NN enhancer_NN ;_: the_DT 65-kDa_JJ plus_CC 50-kDa_JJ NF-kappa_NN B_NN heterodimer_NN was_VBD preferentially_RB lost_VBN ._.
 Adding_VBG purified_VBN NF-kappa_NN B_NN protein_NN to_TO nuclear_JJ extracts_NNS from_IN cells_NNS with_IN restricted_JJ expression_NN overcomes_VBZ this_DT lack_NN of_IN binding_NN ._.
 In_IN addition_NN ,_, treatment_NN of_IN these_DT nuclear_JJ extracts_NNS with_IN sodium_NN deoxycholate_NN restored_VBD their_PRP$ ability_NN to_TO form_VB the_DT heterodimer_NN ,_, suggesting_VBG the_DT presence_NN of_IN an_DT inhibitor_NN of_IN NF-kappa_NN B_NN activity_NN ._.
 Furthermore_RB ,_, treatment_NN of_IN nuclear_JJ extracts_NNS from_IN these_DT cells_NNS that_WDT had_VBD restricted_JJ expression_NN with_IN lipopolysaccharide_NN increased_VBD viral_JJ production_NN and_CC NF-kappa_NN B_NN activity_NN ._.
 Antiserum_NN specific_JJ for_IN NF-kappa_NN B_NN binding_NN proteins_NNS ,_, but_CC not_RB c-rel-specific_JJ antiserum_NN ,_, disrupted_VBD heterodimer_NN complex_NN formation_NN ._.
 Thus_RB ,_, both_DT NF-kappa_NN B-binding_JJ complexes_NNS are_VBP needed_VBN for_IN optimal_JJ viral_JJ transcription_NN ._.
 Binding_NN of_IN the_DT 65-kDa_JJ plus_CC 50-kDa_JJ heterodimer_NN to_TO the_DT HIV-1_NN enhancer_NN can_MD be_VB negatively_RB regulated_VBN in_IN monocytes_NNS ,_, providing_VBG one_CD mechanism_NN restricting_VBG HIV-1_NN gene_NN expression_NN ._.
 Isolation_NN of_IN a_DT candidate_NN repressor/activator_NN ,_, NF-E1_NN (_( YY-1_NN ,_, delta_NN )_) ,_, that_WDT binds_VBZ to_TO the_DT immunoglobulin_NN kappa_NN 3'_JJ enhancer_NN and_CC the_DT immunoglobulin_NN heavy-chain_NN mu_NN E1_NN site_NN ._.
 We_PRP have_VBP determined_VBN that_IN the_DT developmental_JJ control_NN of_IN immunoglobulin_NN kappa_NN 3'_JJ enhancer_NN (_( kappa_NN E3'_NN )_) activity_NN is_VBZ the_DT result_NN of_IN the_DT combined_JJ influence_NN of_IN positive-_JJ and_CC negative-acting_JJ elements_NNS ._.
 We_PRP show_VBP that_IN a_DT central_JJ core_NN in_IN the_DT kappa_NN E3'_NN enhancer_NN is_VBZ active_JJ at_IN the_DT pre-B-cell_JJ stage_NN but_CC is_VBZ repressed_VBN by_IN flanking_VBG negative-acting_JJ elements_NNS ._.
 The_DT negative-acting_JJ sequences_NNS repress_VBP enhancer_NN activity_NN in_IN a_DT position-_NN and_CC orientation-independent_JJ manner_NN at_IN the_DT pre-B-cell_JJ stage_NN ._.
 We_PRP have_VBP isolated_VBN a_DT human_JJ cDNA_NN clone_NN encoding_VBG a_DT zinc_NN finger_NN protein_NN (_( NF-E1_NN )_) that_WDT binds_VBZ to_TO the_DT negative-acting_JJ segment_NN of_IN the_DT kappa_NN E3'_NN enhancer_NN ._.
 This_DT protein_NN also_RB binds_VBZ to_TO the_DT immunoglobulin_NN heavy-chain_NN enhancer_NN mu_NN E1_NN site_NN ._.
 NF-E1_NN is_VBZ encoded_VBN by_IN the_DT same_JJ gene_NN as_IN the_DT YY-1_NN protein_NN ,_, which_WDT binds_VBZ to_TO the_DT adeno-associated_JJ virus_NN P5_NN promoter_NN ._.
 NF-E1_NN is_VBZ also_RB the_DT human_JJ homologue_NN of_IN the_DT mouse_NN delta_NN protein_NN ,_, which_WDT binds_VBZ to_TO ribosomal_JJ protein_NN gene_NN promoters_NNS ._.
 The_DT predicted_VBN amino_NN acid_NN sequence_NN of_IN this_DT protein_NN contains_VBZ features_NNS characteristic_JJ of_IN transcriptional_JJ activators_NNS as_RB well_RB as_IN transcriptional_JJ repressors_NNS ._.
 Cotransfection_NN studies_NNS with_IN this_DT cDNA_NN indicate_VBP that_IN it_PRP can_MD repress_VB basal_JJ promoter_NN activity_NN ._.
 The_DT apparent_JJ dual_JJ function_NN of_IN this_DT protein_NN is_VBZ discussed_VBN ._.
 Clone_NN pAT_NN 133_CD identifies_VBZ a_DT gene_NN that_WDT encodes_VBZ another_DT human_JJ member_NN of_IN a_DT class_NN of_IN growth_NN factor-induced_JJ genes_NNS with_IN almost_RB identical_JJ zinc-finger_NN domains_NNS ._.
 We_PRP report_VBP the_DT structure_NN and_CC regulation_NN of_IN a_DT gene_NN represented_VBN by_IN clone_NN pAT_NN 133_CD ,_, which_WDT is_VBZ induced_VBN upon_IN transition_NN from_IN a_DT resting_JJ state_NN (_( G0_NN )_) through_IN the_DT early_JJ phase_NN of_IN the_DT cell_NN cycle_NN (_( G1_NN )_) ._.
 The_DT pAT_NN 133_CD gene_NN is_VBZ immediately_RB induced_VBN ,_, with_IN FOS-like_JJ kinetics_NNS ,_, in_IN human_JJ T_NN cells_NNS and_CC in_IN fibroblasts_NNS ._.
 Primary_JJ structure_NN analysis_NN showed_VBD that_IN the_DT encoded_VBN protein_NN contains_VBZ three_CD tandem_JJ zinc-finger_NN sequences_NNS of_IN the_DT type_NN Cys2-Xaa12-His2_NN ._.
 This_DT zinc-finger_NN region_NN ,_, which_WDT is_VBZ thought_VBN to_TO bind_VB DNA_NN in_IN a_DT sequence-specific_JJ manner_NN ,_, is_VBZ similar_JJ (_( greater_JJR than_IN 80_CD %_NN on_IN the_DT amino_NN acid_NN level_NN )_) to_TO two_CD previously_RB described_VBN transcription_NN factors_NNS pAT_NN 225/EGR1_NN and_CC pAT_NN 591/EGR2_NN ._.
 Except_IN for_IN the_DT conserved_VBN zinc-finger_NN domains_NNS ,_, the_DT amino_NN acid_NN sequences_NNS of_IN the_DT three_CD proteins_NNS are_VBP distinct_JJ ._.
 This_DT structural_JJ similarity_NN suggests_VBZ that_IN the_DT pAT_NN 133_CD gene_NN encodes_VBZ a_DT transcription_NN factor_NN with_IN a_DT specific_JJ biological_JJ function_NN ._.
 Comparing_VBG the_DT regulation_NN of_IN these_DT related_JJ zinc-finger-encoding_JJ genes_NNS showed_VBD coordinate_JJ induction_NN upon_IN mitogenic_JJ stimulation_NN of_IN resting_VBG T_NN lymphocytes_NNS and_CC of_IN resting_VBG fibroblasts_NNS ._.
 However_RB ,_, upon_IN transition_NN from_IN a_DT proliferating_JJ (_( G1_NN )_) to_TO a_DT resting_JJ state_NN of_IN the_DT cell_NN cycle_NN the_DT three_CD genes_NNS were_VBD differently_RB regulated_VBN ._.
 In_IN human_JJ histiocytic_JJ U937_NN cells_NNS mRNA_NN of_IN clone_NN pAT_NN 133_CD was_VBD constitutively_RB expressed_VBN ,_, whereas_IN mRNA_NN of_IN pAT_NN 225/EGR1_NN was_VBD induced_VBN upon_IN induction_NN of_IN terminal_JJ differentiation_NN ._.
 In_IN contrast_NN mRNA_NN representing_VBG pAT_NN 591/EGR2_NN was_VBD not_RB expressed_VBN in_IN these_DT cells_NNS ._.
 This_DT difference_NN in_IN gene_NN regulation_NN suggests_VBZ distinct_JJ biological_JJ roles_NNS in_IN the_DT control_NN of_IN cell_NN proliferation_NN for_IN the_DT respective_JJ proteins_NNS ._.
 cAMP-dependent_JJ regulation_NN of_IN proenkephalin_NN by_IN JunD_NN and_CC JunB_NN :_: positive_JJ and_CC negative_JJ effects_NNS of_IN AP-1_NN proteins_NNS ._.
 We_PRP demonstrate_VBP that_IN JunD_NN ,_, a_DT component_NN of_IN the_DT AP-1_NN transcription_NN factor_NN complex_NN ,_, activates_VBZ transcription_NN of_IN the_DT human_JJ proenkephalin_NN gene_NN in_IN a_DT fashion_NN that_WDT is_VBZ completely_RB dependent_JJ upon_IN the_DT cAMP-dependent_JJ protein_NN kinase_NN ,_, protein_NN kinase_NN A_NN ._.
 Activation_NN of_IN proenkephalin_NN transcription_NN by_IN JunD_NN is_VBZ dependent_JJ upon_IN a_DT previously_RB characterized_VBN cAMP-_NN ,_, phorbol_NN ester-_NN ,_, and_CC Ca(2+)-inducible_JJ enhancer_NN ,_, and_CC JunD_NN is_VBZ shown_VBN to_TO bind_VB the_DT enhancer_NN as_IN a_DT homodimer_NN ._.
 Another_DT component_NN of_IN the_DT AP-1_NN transcription_NN complex_NN ,_, JunB_NN ,_, is_VBZ shown_VBN to_TO inhibit_VB activation_NN mediated_VBN by_IN JunD_NN ._.
 As_IN a_DT homodimer_NN JunB_NN is_VBZ unable_JJ to_TO bind_VB the_DT enhancer_NN ;_: however_RB in_IN the_DT presence_NN of_IN c-Fos_NN ,_, high-affinity_JJ binding_NN is_VBZ observed_VBN ._.
 Furthermore_RB ,_, JunD_NN is_VBZ shown_VBN to_TO activate_VB transcription_NN of_IN genes_NNS linked_VBN to_TO both_CC cAMP_NN and_CC phorbol_NN ester_NN response_NN elements_NNS in_IN a_DT protein_NN kinase_NN A-dependent_JJ fashion_NN ,_, further_RB blurring_VBG the_DT distinction_NN between_IN these_DT response_NN elements_NNS ._.
 These_DT results_NNS demonstrate_VBP that_IN the_DT transcriptional_JJ activity_NN of_IN an_DT AP-1-related_JJ protein_NN is_VBZ regulated_VBN by_IN the_DT cAMP-dependent_JJ second-messenger_NN pathway_NN and_CC suggest_VBP that_IN JunD_NN and_CC other_JJ AP-1-related_JJ proteins_NNS may_MD play_VB an_DT important_JJ role_NN in_IN the_DT regulation_NN of_IN gene_NN expression_NN by_IN cAMP-dependent_JJ intracellular_JJ signaling_NN pathways_NNS ._.
 Glucocorticoid_NN resistance_NN in_IN chronic_JJ asthma_NN ._.
 Glucocorticoid_NN pharmacokinetics_NNS ,_, glucocorticoid_NN receptor_NN characteristics_NNS ,_, and_CC inhibition_NN of_IN peripheral_JJ blood_NN T_NN cell_NN proliferation_NN by_IN glucocorticoids_NNS in_FW vitro_FW ._.
 A_DT total_NN of_IN 37_CD chronic_JJ ,_, severe_JJ ,_, nonsmoking_JJ asthmatic_JJ patients_NNS with_IN documented_JJ|VBN reversible_JJ airways_NNS obstruction_NN were_VBD classified_VBN as_IN glucocorticoid-sensitive_JJ or_CC -resistant_JJ on_IN the_DT basis_NN of_IN changes_NNS in_IN FEV1_NN ,_, FVC_NN ,_, and_CC peak_JJ expiratory_NN flow_NN (_( PEF_NN )_) after_IN oral_JJ prednisolone_NN ._.
 The_DT resistant_JJ patients_NNS showed_VBD no_DT significant_JJ improvements_NNS in_IN airflow_NN limitation_NN ._.
 Phytohemagglutinin_NN (_( PHA_NN )_) -induced_JJ proliferation_NN of_IN peripheral_JJ blood_NN T_NN lymphocytes_NNS from_IN the_DT sensitive_JJ but_CC not_RB the_DT resistant_JJ asthmatic_JJ patients_NNS was_VBD significantly_RB (_( p_NN less_JJR than_IN 0.01_CD )_) inhibited_VBN by_IN dexamethasone_NN (_( 10(-7)_CD mol/L_NN )_) ,_, reflecting_VBG a_DT shift_NN of_IN the_DT dose-response_JJ curve_NN ._.
 When_WRB all_PDT the_DT asthmatic_JJ patients_NNS were_VBD analyzed_VBN together_RB ,_, there_EX was_VBD a_DT significant_JJ correlation_NN between_IN the_DT degree_NN of_IN sensitivity_NN of_IN T_NN cells_NNS to_TO dexamethasone_NN and_CC the_DT clinical_JJ responsiveness_NN to_TO prednisolone_JJ (_( p_NN less_RBR than_IN 0.01_CD )_) ._.
 No_DT differences_NNS were_VBD observed_VBN between_IN six_CD of_IN the_DT sensitive_JJ and_CC resistant_JJ patients_NNS in_IN the_DT clearance_NN of_IN plasma_NN prednisolone_JJ derived_VBN from_IN orally_RB administered_VBN prednisone_NN ._.
 Peripheral_JJ blood_NN mononuclear_JJ cell_NN glucocorticoid_NN receptors_NNS were_VBD also_RB characterized_VBN in_IN five_CD sensitive_JJ and_CC seven_CD resistant_JJ patients_NNS ._.
 The_DT numbers_NNS and_CC binding_NN affinities_NNS of_IN these_DT receptors_NNS could_MD not_RB account_VB for_IN the_DT observed_VBN difference_NN in_IN the_DT susceptibility_NN of_IN these_DT cells_NNS to_TO functional_JJ inhibition_NN by_IN dexamethasone_NN in_FW vitro_FW ._.
 These_DT results_NNS suggest_VBP that_IN clinical_JJ glucocorticoid_NN resistance_NN in_IN chronic_JJ asthma_NN does_VBZ not_RB reflect_VB abnormal_JJ glucocorticoid_NN clearance_NN but_CC may_MD be_VB due_JJ at_IN least_JJS partly_RB to_TO a_DT relative_JJ insensitivity_NN of_IN T_NN lymphocytes_NNS to_TO glucocorticoids_NNS ._.
 This_DT lack_NN of_IN sensitivity_NN is_VBZ unexplained_JJ but_CC is_VBZ not_RB attributable_JJ to_TO abnormalities_NNS of_IN cellular_JJ glucocorticoid_NN receptors_NNS ._.
 Regulation_NN of_IN interleukin-1_NN beta_NN production_NN by_IN glucocorticoids_NNS in_IN human_JJ monocytes_NNS :_: the_DT mechanism_NN of_IN action_NN depends_VBZ on_IN the_DT activation_NN signal_NN ._.
 Glucocorticoids_NNS are_VBP known_VBN to_TO downregulate_VB interleukin-1_NN beta_NN production_NN in_IN monocytic_JJ cells_NNS by_IN two_CD different_JJ mechanims_NNS :_: direct_JJ inhibition_NN of_IN the_DT gene_NN transcription_NN and_CC destabilization_NN of_IN the_DT preformed_JJ interleukin-1_NN beta_NN mRNA_NN ._.
 Now_RB we_PRP have_VBP examined_VBN the_DT effect_NN of_IN the_DT nature_NN of_IN the_DT monocyte_NN activating_NN signal_NN on_IN these_DT two_CD inhibitory_JJ mechanims_NNS ._.
 When_WRB human_JJ monocytes_NNS were_VBD preincubated_VBN with_IN dexamethasone_NN for_IN 1_CD hour_NN and_CC then_RB stimulated_VBN either_CC with_IN bacterial_JJ lipopolysaccharide_NN or_CC phorbol_NN myristate_NN ,_, it_PRP was_VBD found_VBN that_IN dexamethasone_NN inhibited_VBD the_DT lipopolysaccharide-induced_JJ interleukin-1_NN beta_NN protein_NN production_NN ,_, but_CC the_DT phorbol_NN myristate-induced_JJ production_NN was_VBD increased_VBN 3-10_CD fold_RB ._.
 This_DT difference_NN was_VBD also_RB seen_VBN at_IN the_DT mRNA_NN level_NN ._.
 When_WRB dexamethasone_NN was_VBD added_VBN to_TO the_DT cultures_NNS 3_CD hours_NNS after_IN the_DT stimulators_NNS ,_, it_PRP clearly_RB decreased_VBD the_DT interleukin-1_NN beta_NN mRNA_NN levels_NNS regardless_RB of_IN the_DT stimulator_NN used_VBN (_( although_IN the_DT effect_NN was_VBD clearly_RB weaker_JJR on_IN the_DT PMA-induced_JJ mRNA_NN )_) ._.
 Thus_RB these_DT data_NNS suggest_VBP that_IN the_DT phorbol_NN myristate-induced_JJ signal_NN (_( prolonged_JJ protein_NN kinase_NN C_NN activation_NN ?_. )_) can_MD not_RB be_VB inhibited_VBN by_IN prior_JJ incubation_NN with_IN dexamethasone_NN and_CC it_PRP also_RB protects_VBZ the_DT induced_VBN mRNA_NN for_IN the_DT degradative_JJ action_NN of_IN dexamethasone_NN ._.
 Identification_NN of_IN transcriptional_JJ suppressor_NN proteins_NNS that_WDT bind_VBP to_TO the_DT negative_JJ regulatory_JJ element_NN of_IN the_DT human_JJ immunodeficiency_NN virus_NN type_NN 1_CD ._.
 Two_CD different_JJ proteins_NNS which_WDT independently_RB bound_VBD to_TO neighboring_VBG sequences_NNS within_IN the_DT negative_JJ regulatory_JJ element_NN (_( NRE_NN )_) of_IN human_JJ immunodeficiency_NN virus_NN type_NN 1_CD (_( HIV-1_NN )_) were_VBD detected_VBN in_IN the_DT nuclear_JJ extract_NN of_IN a_DT virus-infected_JJ human_JJ T_NN cell_NN line_NN ._.
 One_CD of_IN the_DT factors_NNS bound_VBD to_TO a_DT novel_JJ dyad_NN symmetrical_JJ sequence_NN ._.
 This_DT sequence_NN is_VBZ well_RB conserved_VBN in_IN various_JJ HIV-1_NN isolates_NNS and_CC partial_JJ homology_NN was_VBD found_VBN with_IN the_DT promoter_JJ region_NN of_IN the_DT human_JJ retinoblastoma_NN gene_NN ._.
 Similar_JJ DNA_NN binding_NN activity_NN was_VBD detected_VBN in_IN a_DT variety_NN of_IN virus-uninfected_JJ human_JJ T_NN cell_NN lines_NNS and_CC HeLa_NN cells_NNS by_IN means_NNS of_IN a_DT gel_NN mobility_NN shift_NN assay_NN ._.
 The_DT other_JJ factor_NN bound_VBN to_TO a_DT putative_JJ AP-1_NN recognition_NN sequence_NN predicted_VBD for_IN the_DT HIV-1_NN NRE_NN ._.
 However_RB ,_, this_DT factor_NN did_VBD not_RB bind_VB to_TO a_DT typical_JJ AP-1_NN site_NN ._.
 The_DT insertion_NN of_IN multiple_JJ copies_NNS of_IN the_DT binding_VBG site_NN for_IN the_DT former_JJ or_CC latter_JJ factor_NN into_IN a_DT heterologous_JJ promoter_NN reduced_VBD the_DT promoter_NN activity_NN to_TO one-tenth_CD or_CC one-third_CD ,_, respectively_RB ._.
 Thus_RB ,_, each_DT factor_NN may_MD function_VB as_IN a_DT novel_JJ negative_JJ regulator_NN of_IN transcription_NN ._.
 Constitutive_JJ activation_NN of_IN NF-kB_NN in_IN human_JJ thymocytes_NNS ._.
 NF-kB_NN is_VBZ a_DT eukaryotic_JJ transcription_NN regulatory_JJ factor_NN ._.
 In_IN T_NN cells_NNS and_CC T_NN cell_NN lines_NNS ,_, NF-kB_NN is_VBZ bound_VBN to_TO a_DT cytoplasmic_JJ proteic_JJ inhibitor_NN ,_, the_DT IkB_NN ._.
 Treatment_NN of_IN T_NN cells_NNS with_IN mitogens_NNS (_( phorbol_NN esters_NNS )_) or_CC cytokines_NNS (_( TNF_NN alpha_NN )_) induces_VBZ NF-kB_NN nuclear_JJ translocation_NN and_CC the_DT subsequent_JJ expression_NN of_IN NF-kB_NN dependent_JJ T_NN cell_NN genes_NNS ._.
 Here_RB we_PRP examined_VBD the_DT activation_NN of_IN NF-kB_NN in_IN human_JJ T_NN cell_NN thymic_JJ progenitors_NNS ._.
 We_PRP report_VBP differences_NNS in_IN (Ca2+)i_NN requirement_NN for_IN NF-kB_NN activation_NN in_IN thymocytes_NNS as_IN compared_VBN to_TO mature_JJ T_NN cells_NNS ._.
 Furthermore_RB ,_, our_PRP$ results_NNS indicated_VBD that_IN thymocytes_NNS have_VBP a_DT constitutively_RB active_JJ form_NN of_IN NF-kB_NN ,_, suggesting_VBG that_IN they_PRP are_VBP activated_VBN in_FW vivo_FW ._.
 The_DT role_NN of_IN jun_NN and_CC fos_NN gene_NN family_NN members_NNS in_IN 12-O-tetradecanoylphorbol-13-acetate_NN induced_VBD hemopoietic_JJ differentiation_NN ._.
 Terminal_JJ differentiation_NN of_IN the_DT leukemic_JJ cell_NN lines_NNS U-937_NN and_CC HL-60_NN by_IN 12-O-tetradecanoylphorbol-13-acetate_NN is_VBZ accompanied_VBN by_IN marked_JJ changes_NNS in_IN gene_NN expression_NN ._.
 In_IN this_DT study_NN ,_, we_PRP demonstrate_VBP that_IN the_DT expression_NN of_IN jun_NN and_CC fos_NN gene_NN family_NN members_NNS is_VBZ induced_VBN with_IN variable_JJ kinetics_NNS during_IN 12-O-tetradecanoylphorbol-13-acetate_NN induced_VBD differentiation_NN ,_, with_IN c-jun_NN expression_NN best_RB paralleling_JJ differentiation_NN ._.
 The_DT generation_NN of_IN AP-1_NN complexes_NNS ,_, as_IN measured_VBN by_IN DNA_NN binding_NN activity_NN ,_, closely_RB parallels_VBZ morphological_JJ differentiation_NN ._.
 Furthermore_RB ,_, the_DT ability_NN of_IN these_DT complexes_NNS to_TO regulate_VB gene_NN expression_NN is_VBZ demonstrated_VBN by_IN increased_VBN transcription_NN from_IN an_DT AP-1_NN driven_VBN reporter_NN construct_NN and_CC marked_JJ increases_NNS in_IN the_DT expression_NN of_IN endogenous_JJ AP-1_NN regulated_JJ genes_NNS ._.
 Differentiation_NN assays_NNS using_VBG water_NN soluble_JJ phorbol_NN esters_NNS reveal_VBP that_IN differentiation_NN becomes_VBZ irreversible_JJ soon_RB after_IN AP-1_NN appears_VBZ ._.
 This_DT tight_JJ correlation_NN between_IN c-jun_NN expression_NN ,_, the_DT generation_NN of_IN AP-1_NN activity_NN ,_, and_CC differentiation_NN suggests_VBZ a_DT critical_JJ role_NN for_IN this_DT gene_NN and_CC transcriptional_JJ complex_NN during_IN this_DT process_NN ._.
 TCF-1_NN ,_, a_DT T_NN cell-specific_JJ transcription_NN factor_NN of_IN the_DT HMG_NN box_NN family_NN ,_, interacts_VBZ with_IN sequence_NN motifs_NNS in_IN the_DT TCR_NN beta_NN and_CC TCR_NN delta_NN enhancers_NNS ._.
 We_PRP have_VBP recently_RB identified_VBN and_CC cloned_VBN TCF-1_NN ,_, a_DT T_NN cell-specific_JJ transcription_NN factor_NN with_IN specificity_NN for_IN the_DT AACAAAG_NN motif_NN in_IN the_DT CD3_NN epsilon_NN enhancer_NN and_CC for_IN the_DT TTCAAAG_NN motif_NN in_IN the_DT TCR_NN alpha_NN enhancer_NN ._.
 TCF-1_NN belongs_VBZ to_TO the_DT family_NN of_IN transcription-regulating_JJ proteins_NNS which_WDT share_VBP a_DT region_NN of_IN homology_NN termed_VBN the_DT HMG-box_NN ._.
 Here_RB ,_, we_PRP show_VBP by_IN gel_NN retardation_NN analysis_NN that_IN TCF-1_NN specifically_RB recognizes_VBZ the_DT T_NN beta_NN 5_CD element_NN of_IN the_DT TCR_NN beta_NN enhancer_NN and_CC the_DT T_NN delta_NN 7_CD element_NN of_IN the_DT TCR_NN delta_NN enhancer_NN ._.
 Comparison_NN of_IN the_DT sequences_NNS of_IN all_DT elements_NNS recognized_VBN by_IN TCF-1_NN defines_VBZ a_DT consensus_NN motif_NN A/T_NN A/T_NN C_NN A_NN A/G_NN A_NN G_NN ._.
 These_DT observations_NNS imply_VBP that_IN TCF-1_NN is_VBZ involved_VBN in_IN the_DT control_NN of_IN several_JJ T_NN cell-specific_JJ genes_NNS and_CC might_MD thus_RB play_VB an_DT important_JJ role_NN in_IN the_DT establishment_NN and_CC maintenance_NN of_IN the_DT mature_JJ T_NN cell_NN phenotype_NN ._.
 The_DT cellular_JJ oncogene_NN c-myb_NN can_MD interact_VB synergistically_RB with_IN the_DT Epstein-Barr_JJ virus_NN BZLF1_NN transactivator_NN in_IN lymphoid_JJ cells_NNS ._.
 Regulation_NN of_IN replicative_JJ functions_NNS in_IN the_DT Epstein-Barr_JJ virus_NN (_( EBV_NN )_) genome_NN is_VBZ mediated_VBN through_IN activation_NN of_IN a_DT virally_RB encoded_VBN transcription_NN factor_NN ,_, Z_NN (_( BZLF1_NN )_) ._.
 We_PRP have_VBP shown_VBN that_IN the_DT Z_NN gene_NN product_NN ,_, which_WDT binds_VBZ to_TO AP-1_NN sites_NNS as_IN a_DT homodimer_NN and_CC has_VBZ sequence_NN similarity_NN to_TO c-Fos_NN ,_, can_MD efficiently_RB activate_VB the_DT EBV_NN early_JJ promoter_NN ,_, BMRF1_NN ,_, in_IN certain_JJ cell_NN types_NNS (_( i.e._FW ,_, HeLa_NN cells_NNS )_) but_CC not_RB others_NNS (_( i.e._FW ,_, Jurkat_NN cells_NNS )_) ._.
 Here_RB we_PRP demonstrate_VBP that_IN the_DT c-myb_NN proto-oncogene_NN product_NN ,_, which_WDT is_VBZ itself_PRP a_DT DNA-binding_JJ protein_NN and_CC transcriptional_JJ transactivator_NN ,_, can_MD interact_VB synergistically_RB with_IN Z_NN in_IN activating_VBG the_DT BMRF1_NN promoter_NN in_IN Jurkat_NN cells_NNS (_( a_DT T-cell_NN line_NN )_) or_CC Raji_NN cells_NNS (_( an_DT EBV-positive_JJ B-cell_NN )_) ,_, whereas_IN the_DT c-myb_NN gene_NN product_NN by_IN itself_PRP has_VBZ little_JJ effect_NN ._.
 The_DT simian_JJ virus_NN 40_CD early_JJ promoter_NN is_VBZ also_RB synergistically_RB activated_VBN by_IN the_DT Z/c-myb_NN combination_NN ._.
 Synergistic_JJ transactivation_NN of_IN the_DT BMRF1_NN promoter_NN by_IN the_DT Z/c-myb_NN combination_NN appears_VBZ to_TO involve_VB direct_JJ binding_NN by_IN the_DT Z_NN protein_NN but_CC not_RB the_DT c-myb_NN protein_NN ._.
 A_DT 30-bp_JJ sequence_NN in_IN the_DT BMRF1_NN promoter_NN which_WDT contains_VBZ a_DT Z_NN binding_NN site_NN (_( a_DT consensus_NN AP-1_NN site_NN )_) is_VBZ sufficient_JJ to_TO transfer_VB high-level_JJ lymphoid-specific_JJ responsiveness_NN to_TO the_DT Z/c-myb_NN combination_NN to_TO a_DT heterologous_JJ promoter_NN ._.
 That_IN the_DT c-myb_NN oncogene_NN product_NN can_MD interact_VB synergistically_RB with_IN an_DT EBV-encoded_JJ member_NN of_IN the_DT leucine_NN zipper_NN protein_NN family_NN suggests_VBZ c-myb_NN is_VBZ likely_JJ to_TO engage_VB in_IN similar_JJ interactions_NNS with_IN cellularly_RB encoded_VBN transcription_NN factors_NNS ._.
 The_DT 29-kDa_JJ proteins_NNS phosphorylated_VBN in_IN thrombin-activated_JJ human_JJ platelets_NNS are_VBP forms_NNS of_IN the_DT estrogen_NN receptor-related_JJ 27-kDa_JJ heat_NN shock_NN protein_NN ._.
 Thrombin_NN plays_VBZ a_DT critical_JJ role_NN in_IN platelet_NN activation_NN ,_, hemostasis_NN ,_, and_CC thrombosis_NN ._.
 Cellular_JJ activation_NN by_IN thrombin_NN leads_VBZ to_TO the_DT phosphorylation_NN of_IN multiple_JJ proteins_NNS ,_, most_JJS of_IN which_WDT are_VBP unidentified_JJ ._.
 We_PRP have_VBP characterized_VBN several_JJ 29-kDa_JJ proteins_NNS that_WDT are_VBP rapidly_RB phosphorylated_VBN following_VBG exposure_NN of_IN intact_JJ human_JJ platelets_NNS to_TO thrombin_NN ._.
 A_DT murine_JJ monoclonal_JJ antibody_NN raised_VBN to_TO an_DT unidentified_JJ estrogen_NN receptor-related_JJ 29-kDa_JJ protein_NN selectively_RB recognized_VBD these_DT proteins_NNS as_RB well_RB as_IN a_DT more_RBR basic_JJ ,_, unphosphorylated_JJ 27-kDa_JJ protein_NN ._.
 Cellular_JJ activation_NN by_IN thrombin_NN led_VBN to_TO a_DT marked_JJ shift_NN in_IN the_DT proportion_NN of_IN protein_NN from_IN the_DT 27-kDa_JJ unphosphorylated_JJ form_NN to_TO the_DT 29-kDa_JJ phosphoprotein_NN species_NNS ._.
 Using_VBG this_DT antibody_NN ,_, we_PRP isolated_VBD and_CC sequenced_VBD a_DT human_JJ cDNA_NN clone_NN encoding_VBG a_DT protein_NN that_WDT was_VBD identical_JJ to_TO the_DT mammalian_JJ 27-kDa_JJ heat_NN shock_NN protein_NN (_( HSP27_NN )_) ,_, a_DT protein_NN of_IN uncertain_JJ function_NN that_WDT is_VBZ known_VBN to_TO be_VB phosphorylated_VBN to_TO several_JJ forms_NNS and_CC to_TO be_VB transcriptionally_RB induced_VBN by_IN estrogen_NN ._.
 The_DT 29-kDa_JJ proteins_NNS were_VBD confirmed_VBN to_TO be_VB phosphorylated_VBN forms_NNS of_IN HSP27_NN by_IN immunoprecipitation_NN studies_NNS ._.
 Thus_RB ,_, the_DT "_[[DQS]] estrogen_NN receptor-related_JJ protein_NN "_[[DQE]] is_VBZ HSP27_NN ,_, and_CC the_DT three_CD major_JJ 29-kDa_JJ proteins_NNS phosphorylated_VBN in_IN thrombin-activated_JJ platelets_NNS are_VBP forms_NNS of_IN HSP27_NN ._.
 These_DT data_NNS suggest_VBP a_DT role_NN for_IN HSP27_NN in_IN the_DT signal_NN transduction_NN events_NNS of_IN platelet_NN activation_NN ._.
 Characterization_NN of_IN a_DT cofactor_NN that_WDT regulates_VBZ dimerization_NN of_IN a_DT mammalian_JJ homeodomain_NN protein_NN ._.
 Dimerization_NN among_IN transcription_NN factors_NNS has_VBZ become_VBN a_DT recurrent_JJ theme_NN in_IN the_DT regulation_NN of_IN eukaryotic_JJ gene_NN expression_NN ._.
 Hepatocyte_NN nuclear_JJ factor-1_NN alpha_NN (_( HNF-1_NN alpha_NN )_) is_VBZ a_DT homeodomain-containing_JJ protein_NN that_WDT functions_VBZ as_IN a_DT dimer_NN ._.
 A_DT dimerization_NN cofactor_NN of_IN HNF-1_NN alpha_NN (_( DCoH_NN )_) was_VBD identified_VBN that_WDT displayed_VBD a_DT restricted_JJ tissue_NN distribution_NN and_CC did_VBD not_RB bind_VB to_TO DNA_NN ,_, but_CC ,_, rather_RB ,_, selectively_RB stabilized_VBD HNF-1_NN alpha_NN dimers_NNS ._.
 The_DT formation_NN of_IN a_DT stable_JJ tetrameric_JJ DCoH-HNF-1_NN alpha_NN complex_NN ,_, which_WDT required_VBD the_DT dimerization_NN domain_NN of_IN HNF-1_NN alpha_NN ,_, did_VBD not_RB change_VB the_DT DNA_NN binding_NN characteristics_NNS of_IN HNF-1_NN alpha_NN ,_, but_CC enhanced_VBD its_PRP$ transcriptional_JJ activity_NN ._.
 However_RB ,_, DCoH_NN did_VBD not_RB confer_VB transcriptional_JJ activation_NN to_TO the_DT GAL4_NN DNA_NN binding_NN domain_NN ._.
 These_DT results_NNS indicate_VBP that_IN DCoH_NN regulates_VBZ formation_NN of_IN transcriptionally_RB active_JJ tetrameric_JJ complexes_NNS and_CC may_MD contribute_VB to_TO the_DT developmental_JJ specificity_NN of_IN the_DT complex_NN ._.
 High_JJ affinity_NN aldosterone_NN binding_VBG to_TO plasma_NN membrane_NN rich_JJ fractions_NNS from_IN mononuclear_JJ leukocytes_NNS :_: is_VBZ there_EX a_DT membrane_NN receptor_NN for_IN mineralocorticoids_NNS ?_.
 In_FW vitro_FW effects_NNS of_IN aldosterone_NN on_IN the_DT intracellular_JJ concentrations_NNS of_IN sodium_NN ,_, potassium_NN and_CC calcium_NN ,_, cell_NN volume_NN and_CC the_DT sodium-proton-antiport_NN have_VBP been_VBN described_VBN in_IN intact_JJ human_JJ mononuclear_JJ leukocytes_NNS (_( HML_NN )_) ._.
 In_IN the_DT present_JJ paper_NN ,_, the_DT binding_NN of_IN a_DT (125I)-labeled_JJ aldosterone_NN derivative_JJ to_TO plasma_NN membrane_NN rich_JJ fractions_NNS of_IN HML_NN was_VBD studied_VBN ._.
 High_JJ affinity_NN binding_NN of_IN the_DT radioligand_NN with_IN an_DT apparent_JJ Kd_NN of_IN approximately_RB 0.1_CD nM_NN was_VBD found_VBN ._.
 Aldosterone_NN displaced_VBD the_DT tracer_NN at_IN a_DT similar_JJ Kd_NN ._.
 Both_CC canrenone_NN and_CC cortisol_NN were_VBD inactive_JJ as_IN ligands_NNS up_RB to_TO concentrations_NNS of_IN 0.1_CD microM_NN ._.
 The_DT findings_NNS are_VBP the_DT first_JJ to_TO demonstrate_VB membrane_NN binding_NN sites_NNS with_IN a_DT high_JJ affinity_NN for_IN aldosterone_NN ,_, but_CC not_RB for_IN cortisol_NN ._.
 These_DT data_NNS are_VBP perfectly_RB compatible_JJ with_IN major_JJ properties_NNS of_IN steroidal_JJ effects_NNS on_IN the_DT sodium-proton-antiport_NN in_IN HML_NN and_CC thus_RB very_RB likely_RB represent_VBP membrane_NN receptors_NNS for_IN aldosterone_NN ._.
 Transcription_NN factor_NN requirements_NNS for_IN U2_NN snRNA-encoding_JJ gene_NN activation_NN in_IN B_NN lymphoid_JJ cells_NNS ._.
 Transcription_NN of_IN a_DT human_JJ U2_NN small_JJ nuclear_JJ RNA_NN (_( snRNA_NN )_) -encoding_JJ gene_NN in_IN HeLa_NN cells_NNS requires_VBZ a_DT distal_JJ enhancer_NN element_NN ,_, which_WDT is_VBZ composed_VBN of_IN one_CD octamer_NN motif_NN (_( Oct_NN )_) and_CC three_CD Sp_NN 1-binding_JJ sites_NNS ._.
 To_TO study_VB the_DT transcription_NN factor_NN requirement_NN in_IN B-cells_NNS ,_, different_JJ U2_NN enhancer_NN constructions_NNS were_VBD transfected_VBN into_IN the_DT lymphoid_JJ cell_NN line_NN ,_, BJA-B_NN ._.
 The_DT results_NNS showed_VBD that_IN the_DT activation_NN of_IN U2_NN snRNA_NN transcription_NN in_IN B-cells_NNS also_RB requires_VBZ an_DT enhancer_NN comprising_VBG both_CC the_DT Oct_NN and_CC at_IN least_JJS one_CD Sp_NN 1-binding_JJ site_NN ._.
 Deletion_NN of_IN all_PDT the_DT Sp_NN 1-binding_JJ sites_NNS from_IN the_DT enhancer_NN reduces_VBZ transcription_NN by_IN 80-90_CD %_NN in_IN HeLa_NN ,_, as_RB well_RB as_IN in_IN BJA-B_NN cells_NNS ,_, whereas_IN the_DT removal_NN of_IN the_DT octamer-binding_JJ site_NN reduces_VBZ transcription_NN to_TO levels_NNS below_IN detection_NN in_IN both_DT cell_NN types_NNS ._.
 Enhancers_NNS containing_VBG a_DT single_JJ Oct_NN have_VBP ,_, nevertheless_RB ,_, the_DT capacity_NN to_TO partially_RB activate_VB U2_NN snRNA_NN transcription_NN in_IN both_DT HeLa_NN cells_NNS ,_, in_IN which_WDT only_RB OTF-1_NN is_VBZ expressed_VBN ,_, and_CC in_IN BJA-B_NN cells_NNS in_IN which_WDT OTF-2_NN is_VBZ the_DT predominantly_RB expressed_VBN octamer-binding_JJ factor_NN ._.
 The_DT most_RBS likely_JJ interpretation_NN of_IN our_PRP$ results_NNS is_VBZ that_IN both_CC the_DT ubiquitous_JJ transcription_NN factor_NN ,_, OTF-1_NN ,_, and_CC the_DT B-cell-specific_JJ transcription_NN factor_NN ,_, OTF-2_NN ,_, can_MD activate_VB U2_NN snRNA_NN transcription_NN ._.
 The_DT results_NNS also_RB revealed_VBD a_DT similar_JJ functional_JJ cooperation_NN between_IN the_DT transcription_NN factors_NNS which_WDT bind_VBP to_TO the_DT Oct_NN and_CC the_DT adjacent_JJ Sp_NN 1-binding_JJ site_NN in_IN BJA-B_NN cells_NNS ,_, as_IN has_VBZ been_VBN observed_VBN in_IN HeLa_NN cells_NNS ,_, since_IN a_DT template_NN which_WDT contains_VBZ a_DT weak_JJ binding_VBG site_NN for_IN OTFs_NNS expresses_VBZ wild-type_JJ levels_NNS of_IN U2_NN snRNA_NN in_IN both_DT cell_NN types_NNS when_WRB the_DT weak_JJ octamer-binding_JJ site_NN is_VBZ combined_VBN with_IN a_DT Sp_NN 1-binding_JJ site_NN ._.
 Cortisol_NN receptor_NN resistance_NN :_: the_DT variability_NN of_IN its_PRP$ clinical_JJ presentation_NN and_CC response_NN to_TO treatment_NN ._.
 Primary_JJ (_( partial_JJ )_) cortisol_NN receptor_NN resistance_NN was_VBD previously_RB reported_VBN in_IN a_DT total_NN of_IN 7_CD patients_NNS and_CC 14_CD asymptomatic_JJ family_NN members_NNS ._.
 Its_PRP$ occurrence_NN is_VBZ considered_VBN to_TO be_VB extremely_RB rare_JJ ._.
 In_IN the_DT present_JJ study_NN we_PRP report_VBP on_IN 6_CD patients_NNS (_( 2_CD males_NNS and_CC 4_CD females_NNS )_) with_IN the_DT syndrome_NN ._.
 The_DT first_JJ male_JJ patient_NN presented_VBD with_IN mild_JJ hypertension_NN ._.
 Hydrochlorothiazide_NN therapy_NN resulted_VBD in_IN life-threatening_JJ hypokalemia_NN ._.
 The_DT second_JJ male_JJ patient_NN had_VBD slight_JJ hypertension_NN without_IN hypokalemia_NN ._.
 All_DT four_CD female_JJ patients_NNS presented_VBD between_IN the_DT age_NN of_IN 20-30_CD yr_NN with_IN acne_NN ,_, hirsutism_NN ,_, and_CC irregular_JJ menstruations_NNS ._.
 Low_JJ dose_NN dexamethasone_NN therapy_NN (_( 1-1.5_CD mg/day_NN )_) was_VBD of_IN clinical_JJ benefit_NN in_IN these_DT patients_NNS ._.
 All_DT patients_NNS showed_VBD insufficient_JJ suppression_NN of_IN serum_NN cortisol_NN concentrations_NNS in_IN the_DT overnight_JJ 1-mg_JJ dexamethasone_NN test_NN ._.
 The_DT diurnal_JJ rhythm_NN of_IN ACTH_NN and_CC cortisol_NN was_VBD intact_JJ ,_, albeit_IN at_IN an_DT elevated_JJ level_NN ._.
 There_EX was_VBD a_DT normal_JJ increase_NN in_IN ACTH_NN ,_, cortisol_NN ,_, and_CC GH_NN (_( except_IN in_IN one_CD obese_JJ patient_NN )_) in_IN response_NN to_TO insulin-induced_JJ hypoglycemia_NN ,_, while_IN cortisol_NN production_NN was_VBD elevated_JJ in_IN three_CD patients_NNS ._.
 Circulating_VBG adrenal_JJ androgen_NN levels_NNS were_VBD increased_VBN in_IN all_DT patients_NNS ._.
 Glucocorticoid_NN receptors_NNS were_VBD investigated_VBN in_IN a_DT whole_JJ cell_NN dexamethasone_NN binding_NN assay_NN in_IN mononuclear_JJ leukocytes_NNS ._.
 In_IN the_DT first_JJ male_JJ patient_NN ,_, the_DT number_NN of_IN receptors_NNS was_VBD very_RB low_JJ ,_, while_IN the_DT affinity_NN was_VBD lower_JJR than_IN that_DT in_IN controls_NNS ._.
 A_DT lowered_JJ affinity_NN to_TO dexamethasone_NN was_VBD found_VBN in_IN one_CD female_JJ patient_NN ,_, while_IN a_DT lowered_JJ number_NN of_IN receptors_NNS was_VBD found_VBN in_IN three_CD patients_NNS ._.
 In_IN the_DT second_JJ male_JJ patient_NN ,_, no_DT abnormalities_NNS were_VBD found_VBN ._.
 As_IN a_DT bioassay_NN for_IN glucocorticoid_NN action_NN we_PRP also_RB measured_VBD dexamethasone_NN suppressibility_NN of_IN mitogen-stimulated_JJ incorporation_NN of_IN (3H)thymidine_NN in_IN mononuclear_JJ leukocytes_NNS ._.
 In_IN the_DT male_JJ patient_NN with_IN normal_JJ receptor_NN status_NN ,_, dexamethasone_NN suppressibility_NN of_IN (3H)thymidine_NN incorporation_NN was_VBD significantly_RB lower_JJR than_IN that_DT in_IN healthy_JJ controls_NNS with_IN respect_NN to_TO both_CC maximal_JJ suppression_NN and_CC IC50_NN ._.
 Partial_JJ cortisol_NN receptor_NN resistance_NN might_MD be_VB less_RBR rare_JJ than_IN previously_RB thought_VBN ._.
 In_IN the_DT six_CD patients_NNS presented_VBN ,_, at_IN least_JJS three_CD different_JJ forms_NNS can_MD be_VB recognized_VBN ._.
 Therapy_NN with_IN dexamethasone_NN was_VBD successful_JJ in_IN female_JJ patients_NNS with_IN acne_NN and_CC hirsutism_NN ,_, as_IN the_DT secondary_JJ increase_NN in_IN the_DT production_NN of_IN adrenal_JJ androgens_NNS was_VBD effectively_RB controlled_VBN ._.
 Kappa_NN B-specific_JJ DNA_NN binding_NN proteins_NNS are_VBP differentially_RB inhibited_VBN by_IN enhancer_NN mutations_NNS and_CC biological_JJ oxidation_NN ._.
 Kappa_NN B_NN (_( kappa_NN B_NN )_) enhancer_NN binding_NN proteins_NNS isolated_VBN from_IN the_DT nuclei_NNS of_IN activated_VBN human_JJ T_NN cells_NNS produce_VBP two_CD distinct_JJ nucleoprotein_NN complexes_NNS when_WRB incubated_VBN with_IN the_DT kappa_NN B_NN element_NN from_IN the_DT interleukin-2_NN receptor-alpha_NN (_( IL-2R_NN alpha_NN )_) gene_NN ._.
 These_DT two_CD DNA-protein_JJ complexes_NNS are_VBP composed_VBN of_IN at_IN least_JJS four_CD host_NN proteins_NNS (_( p50_NN ,_, p55_NN ,_, p75_NN ,_, p85_NN )_) ,_, each_DT of_IN which_WDT shares_VBZ structural_JJ similarity_NN with_IN the_DT v-rel_NN oncogene_NN product_NN ._.
 Nuclear_JJ expression_NN of_IN these_DT proteins_NNS is_VBZ induced_VBN with_IN distinctly_RB biphasic_JJ kinetics_NNS following_VBG phorbol_NN ester_NN activation_NN of_IN T_NN cells_NNS (_( p55/p75_NN early_JJ and_CC p50/p85_NN late_JJ )_) ._.
 DNA-protein_JJ crosslinking_NN studies_NNS have_VBP revealed_VBN that_IN the_DT more_RBR rapidly_RB migrating_VBG B2_NN complex_NN contains_VBZ both_CC p50_NN and_CC p55_NN while_IN the_DT more_RBR slowly_RB migrating_VBG B1_NN complex_NN is_VBZ composed_VBN of_IN p50_NN ,_, p55_NN ,_, p75_NN ,_, and_CC p85_NN ._.
 Site-directed_JJ mutagenesis_NN of_IN the_DT wild-type_JJ IL-2R_NN alpha_NN kappa_NN B_NN enhancer_NN (_( GGGGAATCTCCC_NN )_) has_VBZ revealed_VBN that_IN the_DT binding_NN of_IN p50_NN and_CC p55_NN (_( B2_NN complex_NN )_) is_VBZ particularly_RB sensitive_JJ to_TO alteration_NN of_IN the_DT 5'_JJ triplet_NN of_IN deoxyguanosine_NN residues_NNS ._.
 In_IN contrast_NN ,_, formation_NN of_IN the_DT B1_NN complex_NN ,_, reflecting_VBG the_DT binding_NN of_IN p75_NN and_CC p85_NN ,_, critically_RB depends_VBZ upon_IN the_DT more_RBR 3'_JJ sequences_NNS of_IN this_DT enhancer_NN element_NN ._.
 DNA_NN binding_NN by_IN all_DT four_CD of_IN these_DT Rel-related_JJ factors_NNS is_VBZ blocked_VBN by_IN selective_JJ chemical_JJ modification_NN of_IN lysine_NN and_CC arginine_NN residues_NNS ,_, suggesting_VBG that_IN both_DT of_IN these_DT basic_JJ amino_NN acids_NNS are_VBP required_VBN for_IN binding_VBG to_TO the_DT kappa_NN B_NN element_NN ._.
 Similarly_RB ,_, covalent_JJ modification_NN of_IN free_JJ sulfhydryl_NN groups_NNS with_IN diamide_NN (_( reversible_JJ )_) or_CC N-ethylmaleimide_NN (_( irreversible_JJ )_) results_VBZ in_IN a_DT complete_JJ loss_NN of_IN DNA_NN binding_NN activity_NN ._.
 In_IN contrast_NN ,_, mild_JJ oxidation_NN with_IN glucose_NN oxidase_NN selectively_RB inhibits_VBZ p75_NN and_CC p85_NN binding_NN while_IN not_RB blocking_VBG p50_NN and_CC p55_NN interactions_NNS ._.
 These_DT findings_NNS suggest_VBP that_IN reduced_VBN cysteine_NN thiols_NNS play_VBP an_DT important_JJ role_NN in_IN the_DT DNA_NN binding_NN activity_NN of_IN this_DT family_NN of_IN Rel-related_JJ transcription_NN factors_NNS ._.
 A_DT novel_JJ mitogen-inducible_JJ gene_NN product_NN related_JJ to_TO p50/p105-NF-kappa_NN B_NN participates_VBZ in_IN transactivation_NN through_IN a_DT kappa_NN B_NN site_NN ._.
 A_DT Rel-related_JJ ,_, mitogen-inducible_JJ ,_, kappa_NN B-binding_JJ protein_NN has_VBZ been_VBN cloned_VBN as_IN an_DT immediate-early_JJ activation_NN gene_NN of_IN human_JJ peripheral_JJ blood_NN T_NN cells_NNS ._.
 The_DT cDNA_NN has_VBZ an_DT open_JJ reading_NN frame_NN of_IN 900_CD amino_NN acids_NNS capable_JJ of_IN encoding_VBG a_DT 97-kDa_JJ protein_NN ._.
 This_DT protein_NN is_VBZ most_RBS similar_JJ to_TO the_DT 105-kDa_JJ precursor_NN polypeptide_NN of_IN p50-NF-kappa_NN B_NN ._.
 Like_IN the_DT 105-kDa_JJ precursor_NN ,_, it_PRP contains_VBZ an_DT amino-terminal_JJ Rel-related_JJ domain_NN of_IN about_IN 300_CD amino_NN acids_NNS and_CC a_DT carboxy-terminal_JJ domain_NN containing_VBG six_CD full_JJ cell_NN cycle_NN or_CC ankyrin_NN repeats_NNS ._.
 In_FW vitro-translated_JJ proteins_NNS ,_, truncated_VBN downstream_RB of_IN the_DT Rel_NN domain_NN and_CC excluding_VBG the_DT repeats_NNS ,_, bind_VBP kappa_NN B_NN sites_NNS ._.
 We_PRP refer_VBP to_TO the_DT kappa_NN B-binding_JJ ,_, truncated_VBN protein_NN as_IN p50B_NN by_IN analogy_NN with_IN p50-NF-kappa_NN B_NN and_CC to_TO the_DT full-length_JJ protein_NN as_IN p97_NN ._.
 p50B_NN is_VBZ able_JJ to_TO form_VB heteromeric_JJ kappa_NN B-binding_JJ complexes_NNS with_IN RelB_NN ,_, as_RB well_RB as_IN with_IN p65_NN and_CC p50_NN ,_, the_DT two_CD subunits_NNS of_IN NF-kappa_NN B_NN ._.
 Transient-transfection_NN experiments_NNS in_IN embryonal_JJ carcinoma_NN cells_NNS demonstrate_VBP a_DT functional_JJ cooperation_NN between_IN p50B_NN and_CC RelB_NN or_CC p65_NN in_IN transactivation_NN of_IN a_DT reporter_NN plasmid_NN dependent_JJ on_IN a_DT kappa_NN B_NN site_NN ._.
 The_DT data_NNS imply_VBP the_DT existence_NN of_IN a_DT complex_JJ family_NN of_IN NF-kappa_NN B-like_JJ transcription_NN factors_NNS ._.
 (_( Changes_NNS in_IN leucocytic_JJ estrogen_NN receptor_NN levels_NNS in_IN patients_NNS with_IN climacteric_JJ syndrome_NN and_CC therapeutic_JJ effect_NN of_IN liuwei_FW dihuang_FW pills_NNS )_)
 The_DT numbers_NNS of_IN estrogen_NN receptor_NN (_( ER_NN )_) in_IN human_JJ peripheral_JJ leucocytes_NNS in_IN 22_CD women_NNS with_IN climacteric_JJ syndrome_NN were_VBD measured_VBN by_IN radioligand_NN method_NN ._.
 The_DT results_NNS were_VBD compared_VBN with_IN those_DT of_IN 12_CD normal_JJ child-bearing-age_JJ women_NNS ._.
 It_PRP wat_VBD found_VBN that_IN the_DT contents_NNS of_IN leucocytic_JJ ER_NN in_IN climacteric_JJ syndrome_NN patients_NNS were_VBD significantly_RB lower_JJR than_IN normal_JJ child-bearing-age_JJ women_NNS ._.
 The_DT authors_NNS used_VBD a_DT Chinese_JJ prescription_NN --_: Liuwei_FW Dihuang_FW Pills_NNS (_( LDP_NN )_) to_TO treat_VB the_DT patients_NNS for_IN 2_CD months_NNS ._.
 The_DT numbers_NNS of_IN leucocytic_JJ ER_NN were_VBD significantly_RB increased_VBN after_IN treatment_NN ._.
 The_DT data_NNS indicate_VBP that_IN decrease_NN of_IN ER_NN levels_NNS in_IN cell_NN may_MD involve_VB in_IN the_DT pathogenesis_NN of_IN climacteric_JJ syndrome_NN ._.
 LDP_NN not_RB only_RB increases_VBZ plasma_NN estradiol_NN levels_NNS ,_, but_CC also_RB increases_VBZ the_DT leucocytic_JJ ER_NN levels_NNS ._.
 This_DT may_MD be_VB the_DT basis_NN of_IN the_DT therapeutic_JJ effect_NN on_IN the_DT disease_NN ._.
 A_DT novel_JJ primer_NN extension_NN method_NN to_TO detect_VB the_DT number_NN of_IN CAG_NN repeats_NNS in_IN the_DT androgen_NN receptor_NN gene_NN in_IN families_NNS with_IN X-linked_JJ spinal_JJ and_CC bulbar_JJ muscular_JJ atrophy_NN ._.
 X-linked_JJ spinal_JJ and_CC bulbar_JJ muscular_JJ atrophy_NN (_( SBMA_NN )_) ,_, an_DT adult-onset_JJ form_NN of_IN motor_NN neuron_NN disease_NN ,_, was_VBD recently_RB reported_VBN to_TO be_VB caused_VBN by_IN amplification_NN of_IN the_DT CAG_NN repeats_NNS in_IN the_DT androgen_NN receptor_NN gene_NN ._.
 We_PRP report_VBP here_RB a_DT simple_JJ and_CC rapid_JJ strategy_NN to_TO detect_VB the_DT precise_JJ number_NN of_IN the_DT CAGs_NNS ._.
 After_IN the_DT DNA_NN fragment_NN containing_VBG the_DT CAG_NN repeats_NNS is_VBZ amplified_VBN by_IN the_DT polymerase_NN chain_NN reaction_NN ,_, a_DT primer_NN extension_NN is_VBZ carried_VBN out_RP ;_: the_DT extension_NN of_IN the_DT end-labelled_JJ reverse_JJ primer_NN adjacent_JJ to_TO 3'_JJ end_NN of_IN CAG_NN repeats_NNS stops_VBZ at_IN the_DT first_JJ T_NN after_IN CAG_NN repeats_NNS with_IN the_DT incorporation_NN of_IN dideoxy_JJ ATP_NN in_IN the_DT reaction_NN mixture_NN ._.
 The_DT resultant_JJ primer_NN products_NNS are_VBP analysed_VBN by_IN denaturing_VBG polyacrylamide_NN gel_NN electrophoresis_NN and_CC autoradiography_NN ._.
 This_DT method_NN could_MD be_VB quite_RB useful_JJ to_TO detect_VB not_RB only_RB CAG_NN repeats_NNS in_IN SBMA_NN but_CC also_RB other_JJ polymorphic_JJ dinucleotide_JJ and_CC trinucleotide_JJ repeats_NNS ._.
 Activity_NN of_IN the_DT kappa_NN B_NN enhancer_NN of_IN the_DT interleukin-2_NN receptor_NN alpha_NN chain_NN in_IN somatic_JJ cell_NN hybrids_NNS is_VBZ accompanied_VBN by_IN the_DT nuclear_JJ localization_NN of_IN NF-kappa_NN B_NN ._.
 The_DT two_CD nuclear_JJ proteins_NNS NF-kappa_NN B_NN (_( consisting_VBG of_IN subunits_NNS p50_NN and_CC p65_NN )_) and_CC the_DT DNA-binding_JJ subunit_NN of_IN NF-kappa_NN B_NN (_( p50_NN )_) by_IN itself_PRP ,_, also_RB called_VBN KBF1_NN ,_, are_VBP constitutively_RB expressed_VBN and_CC localized_JJ in_IN the_DT nucleus_NN of_IN the_DT human_JJ T-cell_NN line_NN IARC_NN 301.5_CD ._.
 In_IN order_NN to_TO define_VB the_DT roles_NNS of_IN these_DT two_CD factors_NNS ,_, which_WDT bind_VBP to_TO the_DT same_JJ kappa_NN B_NN enhancers_NNS ,_, in_IN transcription_NN activation_NN we_PRP have_VBP prepared_VBN somatic_JJ cell_NN hybrids_NNS between_IN IARC_NN 301.5_CD and_CC a_DT murine_JJ myeloma_NN ._.
 Most_JJS hybrids_NNS express_VBP both_CC KBF1_NN and_CC NF-kappa_NN B_NN in_IN their_PRP$ nuclei_NNS ,_, but_CC one_CD hybrid_NN expresses_VBZ only_RB KBF1_NN ._.
 The_DT kappa_NN B_NN enhancer_NN of_IN the_DT gene_NN encoding_VBG the_DT interleukin-2_NN (_( IL-2_NN )_) receptor_NN alpha_NN chain_NN (_( IL-2R_NN alpha_NN )_) is_VBZ functional_JJ only_RB in_IN the_DT hybrids_NNS expressing_VBG nuclear_JJ NF-kappa_NN B_NN ._.
 These_DT findings_NNS show_VBP that_IN nuclear_JJ NF-kappa_NN B_NN is_VBZ necessary_JJ to_TO activate_VB the_DT kappa_NN B_NN enhancer_NN ,_, while_IN KBF1_NN by_IN itself_PRP is_VBZ not_RB sufficient_JJ ._.
 We_PRP propose_VBP that_IN KBF1_NN is_VBZ a_DT competitive_JJ inhibitor_NN of_IN NF-kappa_NN B_NN and_CC discuss_VB how_WRB these_DT factors_NNS may_MD be_VB involved_VBN in_IN the_DT transient_JJ expression_NN of_IN IL-2_NN and_CC IL-2_NN alpha_NN genes_NNS during_IN the_DT immune_JJ response_NN ._.
 Influence_NN of_IN estradiol_NN and_CC tamoxifen_NN on_IN susceptibility_NN of_IN human_JJ breast_NN cancer_NN cell_NN lines_NNS to_TO lysis_NN by_IN lymphokine-activated_JJ killer_NN cells_NNS ._.
 The_DT design_NN of_IN combination_NN hormonal_JJ and_CC immunotherapeutic_JJ protocols_NNS for_IN breast_NN cancer_NN patients_NNS may_MD be_VB facilitated_VBN by_IN analysis_NN of_IN preclinical_JJ in_FW vitro_FW model_JJ systems_NNS ._.
 Estrogen_NN receptor_NN positive_JJ (_( ER+_JJ :_: MCF-7_NN )_) and_CC negative_JJ (_( ER-_JJ :_: MDA-MB-231_NN )_) human_JJ breast_NN cancer_NN cell_NN lines_NNS were_VBD utilized_VBN to_TO evaluate_VB the_DT effects_NNS of_IN tamoxifen_NN (_( TAM_NN )_) and_CC estradiol_NN (_( E2_NN )_) on_IN modulation_NN of_IN breast_NN cancer_NN target_NN susceptibility_NN to_TO lysis_NN by_IN lymphokine-activated_JJ killer_NN (_( LAK_NN )_) cells_NNS ._.
 E2-stimulated_JJ ER+_JJ cells_NNS were_VBD more_RBR susceptible_JJ to_TO lysis_NN by_IN LAK_NN cells_NNS than_IN corresponding_VBG TAM-treated_JJ or_CC control_NN cells_NNS ,_, while_IN treatment_NN of_IN ER-_JJ cells_NNS with_IN either_CC E2_NN or_CC TAM_NN alone_RB did_VBD not_RB alter_VB from_IN control_NN their_PRP$ susceptibility_NN to_TO this_DT immune-mediated_JJ lysis_NN ._.
 All_DT ER+_JJ and_CC ER-_JJ cells_NNS tested_VBN remained_VBD sensitive_JJ after_IN treatment_NN with_IN TAM_NN to_TO lysis_NN by_IN LAK_NN cells_NNS ._.
 In_IN addition_NN ,_, an_DT adenocarcinoma_NN reactive_JJ human-mouse_JJ chimeric_JJ monoclonal_JJ antibody_NN (_( ING-1_NN )_) was_VBD able_JJ to_TO significantly_RB boost_VB in_FW vivo_FW generated_VBN LAK_NN cell-mediated_JJ lysis_NN of_IN control_NN ,_, E2-treated_JJ ,_, and_CC TAM-treated_JJ ER+_JJ and_CC ER-_JJ cells_NNS ._.
 These_DT in_FW vitro_FW results_NNS provide_VBP a_DT preclinical_JJ rationale_NN for_IN in_FW vivo_FW testing_NN of_IN TAM_NN ,_, interleukin-2_NN (_( IL-2_NN )_) ,_, and_CC breast_NN cancer_NN reactive_JJ antibody-dependent_JJ cellular_JJ cytotoxicity_NN facilitating_VBG antibody_NN in_IN patients_NNS with_IN refractory_JJ or_CC high_JJ risk_NN breast_NN cancer_NN ._.
 Glucocorticoid_NN receptor_NN and_CC inhibition_NN of_IN 3-O-methyl-D-glucose_NN uptake_NN by_IN glucocorticoids_NNS in_IN peripheral_JJ blood_NN leukocytes_NNS from_IN normal_JJ humans_NNS :_: correlation_NN between_IN receptor_NN level_NN and_CC hormone_NN effect_NN in_FW vitro_FW ._.
 We_PRP have_VBP measured_VBN the_DT glucocorticoid_NN receptor_NN concentration_NN in_IN mononuclear_JJ and_CC polymorphonuclear_JJ leukocytes_NNS ,_, both_DT of_IN which_WDT were_VBD isolated_VBN from_IN peripheral_JJ blood_NN from_IN ten_CD healthy_JJ male_JJ volunteers_NNS ._.
 In_IN parallel_NN ,_, the_DT inhibitory_JJ effect_NN of_IN dexamethasone_NN on_IN 3-O-methyl-D-glucose_NN uptake_NN was_VBD assayed_VBN in_IN the_DT corresponding_JJ mononuclear_JJ leukocytes_NNS ._.
 The_DT glucocorticoid_NN receptor_NN levels_NNS in_IN mononuclear_JJ leukocytes_NNS correlated_VBD with_IN those_DT in_IN polymorphonuclear_JJ leukocytes_NNS ,_, and_CC there_EX was_VBD a_DT linear_JJ relationship_NN between_IN the_DT cellular_JJ glucocorticoid_NN receptor_NN levels_NNS and_CC glucocorticoid-mediated_JJ inhibition_NN of_IN the_DT uptake_NN of_IN 3-O-methyl-D-glucose_NN in_IN mononuclear_JJ leukocytes_NNS ._.
 When_WRB mononuclear_JJ leukocytes_NNS were_VBD incubated_VBN in_IN the_DT presence_NN of_IN 8-bromo-cAMP_NN ,_, cellular_JJ glucocorticoid_NN receptor_NN levels_NNS increased_VBD and_CC a_DT more_RBR pronounced_JJ inhibitory_JJ effect_NN of_IN dexamethasone_NN was_VBD observed_VBN on_IN the_DT transport_NN of_IN 3-O-methyl-D-glucose_NN ._.
 We_PRP conclude_VBP that_IN the_DT cellular_JJ glucocorticoid_NN receptor_NN levels_NNS in_IN peripheral_JJ blood_NN leukocytes_NNS reflect_VBP in_FW vitro_FW responsiveness_NN to_TO glucocorticoids_NNS in_IN mononuclear_JJ leukocytes_NNS from_IN healthy_JJ males_NNS ,_, and_CC that_IN the_DT individual_JJ responsiveness_NN may_MD alter_VB upon_IN changes_NNS in_IN the_DT cellular_JJ levels_NNS of_IN glucocorticoid_NN receptor_NN ._.
 Stimulation_NN of_IN interferon_NN beta_NN gene_NN transcription_NN in_FW vitro_FW by_IN purified_VBN NF-kappa_NN B_NN and_CC a_DT novel_JJ TH_NN protein_NN ._.
 The_DT human_JJ interferon_NN beta_NN (_( IFN-beta_NN )_) regulatory_JJ element_NN consists_VBZ of_IN multiple_JJ enhanson_NN domains_NNS which_WDT are_VBP targets_NNS for_IN transcription_NN factors_NNS involved_VBN in_IN inducible_JJ expression_NN of_IN the_DT promoter_NN ._.
 To_TO further_RB characterize_VB the_DT protein-DNA_JJ interactions_NNS mediating_VBG IFN-beta_NN induction_NN ,_, positive_JJ regulatory_JJ domain_NN (_( PRD_NN )_) II_CD binding_NN proteins_NNS were_VBD purified_VBN from_IN phorbol_NN ester_NN induced_JJ Jurkat_NN T-cells_NNS and_CC from_IN IFN_NN primed_VBN ,_, cycloheximide/polyinosinic-polycytidylic_JJ acid_NN treated_VBN HeLa_NN S3_NN cells_NNS ._.
 From_IN HeLa_NN cells_NNS ,_, two_CD major_JJ proteins_NNS of_IN 52_CD and_CC 45_CD kilodaltons_NNS (_( kD_NN )_) copurified_VBD with_IN DNA_NN binding_NN activity_NN ,_, whereas_IN from_IN T-cells_NNS ,_, four_CD proteins_NNS --_: a_DT major_JJ protein_NN of_IN 52_CD kD_NN and_CC three_CD minor_JJ proteins_NNS of_IN 82_CD ,_, 67_CD ,_, and_CC 43-47_CD kD_NN --_: were_VBD purified_VBN ._.
 Also_RB ,_, an_DT induction_NN specific_JJ DNA_NN binding_NN protein_NN was_VBD purified_VBN from_IN HeLa_NN cells_NNS that_WDT interacted_VBD with_IN the_DT (_( AAGTGA_NN )_) 4_CD tetrahexamer_NN sequence_NN and_CC the_DT PRDI_NN domain_NN ._.
 This_DT protein_NN is_VBZ immunologically_RB distinct_JJ from_IN IRF-1/ISGF2_NN ._.
 Uninduced_JJ or_CC Sendai_NN virus_NN induced_JJ HeLa_NN extracts_NNS were_VBD used_VBN to_TO examine_VB transcription_NN in_FW vitro_FW using_VBG a_DT series_NN of_IN IFN_NN beta_NN promoter_NN deletions_NNS ._.
 Deletions_NNS upstream_JJ of_IN the_DT PRDII_NN element_NN increased_VBD transcription_NN in_IN the_DT uninduced_JJ extract_NN ,_, indicating_VBG predominantly_RB negative_JJ regulation_NN of_IN the_DT promoter_NN ._.
 A_DT 2-4-fold_JJ increase_NN in_IN IFN-beta_NN promoter_NN transcription_NN was_VBD observed_VBN in_IN Sendai_NN virus_NN induced_JJ extracts_NNS ,_, and_CC deletion_NN of_IN PRDI_NN and_CC PRDII_NN elements_NNS decreased_VBD this_DT induced_VBN level_NN of_IN transcription_NN ._.
 When_WRB purified_VBN PRDII_NN and_CC tetrahexamer_NN binding_NN proteins_NNS were_VBD added_VBN to_TO the_DT induced_VBN extract_NN ,_, a_DT 4-fold_JJ increase_NN in_IN transcription_NN was_VBD observed_VBN ._.
 These_DT experiments_NNS demonstrate_VBP that_IN it_PRP is_VBZ possible_JJ to_TO modulate_VB IFN-beta_NN transcription_NN in_FW vitro_FW but_CC indicate_VBP that_IN additional_JJ proteins_NNS may_MD be_VB required_VBN to_TO fully_RB activate_VB IFN-beta_NN transcription_NN ._.
 Structure_NN function_NN analysis_NN of_IN vitamin_NN D_NN analogs_NNS with_IN C-ring_NN modifications_NNS ._.
 Analogs_NNS of_IN 1_CD alpha,25-dihydroxyvitamin_NN D3_NN (_( 1_CD alpha,25-(OH)_NN 2D3_NN )_) with_IN substitutions_NNS on_IN C-11_NN were_VBD synthesized_VBN ._.
 Small_JJ apolar_JJ substitutions_NNS (_( 11_CD alpha-methyl_NN ,_, 11_CD alpha-fluoromethyl_NN )_) did_VBD not_RB markedly_RB decrease_VB the_DT affinity_NN for_IN the_DT vitamin_NN D_NN receptor_NN ,_, but_CC larger_JJR (_( 11_CD alpha-chloromethyl_NN or_CC 11_CD alpha-_NN or_CC 11_CD beta-phenyl_NN )_) or_CC more_RBR polar_JJ substitutions_NNS (_( 11_CD alpha-hydroxymethyl_NN ,_, 11_CD alpha-(2-hydroxyethyl_NN )_) decreased_VBD the_DT affinity_NN to_TO less_JJR than_IN 5_CD %_NN of_IN that_DT of_IN 1_CD alpha,25-OH)2D3_NN ._.
 Their_PRP$ affinity_NN for_IN the_DT vitamin_NN D-binding_JJ protein_NN ,_, however_RB ,_, increased_VBD up_RB to_TO 4-fold_RB ._.
 The_DT biological_JJ activity_NN of_IN 11_CD alpha-methyl-1_NN alpha,25-(OH)2D3_NN closely_RB resembled_VBD that_DT of_IN the_DT natural_JJ hormone_NN on_IN normal_JJ and_CC leukemic_JJ cell_NN proliferation_NN and_CC bone_NN resorption_NN ,_, whereas_IN its_PRP$ in_FW vivo_FW effect_NN on_IN calcium_NN metabolism_NN of_IN the_DT rachitic_JJ chick_NN was_VBD about_IN 50_CD %_NN of_IN that_DT of_IN 1_CD alpha,25-(OH)2D3_NN ._.
 The_DT 11_CD beta-methyl_NN analog_NN had_VBD a_DT greater_JJR than_IN 10-fold_RB lower_JJR activity_NN ._.
 The_DT differentiating_JJ effects_NNS of_IN the_DT other_JJ C-11_NN analogs_NNS on_IN human_JJ promyeloid_JJ leukemia_NN cells_NNS (_( HL-60_NN )_) agreed_VBD well_RB with_IN their_PRP$ bone-resorbing_JJ activity_NN and_CC receptor_NN affinity_NN ,_, but_CC they_PRP demonstrated_VBD lower_JJR calcemic_JJ effects_NNS in_FW vivo_FW ._.
 Large_JJ or_CC polar_JJ substitutions_NNS on_IN C-11_NN of_IN 1_CD alpha,25-(OH)2D3_NN thus_RB impair_VBP the_DT binding_NN of_IN the_DT vitamin_NN D_NN receptor_NN but_CC increase_VBP the_DT affinity_NN to_TO vitamin_NN D-binding_JJ protein_NN ._.
 The_DT effects_NNS of_IN many_JJ C-11-substituted_JJ 1_CD alpha,25-(OH)2D3_NN analogs_NNS on_IN HL-60_NN cell_NN differentiation_NN exceeded_VBD their_PRP$ activity_NN on_IN calcium_NN metabolism_NN ._.
 Transcriptional_JJ regulation_NN during_IN T-cell_NN development_NN :_: the_DT alpha_NN TCR_NN gene_NN as_IN a_DT molecular_JJ model_NN ._.
 The_DT regulation_NN of_IN gene_NN expression_NN during_IN lymphocyte_NN differentiation_NN is_VBZ a_DT complex_JJ process_NN involving_VBG interactions_NNS between_IN multiple_JJ positive_JJ and_CC negative_JJ transcriptional_JJ regulatory_JJ elements_NNS ._.
 In_IN this_DT article_NN ,_, transcriptional_JJ regulation_NN of_IN the_DT archetypal_JJ T-cell-specific_JJ gene_NN ,_, alpha_NN TCR_NN ,_, is_VBZ discussed_VBN ._.
 Major_JJ recent_JJ developments_NNS ,_, including_VBG the_DT identification_NN of_IN novel_JJ families_NNS of_IN transcription_NN factors_NNS that_WDT regulate_VBP multiple_JJ T-cell_NN genes_NNS during_IN thymocyte_NN ontogeny_NN and_CC T-cell_NN activation_NN ,_, are_VBP described_VBN ._.
 Cortisol_NN resistance_NN in_IN acquired_VBN immunodeficiency_NN syndrome_NN ._.
 This_DT study_NN concerns_VBZ 9_CD iv_NN drug_NN abusers_NNS with_IN acquired_VBN immunodeficiency_NN syndrome_NN (_( AIDS_NN )_) who_WP developed_VBD hypercortisolism_NN without_IN the_DT clinical_JJ signs_NNS or_CC metabolic_JJ consequences_NNS of_IN hypercortisolism_NN ._.
 All_DT patients_NNS were_VBD characterized_VBN by_IN an_DT Addisonian_JJ picture_NN (_( weakness_NN ,_, weight_NN loss_NN ,_, hypotension_NN ,_, hyponatremia_NN ,_, and_CC intense_JJ mucocutaneous_JJ melanosis_NN )_) ._.
 An_DT acquired_JJ form_NN of_IN peripheral_JJ resistance_NN to_TO glucocorticoids_NNS was_VBD suspected_VBN ._.
 We_PRP ,_, therefore_RB ,_, examined_VBD glucocorticoid_NN receptor_NN characteristics_NNS on_IN mononuclear_JJ leukocytes_NNS by_IN measuring_VBG (3H)dexamethasone_NN binding_NN and_CC the_DT effect_NN of_IN dexamethasone_NN on_IN (3H)thymidine_NN incorporation_NN ,_, which_WDT is_VBZ one_CD of_IN the_DT effects_NNS of_IN glucocorticoid_NN receptor_NN activation_NN ._.
 Glucocorticoid_NN receptor_NN density_NN was_VBD increased_VBN in_IN AIDS_NN patients_NNS with_IN an_DT Addisonian_JJ picture_NN (_( group_NN 1_CD ;_: 16.2_CD +/-_CC 9.4_CD fmol/million_NN cells_NNS )_) compared_VBN to_TO values_NNS in_IN 12_CD AIDS_NN patients_NNS without_IN an_DT Addisonian_JJ picture_NN (_( group_NN 2_CD ;_: 6.05_CD +/-_CC 2.6_CD fmol/million_NN cells_NNS ;_: P_NN less_JJR than_IN 0.01_CD )_) and_CC sex-_NN and_CC age-matched_JJ controls_NNS (_( 3.15_CD +/-_CC 2.3_CD fmol/million_NN cells_NNS ;_: P_NN less_JJR than_IN 0.01_CD )_) ._.
 The_DT affinity_NN of_IN glucocorticoid_NN receptors_NNS (_( Kd_NN )_) was_VBD strikingly_RB decreased_VBN (_( 9.36_CD +/-_CC 3.44_CD nM_NN in_IN group_NN 1_CD ;_: 3.2_CD +/-_CC 1.5_CD nM_NN in_IN group_NN 2_CD ;_: 2.0_CD +/-_CC 0.8_CD nM_NN in_IN controls_NNS ;_: P_NN less_JJR than_IN 0.01_CD )_) ._.
 (3H)Thymidine_NN incorporation_NN was_VBD decreased_VBN dose-dependently_RB by_IN dexamethasone_NN in_IN controls_NNS and_CC patients_NNS ;_: the_DT effect_NN was_VBD significantly_RB blunted_VBN (_( P_NN less_JJR than_IN 0.05_CD )_) in_IN group_NN 1_CD patients_NNS ,_, which_WDT suggests_VBZ that_IN activation_NN of_IN glucocorticoid_NN receptor_NN is_VBZ impaired_JJ as_IN a_DT result_NN of_IN the_DT glucocorticoid_NN receptor_NN abnormality_NN ._.
 In_IN conclusion_NN ,_, AIDS_NN patients_NNS with_IN hypercortisolism_NN and_CC clinical_JJ features_NNS of_IN peripheral_JJ resistance_NN to_TO glucocorticoids_NNS are_VBP characterized_VBN by_IN abnormal_JJ glucocorticoid_NN receptors_NNS on_IN lymphocytes_NNS ._.
 Resistance_NN to_TO glucocorticoids_NNS implies_VBZ a_DT complex_JJ change_NN in_IN immune-endocrine_JJ function_NN ,_, which_WDT may_MD be_VB important_JJ in_IN the_DT course_NN of_IN immunodeficiency_NN syndrome_NN ._.
 Induction_NN of_IN monocytic_JJ differentiation_NN and_CC NF-kappa_NN B-like_JJ activities_NNS by_IN human_JJ immunodeficiency_NN virus_NN 1_CD infection_NN of_IN myelomonoblastic_JJ cells_NNS ._.
 The_DT effects_NNS of_IN human_JJ immunodeficiency_NN virus_NN 1_CD (_( HIV-1_NN )_) infection_NN on_IN cellular_JJ differentiation_NN and_CC NF-kappa_NN B_NN DNA_NN binding_NN activity_NN have_VBP been_VBN investigated_VBN in_IN a_DT new_JJ model_NN of_IN myeloid_JJ differentiation_NN ._.
 PLB-985_NN cells_NNS represent_VBP a_DT bipotential_JJ myelomonoblastic_JJ cell_NN population_NN capable_JJ of_IN either_CC granulocytic_JJ or_CC monocytic_JJ differentiation_NN after_IN induction_NN with_IN appropriate_JJ inducers_NNS ._.
 By_IN virtue_NN of_IN the_DT presence_NN of_IN CD4_NN on_IN the_DT cell_NN surface_NN ,_, PLB-985_NN cells_NNS were_VBD chronically_RB infected_VBN with_IN HIV-1_NN strain_NN IIIB_NN ._.
 PLB-IIIB_NN cells_NNS clearly_RB possessed_VBD a_DT more_RBR monocytic_JJ phenotype_NN than_IN the_DT parental_JJ myeloblasts_NNS ,_, as_IN determined_VBN by_IN differential_JJ staining_NN ,_, increased_VBN expression_NN of_IN the_DT myeloid-specific_JJ surface_NN markers_NNS ,_, and_CC transcription_NN of_IN the_DT c-fms_NN proto-oncogene_NN ._.
 NF-kappa_NN B_NN binding_NN activity_NN was_VBD inducible_JJ by_IN tumor_NN necrosis_NN factor_NN and_CC phorbol_NN myristate_NN acetate_NN in_IN PLB-985_NN ._.
 However_RB ,_, in_IN PLB-IIIB_NN cells_NNS ,_, constitutive_JJ expression_NN of_IN a_DT novel_JJ NF-kappa_NN B_NN complex_NN was_VBD detected_VBN ,_, composed_VBN of_IN proteins_NNS ranging_VBG between_IN 70_CD and_CC 110_CD kD_NN ._.
 These_DT proteins_NNS interacted_VBD specifically_RB with_IN the_DT symmetric_JJ NF-kappa_NN B_NN site_NN from_IN the_DT interferon_NN beta_NN (_( IFN-beta_NN )_) promoter_NN ._.
 Mutations_NNS affecting_VBG the_DT 5'_JJ guanine_JJ residues_NNS of_IN the_DT kappa_NN B_NN site_NN were_VBD unable_JJ to_TO compete_VB for_IN these_DT NF-kappa_NN B-related_JJ proteins_NNS ._.
 Inducibility_NN of_IN endogenous_JJ IFN-beta_NN and_CC IFN-alpha_NN RNA_NN was_VBD also_RB increased_VBN in_IN PLB-IIIB_NN cells_NNS ._.
 These_DT studies_NNS indicate_VBP that_IN HIV-1_NN infection_NN of_IN myelomonoblastic_JJ cells_NNS may_MD select_VB for_IN a_DT more_RBR mature_JJ monocytic_JJ phenotype_NN and_CC that_IN unique_JJ subunit_NN associations_NNS of_IN NF-kappa_NN B_NN DNA_NN binding_NN proteins_NNS may_MD contribute_VB to_TO differential_JJ NF-kappa_NN B-mediated_JJ gene_NN expression_NN ._.
 The_DT AP-1_NN site_NN at_IN -150_CD bp_NN ,_, but_CC not_RB the_DT NF-kappa_NN B_NN site_NN ,_, is_VBZ likely_JJ to_TO represent_VB the_DT major_JJ target_NN of_IN protein_NN kinase_NN C_NN in_IN the_DT interleukin_NN 2_CD promoter_NN ._.
 Stimulation_NN of_IN T_NN cells_NNS with_IN antigen_NN results_VBZ in_IN activation_NN of_IN several_JJ kinases_NNS ,_, including_VBG protein_NN kinase_NN C_NN (_( PKC_NN )_) ,_, that_WDT may_MD mediate_VB the_DT later_JJ induction_NN of_IN activation-related_JJ genes_NNS ._.
 We_PRP have_VBP examined_VBN the_DT potential_JJ role_NN of_IN PKC_NN in_IN induction_NN of_IN the_DT interleukin_NN 2_CD (_( IL-2_NN )_) gene_NN in_IN T_NN cells_NNS stimulated_VBN through_IN the_DT T_NN cell_NN receptor/CD3_NN complex_NN ._.
 We_PRP have_VBP previously_RB shown_VBN that_IN prolonged_JJ treatment_NN of_IN the_DT untransformed_JJ T_NN cell_NN clone_NN Ar-5_NN with_IN phorbol_NN esters_NNS results_VBZ in_IN downmodulation_NN of_IN the_DT alpha_NN and_CC beta_NN isozymes_NNS of_IN PKC_NN ,_, and_CC abrogates_VBZ induction_NN of_IN IL-2_NN mRNA_NN and_CC protein_NN ._.
 Here_RB we_PRP show_VBP that_IN phorbol_NN ester_NN treatment_NN also_RB abolishes_VBZ induction_NN of_IN chloramphenicol_JJ acetyltransferase_NN activity_NN in_IN Ar-5_NN cells_NNS transfected_VBN with_IN a_DT plasmid_NN containing_VBG the_DT IL-2_NN promoter_NN linked_VBN to_TO this_DT reporter_NN gene_NN ._.
 The_DT IL-2_NN promoter_NN contains_VBZ binding_VBG sites_NNS for_IN nuclear_JJ factors_NNS including_VBG NFAT-1_NN ,_, Oct_NN ,_, NF-kappa_NN B_NN ,_, and_CC AP-1_NN ,_, which_WDT are_VBP all_DT potentially_RB sensitive_JJ to_TO activation_NN of_IN PKC_NN ._.
 We_PRP show_VBP that_IN induction_NN of_IN a_DT trimer_NN of_IN the_DT NFAT_NN and_CC Oct_NN sites_NNS is_VBZ not_RB sensitive_JJ to_TO phorbol_NN ester_NN treatment_NN ,_, and_CC that_IN mutations_NNS in_IN the_DT NF-kappa_NN B_NN site_NN have_VBP no_DT effect_NN on_IN inducibility_NN of_IN the_DT IL-2_NN promoter_NN ._.
 In_IN contrast_NN ,_, mutations_NNS in_IN the_DT AP-1_NN site_NN located_JJ at_IN -150_CD bp_NN almost_RB completely_RB abrogate_VBP induction_NN of_IN the_DT IL-2_NN promoter_NN ,_, and_CC appearance_NN of_IN an_DT inducible_JJ nuclear_JJ factor_NN binding_VBG to_TO this_DT site_NN is_VBZ sensitive_JJ to_TO PKC_NN depletion_NN ._.
 Moreover_RB ,_, cotransfections_NNS with_IN c-fos_NN and_CC c-jun_NN expression_NN plasmids_NNS markedly_RB enhance_VBP induction_NN of_IN the_DT IL-2_NN promoter_NN in_IN minimally_RB stimulated_VBN T_NN cells_NNS ._.
 Our_PRP$ results_NNS indicate_VBP that_IN the_DT AP-1_NN site_NN at_IN -150_CD bp_NN represents_VBZ a_DT major_JJ ,_, if_IN not_RB the_DT only_JJ ,_, site_NN of_IN PKC_NN responsiveness_NN in_IN the_DT IL-2_NN promoter_NN ._.
 Interleukin_NN 6-induced_JJ differentiation_NN of_IN a_DT human_JJ B_NN cell_NN line_NN into_IN IgM-secreting_JJ plasma_NN cells_NNS is_VBZ mediated_VBN by_IN c-fos_NN ._.
 The_DT role_NN of_IN the_DT protooncogene_NN c-fos_NN in_IN interleukin_NN (_( IL_NN )_) 6-induced_JJ B_NN cell_NN differentiation_NN was_VBD assessed_VBN ._.
 Treatment_NN of_IN SKW_NN 6.4_CD cells_NNS with_IN IL_NN 6_CD induced_VBD a_DT transient_JJ and_CC early_JJ stimulation_NN of_IN c-fos_NN sense_NN mRNA_NN expression_NN ._.
 The_DT effect_NN appeared_VBD within_IN 30_CD min_NN and_CC returned_VBD to_TO basal_JJ levels_NNS after_IN 2_CD h_NN ._.
 The_DT addition_NN of_IN antisense_JJ oligonucleotides_NNS to_TO c-fos_NN significantly_RB inhibited_VBD IL_NN 6-induced_JJ IgM_NN production_NN by_IN SKW_NN 6.4_CD cells_NNS (_( p_NN less_JJR than_IN 0.001_CD )_) ,_, whereas_IN control_NN oligonucleotides_NNS had_VBD no_DT inhibitory_JJ effect_NN ._.
 These_DT results_NNS indicate_VBP that_IN activation_NN of_IN c-fos_NN is_VBZ involved_VBN in_IN IL_NN 6-induced_JJ differentiation_NN of_IN SKW_NN 6.4_CD cells_NNS into_IN IgM-secreting_JJ cells_NNS ._.
 Binding_NN of_IN erythroid_JJ and_CC non-erythroid_JJ nuclear_JJ proteins_NNS to_TO the_DT silencer_NN of_IN the_DT human_JJ epsilon-globin-encoding_JJ gene_NN ._.
 To_TO clarify_VB the_DT molecular_JJ mechanisms_NNS involved_VBN in_IN the_DT developmental_JJ control_NN of_IN hemoglobin-encoding_JJ genes_NNS we_PRP have_VBP been_VBN studying_VBG the_DT expression_NN of_IN these_DT genes_NNS in_IN human_JJ cells_NNS in_IN continuous_JJ culture_NN ._.
 We_PRP have_VBP previously_RB reported_VBN the_DT presence_NN of_IN a_DT transcriptional_JJ control_NN element_NN with_IN the_DT properties_NNS of_IN a_DT silencer_NN extending_VBG from_IN -392_CD to_TO -177_CD bp_NN relative_JJ to_TO the_DT cap_NN site_NN of_IN the_DT human_JJ epsilon-globin-encoding_JJ gene_NN (_( Cao_NNP et_FW al._FW ,_, Proc.Natl.Acad.Sci.USA_NNP 86_CD (_( 1989_CD )_) 5306-5309_CD )_) ._.
 We_PRP also_RB showed_VBD that_IN this_DT silencer_NN has_VBZ stronger_JJR inhibitory_JJ activity_NN in_IN HeLa_NN cells_NNS ,_, as_IN compared_VBN to_TO K562_NN human_JJ erythroleukemia_NN cells_NNS ._.
 Using_VBG deletion_NN mutants_NNS and_CC cis-cloned_JJ synthetic_JJ oligodeoxyribonucleotides_NNS in_IN transient_JJ expression_NN assays_NNS ,_, nucleotide_NN sequences_NNS responsible_JJ for_IN this_DT effect_NN have_VBP now_RB been_VBN further_RBR delimited_VBN to_TO 44_CD bp_NN located_JJ from_IN -294_CD to_TO -251_CD bp_NN ._.
 Gel_NN electrophoresis_NN mobility_NN shift_NN assays_NNS and_CC DNaseI_NN footprinting_NN assays_NNS demonstrate_VBP that_IN these_DT negative_JJ regulatory_JJ sequences_NNS are_VBP recognized_VBN differently_RB by_IN proteins_NNS present_JJ in_IN nuclear_JJ extracts_NNS obtained_VBN from_IN HeLa_NN and_CC K562_NN cells_NNS ._.
 Two_CD binding_VBG proteins_NNS are_VBP detected_VBN in_IN K562_NN nuclear_JJ extracts_NNS ,_, while_IN only_RB one_CD is_VBZ found_VBN in_IN extracts_NNS from_IN HeLa_NN cells_NNS ._.
 Possible_JJ mechanisms_NNS by_IN which_WDT these_DT proteins_NNS may_MD regulate_VB transcription_NN of_IN the_DT epsilon-globin-encoding_JJ gene_NN in_IN erythroid_JJ and_CC non-erythroid_JJ cells_NNS are_VBP discussed_VBN ._.
 Gangliosides_NN suppress_VBP tumor_NN necrosis_NN factor_NN production_NN in_IN human_JJ monocytes_NNS ._.
 Both_CC normal_JJ and_CC malignant_JJ cells_NNS contain_VBP gangliosides_NNS as_IN important_JJ cell_NN membrane_NN constituents_NNS that_WDT ,_, after_IN being_VBG shed_VBN ,_, may_MD influence_VB cells_NNS of_IN the_DT immune_JJ system_NN ._.
 We_PRP have_VBP studied_VBN the_DT impact_NN of_IN gangliosides_NNS on_IN the_DT expression_NN of_IN TNF_NN in_IN blood_NN monocytes_NNS and_CC in_IN the_DT monocytic_JJ cell_NN line_NN Mono_NN Mac_NN 6_CD ._.
 Although_IN under_IN standard_JJ culture_NN conditions_NNS ,_, bovine_JJ brain_NN gangliosides_NNS (_( 100_CD micrograms/ml_NNS )_) suppressed_VBD LPS-stimulated_JJ TNF_NN production_NN 5-fold_RB in_IN PBMC_NN and_CC 10-fold_RB in_IN Mono_NN Mac_NN 6_CD cells_NNS ,_, suppression_NN was_VBD more_RBR efficient_JJ under_IN serum-free_JJ conditions_NNS ._.
 Looking_VBG at_IN highly_RB purified_VBN gangliosides_NNS ,_, GD3_NN ,_, GD1a_NN ,_, GM3_NN ,_, GM2_NN ,_, and_CC GM1_NN were_VBD all_DT effective_JJ in_IN reducing_VBG TNF_NN production_NN in_IN PBMC_NN ,_, and_CC in_IN Mono_NN Mac_NN 6_CD by_IN factor_NN 10_CD to_TO 50_CD ._.
 The_DT suppressive_JJ activity_NN was_VBD lost_VBN in_IN molecules_NNS ,_, lacking_VBG the_DT sugar_NN moiety_NN or_CC the_DT lipid_NN moiety_NN ._.
 Gangliosides_NNS appear_VBP to_TO act_VB at_IN an_DT early_JJ step_NN of_IN activation_NN in_IN that_IN TNF_NN transcripts_NNS were_VBD reduced_VBN and_CC the_DT mobilization_NN of_IN the_DT nuclear_JJ factor_NN kappa_NN B_NN was_VBD blocked_VBN ._.
 Furthermore_RB ,_, in_IN time_NN kinetics_NNS ,_, gangliosides_NNS were_VBD effective_JJ for_IN up_RB to_TO 30_CD min_NN after_IN addition_NN of_IN LPS_NN ,_, but_CC not_RB thereafter_RB ._.
 However_RB ,_, the_DT expression_NN of_IN the_DT CD14_NN Ag_NN ,_, a_DT receptor_NN molecule_NN for_IN LPS-LPS_NN binding_NN protein_NN complexes_NNS ,_, was_VBD unaffected_JJ by_IN gangliosides_NNS ._.
 Finally_RB ,_, when_WRB using_VBG Staphylococcus_FW aureus_FW or_CC platelet_NN activating_NN factor_NN as_IN a_DT stimulus_NN ,_, gangliosides_NNS were_VBD able_JJ to_TO suppress_VB TNF_NN production_NN in_IN Mono_NN Mac_NN 6_CD cells_NNS by_IN factor_NN 5_CD to_TO 10_CD ,_, as_RB well_RB ._.
 On_IN the_DT other_JJ hand_NN ,_, phorbol_NN ester-induced_JJ production_NN of_IN O2-_NN was_VBD similar_JJ in_IN cells_NNS treated_VBN with_IN and_CC without_IN gangliosides_NNS ._.
 Taken_VBN together_RB ,_, our_PRP$ data_NNS demonstrate_VBP that_IN TNF_NN gene_NN expression_NN in_IN monocytes_NNS induced_VBN by_IN different_JJ types_NNS of_IN stimuli_NNS can_MD be_VB blocked_VBN by_IN gangliosides_NNS at_IN an_DT early_JJ step_NN of_IN signal_JJ transduction_NN ._.
 T_NN cell-specific_JJ negative_JJ regulation_NN of_IN transcription_NN of_IN the_DT human_JJ cytokine_NN IL-4_NN ._.
 IL-4_NN secreted_VBN by_IN activated_VBN T_NN cells_NNS is_VBZ a_DT pleiotropic_JJ cytokine_NN affecting_VBG growth_NN and_CC differentiation_NN of_IN diverse_JJ cell_NN types_NNS such_JJ as_IN T_NN cells_NNS ,_, B_NN cells_NNS ,_, and_CC mast_NN cells_NNS ._.
 We_PRP investigated_VBD the_DT upstream_JJ regulatory_JJ elements_NNS of_IN the_DT human_JJ IL-4_NN promoter_NN ._.
 A_DT novel_JJ T_NN cell-specific_JJ negative_JJ regulatory_JJ element_NN (_( NRE_NN )_) composed_VBN of_IN two_CD protein-binding_JJ sites_NNS were_VBD mapped_VBN in_IN the_DT 5'_JJ flanking_JJ region_NN of_IN the_DT IL-4_NN gene_NN :_: -311CTCCCTTCT-303_NN (_( NRE-I_NN )_) and_CC -288CTTTTTGCTT-TGC-300_NN (_( NRE-II_NN )_) ._.
 A_DT T_NN cell-specific_JJ protein_NN Neg-1_NN and_CC a_DT ubiquitous_JJ protein_NN Neg-2_NN binding_VBG to_TO NRE-I_NN and_CC NRE-II_NN ,_, respectively_RB ,_, were_VBD identified_VBN ._.
 Furthermore_RB ,_, a_DT positive_JJ regulatory_JJ element_NN was_VBD found_VBN 45_CD bp_NN downstream_RB of_IN the_DT NRE_NN ._.
 The_DT enhancer_NN activity_NN of_IN the_DT PRE_NN was_VBD completely_RB suppressed_VBN when_WRB the_DT NRE_NN was_VBD present_JJ ._.
 These_DT data_NNS suggest_VBP that_IN IL-4_NN promoter_NN activity_NN is_VBZ normally_RB down-regulated_VBN by_IN an_DT NRE_NN via_IN repression_NN of_IN the_DT enhancer_NN positive_JJ regulatory_JJ element_NN ._.
 These_DT data_NNS may_MD have_VB implications_NNS for_IN the_DT stringent_JJ control_NN of_IN IL-4_NN expression_NN in_IN T_NN cells_NNS ._.
 (_( Regulatory_JJ effect_NN of_IN insulin_NN on_IN glucocorticoid_NN receptor_NN in_IN human_JJ peripheral_JJ leukocytes_NNS )_)
 The_DT regulatory_JJ effect_NN of_IN insulin_NN on_IN the_DT specific_JJ binding_VBG power_NN of_IN glucocorticoid_NN receptor_NN (_( GR_NN )_) of_IN human_JJ leukocytes_NNS was_VBD assessed_VBN by_IN the_DT unoccupied_JJ receptor_NN sites_NNS capable_JJ of_IN combining_VBG with_IN (3H)_NN labelled_JJ dexamethasone_NN measured_VBN at_IN 3_CD and_CC 24_CD h_NN after_IN incubation_NN with_IN various_JJ concentrations_NNS of_IN insulin_NN added_VBN to_TO the_DT medium_NN ._.
 After_IN 3_CD h_NN incubation_NN the_DT specific_JJ binding_VBG power_NN with_IN (3H)_NN Dex_NN was_VBD decreased_VBN by_IN 23.3_CD +/-_CC 10.0_CD ,_, 32.2_CD +/-_CC 13.2_CD and_CC 54.3_CD +/-_CC 9.2_CD %_NN (_( P_NN greater_JJR than_IN 0.05_CD ,_, P_NN greater_JJR than_IN 0.05_CD and_CC P_NN less_JJR than_IN 0.01_CD as_IN compared_VBN with_IN the_DT control_NN value_NN of_IN 100_CD in_IN the_DT absence_NN of_IN insulin_NN )_) respectively_RB in_IN the_DT presence_NN of_IN 20_CD mU/L_NN (_( physiological_JJ testing_NN concentration_NN )_) ,_, 200_CD mU/L_NN (_( physiological_JJ upper_JJ limit_NN )_) and_CC 2,000_CD mU/L_NN (_( pharmacological_JJ concentration_NN )_) insulin_NN in_IN the_DT incubation_NN medium_NN ._.
 After_IN 24_CD h_NN incubation_NN the_DT decrease_NN of_IN these_DT values_NNS increased_VBD respectively_RB to_TO 43.5_CD +/-_CC 19.0_CD ,_, 56.1_CD +/-_CC 20.7_CD and_CC 80.2_CD +/-_CC 15.5_CD (_( P_NN less_JJR than_IN 0.05_CD ,_, P_NN less_JJR than_IN 0.01_CD and_CC P_NN less_JJR than_IN 0.01_CD compared_VBN with_IN control_NN )_) ._.
 Thus_RB the_DT inhibitory_JJ effect_NN of_IN insulin_NN on_IN the_DT GR_NN binding_NN power_NN is_VBZ both_CC dose-_NN and_CC time-dependent_JJ ,_, which_WDT strongly_RB suggests_VBZ that_IN GR_NN is_VBZ tonically_RB controlled_VBN by_IN insulin_NN concentration_NN change_NN under_IN physiological_JJ conditions_NNS ._.
 Human_JJ T_NN cell_NN activation_NN through_IN the_DT activation-inducer_JJ molecule/CD69_NN enhances_VBZ the_DT activity_NN of_IN transcription_NN factor_NN AP-1_NN ._.
 The_DT induction_NN of_IN the_DT AP-1_NN transcription_NN factor_NN has_VBZ been_VBN ascribed_VBN to_TO the_DT early_JJ events_NNS leading_VBG to_TO T_NN cell_NN differentiation_NN and_CC activation_NN ._.
 We_PRP have_VBP studied_VBN the_DT regulation_NN of_IN AP-1_NN activity_NN in_IN human_JJ peripheral_JJ blood_NN T_NN lymphocytes_NNS stimulated_VBN through_IN the_DT activation_NN inducer_NN molecule_NN (_( AIM_NN )_) /CD69_NN activation_NN pathway_NN ._.
 Phorbol_NN esters_NNS are_VBP required_VBN to_TO induce_VB AIM/CD69_NN cell-surface_JJ expression_NN as_RB well_RB as_IN for_IN triggering_VBG the_DT proliferation_NN of_IN T_NN cells_NNS in_IN conjunction_NN with_IN anti-AIM_JJ mAb_NN ._.
 Mobility_NN shift_NN assays_NNS showed_VBD that_IN addition_NN of_IN anti-AIM_JJ mAb_NN to_TO PMA-treated_JJ T_NN lymphocytes_NNS markedly_RB enhanced_VBD the_DT binding_NN activity_NN of_IN AP-1_NN to_TO its_PRP$ cognate_JJ sequence_NN ,_, the_DT phorbol_NN ester_NN response_NN element_NN ._.
 In_IN contrast_NN ,_, anti-AIM_NN mAb_NN did_VBD not_RB induce_VB any_DT change_NN in_IN the_DT binding_NN activity_NN of_IN NF-kappa_NN B_NN ,_, a_DT transcription_NN factor_NN whose_WP$ activity_NN is_VBZ also_RB regulated_VBN by_IN protein_NN kinase_NN C_NN ._.
 The_DT increase_NN in_IN AP-1-binding_JJ activity_NN was_VBD accompanied_VBN by_IN the_DT marked_JJ stimulation_NN of_IN the_DT transcription_NN of_IN c-fos_NN but_CC not_RB that_DT of_IN c-jun_NN ._.
 Blockade_NN of_IN the_DT DNA-binding_JJ complexes_NNS with_IN an_DT anti-Fos_JJ mAb_NN demonstrated_VBD a_DT direct_JJ participation_NN of_IN c-Fos_NN in_IN the_DT AP-1_NN complexes_NNS induced_VBN by_IN anti-AIM_NN mAb_NN ._.
 Most_JJS of_IN the_DT AP-1_NN activity_NN could_MD be_VB eliminated_VBN when_WRB the_DT anti-AIM_NN mAb_NN was_VBD added_VBN to_TO the_DT culture_NN medium_NN in_IN the_DT presence_NN of_IN cycloheximide_NN ,_, suggesting_VBG that_IN de_FW novo_FW protein_NN synthesis_NN is_VBZ crucial_JJ for_IN the_DT induction_NN of_IN AP-1-binding_JJ activity_NN ._.
 These_DT data_NNS provide_VBP the_DT evidence_NN that_IN activation_NN of_IN human_JJ peripheral_JJ blood_NN T_NN cells_NNS through_IN the_DT AIM_NN activation_NN pathway_NN regulate_VBP the_DT activity_NN of_IN AP-1_NN ._.
 Therefore_RB ,_, this_DT pathway_NN appears_VBZ as_IN a_DT crucial_JJ step_NN in_IN the_DT initiation_NN of_IN early_JJ T_NN cell_NN activation_NN events_NNS ._.
 cis-acting_JJ sequences_NNS required_VBN for_IN inducible_JJ interleukin-2_NN enhancer_NN function_NN bind_VBP a_DT novel_JJ Ets-related_JJ protein_NN ,_, Elf-1_NN ._.
 The_DT recent_JJ definition_NN of_IN a_DT consensus_NN DNA_NN binding_NN sequence_NN for_IN the_DT Ets_NN family_NN of_IN transcription_NN factors_NNS has_VBZ allowed_VBN the_DT identification_NN of_IN potential_JJ Ets_NN binding_NN sites_NNS in_IN the_DT promoters_NNS and_CC enhancers_NNS of_IN many_JJ inducible_JJ T-cell_NN genes_NNS ._.
 In_IN the_DT studies_NNS described_VBN in_IN this_DT report_NN ,_, we_PRP have_VBP identified_VBN two_CD potential_JJ Ets_NNS binding_NN sites_NNS ,_, EBS1_NN and_CC EBS2_NN ,_, which_WDT are_VBP conserved_VBN in_IN both_CC the_DT human_JJ and_CC murine_JJ interleukin-2_NN enhancers_NNS ._.
 Within_IN the_DT human_JJ enhancer_NN ,_, these_DT two_CD sites_NNS are_VBP located_JJ within_IN the_DT previously_RB defined_VBN DNase_NN I_CD footprints_NNS ,_, NFAT-1_NN and_CC NFIL-2B_NN ,_, respectively_RB ._.
 Electrophoretic_JJ mobility_NN shift_NN and_CC methylation_NN interference_NN analyses_NNS demonstrated_VBD that_IN EBS1_NN and_CC EBS2_NN are_VBP essential_JJ for_IN the_DT formation_NN of_IN the_DT NFAT-1_NN and_CC NFIL-2B_NN nuclear_JJ protein_NN complexes_NNS ._.
 Furthermore_RB ,_, in_FW vitro_FW mutagenesis_NN experiments_NNS demonstrated_VBD that_IN inducible_JJ interleukin-2_NN enhancer_NN function_NN requires_VBZ the_DT presence_NN of_IN either_CC EBS1_NN or_CC EBS2_NN ._.
 Two_CD well-characterized_JJ Ets_NN family_NN members_NNS ,_, Ets-1_NN and_CC Ets-2_NN ,_, are_VBP reciprocally_RB expressed_VBN during_IN T-cell_NN activation_NN ._.
 Surprisingly_RB ,_, however_RB ,_, neither_DT of_IN these_DT proteins_NNS bound_VBD in_FW vitro_FW to_TO EBS1_NN or_CC EBS2_NN ._.
 We_PRP therefore_RB screened_VBD a_DT T-cell_NN cDNA_NN library_NN under_IN low-stringency_NN conditions_NNS with_IN a_DT probe_NN from_IN the_DT DNA_NN binding_NN domain_NN of_IN Ets-1_NN and_CC isolated_VBD a_DT novel_JJ Ets_NN family_NN member_NN ,_, Elf-1_NN ._.
 Elf-1_NN contains_VBZ a_DT DNA_NN binding_NN domain_NN that_WDT is_VBZ nearly_RB identical_JJ to_TO that_DT of_IN E74_NN ,_, the_DT ecdysone-inducible_JJ Drosophila_NN transcription_NN factor_NN required_VBN for_IN metamorphosis_NN (_( hence_RB the_DT name_NN Elf-1_NN ,_, for_IN E74-like_JJ factor_NN 1_CD )_) ._.
 Elf-1_NN bound_VBD specifically_RB to_TO both_CC EBS1_NN and_CC EBS2_NN in_IN electrophoretic_JJ mobility_NN shift_NN assays_NNS ._.
 It_PRP also_RB bound_VBD to_TO the_DT purine-rich_JJ CD3R_NN element_NN from_IN the_DT human_JJ immunodeficiency_NN virus_NN type_NN 2_CD long_JJ terminal_JJ repeat_NN ,_, which_WDT is_VBZ required_VBN for_IN inducible_JJ virus_NN expression_NN in_IN response_NN to_TO signalling_NN through_IN the_DT T-cell_NN receptor_NN ._.
 Taken_VBN together_RB ,_, these_DT results_NNS demonstrate_VBP that_IN multiple_JJ Ets_NN family_NN members_NNS with_IN apparently_RB distinct_JJ DNA_NN binding_NN specificities_NNS regulate_VBP differential_JJ gene_NN expression_NN in_IN resting_VBG and_CC activated_VBN T_NN cells_NNS ._.
 Mineralocorticoids_NNPS and_CC mineralocorticoid_NN receptors_NNS in_IN mononuclear_JJ leukocytes_NNS in_IN patients_NNS with_IN pregnancy-induced_JJ hypertension_NN ._.
 To_TO examine_VB the_DT role_NN of_IN mineralocorticoids_NNS in_IN the_DT pathophysiology_NN of_IN pregnancy-induced_JJ hypertension_NN (_( PIH_NN )_) ,_, we_PRP studied_VBD plasma_NN aldosterone_NN and_CC 18-hydroxycorticosterone_NN levels_NNS in_IN 25_CD women_NNS with_IN PIH_NN and_CC 25_CD normal_JJ pregnant_JJ women_NNS ,_, as_IN controls_NNS ._.
 Furthermore_RB ,_, we_PRP evaluated_VBD the_DT mineralocorticoid_NN receptor_NN (_( MR_NN )_) status_NN in_IN mononuclear_JJ leukocytes_NNS in_IN the_DT 2_CD groups_NNS ._.
 MR_NN count_NN was_VBD significantly_RB (_( P_NN less_JJR than_IN 0.0005_CD )_) decreased_VBN in_IN the_DT PIH_NN group_NN (_( 148_CD +/-_CC 9_CD binding_VBG sites/cell_NNS )_) compared_VBN with_IN the_DT control_NN group_NN (_( 300_CD +/-_CC 17_CD binding_VBG sites/cell_NNS ;_: mean_NN +/-_CC SEM_NN )_) ._.
 Plasma_NN aldosterone_NN in_IN women_NNS with_IN PIH_NN was_VBD 281_CD +/-_CC 61_CD pmol/L_NN ;_: in_IN normal_JJ pregnant_JJ women_NNS it_PRP was_VBD 697_CD +/-_CC 172_CD pmol/L_NN (_( P_NN less_JJR than_IN 0.025_CD )_) ._.
 Plasma_NN 18-hydroxycorticosterone_NN was_VBD also_RB significantly_RB (_( P_NN less_JJR than_IN 0.025_CD )_) lower_JJR (_( PIH_NN ,_, 1071_CD +/-_CC 149_CD pmol/L_NN ;_: controls_NNS ,_, 1907_CD +/-_CC 318_CD pmol/L_NN )_) ._.
 These_DT values_NNS were_VBD determined_VBN at_IN the_DT onset_NN of_IN clinical_JJ symptoms_NNS of_IN PIH_NN ._.
 These_DT results_NNS can_MD not_RB be_VB explained_VBN by_IN receptor_NN down-regulation_NN due_JJ to_TO higher_JJR levels_NNS of_IN mineralocorticoids_NNS in_IN PIH_NN ;_: a_DT hitherto_RB unknown_JJ mineralocorticoid_NN may_MD ,_, thus_RB ,_, be_VB responsible_JJ for_IN the_DT hypertension_NN and_CC altered_JJ MR_NN status_NN ._.
 Mineralocorticoid_NN effector_NN mechanism_NN in_IN preeclampsia_NN ._.
 Mineralocorticoid_NN effector_NN mechanisms_NNS were_VBD evaluated_VBN in_IN 29_CD patients_NNS with_IN preeclampsia_NN and_CC in_IN 25_CD uncomplicated_JJ pregnancies_NNS by_IN measurement_NN of_IN plasma_NN aldosterone_NN ,_, levels_NNS of_IN mineralocorticoid_NN receptor_NN (_( MR_NN )_) in_IN mononuclear_JJ leucocytes_NNS ,_, and_CC subtraction_NN potential_NN difference_NN (_( SPD_NN ;_: rectal_JJ minus_CC oral_JJ values_NNS )_) ._.
 Mean_NN values_NNS for_IN plasma_NN aldosterone_NN were_VBD not_RB different_JJ between_IN the_DT two_CD groups_NNS ,_, but_CC significant_JJ differences_NNS were_VBD observed_VBN for_IN MR_NN (_( preeclampsia_NN ,_, 81_CD +/-_CC 44_CD receptors/cell_NNS ;_: controls_NNS ,_, 306_CD +/-_CC 168_CD )_) and_CC SPD_NN (_( preeclampsia_NN ,_, 65_CD +/-_CC 7_CD mV_NN ;_: controls_NNS ,_, 12_CD +/-_CC 5_CD mV_NN )_) ._.
 In_IN six_CD cases_NNS we_PRP determined_VBD MR_NN ,_, plasma_NN aldosterone_NN ,_, and_CC SPD_NN in_IN patients_NNS with_IN preeclampsia_NN before_IN and_CC 3_CD months_NNS after_IN delivery_NN ._.
 MR_NNS were_VBD reduced_VBN before_IN delivery_NN (_( 96_CD +/-_CC 27_CD receptors/cell_NNS )_) ,_, and_CC SPD_NN increased_VBD (_( 64_CD +/-_CC 8_CD mV_NN )_) ,_, with_IN both_DT parameters_NNS normalizing_VBG after_IN delivery_NN (_( MR_NN ,_, 242_CD +/-_CC 79_CD ;_: SPD_NN ,_, 14.0_CD +/-_CC 4_CD mV_NN )_) ._.
 Aldosterone_NN levels_NNS returned_VBD to_TO normal_JJ nonpregnant_JJ values_NNS after_IN delivery_NN ._.
 These_DT data_NNS suggest_VBP an_DT important_JJ role_NN for_IN abnormalities_NNS in_IN mineralocorticoid_NN effector_NN mechanisms_NNS in_IN the_DT etiology_NN of_IN preeclampsia_NN and_CC could_MD be_VB an_DT useful_JJ marker_NN for_IN diagnosis_NN ._.
 A_DT lymphoid_JJ cell-specific_JJ nuclear_JJ factor_NN containing_VBG c-Rel-like_JJ proteins_NNS preferentially_RB interacts_VBZ with_IN interleukin-6_NN kappa_NN B-related_JJ motifs_NNS whose_WP$ activities_NNS are_VBP repressed_VBN in_IN lymphoid_JJ cells_NNS ._.
 The_DT proto-oncoprotein_NN c-Rel_NN is_VBZ a_DT member_NN of_IN the_DT nuclear_JJ factor_NN kappa_NN B_NN transcription_NN factor_NN family_NN ,_, which_WDT includes_VBZ the_DT p50_NN and_CC p65_NN subunits_NNS of_IN nuclear_JJ factor_NN kappa_NN B_NN ._.
 We_PRP show_VBP here_RB that_IN c-Rel_NN binds_VBZ to_TO kappa_NN B_NN sites_NNS as_IN homodimers_NNS as_RB well_RB as_IN heterodimers_NNS with_IN p50_NN ._.
 These_DT homodimers_NNS and_CC heterodimers_NNS show_VBP distinct_JJ DNA-binding_JJ specificities_NNS and_CC affinities_NNS for_IN various_JJ kappa_NN B_NN motifs_NNS ._.
 In_IN particular_JJ ,_, the_DT c-Rel_NN homodimer_NN has_VBZ a_DT high_JJ affinity_NN for_IN interleukin-6_NN (_( IL-6_NN )_) and_CC beta_NN interferon_NN kappa_NN B_NN sites_NNS ._.
 In_IN spite_NN of_IN its_PRP$ association_NN with_IN p50_NN in_FW vitro_FW ,_, however_RB ,_, we_PRP found_VBD a_DT lymphoid_JJ cell-specific_JJ nuclear_JJ factor_NN in_FW vivo_FW that_WDT contains_VBZ c-Rel_NN but_CC not_RB p50_NN epitopes_NNS ;_: this_DT factor_NN ,_, termed_VBN IL-6_NN kappa_NN B_NN binding_NN factor_NN II_CD ,_, appears_VBZ to_TO contain_VB the_DT c-Rel_NN homodimer_NN and_CC preferentially_RB recognizes_VBZ several_JJ IL-6_NN kappa_NN B-related_JJ kappa_NN B_NN motifs_NNS ._.
 Although_IN it_PRP has_VBZ been_VBN previously_RB shown_VBN that_IN the_DT IL-6_NN kappa_NN B_NN motif_NN functions_VBZ as_IN a_DT potent_JJ IL-1/tumor_NN necrosis_NN factor-responsive_JJ element_NN in_IN nonlymphoid_JJ cells_NNS ,_, its_PRP$ activity_NN was_VBD found_VBN to_TO be_VB repressed_VBN in_IN lymphoid_JJ cells_NNS such_JJ as_IN a_DT Jurkat_NN T-cell_NN line_NN ._.
 We_PRP also_RB present_VBP evidence_NN that_IN IL-6_NN kappa_NN B_NN binding_NN factor_NN II_CD functions_VBZ as_IN a_DT repressor_NN specific_JJ for_IN IL-6_NN kappa_NN B-related_JJ kappa_NN B_NN motifs_NNS in_IN lymphoid_JJ cells_NNS ._.
 Modulation_NN of_IN normal_JJ erythroid_JJ differentiation_NN by_IN the_DT endogenous_JJ thyroid_NN hormone_NN and_CC retinoic_JJ acid_NN receptors_NNS :_: a_DT possible_JJ target_NN for_IN v-erbA_NN oncogene_NN action_NN ._.
 The_DT v-erbA_NN oncogene_NN ,_, a_DT mutated_VBN version_NN of_IN the_DT thyroid_NN hormone_NN receptor_NN alpha_NN (_( c-erbA/TR-alpha_NN )_) ,_, inhibits_VBZ erythroid_JJ differentiation_NN and_CC constitutively_RB represses_VBZ transcription_NN of_IN certain_JJ erythrocyte_NN genes_NNS ,_, suggesting_VBG a_DT normal_JJ function_NN of_IN the_DT proto-oncogene_NN c-erbA_NN in_IN erythropoiesis_NN ._.
 Here_RB we_PRP demonstrate_VBP that_IN the_DT endogenous_JJ thyroid_NN hormone_NN receptor_NN alpha_NN (_( c-erbA/TR-alpha_NN )_) and_CC the_DT closely_RB related_JJ retinoic_JJ acid_NN receptor_NN alpha_NN (_( RAR-alpha_NN )_) play_VBP a_DT role_NN in_IN the_DT regulation_NN of_IN normal_JJ erythroid_JJ differentiation_NN ._.
 Retinoic_JJ acid_NN (_( RA_NN )_) distinctly_RB modulated_VBD the_DT erythroid_JJ differentiation_NN program_NN of_IN normal_JJ erythroid_JJ progenitors_NNS and_CC erythroblasts_NNS reversibly_RB transformed_VBN by_IN a_DT conditional_JJ tyrosine_NN kinase_NN oncogene_NN ._.
 When_WRB added_VBN pulsewise_RB to_TO immature_JJ cells_NNS ,_, differentiation_NN was_VBD accelerated_VBN while_IN more_RBR mature_JJ cells_NNS underwent_VBD premature_JJ cell_NN death_NN ._.
 Thyroid_NN hormone_NN (_( T3_NN )_) alone_RB caused_VBD similar_JJ but_CC weaker_JJR effects_NNS ._.
 Interestingly_RB ,_, T3_NN strongly_RB enhanced_VBD the_DT action_NN of_IN RA_NN ,_, suggesting_VBG cooperative_JJ action_NN of_IN the_DT two_CD receptors_NNS in_IN modulating_VBG erythroid_JJ differentiation_NN ._.
 Expression_NN of_IN the_DT human_JJ RAR-alpha_NN in_IN receptor-negative_JJ erythroblasts_NNS conferred_VBD RA-induced_JJ regulation_NN of_IN differentiation_NN to_TO the_DT otherwise_RB unresponsive_JJ cells_NNS ,_, thus_RB showing_VBG that_IN the_DT RAR-alpha_NN is_VBZ essential_JJ for_IN the_DT RA_NN effect_NN ._.
 Likewise_RB ,_, enhanced_VBN expression_NN of_IN exogenous_JJ c-erbA/TR-alpha_NN in_IN erythroblasts_NNS rendered_VBD them_PRP susceptible_JJ to_TO modulation_NN of_IN differentiation_NN by_IN T3_NN ,_, suggesting_VBG a_DT similar_JJ function_NN of_IN both_DT receptors_NNS ._.
 Leukotriene_NN B4_NN stimulates_VBZ c-fos_NN and_CC c-jun_NN gene_NN transcription_NN and_CC AP-1_NN binding_NN activity_NN in_IN human_JJ monocytes_NNS ._.
 We_PRP have_VBP examined_VBN the_DT effect_NN of_IN leukotriene_NN B4_NN (_( LTB4_NN )_) ,_, a_DT potent_JJ lipid_NN proinflammatory_JJ mediator_NN ,_, on_IN the_DT expression_NN of_IN the_DT proto-oncogenes_NNS c-jun_NN and_CC c-fos_NN ._.
 In_IN addition_NN ,_, we_PRP looked_VBD at_IN the_DT modulation_NN of_IN nuclear_JJ factors_NNS binding_VBG specifically_RB to_TO the_DT AP-1_NN element_NN after_IN LTB4_NN stimulation_NN ._.
 LTB4_NN increased_VBD the_DT expression_NN of_IN the_DT c-fos_NN gene_NN in_IN a_DT time-_NN and_CC concentration-dependent_JJ manner_NN ._.
 The_DT c-jun_NN mRNA_NN ,_, which_WDT is_VBZ constitutively_RB expressed_VBN in_IN human_JJ peripheral-blood_NN monocytes_NNS at_IN relatively_RB high_JJ levels_NNS ,_, was_VBD also_RB slightly_RB augmented_JJ by_IN LTB4_NN ,_, although_IN to_TO a_DT much_RB lower_JJR extent_NN than_IN c-fos_NN ._.
 The_DT kinetics_NNS of_IN expression_NN of_IN the_DT two_CD genes_NNS were_VBD also_RB slightly_RB different_JJ ,_, with_IN c-fos_NN mRNA_NN reaching_VBG a_DT peak_NN at_IN 15_CD min_NN after_IN stimulation_NN and_CC c-jun_NN at_IN 30_CD min_NN ._.
 Both_DT messages_NNS rapidly_RB declined_VBD thereafter_RB ._.
 Stability_NN of_IN the_DT c-fos_NN and_CC c-jun_NN mRNA_NN was_VBD not_RB affected_VBN by_IN LTB4_NN ,_, as_IN assessed_VBN after_IN actinomycin_NN D_NN treatment_NN ._.
 Nuclear_JJ transcription_NN studies_NNS in_FW vitro_FW showed_VBD that_IN LTB4_NN increased_VBD the_DT transcription_NN of_IN the_DT c-fos_NN gene_NN 7-fold_RB and_CC the_DT c-jun_NN gene_NN 1.4-fold_RB ._.
 Resting_VBG monocytes_NNS contained_VBD nuclear_JJ factors_NNS binding_VBG to_TO the_DT AP-1_NN element_NN ,_, but_CC stimulation_NN of_IN monocytes_NNS with_IN LTB4_NN induced_VBD greater_JJR AP-1-binding_JJ activity_NN of_IN nuclear_JJ proteins_NNS ._.
 These_DT results_NNS indicate_VBP that_IN LTB4_NN may_MD regulate_VB the_DT production_NN of_IN different_JJ cytokines_NNS by_IN modulating_VBG the_DT yield_NN and/or_CC the_DT function_NN of_IN transcription_NN factors_NNS such_JJ as_IN AP-1-binding_JJ proto-oncogene_NN products_NNS ._.
 An_DT 11-base-pair_JJ DNA_NN sequence_NN motif_NN apparently_RB unique_JJ to_TO the_DT human_JJ interleukin_NN 4_CD gene_NN confers_VBZ responsiveness_NN to_TO T-cell_NN activation_NN signals_NNS ._.
 We_PRP have_VBP identified_VBN a_DT DNA_NN segment_NN that_WDT confers_VBZ responsiveness_NN to_TO antigen_NN stimulation_NN signals_NNS on_IN the_DT human_JJ interleukin_NN (_( IL_NN )_) 4_CD gene_NN in_IN Jurkat_NN cells_NNS ._.
 The_DT human_JJ IL-4_NN gene_NN ,_, of_IN 10_CD kilobases_NNS ,_, is_VBZ composed_VBN of_IN four_CD exons_NNS and_CC three_CD introns_NNS ._.
 A_DT cis-acting_JJ element_NN (_( P_NN sequence_NN )_) resides_VBZ in_IN the_DT 5'_JJ upstream_JJ region_NN ;_: no_DT additional_JJ DNA_NN segments_NNS with_IN enhancer_NN activity_NN were_VBD identified_VBN in_IN the_DT human_JJ IL-4_NN gene_NN ._.
 For_IN further_JJ mapping_NN purposes_NNS ,_, a_DT fusion_NN promoter_NN was_VBD constructed_VBN with_IN the_DT granulocyte/macrophage_JJ colony-stimulating_JJ factor_NN basic_JJ promoter_NN containing_VBG 60_CD base_NN pairs_NNS of_IN sequence_NN upstream_JJ from_IN the_DT cap_NN site_NN of_IN the_DT mouse_NN granulocyte/macrophage_JJ colony-stimulating_JJ factor_NN gene_NN and_CC various_JJ lengths_NNS of_IN the_DT 5'_JJ upstream_JJ sequence_NN of_IN the_DT IL-4_NN gene_NN ._.
 The_DT P_NN sequence_NN was_VBD located_JJ between_IN positions_NNS -79_CD and_CC -69_CD relative_JJ to_TO the_DT transcription_NN start_NN site_NN of_IN the_DT human_JJ IL-4_NN gene_NN ,_, and_CC this_DT location_NN was_VBD confirmed_VBN by_IN base-substitution_NN mutations_NNS ._.
 The_DT plasmids_NNS carrying_VBG multiple_JJ copies_NNS of_IN the_DT P_NN sequence_NN showed_VBD higher_JJR responsiveness_NN to_TO the_DT stimulation_NN ._.
 The_DT binding_VBG protein_NN (_( s_NNS )_) that_WDT recognize_VBP the_DT P_NN sequence_NN of_IN the_DT IL-4_NN gene_NN were_VBD identified_VBN by_IN DNA-mobility-shift_JJ assays_NNS ._.
 The_DT binding_NN of_IN NF(P)_NN (_( a_DT DNA_NN binding_NN protein_NN that_WDT specifically_RB recognizes_VBZ the_DT P_NN sequence_NN )_) to_TO the_DT P_NN sequence_NN was_VBD abolished_VBN when_WRB oligonucleotides_NNS carrying_VBG base_NN substitutions_NNS were_VBD used_VBN ,_, indicating_VBG that_IN the_DT NF(P)_NN interaction_NN is_VBZ sequence-specific_JJ and_CC that_IN binding_NN specificity_NN of_IN the_DT protein_NN paralleled_VBD the_DT sequence_NN requirements_NNS for_IN IL-4_NN expression_NN in_FW vivo_FW ._.
 The_DT P_NN sequence_NN does_VBZ not_RB share_VB homology_NN with_IN the_DT 5'_JJ upstream_JJ sequence_NN of_IN the_DT IL-2_NN gene_NN ,_, even_RB though_IN surrounding_VBG sequences_NNS of_IN the_DT IL-4_NN gene_NN share_NN high_JJ homology_NN with_IN the_DT IL-2_NN gene_NN ._.
 We_PRP conclude_VBP that_IN a_DT different_JJ set_NN of_IN proteins_NNS recognize_VBP IL-2_NN and_CC IL-4_NN genes_NNS ._.
 Glucocorticoid_NN receptor_NN binding_NN in_IN three_CD different_JJ cell_NN types_NNS in_IN major_JJ depressive_JJ disorder_NN :_: lack_NN of_IN evidence_NN of_IN receptor_NN binding_NN defect_NN ._.
 1_LS ._. In_IN order_NN to_TO further_RB understand_VB the_DT apparent_JJ glucocorticoid_NN resistance_NN in_IN major_JJ depressive_JJ disorder_NN ,_, circadian_JJ variation_NN in_IN cortisol_NN concentration_NN ,_, dexamethasone_NN suppression_NN and_CC glucocorticoid_NN receptor_NN binding_NN in_IN mononuclear_JJ leukocytes_NNS ,_, polymorphonuclear_JJ leukocytes_NNS and_CC cultured_VBN skin_NN fibroblasts_NNS were_VBD measured_VBN in_IN rigidly_RB defined_VBN major_JJ depressive_JJ disorder_NN patients_NNS and_CC non-depressed_JJ psychiatric_JJ controls_NNS ._.
 2_LS ._. Mononuclear_JJ leukocytes_NNS binding_VBG to_TO glucocorticoid_NN correlated_VBD significantly_RB with_IN polymorphonuclear_JJ leukocytes_NNS binding_VBG to_TO glucocorticoid_NN ,_, but_CC both_DT determinations_NNS failed_VBD to_TO differentiate_VB major_JJ depressive_JJ disorder_NN and_CC control_NN subjects_NNS ._.
 3_LS ._. Initial_JJ and_CC post-dexamethasone_JJ in_FW vitro_FW fibroblast_NN binding_VBG to_TO glucocorticoid_NN was_VBD not_RB different_JJ between_IN major_JJ depressive_JJ disorder_NN and_CC non-depressed_JJ control_NN subjects_NNS ._.
 4_LS ._. The_DT phenomenon_NN of_IN glucocorticoid_NN resistance_NN in_IN major_JJ depressive_JJ disorder_NN remains_VBZ unexplained_JJ ._.
 Kinetics_NNS of_IN nuclear_JJ translocation_NN and_CC turnover_NN of_IN the_DT vitamin_NN D_NN receptor_NN in_IN human_JJ HL60_NN leukemia_NN cells_NNS and_CC peripheral_JJ blood_NN lymphocytes_NNS --_: coincident_JJ rise_NN of_IN DNA-relaxing_JJ activity_NN in_IN nuclear_JJ extracts_NNS ._.
 High_JJ affinity_NN receptors_NNS (_( VDR_NN )_) for_IN 1,25-dihydroxycholecalciferol_NN (_( calcitriol_NN )_) are_VBP expressed_VBN in_IN HL60_NN human_JJ leukemia_NN cells_NNS and_CC in_IN low_JJ numbers_NNS in_IN peripheral_JJ blood_NN lymphocytes_NNS (_( PBL_NN )_) ._.
 HL60_NN cells_NNS ,_, expressing_VBG some_DT characteristics_NNS of_IN promyelocytes_NNS ,_, can_MD be_VB induced_VBN to_TO monocytoid_NN differentiation_NN by_IN calcitriol_NN ._.
 Specific_JJ nuclear_JJ translocation_NN of_IN (3H)calcitriol/VDR_NN was_VBD examined_VBN after_IN exposure_NN of_IN whole_JJ cells_NNS to_TO 10(-9)_CD M/l_NN calcitriol_NN in_IN the_DT presence_NN and_CC absence_NN of_IN a_DT 500-fold_JJ excess_NN of_IN unlabeled_JJ ligand_NN and_CC subsequent_JJ isolation_NN of_IN nuclei_NNS ._.
 Specific_JJ nuclear_JJ translocation_NN of_IN (3H)calcitriol/VDR_NN was_VBD found_VBN to_TO be_VB time_NN dependent_JJ reaching_VBG a_DT maximum_NN of_IN approximately_RB 2100_CD binding_VBG sites/nucleus_NNS after_IN 3_CD h_NN of_IN incubation_NN in_IN HL60_NN cells_NNS ,_, whereas_IN a_DT maximum_NN of_IN approximately_RB 310_CD binding_VBG sites/nucleus_NNS was_VBD found_VBN after_IN 3_CD h_NN in_IN PBL_NN ._.
 Pulse_NN exposure_NN of_IN HL60_NN to_TO radiolabeled_VBN hormone_NN for_IN 3_CD h_NN followed_VBN by_IN culture_NN in_IN medium_NN without_IN serum_NN and_CC calcitriol_NN lead_VBD to_TO nuclear_JJ retention_NN of_IN approximately_RB 1600_CD radiolabeled_VBN VDR_NN by_IN 8_CD h_NN and_CC approximately_RB 1000_CD VDR_NN by_IN 24_CD h_NN ._.
 Radiolabeled_VBN VDR_NN disappeared_VBD from_IN the_DT nuclear_JJ compartment_NN with_IN a_DT halflife_NN of_IN approximately_RB 30_CD min_NN if_IN cells_NNS were_VBD cultured_VBN with_IN identical_JJ concentrations_NNS of_IN unlabeled_JJ hormone_NN after_IN the_DT pulse_NN (_( pulse/chase-experiments_NNS )_) ._.
 No_DT difference_NN of_IN VDR_NN retention_NN in_IN pulse_NN and_CC pulse/chase-experiments_NNS was_VBD seen_VBN in_IN PBL_NN ,_, where_WRB VDR_NN halflife_NN was_VBD approximately_RB 30_CD min_NN ._.
 No_DT specific_JJ translocation_NN into_IN the_DT nuclear_JJ compartment_NN was_VBD seen_VBN when_WRB isolated_VBN nuclei_NNS were_VBD incubated_VBN in_IN (3H)calcitriol_NN ._.
 Radiolabeled_VBN hormone/receptor_NN complexes_NNS of_IN nuclei_NNS isolated_VBN from_IN cells_NNS exposed_VBN for_IN 3_CD h_NN to_TO radiolabeled_VBN hormone_NN --_: in_IN contrast_NN to_TO identical_JJ experiments_NNS with_IN intact_JJ cells_NNS --_: did_VBD not_RB disappear_VB from_IN the_DT nuclear_JJ compartment_NN upon_IN incubation_NN of_IN nuclei_NNS with_IN identical_JJ concentrations_NNS of_IN the_DT unlabeled_JJ compound_NN ._.
 The_DT activity_NN of_IN DNA_NN relaxing_NN enzymes_NNS (_( e.g._FW topoisomerases_NNS I_CD and_CC II_CD )_) in_IN nuclear_JJ extracts_NNS was_VBD measured_VBN using_VBG a_DT PBR_NN 322-relaxation-assay_NN ._.
 Enhanced_VBN overall_JJ enzyme_NN activity_NN was_VBD found_VBN in_IN nuclear_JJ extracts_NNS by_IN 1_CD h_NN after_IN incubation_NN with_IN calcitriol_NN (_( final_JJ ethanol_NN concentration_NN 0.0001_CD %_NN v/v_NN )_) in_IN HL60_NN and_CC PBL_NN ._.
 The_DT enhanced_VBN activity_NN disappeared_VBD after_IN 2_CD h_NN in_IN PBL_NN ,_, whereas_IN it_PRP was_VBD still_RB enhanced_VBN by_IN 4_CD h_NN in_IN HL60_NN ._.
 No_DT effect_NN was_VBD seen_VBN in_IN ethanol_NN treated_JJ controls_NNS ._.
 We_PRP conclude_VBP that_IN a_DT specific_JJ nuclear_JJ translocation_NN mechanism_NN exists_VBZ for_IN calcitriol_NN in_IN both_DT cell_NN types_NNS examined_VBN ,_, most_RBS likely_RB due_IN to_TO translocation_NN of_IN receptor_NN proteins_NNS after_IN hormone_NN binding_NN ._.
 Translocated_VBN hormone/receptor_NN complexes_NNS compete_VBP for_IN a_DT limited_JJ number_NN of_IN specific_JJ nuclear_JJ binding_VBG sites_NNS ._.
 Enhanced_VBN activity_NN of_IN topoisomerases_NNS in_IN nuclear_JJ extracts_NNS upon_IN translocation_NN of_IN VDR_NN might_MD reflect_VB interaction_NN of_IN both_DT within_IN the_DT nuclear_JJ compartment_NN ,_, thus_RB initiating_VBG DNA-unwinding_NN ,_, a_DT prerequisite_NN of_IN transcription_NN initiation_NN ._.
 The_DT B_NN cell-specific_JJ nuclear_JJ factor_NN OTF-2_NN positively_RB regulates_VBZ transcription_NN of_IN the_DT human_JJ class_NN II_CD transplantation_NN gene_NN ,_, DRA_NN ._.
 The_DT promoter_NN of_IN the_DT major_JJ histocompatibility_NN class_NN II_CD gene_NN DRA_NN contains_VBZ an_DT octamer_NN element_NN (_( ATTTGCAT_NN )_) that_WDT is_VBZ required_VBN for_IN efficient_JJ DRA_NN expression_NN in_IN B_NN cells_NNS ._.
 Several_JJ DNA-binding_JJ proteins_NNS are_VBP known_VBN to_TO bind_VB this_DT sequence_NN ._.
 The_DT best_RBS characterized_VBN are_VBP the_DT B_NN cell-specific_JJ OTF-2_NN and_CC the_DT ubiquitous_JJ OTF-1_NN ._.
 This_DT report_NN directly_RB demonstrates_VBZ that_IN OTF-2_NN but_CC not_RB OTF-1_NN regulates_VBZ the_DT DRA_NN gene_NN ._.
 In_FW vitro_FW transcription_NN analysis_NN using_VBG protein_NN fractions_NNS enriched_VBN for_IN the_DT octamer-binding_JJ protein_NN OTF-2_NN demonstrate_VBP a_DT positive_JJ functional_JJ role_NN for_IN OTF-2_NN in_IN DRA_NN gene_NN transcription_NN ._.
 In_IN contrast_NN ,_, OTF-1-enriched_JJ protein_NN fractions_NNS did_VBD not_RB affect_VB DRA_NN gene_NN transcription_NN although_IN it_PRP functionally_RB enhanced_VBD the_DT transcription_NN of_IN another_DT gene_NN ._.
 Recombinant_JJ OTF-2_NN protein_NN produced_VBN by_IN in_FW vitro_FW transcription/translation_NN could_MD also_RB enhance_VB DRA_NN gene_NN transcription_NN in_FW vitro_FW ._.
 In_FW vivo_FW transient_JJ transfection_NN studies_NNS utilizing_VBG an_DT OTF-2_NN expression_NN vector_NN resulted_VBD in_IN similar_JJ findings_NNS :_: that_IN OTF-2_NN protein_NN enhanced_VBD DRA_NN gene_NN transcription_NN ,_, and_CC that_IN this_DT effect_NN requires_VBZ an_DT intact_JJ octamer_NN element_NN ._.
 Together_RB these_DT results_NNS constitute_VBP the_DT first_JJ direct_JJ evidence_NN of_IN a_DT positive_JJ role_NN for_IN the_DT lymphoid-specific_JJ octamer-binding_JJ factor_NN in_IN DRA_NN gene_NN transcription_NN ._.
 (_( Regulation_NN of_IN intracellular_JJ cholesterol_NN synthesis_NN in_IN hypercholesterolemia_NN by_IN glucocorticoids_NNS )_)
 The_DT rate_NN of_IN endogenous_JJ cholesterol_NN synthesis_NN in_IN blood_NN lymphocytes_NNS and_CC skin_NN fibroblasts_NNS from_IN patients_NNS with_IN type_NN IIa_NN hyperlipidemia_NN was_VBD found_VBN to_TO be_VB increased_VBN in_IN comparison_NN with_IN healthy_JJ donors_NNS ._.
 The_DT cells_NNS of_IN hyperlipidemic_JJ patients_NNS had_VBD lowered_JJ levels_NNS of_IN glucocorticoid_NN receptors_NNS concomitantly_RB with_IN a_DT partial_JJ loss_NN of_IN their_PRP$ sensitivity_NN to_TO glucocorticoids_NNS ._.
 In_IN fibroblasts_NNS from_IN patients_NNS with_IN hereditary_JJ hypercholesteremia_NN of_IN homozygous_JJ type_NN the_DT number_NN of_IN glucocorticoid_NN receptors_NNS did_VBD not_RB exceed_VB 10_CD %_NN of_IN their_PRP$ content_NN in_IN normal_JJ cells_NNS ._.
 The_DT decrease_NN of_IN the_DT number_NN of_IN glucocorticoid_NN receptors_NNS in_IN patients_NNS with_IN type_NN IIa_NN hyperlipidemia_NN seems_VBZ to_TO be_VB a_DT compensatory_JJ response_NN of_IN cells_NNS culminating_VBG in_IN activation_NN of_IN endogenous_JJ cholesterol_NN synthesis_NN ._.
 Transcription_NN factor_NN activation_NN and_CC functional_JJ stimulation_NN of_IN human_JJ monocytes_NNS ._.
 Activation_NN of_IN expression_NN of_IN genes_NNS encoding_VBG transcription_NN factors_NNS :_: c-fos_NN and_CC c-jun_NN and_CC formation_NN of_IN AP1_NN transcriptional_JJ complex_NN in_IN human_JJ monocytes_NNS was_VBD investigated_VBN ._.
 It_PRP was_VBD found_VBN that_IN lipopolysaccharide_NN induced_VBD strongly_RB both_CC c-fos_NN and_CC c-jun_NN expression_NN as_RB well_RB as_IN AP1_NN formation_NN ._.
 Interferon_NN gamma_NN activated_VBD strongly_RB c-fos_NN and_CC weakly_RB c-jun_NN and_CC AP1_NN ._.
 Tumor_NN necrosis_NN factor_NN induced_VBD slightly_RB c-fos_NN and_CC had_VBD almost_RB no_DT effect_NN on_IN c-jun_NN and_CC AP1_NN ._.
 The_DT data_NNS suggest_VBP that_IN differences_NNS in_IN functional_JJ responses_NNS elicited_VBN in_IN monocytes_NNS by_IN all_DT three_CD factors_NNS may_MD be_VB dependent_JJ on_IN different_JJ routes_NNS on_IN nuclear_JJ signalling_NN employed_VBN by_IN the_DT factors_NNS ._.
 Corticosteroid_NN receptors_NNS and_CC lymphocyte_NN subsets_NNS in_IN mononuclear_JJ leukocytes_NNS in_IN aging_NN ._.
 Plasma_NN cortisol_NN and_CC aldosterone_NN levels_NNS and_CC number_NN of_IN related_JJ receptors_NNS in_IN mononuclear_JJ leukocytes_NNS were_VBD measured_VBN in_IN 49_CD healthy_JJ aged_JJ subjects_NNS (_( 62-97_CD yr_NN )_) and_CC in_IN 21_CD adult_JJ controls_NNS (_( 21-50_CD yr_NN )_) ._.
 In_IN all_DT subjects_NNS ,_, in_IN addition_NN ,_, lymphocyte_NN subsets_NNS were_VBD determined_VBN as_IN an_DT index_NN of_IN corticosteroid_NN action_NN ._.
 The_DT mean_NN number_NN of_IN type_NN I_CD and_CC type_NN II_CD receptors_NNS was_VBD significantly_RB lower_JJR in_IN aged_JJ subjects_NNS than_IN in_IN controls_NNS (_( respectively_RB ,_, 198_CD +/-_CC 96_CD and_CC 272_CD +/-_CC 97_CD receptors/cell_NNS for_IN type_NN I_CD ,_, and_CC 1,794_CD +/-_CC 803_CD and_CC 3,339_CD +/-_CC 918_CD for_IN type_NN II_CD receptors_NNS )_) ._.
 Plasma_NN aldosterone_NN and_CC cortisol_NN and_CC lymphocyte_NN subsets_NNS were_VBD not_RB different_JJ in_IN the_DT two_CD groups_NNS ._.
 All_DT of_IN the_DT parameters_NNS were_VBD also_RB tested_VBN for_IN correlation_NN ,_, and_CC a_DT significant_JJ inverse_JJ correlation_NN was_VBD found_VBN between_IN age_NN and_CC type_NN I_CD and_CC type_NN II_CD receptors_NNS when_WRB all_DT subjects_NNS were_VBD plotted_VBN and_CC between_IN aged_JJ and_CC CD4_NN and_CC age_NN and_CC CD4/CD8_NN in_IN the_DT aged_JJ group_NN ._.
 These_DT data_NNS show_VBP that_IN aged_JJ subjects_NNS have_VBP reductions_NNS of_IN corticosteroid_NN receptors_NNS that_WDT are_VBP not_RB associated_VBN with_IN increase_NN of_IN related_JJ steroids_NNS and_CC that_IN this_DT situation_NN probably_RB represents_VBZ a_DT concomitant_NN of_IN the_DT normal_JJ aging_NN process_NN ._.
 Stable_JJ expression_NN of_IN HB24_NN ,_, a_DT diverged_JJ human_JJ homeobox_NN gene_NN ,_, in_IN T_NN lymphocytes_NNS induces_VBZ genes_NNS involved_VBN in_IN T_NN cell_NN activation_NN and_CC growth_NN ._.
 A_DT diverged_JJ homeobox_NN gene_NN ,_, HB24_NN ,_, which_WDT is_VBZ known_VBN to_TO be_VB induced_VBN following_VBG lymphocyte_NN activation_NN ,_, was_VBD introduced_VBN into_IN Jurkat_NN T_NN cells_NNS under_IN the_DT control_NN of_IN a_DT constitutive_JJ promoter_NN ._.
 Stable_JJ transfectants_NNS of_IN HB24_NN were_VBD established_VBN that_WDT expressed_VBD high_JJ levels_NNS of_IN HB24_NN mRNA_NN and_CC possessed_VBD an_DT altered_JJ phenotype_NN suggestive_JJ of_IN activated_VBN T_NN cells_NNS ._.
 A_DT number_NN of_IN genes_NNS known_VBN to_TO be_VB induced_VBN following_VBG T_NN cell_NN activation_NN and_CC associated_VBN with_IN cell_NN growth_NN were_VBD increased_VBN in_IN the_DT transfectants_NNS ,_, including_VBG c-fos_NN ,_, c-myc_NN ,_, c-myb_NN ,_, HLA-DR_NN ,_, lck_NN ,_, NF-kappa_NN B_NN ,_, interleukin-2_NN and_CC interleukin-2_NN receptor_NN alpha_NN (_( IL-2R_NN alpha_NN )_) ._.
 Analysis_NN of_IN IL-2R_NN alpha_NN expression_NN by_IN transient_JJ transfection_NN of_IN IL-2R_NN alpha_NN promoter_NN constructs_NNS into_IN the_DT HB24_NN transfectants_NNS revealed_VBD constitutive_JJ expression_NN (_( about_RB 60_CD %_NN of_IN phytohemagglutinin-_NN and_CC phorbol_NN ester-activated_JJ Jurkat_NN cells_NNS )_) that_WDT was_VBD dependent_JJ on_IN the_DT kappa_NN B_NN site_NN in_IN the_DT IL-2R_NN alpha_NN promoter_NN ._.
 Furthermore_RB ,_, as_IN a_DT consequence_NN of_IN the_DT increased_VBN HB24_NN mRNA_NN levels_NNS ,_, the_DT Jurkat_NN HB24_NN transfectants_NNS proliferated_VBD more_RBR rapidly_RB than_IN control_NN cell_NN lines_NNS ._.
 Thus_RB ,_, stable_JJ expression_NN of_IN HB24_NN confers_VBZ an_DT activation_NN phenotype_NN on_IN a_DT human_JJ T_NN cell_NN line_NN ,_, implicating_VBG this_DT gene_NN as_IN an_DT important_JJ transcriptional_JJ factor_NN during_IN T_NN cell_NN activation_NN and_CC growth_NN ._.
 Studies_NNS on_IN the_DT biological_JJ activity_NN of_IN triiodothyronine_NN sulfate_NN ._.
 Hepatic_JJ microsomes_NNS and_CC isolated_VBN hepatocytes_NNS in_IN short_JJ term_NN culture_NN desulfate_VBP T3_NN sulfate_NN (_( T3SO4_NN )_) ._.
 We_PRP ,_, therefore_RB ,_, wished_VBD to_TO determine_VB whether_IN T3SO4_NN could_MD mimic_VB the_DT action_NN of_IN thyroid_NN hormone_NN in_FW vitro_FW ._.
 T3SO4_NN had_VBD no_DT thyromimetic_JJ effect_NN on_IN the_DT activity_NN of_IN Ca(2+)-ATPase_NN in_IN human_JJ erythrocyte_NN membranes_NNS at_IN doses_NNS up_RB to_TO 10,000_CD times_NNS the_DT maximally_RB effective_JJ dose_NN of_IN T3_NN (_( 10/(-10)_CD mol/L_NN )_) ._.
 In_IN GH4C1_NN pituitary_JJ cells_NNS ,_, T3SO4_NN failed_VBD to_TO displace_VB (125I)T3_NN from_IN nuclear_JJ receptors_NNS in_IN intact_JJ cells_NNS or_CC soluble_JJ preparations_NNS ._.
 Thus_RB ,_, T3SO4_NN was_VBD not_RB directly_RB thyromimetic_JJ in_IN either_CC an_DT isolated_VBN human_JJ membrane_NN system_NN or_CC a_DT pituitary_JJ cell_NN system_NN in_IN which_WDT nuclear_JJ receptor_NN occupancy_NN correlates_VBZ with_IN GH_NN synthesis_NN ._.
 Thyroid_NN hormones_NNS inhibit_VBP (3H)glycosaminoglycan_NN synthesis_NN by_IN cultured_VBN human_JJ dermal_JJ fibroblasts_NNS ,_, and_CC T3SO4_NN displayed_VBN about_IN 0.5_CD %_NN the_DT activity_NN of_IN T3_NN at_IN 72_CD h_NN ._.
 Human_JJ fibroblasts_NNS contained_VBD roughly_RB the_DT same_JJ level_NN of_IN microsomal_JJ p-nitrophenyl_NN sulfatase_NN activity_NN as_IN that_DT previously_RB observed_VBN in_IN hepatic_JJ microsomes_NNS ._.
 Propylthiouracil_NN (_( 50_CD mumol/L_NN )_) did_VBD not_RB affect_VB the_DT action_NN of_IN T3SO4_NN ,_, suggesting_VBG that_IN deiodination_NN was_VBD not_RB important_JJ for_IN this_DT activity_NN of_IN T3SO4_NN ._.
 Thus_RB ,_, it_PRP appears_VBZ T3SO4_NN has_VBZ no_DT intrinsic_JJ biological_JJ activity_NN ,_, but_CC ,_, under_IN certain_JJ circumstances_NNS ,_, may_MD be_VB reactivated_VBN by_IN desulfation_NN
 Nuclear_JJ factor_NN of_IN activated_VBN T_NN cells_NNS contains_VBZ Fos_NN and_CC Jun_NN ._.
 The_DT nuclear_JJ factor_NN NF-AT_NN (_( ref._NN 1_CD )_) is_VBZ induced_VBN in_IN T_NN cells_NNS stimulated_VBN through_IN the_DT T-cell_NN receptor/CD3_NN complex_NN ,_, and_CC is_VBZ required_VBN for_IN interleukin-2_NN (_( IL-2_NN )_) gene_NN induction_NN ._.
 Although_IN NF-AT_NN has_VBZ not_RB been_VBN cloned_VBN or_CC purified_VBN ,_, there_EX is_VBZ evidence_NN that_IN it_PRP is_VBZ a_DT major_JJ target_NN for_IN immunosuppression_NN by_IN cyclosporin_NN A_NN (_( CsA_NN )_) and_CC FK506_NN (_( refs_NNS 2-7_CD )_) ._.
 NF-AT_NN induction_NN may_MD require_VB two_CD activation-dependent_JJ events_NNS :_: the_DT CsA-sensitive_JJ translocation_NN of_IN a_DT pre-existing_JJ component_NN and_CC the_DT CsA-resistant_JJ synthesis_NN of_IN a_DT nuclear_JJ component_NN ._.
 Here_RB we_PRP report_VBP that_IN the_DT newly_RB synthesized_VBN nuclear_JJ component_NN of_IN NF-AT_NN is_VBZ the_DT transcription_NN factor_NN AP-1_NN ._.
 We_PRP show_VBP that_IN the_DT inducible_JJ nuclear_JJ form_NN of_IN NF-AT_NN contains_VBZ Fos_NN and_CC Jun_NN proteins_NNS ._.
 Furthermore_RB ,_, we_PRP identify_VBP a_DT pre-existing_JJ NF-AT-binding_JJ factor_NN that_WDT is_VBZ present_JJ in_IN hypotonic_JJ extracts_NNS of_IN unstimulated_JJ T_NN cells_NNS ._.
 On_IN the_DT basis_NN of_IN binding_NN ,_, reconstitution_NN and_CC cotransfection_NN experiments_NNS ,_, we_PRP propose_VBP that_IN activation_NN of_IN NF-AT_NN occurs_VBZ in_IN at_IN least_JJS two_CD stages_NNS :_: a_DT CsA-sensitive_JJ stage_NN involving_VBG modification_NN and/or_CC translocation_NN of_IN the_DT pre-existing_JJ NF-AT_NN complex_NN ,_, and_CC a_DT CsA-insensitive_JJ stage_NN involving_VBG the_DT addition_NN of_IN newly_RB synthesized_VBN Fos_NN or_CC Fos/Jun_NN proteins_NNS to_TO the_DT pre-existing_JJ complex_NN ._.
 Interferon-gamma_NN potentiates_VBZ the_DT antiviral_JJ activity_NN and_CC the_DT expression_NN of_IN interferon-stimulated_JJ genes_NNS induced_VBN by_IN interferon-alpha_NN in_IN U937_NN cells_NNS ._.
 Binding_NN of_IN type_NN I_CD interferon_NN (_( IFN-alpha/beta_NN )_) to_TO specific_JJ receptors_NNS results_VBZ in_IN the_DT rapid_JJ transcriptional_JJ activation_NN ,_, independent_JJ of_IN protein_NN synthesis_NN ,_, of_IN IFN-alpha-stimulated_JJ genes_NNS (_( ISGs_NNS )_) in_IN human_JJ fibroblasts_NNS and_CC HeLa_NN and_CC Daudi_NN cell_NN lines_NNS ._.
 The_DT binding_NN of_IN ISGF3_NN (_( IFN-stimulated_JJ gene_NN factor_NN 3_CD )_) to_TO the_DT conserved_VBN IFN-stimulated_JJ response_NN element_NN (_( ISRE_NN )_) results_VBZ in_IN transcriptional_JJ activation_NN ._.
 This_DT factor_NN is_VBZ composed_VBN of_IN a_DT DNA-binding_JJ protein_NN (_( ISGF3_NN gamma_NN )_) ,_, which_WDT normally_RB is_VBZ present_JJ in_IN the_DT cytoplasm_NN ,_, and_CC other_JJ IFN-alpha-activated_JJ proteins_NNS which_WDT preexist_VBP as_IN latent_JJ cytoplasmic_JJ precursors_NNS (_( ISGF3_NN alpha_NN )_) ._.
 We_PRP have_VBP found_VBN that_IN ISG_NN expression_NN in_IN the_DT monocytic_JJ U937_NN cell_NN line_NN differs_VBZ from_IN most_JJS cell_NN lines_NNS previously_RB examined_VBN ._.
 U937_NN cells_NNS express_VBP both_CC type_NN I_CD and_CC type_NN II_CD IFN_NN receptors_NNS ,_, but_CC only_RB IFN-alpha_NN is_VBZ capable_JJ of_IN inducing_VBG antiviral_JJ protection_NN in_IN these_DT cells_NNS ._.
 Pretreatment_NN with_IN IFN-gamma_NN potentiates_VBZ the_DT IFN-alpha-induced_JJ protection_NN ,_, but_CC IFN-gamma_NN alone_RB does_VBZ not_RB have_VB any_DT antiviral_JJ activity_NN ._.
 ISG15_NN mRNA_NN accumulation_NN in_IN U937_NN cells_NNS is_VBZ not_RB detectable_JJ before_IN 6_CD h_NN of_IN IFN-alpha_NN treatment_NN ,_, peaks_VBZ at_IN 24_CD h_NN ,_, and_CC requires_VBZ protein_NN synthesis_NN ._.
 Although_IN IFN-gamma_NN alone_RB does_VBZ not_RB induce_VB ISG_NN expression_NN ,_, IFN-gamma_NN pretreatment_NN markedly_RB increases_VBZ and_CC hastens_VBZ ISG_NN expression_NN and_CC transcriptional_JJ induction_NN ._.
 Nuclear_JJ extracts_NNS assayed_VBN for_IN the_DT presence_NN of_IN ISRE_NN binding_NN factors_NNS by_IN electrophoretic_JJ mobility_NN shift_NN assays_NNS show_VBP that_IN ISGF3_NN is_VBZ induced_VBN by_IN IFN-alpha_NN within_IN 6_CD h_NN from_IN undetectable_JJ basal_JJ levels_NNS in_IN untreated_JJ U937_NN cells_NNS ._.
 Activation_NN of_IN ISGF3_NN alpha_NN ,_, the_DT latent_JJ component_NN of_IN ISGF3_NN ,_, occurs_VBZ rapidly_RB ._.
 However_RB ,_, the_DT increase_NN in_IN ISGF3_NN activity_NN ultimately_RB correlates_VBZ with_IN the_DT accumulation_NN of_IN ISGF3_NN gamma_NN induced_VBN by_IN IFN-alpha_NN or_CC IFN-gamma_NN ._.
 (_( ABSTRACT_NN TRUNCATED_VBN AT_IN 250_CD WORDS_NNS )_)
 The_DT mechanism_NN of_IN action_NN of_IN cyclosporin_NN A_NN and_CC FK506_NN ._.
 CsA_NN and_CC FK506_NN are_VBP powerful_JJ suppressors_NNS of_IN the_DT immune_JJ system_NN ,_, most_RBS notably_RB of_IN T_NN cells_NNS ._.
 They_PRP act_VBP at_IN a_DT point_NN in_IN activation_NN that_WDT lies_VBZ between_IN receptor_NN ligation_NN and_CC the_DT transcription_NN of_IN early_JJ genes_NNS ._.
 Here_RB ,_, Stuart_NNP Schreiber_NNP and_CC Gerald_NNP Crabtree_NNP review_VBP recent_JJ findings_NNS that_WDT indicate_VBP CsA_NN and_CC FK506_NN operate_VBP as_IN prodrugs_NNS :_: they_PRP bind_VBP endogenous_JJ intracellular_JJ receptors_NNS ,_, the_DT immunophilins_NNS ,_, and_CC the_DT resulting_VBG complex_NN targets_VBZ the_DT protein_NN phosphatase_NN ,_, calcineurin_NN ,_, to_TO exert_VB the_DT immunosuppressive_JJ effect_NN ._.
 (_( Plasma_NN cortisol_NN concentration_NN and_CC blood_NN leukocyte_NN content_NN of_IN glucocorticoid_NN receptors_NNS in_IN patients_NNS with_IN deficiency-cold_JJ vs_CC deficiency-heat_JJ syndromes_NNS )_)
 Plasma_NN cortisol_NN concentration_NN and_CC blood_NN leukocyte_NN content_NN of_IN glucocorticoid_NN receptors_NNS (_( GCR_NN )_) were_VBD assayed_VBN in_IN 20_CD patients_NNS with_IN deficiency_NN syndromes_NNS ,_, 10_CD cold_JJ in_IN property_NN (_( deficiency-cold_JJ )_) ,_, the_DT other_JJ 10_CD hot_JJ in_IN property_NN (_( deficiency-heat_JJ )_) ,_, and_CC also_RB in_IN 10_CD healthy_JJ individuals_NNS as_IN normal_JJ control_NN for_IN the_DT purpose_NN of_IN investigating_VBG the_DT nature_NN of_IN cold_NN and_CC heat_NN syndromes_NNS ._.
 As_IN a_DT result_NN ,_, the_DT cases_NNS of_IN deficiency-cold_JJ syndrome_NN (_( DCS_NN )_) had_VBD a_DT normal_JJ concentration_NN of_IN plasma_NN cortisol_NN but_CC a_DT lowered_JJ content_NN of_IN GCR_NN in_IN leukocytes_NNS when_WRB compared_VBN with_IN the_DT normal_JJ control_NN (_( P_NN less_JJR than_IN 0.05_CD )_) ;_: the_DT cases_NNS of_IN deficiency-heat_JJ syndrome_NN (_( DHS_NN )_) had_VBD a_DT higher_JJR concentration_NN of_IN plasma_NN cortisol_NN than_IN the_DT normal_JJ control_NN (_( P_NN less_JJR than_IN 0.05_CD )_) and_CC a_DT slightly_RB higher_JJR content_NN of_IN GCR_NN in_IN leukocytes_NNS ._.
 It_PRP was_VBD concluded_VBN that_IN the_DT DCS_NN is_VBZ characterized_VBN by_IN diminished_VBN biological_JJ effects_NNS of_IN adrenocortical_JJ activity_NN ,_, while_IN the_DT DHS_NN ,_, by_IN augmented_JJ biological_JJ effects_NNS of_IN adrenocortical_JJ activity_NN ._.
 Specific_JJ NF-kappa_NN B_NN subunits_NNS act_VBP in_IN concert_NN with_IN Tat_NN to_TO stimulate_VB human_JJ immunodeficiency_NN virus_NN type_NN 1_CD transcription_NN ._.
 NF-kappa_NN B_NN is_VBZ a_DT protein_NN complex_NN which_WDT functions_VBZ in_IN concert_NN with_IN the_DT tat-I_NN gene_NN product_NN to_TO stimulate_VB human_JJ immunodeficiency_NN virus_NN (_( HIV_NN )_) transcription_NN ._.
 To_TO determine_VB whether_IN specific_JJ members_NNS of_IN the_DT NF-kappa_NN B_NN family_NN contribute_VBP to_TO this_DT effect_NN ,_, we_PRP have_VBP examined_VBN the_DT abilities_NNS of_IN different_JJ NF-kappa_NN B_NN subunits_NNS to_TO act_VB with_IN Tat-I_NN to_TO stimulate_VB transcription_NN of_IN HIV_NN in_IN Jurkat_NN T-leukemia_NN cells_NNS ._.
 We_PRP have_VBP found_VBN that_IN the_DT p49_NN (_( 100_CD )_) DNA_NN binding_NN subunit_NN ,_, together_RB with_IN p65_NN ,_, can_MD act_VB in_IN concert_NN with_IN Tat-I_NN to_TO stimulate_VB the_DT expression_NN of_IN HIV-CAT_NN plasmid_NN ._.
 Little_JJ effect_NN was_VBD observed_VBN with_IN 50-kDa_JJ forms_NNS of_IN p105_NN NF-kappa_NN B_NN or_CC rel_NN ,_, in_IN combination_NN with_IN p65_NN or_CC full-length_JJ c-rel_NN ,_, which_WDT do_VBP not_RB stimulate_VB the_DT HIV_NN enhancer_NN in_IN these_DT cells_NNS ._.
 These_DT findings_NNS suggest_VBP that_IN the_DT combination_NN of_IN p49_NN (_( 100_CD )_) and_CC p65_NN NF-kappa_NN B_NN can_MD act_VB in_IN concert_NN with_IN the_DT tat-I_NN gene_NN product_NN to_TO stimulate_VB the_DT synthesis_NN of_IN HIV_NN RNA_NN ._.
 Activation_NN of_IN the_DT human_JJ immunodeficiency_NN virus_NN type_NN 1_CD enhancer_NN is_VBZ not_RB dependent_JJ on_IN NFAT-1_NN ._.
 The_DT function_NN of_IN a_DT putative_JJ NFAT-1_NN site_NN in_IN the_DT human_JJ immunodeficiency_NN virus_NN type_NN 1_CD enhancer_NN has_VBZ been_VBN analyzed_VBN ._.
 Activation_NN by_IN the_DT T-cell_NN antigen_NN receptor_NN is_VBZ minimal_JJ in_IN Jurkat_NN cells_NNS and_CC is_VBZ mediated_VBN by_IN the_DT kappa_NN B_NN sites_NNS ._.
 The_DT putative_JJ NFAT-1_NN region_NN is_VBZ not_RB required_VBN for_IN the_DT response_NN to_TO anti-CD3_NN or_CC to_TO mitogens_NNS in_IN T-cell_NN ,_, B-cell_NN ,_, or_CC monocyte/macrophage_NN leukemia_NN lines_NNS ,_, nor_CC is_VBZ it_PRP a_DT cis-acting_JJ negative_JJ regulatory_JJ element_NN ._.
 Protein_NN kinase_NN C_NN activation_NN and_CC protooncogene_NN expression_NN in_IN differentiation/retrodifferentiation_NN of_IN human_JJ U-937_NN leukemia_NN cells_NNS ._.
 Human_JJ U-937_NN leukemia_NN cells_NNS differentiate_VBP along_IN the_DT monocytic_JJ lineage_NN following_VBG 3-day_JJ exposures_NNS to_TO 12-O-tetradecanoylphorbol-13-acetate_NN (_( TPA_NN )_) ._.
 This_DT induction_NN of_IN differentiation_NN is_VBZ accompanied_VBN by_IN adherence_NN and_CC loss_NN of_IN proliferation_NN ,_, as_RB well_RB as_IN expression/repression_NN of_IN differentiation-associated_JJ genes_NNS ._.
 Long_JJ term_NN culture_NN of_IN TPA-differentiated_JJ U-937_NN cells_NNS in_IN the_DT absence_NN of_IN phorbol_NN ester_NN for_IN 32-36_CD days_NNS resulted_VBD in_IN a_DT process_NN of_IN retrodifferentiation_NN ._.
 The_DT retrodifferentiated_VBN cells_NNS detached_VBD from_IN the_DT substrate_NN and_CC reinitiated_VBD proliferation_NN ._.
 Other_JJ cellular_JJ parameters_NNS ,_, such_JJ as_IN glycosidase_NN activities_NNS ,_, cytokine_NN release_NN ,_, and_CC filament_NN expression_NN ,_, returned_VBD to_TO levels_NNS similar_JJ to_TO that_DT observed_VBN in_IN uninduced_JJ cells_NNS ._.
 Treatment_NN of_IN U-937_NN cells_NNS with_IN TPA_NN resulted_VBD in_IN a_DT rapid_JJ translocation_NN of_IN protein_NN kinase_NN C_NN (_( PKC_NN )_) from_IN the_DT cytosol_NN to_TO cell_NN membrane_NN fractions_NNS within_IN 2-8_CD min_NN ._.
 Increased_VBN levels_NNS of_IN membrane-associated_JJ PKC_NN activity_NN persisted_VBD until_IN 17-29_CD days_NNS ._.
 However_RB ,_, longer_JJR periods_NNS of_IN incubation_NN were_VBD associated_VBN with_IN a_DT return_NN to_TO the_DT distribution_NN of_IN PKC_NN in_IN control_NN cells_NNS ._.
 Activation_NN of_IN PKC_NN has_VBZ been_VBN implicated_VBN in_IN the_DT regulation_NN of_IN certain_JJ immediate_JJ early_JJ response_NN genes_NNS ,_, and_CC in_IN the_DT present_JJ studies_NNS ,_, TPA_NN rapidly_RB induced_VBD c-fos_NN and_CC c-jun_NN gene_NN expression_NN ._.
 Levels_NNS of_IN c-fos_NN and_CC c-jun_NN transcripts_NNS remained_VBD elevated_JJ during_IN periods_NNS of_IN PKC_NN activation_NN and_CC also_RB returned_VBD to_TO levels_NNS observed_VBN in_IN control_NN cells_NNS by_IN 30-36_CD days_NNS ,_, when_WRB the_DT cells_NNS entered_VBD retrodifferentiation_NN ._.
 Staurosporine_NN ,_, a_DT nonspecific_JJ inhibitor_NN of_IN PKC_NN ,_, partially_RB blocked_VBD TPA-induced_JJ adherence_NN and_CC growth_NN inhibition_NN and_CC concomitantly_RB prevented_VBD TPA-induced_JJ c-fos_NN and_CC c-jun_NN gene_NN expression_NN ._.
 (_( ABSTRACT_NN TRUNCATED_VBN AT_IN 250_CD WORDS_NNS )_)
 The_DT promoter_NN of_IN the_DT CD19_NN gene_NN is_VBZ a_DT target_NN for_IN the_DT B-cell-specific_JJ transcription_NN factor_NN BSAP_NN ._.
 The_DT CD19_NN protein_NN is_VBZ expressed_VBN on_IN the_DT surface_NN of_IN all_DT B-lymphoid_JJ cells_NNS with_IN the_DT exception_NN of_IN terminally_RB differentiated_VBN plasma_NN cells_NNS and_CC has_VBZ been_VBN implicated_VBN as_IN a_DT signal-transducing_JJ receptor_NN in_IN the_DT control_NN of_IN proliferation_NN and_CC differentiation_NN ._.
 Here_RB we_PRP demonstrate_VBP complete_JJ correlation_NN between_IN the_DT expression_NN pattern_NN of_IN the_DT CD19_NN gene_NN and_CC the_DT B-cell-specific_JJ transcription_NN factor_NN BSAP_NN in_IN a_DT large_JJ panel_NN of_IN B-lymphoid_JJ cell_NN lines_NNS ._.
 The_DT human_JJ CD19_NN gene_NN has_VBZ been_VBN cloned_VBN ,_, and_CC several_JJ BSAP-binding_JJ sites_NNS have_VBP been_VBN mapped_VBN by_IN in_FW vitro_FW protein-DNA_JJ binding_NN studies_NNS ._.
 In_IN particular_JJ ,_, a_DT high-affinity_JJ BSAP-binding_JJ site_NN instead_RB of_IN a_DT TATA_NN sequence_NN is_VBZ located_JJ in_IN the_DT -30_CD promoter_NN region_NN upstream_JJ of_IN a_DT cluster_NN of_IN heterogeneous_JJ transcription_NN start_NN sites_NNS ._.
 Moreover_RB ,_, this_DT site_NN is_VBZ occupied_VBN by_IN BSAP_NN in_FW vivo_FW in_IN a_DT CD19-expressing_JJ B-cell_NN line_NN but_CC not_RB in_IN plasma_NN or_CC HeLa_NN cells_NNS ._.
 This_DT high-affinity_JJ site_NN has_VBZ been_VBN conserved_VBN in_IN the_DT promoters_NNS of_IN both_CC human_JJ and_CC mouse_NN CD19_NN genes_NNS and_CC was_VBD furthermore_RB shown_VBN to_TO confer_VB B-cell_NN specificity_NN to_TO a_DT beta-globin_NN reporter_NN gene_NN in_IN transient_JJ transfection_NN experiments_NNS ._.
 In_IN addition_NN ,_, BSAP_NN was_VBD found_VBN to_TO be_VB the_DT only_RB abundant_JJ DNA-binding_JJ activity_NN of_IN B-cell_NN nuclear_JJ extracts_NNS that_WDT interacts_VBZ with_IN the_DT CD19_NN promoter_NN ._.
 Together_RB ,_, this_DT evidence_NN strongly_RB implicates_VBZ BSAP_NN in_IN the_DT regulation_NN of_IN the_DT CD19_NN gene_NN ._.
 Reduced_VBN susceptibility_NN to_TO HIV-1_NN infection_NN of_IN ethyl-methanesulfonate-treated_JJ CEM_NN subclones_NNS correlates_VBZ with_IN a_DT blockade_NN in_IN their_PRP$ protein_NN kinase_NN C_NN signaling_NN pathway_NN ._.
 We_PRP have_VBP described_VBN the_DT isolation_NN of_IN chemically_RB induced_VBN CEM_NN subclones_NNS that_WDT express_VBP CD4_NN receptors_NNS and_CC bind_VBP soluble_JJ gp120_NN ,_, yet_RB show_VBP a_DT markedly_RB reduced_VBN susceptibility_NN to_TO infection_NN with_IN HIV-1_NN ._.
 Two_CD subclones_NNS were_VBD found_VBN to_TO have_VB an_DT abnormal_JJ response_NN to_TO the_DT protein_NN kinase_NN C_NN (_( PKC_NN )_) activator_NN PMA_NN ._.
 PMA_NN treatment_NN induced_VBD CD3_NN and_CC CD25_NN (_( IL-2R_NN )_) receptors_NNS on_IN the_DT parental_JJ line_NN and_CC on_IN other_JJ ethyl-methanesulfonate-derived_JJ subclones_NNS ,_, but_CC not_RB on_IN these_DT two_CD mutants_NNS ._.
 Direct_JJ assays_NNS of_IN PKC_NN activity_NN were_VBD conducted_VBN ._.
 Total_JJ cellular_JJ PKC_NN enzymatic_JJ activity_NN was_VBD found_VBN to_TO be_VB normal_JJ in_IN these_DT subclones_NNS ._.
 PMA-induced_JJ CD4_NN down-modulation_NN occurred_VBD normally_RB ._.
 In_IN addition_NN ,_, activation_NN of_IN c-raf_NN kinase_NN was_VBD normal_JJ ._.
 Since_IN HIV-1_NN long_JJ terminal_JJ repeat_NN contains_VBZ two_CD functional_JJ nuclear_JJ factor_NN kB_NN (_( NF-kB_NN )_) regulatory_JJ elements_NNS ,_, we_PRP studied_VBD the_DT ability_NN of_IN PMA_NN to_TO induce_VB NF-kB_NN binding_NN activity_NN by_IN different_JJ assays_NNS ._.
 Chloramphenicol_NN acetyl_NN transferase_NN (_( CAT_NN )_) assays_NNS using_VBG the_DT HIV-1_NN (_( -139_CD )_) long_JJ terminal_JJ repeat-CAT_JJ construct_NN showed_VBD no_DT PMA_NN induction_NN of_IN CAT_NN activity_NN in_IN these_DT subclones_NNS (_( unlike_IN the_DT parental_JJ line_NN and_CC other_JJ subclones_NNS )_) ._.
 Okadaic_JJ acid_NN ,_, an_DT inhibitor_NN of_IN phosphatases_NNS 1_CD and_CC 2A_NN ,_, did_VBD not_RB overcome_VB the_DT defect_NN in_IN these_DT subclones_NNS ._.
 Gel_NN retardation_NN assays_NNS ,_, using_VBG a_DT 32P-probe_NN containing_VBG the_DT HIV-1_NN NF-kB_NN probe_NN and_CC nuclear_JJ extracts_NNS from_IN PMA-treated_JJ cells_NNS ,_, showed_VBD significantly_RB reduced_VBN induction_NN of_IN nuclear_JJ NF-kB_NN binding_NN proteins_NNS in_IN these_DT two_CD subclones_NNS compared_VBN with_IN wild_JJ type_NN CEM_NN and_CC a_DT control_NN subclone_NN ._.
 Deoxycholate_JJ treatment_NN of_IN cytoplasmic_JJ extracts_NNS from_IN these_DT subclones_NNS released_VBD much_JJ reduced_VBN NF-kB_NN binding_NN proteins_NNS from_IN their_PRP$ cytoplasmic_JJ pools_NNS ._.
 Thus_RB ,_, reduced_JJ levels_NNS of_IN PKC-induced_JJ nuclear_JJ NF-kB_NN activity_NN in_IN two_CD T_NN cell_NN subclones_NNS did_VBD not_RB affect_VB their_PRP$ normal_JJ cell_NN growth_NN ,_, but_CC correlated_VBD with_IN a_DT pronounced_JJ reduction_NN in_IN their_PRP$ susceptibility_NN to_TO HIV-1_NN infection_NN ._.
 Eicosanoids_NNS in_IN breast_NN cancer_NN patients_NNS before_IN and_CC after_IN mastectomy_NN ._.
 In_IN 19_CD patients_NNS with_IN a_DT malignant_JJ breast_NN tumor_NN ,_, tumor_NN tissue_NN and_CC blood_NN were_VBD taken_VBN to_TO determine_VB the_DT eicosanoid_NN profile_NN and_CC platelet_NN aggregation_NN ._.
 Values_NNS were_VBD compared_VBN with_IN those_DT of_IN patients_NNS with_IN benign_JJ tumors_NNS (_( n_NN =_JJ 4_CD )_) ,_, or_CC undergoing_VBG a_DT mammary_JJ reduction_NN (_( n_NN =_JJ 7_CD )_) ._.
 Postoperatively_RB ,_, blood_NN was_VBD taken_VBN as_RB well_RB in_IN order_NN to_TO compare_VB pre-_JJ and_CC postoperative_JJ values_NNS ._.
 Eicosanoids_NNS were_VBD measured_VBN in_IN peripheral_JJ blood_NN monocytes_NNS and_CC mammary_JJ tissue_NN by_IN means_NNS of_IN HPLC_NN ;_: furthermore_RBR ,_, TXA2_NN ,_, 6-keto-PGF1_NN alpha_NN ,_, and_CC PGE2_NN were_VBD determined_VBN by_IN RIA_NN ._.
 Differences_NNS in_IN pre-_JJ and_CC postoperative_JJ values_NNS of_IN cancer_NN patients_NNS were_VBD seen_VBN in_IN plasma_NN RIA_NN values_NNS :_: PGE2_NN and_CC 6-k-PGF1_NN alpha_NN were_VBD significantly_RB higher_JJR preoperatively_RB when_WRB compared_VBN with_IN postoperatively_RB ,_, however_RB ,_, such_JJ differences_NNS were_VBD seen_VBN in_IN the_DT control_NN groups_NNS as_RB well_RB ._.
 Compared_VBN to_TO benign_JJ tumor_NN or_CC mammary_JJ reduction_NN test_NN material_NN the_DT eicosanoid_NN profile_NN of_IN tissue_NN obtained_VBN from_IN malignant_JJ mammary_JJ tumors_NNS showed_VBD important_JJ differences_NNS ._.
 Except_IN for_IN PGF2_NN alpha_NN ,_, HHT_NN and_CC 15-HETE_NN no_DT detectable_JJ quantities_NNS of_IN eicosanoids_NNS were_VBD found_VBN in_IN the_DT non-tumor_JJ material_NN ,_, whereas_IN in_IN the_DT malignant_JJ tumor_NN material_NN substantial_JJ quantities_NNS of_IN a_DT number_NN of_IN eicosanoid_NN metabolites_NNS were_VBD present_JJ ._.
 Statistically_RB significant_JJ correlations_NNS could_MD be_VB established_VBN between_IN patient/histopathology_NN data_NNS and_CC the_DT results_NNS of_IN the_DT platelet_NN aggregation_NN assays_NNS ,_, e.g._FW between_IN menopausal_JJ status_NN and_CC ADP_NN aggregation_NN ;_: oestrogen_NN receptor_NN (_( +/-_CC )_) and_CC collagen_NN and_CC arachidonic_JJ acid_NN aggregation_NN ,_, inflammatory_JJ cell_NN infiltration_NN score_NN and_CC arachidonic_JJ acid_NN aggregation_NN and_CC fibrosis_NN score_NN and_CC ADP_NN aggregation_NN ._.
 The_DT results_NNS show_VBP that_IN eicosanoid_NN synthesis_NN in_IN material_NN from_IN mammary_JJ cancer_NN patients_NNS is_VBZ different_JJ from_IN that_DT in_IN benign_JJ mammary_JJ tissue_NN ._.
 The_DT implications_NNS ,_, in_IN particular_JJ ,_, in_IN relation_NN to_TO future_JJ prognosis_NN of_IN the_DT patient_NN ,_, remain_VBP obscure_JJ ._.
 c-myc_NN mRNA_NN expression_NN in_IN minor_JJ salivary_JJ glands_NNS of_IN patients_NNS with_IN Sjogren_NN 's_POS syndrome_NN ._.
 c-myc_NN protooncogene_NN is_VBZ implicated_VBN in_IN the_DT pathogenesis_NN of_IN B_NN cell_NN lymphoid_JJ malignancies_NNS and_CC high_JJ levels_NNS of_IN c-myc_NN mRNA_NN expression_NN are_VBP observed_VBN in_IN activated_VBN blood_NN mononuclear_JJ cells_NNS ._.
 Sjogren_NN 's_POS syndrome_NN (_( SS_NN )_) is_VBZ characterized_VBN by_IN lymphocytic_JJ infiltrates_NNS of_IN exocrine_JJ glands_NNS ,_, remarkable_JJ B_NN cell_NN hyperreactivity_NN and_CC a_DT strong_JJ predisposition_NN to_TO B_NN cell_NN neoplasia_NN ._.
 In_IN this_DT study_NN ,_, c-myc_NN protooncogene_NN mRNA_NN expression_NN in_IN 29_CD labial_JJ minor_JJ salivary_JJ gland_NN biopsies_NNS from_IN patients_NNS with_IN primary_JJ SS_NNS and_CC 15_CD controls_NNS was_VBD examined_VBN using_VBG in_FW situ_FW hybridization_NN histochemistry_NN ._.
 Two_CD 40mer_JJ oligonucleotides_NNS from_IN the_DT 1st_JJ and_CC the_DT 2nd_JJ exon_NN of_IN the_DT c-myc_NN gene_NN ,_, labeled_VBN with_IN 35S_NN ,_, were_VBD used_VBN as_IN probes_NNS ._.
 To_TO detect_VB the_DT origin_NN of_IN the_DT cell_NN hybridized_VBN with_IN a_DT c-myc_NN probe_NN ,_, a_DT combined_JJ immunochemistry_NN in_FW situ_FW hybridization_NN histochemistry_NN technique_NN was_VBD used_VBN ._.
 High_JJ c-myc_NN mRNA_NN expression_NN was_VBD detected_VBN on_IN acinar_JJ epithelial_JJ cells_NNS ._.
 c-myc_NN did_VBD not_RB correlate_VB with_IN c-fos_NN and_CC c-jun_NN protein_NN expression_NN ._.
 Stronger_JJR c-myc_NN mRNA_NN expression_NN was_VBD detected_VBN in_IN labial_JJ salivary_JJ glands_NNS of_IN patients_NNS with_IN longer_JJR disease_NN duration_NN (_( p_NN less_JJR than_IN or_CC equal_JJ to_TO 0.002_CD )_) and_CC more_RBR intense_JJ T_NN lymphocyte_NN infiltrates_NNS (_( p_NN less_JJR than_IN 0.05_CD )_) although_IN these_DT patients_NNS revealed_VBD no_DT hypergammaglobulinemia_NN ._.
 No_DT correlation_NN was_VBD observed_VBN between_IN c-myc_NN mRNA_NN and_CC B_NN lymphocyte_NN monoclonicity_NN or_CC lymphoma_NN ._.
 In_IN conclusion_NN ,_, strong_JJ c-myc_NN mRNA_NN expression_NN was_VBD observed_VBN on_IN epithelial_JJ cells_NNS of_IN labial_JJ salivary_JJ glands_NNS from_IN patients_NNS with_IN primary_JJ SS_NN ._.
 Our_PRP$ findings_NNS may_MD indicate_VB the_DT presence_NN of_IN a_DT reactivated_VBN virus_NN hosted_VBN in_IN these_DT cells_NNS ._.
 Cytoplasmic_JJ domain_NN heterogeneity_NN and_CC functions_NNS of_IN IgG_NN Fc_NN receptors_NNS in_IN B_NN lymphocytes_NNS ._.
 B_NN lymphocytes_NNS and_CC macrophages_NNS express_VBP closely_RB related_JJ immunoglobulin_NN G_NN (_( IgG_NN )_) Fc_NN receptors_NNS (_( Fc_NN gamma_NN RII_NN )_) that_WDT differ_VBP only_RB in_IN the_DT structures_NNS of_IN their_PRP$ cytoplasmic_JJ domains_NNS ._.
 Because_IN of_IN cell_NN type-specific_JJ alternative_JJ messenger_NN RNA_NN splicing_NN ,_, B-cell_NN Fc_NN gamma_NN RII_NN contains_VBZ an_DT insertion_NN of_IN 47_CD amino_NN acids_NNS that_WDT participates_VBZ in_IN determining_VBG receptor_NN function_NN in_IN these_DT cells_NNS ._.
 Transfection_NN of_IN an_DT Fc_NN gamma_NN RII-negative_JJ B-cell_NN line_NN with_IN complementary_JJ DNA_NN 's_POS encoding_VBG the_DT two_CD splice_NN products_NNS and_CC various_JJ receptor_NN mutants_NNS indicated_VBD that_IN the_DT insertion_NN was_VBD responsible_JJ for_IN preventing_VBG both_CC Fc_NN gamma_NN RII-mediated_JJ endocytosis_NN and_CC Fc_NN gamma_NN RII-mediated_JJ antigen_NN presentation_NN ._.
 The_DT insertion_NN was_VBD not_RB required_VBN for_IN Fc_NN gamma_NN RII_NN to_TO modulate_VB surface_NN immunoglobulin-triggered_JJ B-cell_NN activation_NN ._.
 Instead_RB ,_, regulation_NN of_IN activation_NN involved_VBD a_DT region_NN of_IN the_DT cytoplasmic_JJ domain_NN common_JJ to_TO both_CC the_DT lymphocyte_NN and_CC macrophage_NN receptor_NN isoforms_NNS ._.
 In_IN contrast_NN ,_, the_DT insertion_NN did_VBD contribute_VB to_TO the_DT formation_NN of_IN caps_NNS in_IN response_NN to_TO receptor_NN cross-linking_NN ,_, consistent_JJ with_IN suggestions_NNS that_IN the_DT lymphocyte_NN but_CC not_RB macrophage_NN form_NN of_IN the_DT receptor_NN can_MD associate_VB with_IN the_DT detergent-insoluble_JJ cytoskeleton_NN ._.
 Every_DT enhancer_NN works_VBZ with_IN every_DT promoter_NN for_IN all_PDT the_DT combinations_NNS tested_VBN :_: could_MD new_JJ regulatory_JJ pathways_NNS evolve_VBP by_IN enhancer_NN shuffling_NN ?_.
 The_DT promoters_NNS and_CC enhancers_NNS of_IN cell_NN type-specific_JJ genes_NNS are_VBP often_RB conserved_VBN in_IN evolution_NN ,_, and_CC hence_RB one_NN might_MD expect_VB that_IN a_DT given_JJ enhancer_NN has_VBZ evolved_VBN to_TO work_VB best_RBS with_IN its_PRP$ own_JJ promoter_NN ._.
 While_IN this_DT expectation_NN may_MD be_VB realized_VBN in_IN some_DT cases_NNS ,_, we_PRP have_VBP not_RB found_VBN evidence_NN for_IN it_PRP ._.
 A_DT total_NN of_IN 27_CD combinations_NNS of_IN different_JJ promoters_NNS and_CC enhancers_NNS were_VBD tested_VBN by_IN transfection_NN into_IN cultured_VBN cells_NNS ._.
 We_PRP found_VBD that_IN the_DT relative_JJ efficiency_NN of_IN the_DT enhancers_NNS is_VBZ approximately_RB the_DT same_JJ ,_, irrespective_JJ of_IN the_DT type_NN of_IN promoter_NN used_VBN ,_, i.e._FW ,_, there_EX was_VBD no_DT strong_JJ preference_NN for_IN any_DT given_JJ enhancer/promoter_JJ combination_NN ._.
 Notably_RB ,_, we_PRP do_VBP not_RB see_VB particularly_RB strong_JJ transcription_NN when_WRB the_DT immunoglobulin_NN kappa_NN enhancer_NN (_( or_CC the_DT immunoglobulin_NN heavy_JJ chain_NN enhancer_NN )_) is_VBZ used_VBN to_TO activate_VB a_DT kappa_NN gene_NN promoter_NN ._.
 We_PRP propose_VBP that_IN a_DT generally_RB permissive_JJ enhancer/promoter_JJ interaction_NN is_VBZ of_IN evolutionary_JJ benefit_NN for_IN higher_JJR eukaryotes_NNS :_: by_IN enhancer_NN shuffling_NN ,_, genes_NNS could_MD be_VB easily_RB brought_VBN under_IN a_DT new_JJ type_NN of_IN inducibility/cell_NN type_NN specificity_NN ._.
 Heterodimerization_NN and_CC transcriptional_JJ activation_NN in_FW vitro_FW by_IN NF-kappa_NN B_NN proteins_NNS ._.
 The_DT NF-kappa_NN B_NN family_NN of_IN transcription_NN proteins_NNS represents_VBZ multiple_JJ DNA_NN binding_NN ,_, rel_NN related_JJ polypeptides_NNS that_WDT contribute_VBP to_TO regulation_NN of_IN genes_NNS involved_VBN in_IN immune_JJ responsiveness_NN and_CC inflammation_NN ,_, as_RB well_RB as_IN activation_NN of_IN the_DT HIV_NN long_JJ terminal_JJ repeat_NN ._.
 In_IN this_DT study_NN multiple_JJ NF-kappa_NN B_NN related_JJ polypeptides_NNS ranging_VBG from_IN 85_CD to_TO 45_CD kDa_NN were_VBD examined_VBN for_IN their_PRP$ capacity_NN to_TO interact_VB with_IN the_DT PRDII_NN regulatory_JJ element_NN of_IN interferon_NN beta_NN and_CC were_VBD shown_VBN to_TO possess_VB distinct_JJ intrinsic_JJ DNA_NN binding_NN affinities_NNS for_IN this_DT NF-kappa_NN B_NN site_NN and_CC form_VB multiple_JJ DNA_NN binding_NN homo-_JJ and_CC heterodimer_NN complexes_NNS in_IN co-renaturation_NN experiments_NNS ._.
 Furthermore_RB ,_, using_VBG DNA_NN templates_NNS containing_VBG two_CD copies_NNS of_IN the_DT PRDII_NN domain_NN linked_VBN to_TO the_DT rabbit_NN beta_NN globin_NN gene_NN ,_, the_DT purified_VBN polypeptides_NNS specifically_RB stimulated_VBD NF-kappa_NN B_NN dependent_JJ transcription_NN in_IN an_DT in_FW vitro_FW reconstitution_NN assay_NN as_IN heterodimers_NNS but_CC not_RB as_IN p50_NN homodimers_NNS ._.
 These_DT experiments_NNS emphasize_VBP the_DT role_NN of_IN NF-kappa_NN B_NN dimerization_NN as_IN a_DT distinct_JJ level_NN of_IN transcriptional_JJ control_NN that_WDT may_MD permit_VB functional_JJ diversification_NN of_IN a_DT limited_JJ number_NN of_IN regulatory_JJ proteins_NNS ._.
 Oct2_NN transactivation_NN from_IN a_DT remote_JJ enhancer_NN position_NN requires_VBZ a_DT B-cell-restricted_JJ activity_NN ._.
 Previous_JJ cotransfection_NN experiments_NNS had_VBD demonstrated_VBN that_IN ectopic_JJ expression_NN of_IN the_DT lymphocyte-specific_JJ transcription_NN factor_NN Oct2_NN could_MD efficiently_RB activate_VB a_DT promoter_NN containing_VBG an_DT octamer_NN motif_NN ._.
 Oct2_NN expression_NN was_VBD unable_JJ to_TO stimulate_VB a_DT multimerized_JJ octamer_NN enhancer_NN element_NN in_IN HeLa_NN cells_NNS ,_, however_RB ._.
 We_PRP have_VBP tested_VBN a_DT variety_NN of_IN Oct2_NN isoforms_VBZ generated_VBN by_IN alternative_JJ splicing_NN for_IN the_DT capability_NN to_TO activate_VB an_DT octamer_NN enhancer_NN in_IN nonlymphoid_JJ cells_NNS and_CC a_DT B-cell_NN line_NN ._.
 Our_PRP$ analyses_NNS show_VBP that_IN several_JJ Oct2_NN isoforms_NNS can_MD stimulate_VB from_IN a_DT remote_JJ position_NN but_CC that_IN this_DT stimulation_NN is_VBZ restricted_JJ to_TO B_NN cells_NNS ._.
 This_DT result_NN indicates_VBZ the_DT involvement_NN of_IN either_CC a_DT B-cell-specific_JJ cofactor_NN or_CC a_DT specific_JJ modification_NN of_IN a_DT cofactor_NN or_CC the_DT Oct2_NN protein_NN in_IN Oct2-mediated_JJ enhancer_NN activation_NN ._.
 Mutational_JJ analyses_NNS indicate_VBP that_IN the_DT carboxy-terminal_JJ domain_NN of_IN Oct2_NN is_VBZ critical_JJ for_IN enhancer_NN activation_NN ._.
 Moreover_RB ,_, this_DT domain_NN conferred_VBD enhancing_NN activity_NN when_WRB fused_VBN to_TO the_DT Oct1_NN protein_NN ,_, which_WDT by_IN itself_PRP was_VBD unable_JJ to_TO stimulate_VB from_IN a_DT remote_JJ position_NN ._.
 The_DT glutamine-rich_JJ activation_NN domain_NN present_JJ in_IN the_DT amino-terminal_JJ portion_NN of_IN Oct2_NN and_CC the_DT POU_NN domain_NN contribute_VBP only_RB marginally_RB to_TO the_DT transactivation_NN function_NN from_IN a_DT distal_JJ position_NN ._.
 Induction_NN of_IN the_DT POU_NN domain_NN transcription_NN factor_NN Oct-2_NN during_IN T-cell_NN activation_NN by_IN cognate_JJ antigen_NN ._.
 Oct-2_NN is_VBZ a_DT transcription_NN factor_NN that_WDT binds_VBZ specifically_RB to_TO octamer_NN DNA_NN motifs_NNS in_IN the_DT promoters_NNS of_IN immunoglobulin_NN and_CC interleukin-2_NN genes_NNS ._.
 All_DT tumor_NN cell_NN lines_NNS from_IN the_DT B-cell_NN lineage_NN and_CC a_DT few_JJ from_IN the_DT T-cell_NN lineage_NN express_VBP Oct-2_NN ._.
 To_TO address_VB the_DT role_NN of_IN Oct-2_NN in_IN the_DT T-cell_NN lineage_NN ,_, we_PRP studied_VBD the_DT expression_NN of_IN Oct-2_NN mRNA_NN and_CC protein_NN in_IN nontransformed_JJ human_JJ and_CC mouse_NN T_NN cells_NNS ._.
 Oct-2_NN was_VBD found_VBN in_IN CD4+_JJ and_CC CD8+_JJ T_NN cells_NNS prepared_VBN from_IN human_JJ peripheral_JJ blood_NN and_CC in_IN mouse_NN lymph_NN node_NN T_NN cells_NNS ._.
 In_IN a_DT T-cell_NN clone_NN specific_JJ for_IN pigeon_NN cytochrome_NN c_NN in_IN the_DT context_NN of_IN I-Ek_NN ,_, Oct-2_NN was_VBD induced_VBN by_IN antigen_NN stimulation_NN ,_, with_IN the_DT increase_NN in_IN Oct-2_NN protein_NN seen_VBN first_RB at_IN 3_CD h_NN after_IN activation_NN and_CC continuing_VBG for_IN at_IN least_JJS 24_CD h_NN ._.
 Oct-2_NN mRNA_NN induction_NN during_IN antigen-driven_JJ T-cell_NN activation_NN was_VBD blocked_VBN by_IN cyclosporin_NN A_NN ,_, as_RB well_RB as_IN by_IN protein_NN synthesis_NN inhibitors_NNS ._.
 These_DT results_NNS suggest_VBP that_IN Oct-2_NN participates_VBZ in_IN transcriptional_JJ regulation_NN during_IN T-cell_NN activation_NN ._. The_DT relatively_RB delayed_VBN kinetics_NNS of_IN Oct-2_NN induction_NN suggests_VBZ that_IN Oct-2_NN mediates_VBZ the_DT changes_NNS in_IN gene_NN expression_NN which_WDT occur_VBP many_JJ hours_NNS or_CC days_NNS following_VBG antigen_NN stimulation_NN of_IN T_NN lymphocytes_NNS ._.
 (_( Changes_NNS in_IN plasma_NN interleukin-1_NN and_CC their_PRP$ possible_JJ relationship_NN with_IN the_DT changes_NNS in_IN glucocorticoid_NN receptor_NN in_IN aged_JJ long-distance_JJ runner_NN )_)
 For_IN the_DT study_NN of_IN the_DT changes_NNS in_IN plasma_NN interleukin-1_NN (_( IL-1_NN )_) and_CC their_PRP$ possible_JJ relationship_NN with_IN the_DT changes_NNS in_IN glucocorticoid_NN receptor_NN (_( GR_NN )_) ,_, plasma_NN IL-1_NN and_CC GR_NN in_IN peripheral_JJ blood_NN leukocytes_NNS in_IN aged_JJ long-distance_JJ runner_NN were_VBD measured_VBN simultaneously_RB ._.
 The_DT activity_NN of_IN IL-1_NN was_VBD expressed_VBN as_IN its_PRP$ ability_NN to_TO stimulate_VB 3H-TdR_NN incorporation_NN in_IN the_DT thymocytes_NNS of_IN C57_NN mice_NNS ._.
 GR_NN was_VBD determined_VBN by_IN whole_JJ cell_NN assay_NN with_IN 3H-Dex_NN ._.
 The_DT results_NNS showed_VBD that_IN the_DT activity_NN of_IN plasma_NN IL-1_NN in_IN aged_JJ long-distance_JJ runner_NN was_VBD 209_CD %_NN ,_, 223_CD %_NN and_CC 145_CD %_NN of_IN the_DT control_NN at_IN 14.7-18.7_CD ,_, 3.8-7.0_CD and_CC 1.5-2.6_CD KD_NN fractions_NNS ._.
 The_DT GR_NN in_IN peripheral_JJ blood_NN leukocytes_NNS in_IN aged_JJ runner_NN was_VBD 65_CD %_NN of_IN the_DT control_NN ._.
 Possible_JJ relationship_NN between_IN the_DT changes_NNS in_IN IL-1_NN and_CC GR_NN in_NN aged_JJ long-distance_JJ runner_NN and_CC its_PRP$ physiological_JJ significance_NN are_VBP discussed_VBN ._.
 Transcription_NN factor_NN AP-2_NN activates_VBZ gene_NN expression_NN of_IN HTLV-I_NN ._.
 The_DT HTLV-I_NN LTR_NN contains_VBZ three_CD conserved_VBN regulatory_JJ elements_NNS known_VBN as_IN 21_CD base_NN pair_NN repeats_NNS which_WDT are_VBP required_VBN for_IN stimulation_NN of_IN gene_NN expression_NN by_IN the_DT transactivator_NN protein_NN tax_NN ._.
 Mutagenesis_NN indicates_VBZ that_IN the_DT 21_CD bp_NN repeats_NNS can_MD be_VB subdivided_VBN into_IN three_CD motifs_NNS ,_, A_NN ,_, B_NN and_CC C_NN ,_, each_DT of_IN which_WDT influences_VBZ the_DT level_NN of_IN tax_NN activation_NN ._.
 The_DT A_NN site_NN in_IN the_DT 21_CD bp_NN repeat_NN has_VBZ strong_JJ homology_NN with_IN previously_RB described_VBN binding_VBG sites_NNS for_IN the_DT transcription_NN factor_NN AP-2_NN ._.
 We_PRP demonstrated_VBD that_IN AP-2_NN mRNA_NN was_VBD present_JJ in_IN T-lymphocytes_NNS and_CC that_IN cellular_JJ factors_NNS from_IN both_CC non-transformed_JJ and_CC transformed_VBN T-lymphocytes_NNS specifically_RB bound_VBD to_TO the_DT consensus_NN motif_NN for_IN AP-2_NN in_IN each_DT 21_CD bp_NN ._.
 To_TO determine_VB the_DT role_NN of_IN AP-2_NN in_IN the_DT regulation_NN of_IN the_DT HTLV-I_NN LTR_NN gene_NN expression_NN ,_, we_PRP used_VBD an_DT AP-2_NN cDNA_NN in_IN DNA_NN binding_NN and_CC transient_JJ expression_NN assays_NNS ._.
 Gel_NN retardation_NN and_CC methylation_NN interference_NN studies_NNS revealed_VBD that_IN bacterially_RB produced_VBN AP-2_NN bound_VBD specifically_RB and_CC with_IN high_JJ affinity_NN to_TO all_DT three_CD 21_CD bp_NN repeats_NNS ,_, and_CC that_IN it_PRP required_VBD the_DT core_NN sequence_NN AGGC_NN for_IN specific_JJ binding_NN ._.
 Binding_NN of_IN AP-2_NN prevented_VBD the_DT subsequent_JJ binding_NN of_IN members_NNS of_IN the_DT CREB/ATF_NN family_NN to_TO an_DT adjacent_JJ regulatory_JJ motif_NN in_IN the_DT 21_CD bp_NN repeat_NN ._.
 Transfection_NN of_IN an_DT AP-2_NN expression_NN construct_NN into_IN T-lymphocytes_NNS activated_VBD gene_NN expression_NN from_IN the_DT HTLV-I_NN LTR_NN ._.
 At_IN least_JJS two_CD 21_CD bp_NN repeats_NNS were_VBD required_VBN for_IN high_JJ levels_NNS of_IN AP-2_NN activation_NN and_CC mutagenesis_NN of_IN the_DT AP-2_NN consensus_NN binding_NN sequences_NNS in_IN the_DT 21_CD bp_NN repeats_NNS eliminate_VBP this_DT activation_NN ._.
 (_( ABSTRACT_NN TRUNCATED_VBN AT_IN 250_CD WORDS_NNS )_)
 Cell_NN cycle-dependent_JJ initiation_NN and_CC lineage-dependent_JJ abrogation_NN of_IN GATA-1_NN expression_NN in_IN pure_JJ differentiating_VBG hematopoietic_JJ progenitors_NNS ._.
 The_DT programmed_VBN activation/repression_NN of_IN transcription_NN factors_NNS in_IN early_JJ hematopoietic_JJ differentiation_NN has_VBZ not_RB yet_RB been_VBN explored_VBN ._.
 The_DT DNA-binding_JJ protein_NN GATA-1_NN is_VBZ required_VBN for_IN normal_JJ erythroid_JJ development_NN and_CC regulates_VBZ erythroid-expressed_JJ genes_NNS in_IN maturing_VBG erythroblasts_NNS ._.
 We_PRP analyzed_VBD GATA-1_NN expression_NN in_IN early_JJ human_JJ adult_JJ hematopoiesis_NN by_IN using_VBG an_DT in_FW vitro_FW system_NN in_IN which_WDT "_[[DQS]] pure_JJ "_[[DQE]] early_JJ hematopoietic_JJ progenitors_NNS are_VBP induced_VBN to_TO gradual_JJ and_CC synchronized_VBD differentiation_NN selectively_RB along_IN the_DT erythroid_JJ or_CC granulocyte-macrophage_JJ pathway_NN by_IN differential_JJ treatment_NN with_IN hematopoietic_JJ growth_NN factors_NNS ._.
 The_DT GATA-1_NN gene_NN ,_, though_IN virtually_RB silent_JJ in_IN quiescent_JJ progenitors_NNS ,_, is_VBZ activated_VBN after_IN entrance_NN into_IN the_DT cell_NN cycle_NN upon_IN stimulation_NN with_IN hematopoietic_JJ growth_NN factors_NNS ._.
 Subsequently_RB ,_, increasing_VBG expression_NN along_IN the_DT erythroid_JJ pathway_NN contrasts_VBZ with_IN an_DT abrupt_JJ downregulation_NN in_IN the_DT granulocyte-macrophage_JJ lineage_NN ._.
 These_DT results_NNS suggest_VBP a_DT microenvironment-directed_JJ ,_, two-step_JJ model_NN for_IN GATA-1_NN expression_NN in_IN differentiating_VBG hematopoietic_JJ progenitors_NNS that_WDT involves_VBZ (_( i_LS )_) cycle-dependent_JJ initiation_NN and_CC (_( ii_LS )_) lineage-dependent_JJ maintenance_NN or_CC suppression_NN ._.
 Hypothetically_RB ,_, on/off_JJ switches_NNS of_IN lineage-restricted_JJ transactivators_NNS may_MD underlie_VB the_DT binary_JJ fate_NN decisions_NNS of_IN hematopoietic_JJ progenitors_NNS ._.
 (_( Age-related_JJ changes_NNS in_IN glucocorticoid_NN and_CC mineralocorticoid_NN receptors_NNS in_IN lymphocytes_NNS of_IN healthy_JJ persons_NNS and_CC patients_NNS with_IN hypertension_NN )_)
 It_PRP has_VBZ been_VBN found_VBN that_IN the_DT number_NN of_IN glucocorticoid_NN receptors_NNS in_IN lymphocytes_NNS of_IN the_DT peripheral_JJ blood_NN of_IN healthy_JJ elderly_JJ subjects_NNS increases_VBZ ,_, while_IN the_DT number_NN of_IN mineralocorticoid_NN receptors_NNS decreases_VBZ ._.
 The_DT mechanisms_NNS of_IN hormone-receptor_NN interactions_NNS in_IN hypertension_NN are_VBP activated_VBN :_: the_DT number_NN of_IN glucocorticoid_NN and_CC mineralocorticoid_NN binding_NN sites_NNS grows_VBZ in_IN hypertensive_JJ patients_NNS ._.
 Still_RB a_DT more_RBR essential_JJ rise_NN in_IN the_DT number_NN of_IN receptors_NNS is_VBZ observed_VBN in_IN mid-age_JJ hypertensive_NN patients_NNS than_IN in_IN elderly_JJ ones_NNS ._.
 In_FW vivo_FW footprint_NN analysis_NN of_IN the_DT HLA-DRA_NN gene_NN promoter_NN :_: cell-specific_JJ interaction_NN at_IN the_DT octamer_NN site_NN and_CC up-regulation_NN of_IN X_NN box_NN binding_NN by_IN interferon_NN gamma_NN ._.
 Analysis_NN of_IN the_DT major_JJ histocompatibility_NN complex_NN class_NN II_CD gene_NN promoter_NN DRA_NN has_VBZ previously_RB identified_VBN at_IN least_JJS five_CD cis-acting_JJ regions_NNS required_VBN for_IN maximal_JJ expression_NN ._.
 We_PRP have_VBP examined_VBN the_DT DRA_NN promoter_NN for_IN protein-DNA_JJ interactions_NNS in_IN the_DT intact_JJ cell_NN ,_, which_WDT may_MD mediate_VB transcriptional_JJ activation_NN ._.
 Using_VBG in_FW vivo_FW genomic_JJ footprinting_NN we_PRP identified_VBD interactions_NNS in_IN B-cell_NN lines_NNS at_IN the_DT octamer_NN site_NN and_CC the_DT Y_NN ,_, X1_NN ,_, and_CC X2_NN boxes_NNS ._.
 Class_NN II_CD antigen_NN expressing_VBG T-cell_NN lines_NNS maintained_VBD contacts_NNS identical_JJ to_TO B-cell_NN lines_NNS ,_, while_IN class_NN II-negative_JJ T-cell_NN lines_NNS exhibited_VBD no_DT interactions_NNS ._.
 In_IN lymphoid_JJ cell_NN lines_NNS ,_, the_DT octamer_NN site_NN is_VBZ occupied_VBN and_CC required_VBN for_IN maximal_JJ expression_NN ._.
 This_DT is_VBZ most_RBS likely_RB due_JJ to_TO the_DT presence_NN of_IN the_DT lymphoid-specific_JJ OTF-2_NN factor_NN ._.
 In_IN contrast_NN ,_, the_DT class_NN II-positive_JJ nonlymphoid_JJ glioblastoma_NN cell_NN line_NN does_VBZ not_RB exhibit_VB interactions_NNS at_IN the_DT octamer_NN site_NN despite_IN the_DT presence_NN of_IN the_DT ubiquitous_JJ OTF-1_NN factor_NN and_CC an_DT open_JJ binding_VBG site_NN ._.
 Thus_RB ,_, the_DT DRA_NN promoter_NN discriminates_VBZ against_IN OTF-1_NN activation_NN at_IN the_DT level_NN of_IN DNA_NN binding_NN in_IN the_DT glioblastoma_NN line_NN ._.
 Interferon_NN gamma_NN induces_VBZ class_NN II_CD expression_NN in_IN this_DT glioblastoma_NN cell_NN line_NN and_CC ,_, in_IN parallel_NN ,_, up-regulates_VBZ X1_NN and_CC X2_NN box_NN protein-DNA_JJ interactions_NNS ,_, while_IN all_DT other_JJ interactions_NNS remain_VBP unchanged_JJ ._.
 These_DT results_NNS suggest_VBP that_IN interferon_NN gamma_NN functions_VBZ on_IN a_DT poised_VBN promoter_NN by_IN altering_VBG weak_JJ ,_, nonproductive_JJ interactions_NNS at_IN the_DT X_NN boxes_NNS to_TO strong_JJ interactions_NNS ._.
 These_DT findings_NNS provide_VBP direct_JJ in_FW vivo_FW evidence_NN to_TO strongly_RB suggest_VB that_IN the_DT modulation_NN of_IN X1_NN and_CC X2_NN interactions_NNS is_VBZ an_DT important_JJ constituent_NN of_IN the_DT interferon_NN gamma_NN induction_NN pathway_NN ._.
 Simple_JJ derivation_NN of_IN TFIID-dependent_JJ RNA_NN polymerase_NN II_CD transcription_NN systems_NNS from_IN Schizosaccharomyces_FW pombe_FW and_CC other_JJ organisms_NNS ,_, and_CC factors_NNS required_VBN for_IN transcriptional_JJ activation_NN ._.
 Resolution_NN of_IN whole_JJ cell_NN extract_NN through_IN two_CD chromatographic_JJ steps_NNS yields_VBZ a_DT single_JJ protein_NN fraction_NN requiring_VBG only_RB the_DT addition_NN of_IN TFIID_NN for_IN the_DT initiation_NN of_IN transcription_NN at_IN RNA_NN polymerase_NN II_CD promoters_NNS ._.
 This_DT approach_NN allows_VBZ the_DT convenient_JJ generation_NN of_IN RNA_NN polymerase_NN II_CD transcription_NN systems_NNS from_IN Saccharomyces_FW cerevisiae_FW ,_, human_JJ lymphocytes_NNS ,_, and_CC Schizosaccharomyces_FW pombe_FW ._.
 TFIIDs_NNS from_IN all_DT three_CD organisms_NNS are_VBP interchangeable_JJ among_IN all_DT three_CD systems_NNS ._.
 The_DT S._FW cerevisiae_FW and_CC Sch._FW pombe_FW systems_NNS support_VBP effects_NNS of_IN acidic_JJ activator_NN proteins_NNS ,_, provided_VBN a_DT further_JJ protein_NN fraction_NN from_IN S._FW cerevisiae_FW is_VBZ supplied_VBN ._.
 This_DT further_JJ fraction_NN is_VBZ distinct_JJ from_IN the_DT mediator_NN of_IN transcriptional_JJ activation_NN described_VBN previously_RB and_CC represents_VBZ a_DT second_JJ component_NN in_IN addition_NN to_TO general_JJ initiation_NN factors_NNS that_WDT may_MD facilitate_VB a_DT response_NN to_TO acidic_JJ activators_NNS ._.
 NF-kappa_NN B-dependent_JJ induction_NN of_IN the_DT NF-kappa_NN B_NN p50_NN subunit_NN gene_NN promoter_NN underlies_VBZ self-perpetuation_NN of_IN human_JJ immunodeficiency_NN virus_NN transcription_NN in_IN monocytic_JJ cells_NNS ._.
 The_DT molecular_JJ mechanisms_NNS underlying_VBG the_DT sustained_JJ nuclear_JJ translocation_NN of_IN NF-kappa_NN B_NN observed_VBN in_IN U937_NN monocytic_JJ cells_NNS chronically_RB infected_VBN with_IN human_JJ immunodeficiency_NN virus_NN (_( HIV_NN )_) were_VBD studied_VBN ._.
 The_DT activity_NN of_IN the_DT promoter_NN regulating_VBG the_DT synthesis_NN of_IN the_DT p105_NN precursor_NN of_IN the_DT NF-kappa_NN B_NN p50_NN subunit_NN was_VBD enhanced_VBN in_IN these_DT cells_NNS ._.
 Deletions_NNS in_IN this_DT promoter_NN indicated_VBD that_IN this_DT upregulation_NN was_VBD mediated_VBN through_IN the_DT NF-kappa_NN B-_NN but_CC not_RB the_DT AP-1-binding_JJ motif_NN ,_, by_IN bona_FW fide_FW p50/p65_NN heterodimers_NNS ._.
 Analysis_NN of_IN cytosolic_JJ extracts_NNS indicated_VBD that_IN NF-kappa_NN B_NN levels_NNS were_VBD increased_VBN in_IN HIV-infected_JJ cells_NNS ._.
 In_IN contrast_NN to_TO the_DT transient_JJ NF-kappa_NN B_NN activation_NN induced_VBN by_IN phorbol_NN ester_NN ,_, the_DT permanent_JJ NF-kappa_NN B_NN translocation_NN induced_VBN by_IN HIV_NN infection_NN was_VBD not_RB dependent_JJ on_IN PKC_NN isoenzymes_NNS alpha_NN and_CC beta_NN as_IN shown_VBN by_IN the_DT use_NN of_IN a_DT specific_JJ inhibitor_NN (_( GF_NN 109203X_NN )_) ._.
 These_DT observations_NNS indicate_VBP that_IN during_IN chronic_JJ HIV_NN infection_NN of_IN U937_NN cells_NNS ,_, continuous_JJ NF-kappa_NN B_NN (_( p50/p65_NN )_) translocation_NN results_VBZ in_IN p105_NN promoter_NN upregulation_NN with_IN subsequent_JJ cytosolic_JJ NF-kappa_NN B_NN accumulation_NN ,_, ready_JJ for_IN further_JJ translocation_NN ._.
 This_DT HIV-mediated_JJ mechanism_NN results_VBZ in_IN a_DT self-perpetuating_JJ loop_NN of_IN NF-kappa_NN B_NN production_NN ._.
 The_DT development_NN of_IN functionally_RB responsive_JJ T_NN cells_NNS ._.
 The_DT work_NN reviewed_VBN in_IN this_DT article_NN separates_VBZ T_NN cell_NN development_NN into_IN four_CD phases_NNS ._.
 First_JJ is_VBZ an_DT expansion_NN phase_NN prior_RB to_TO TCR_NN rearrangement_NN ,_, which_WDT appears_VBZ to_TO be_VB correlated_VBN with_IN programming_NN of_IN at_IN least_JJS some_DT response_NN genes_NNS for_IN inducibility_NN ._.
 This_DT phase_NN can_MD occur_VB to_TO some_DT extent_NN outside_IN of_IN the_DT thymus_NN ._.
 However_RB ,_, the_DT profound_JJ T_NN cell_NN deficit_NN of_IN nude_JJ mice_NNS indicates_VBZ that_IN the_DT thymus_NN is_VBZ by_IN far_RB the_DT most_RBS potent_JJ site_NN for_IN inducing_VBG the_DT expansion_NN per_FW se_FW ,_, even_RB if_IN other_JJ sites_NNS can_MD induce_VB some_DT response_NN acquisition_NN ._.
 Second_JJ is_VBZ a_DT controlled_JJ phase_NN of_IN TCR_NN gene_NN rearrangement_NN ._.
 The_DT details_NNS of_IN the_DT regulatory_JJ mechanism_NN that_WDT selects_VBZ particular_JJ loci_NNS for_IN rearrangement_NN are_VBP still_RB not_RB known_VBN ._.
 It_PRP seems_VBZ that_IN the_DT rearrangement_NN of_IN the_DT TCR_NN gamma_NN loci_NNS in_IN the_DT gamma_NN delta_NN lineage_NN may_MD not_RB always_RB take_VB place_NN at_IN a_DT developmental_JJ stage_NN strictly_RB equivalent_JJ to_TO the_DT rearrangement_NN of_IN TCR_NN beta_NN in_IN the_DT alpha_NN beta_NN lineage_NN ,_, and_CC it_PRP is_VBZ not_RB clear_JJ just_RB how_WRB early_RB the_DT two_CD lineages_NNS diverge_VBP ._.
 In_IN the_DT TCR_NN alpha_NN beta_NN lineage_NN ,_, however_RB ,_, the_DT final_JJ gene_NN rearrangement_NN events_NNS are_VBP accompanied_VBN by_IN rapid_JJ proliferation_NN and_CC an_DT interruption_NN in_IN cellular_JJ response_NN gene_NN inducibility_NN ._.
 The_DT loss_NN of_IN conventional_JJ responsiveness_NN is_VBZ probably_RB caused_VBN by_IN alterations_NNS at_IN the_DT level_NN of_IN signaling_NN ,_, and_CC may_MD be_VB a_DT manifestation_NN of_IN the_DT physiological_JJ state_NN that_WDT is_VBZ a_DT precondition_NN for_IN selection_NN ._.
 Third_JJ is_VBZ the_DT complex_JJ process_NN of_IN selection_NN ._.
 Whereas_IN peripheral_JJ T_NN cells_NNS can_MD undergo_VB forms_NNS of_IN positive_JJ selection_NN (_( by_IN antigen-driven_JJ clonal_JJ expansion_NN )_) and_CC negative_JJ selection_NN (_( by_IN abortive_JJ stimulation_NN leading_VBG to_TO anergy_NN or_CC death_NN )_) ,_, neither_DT is_VBZ exactly_RB the_DT same_JJ phenomenon_NN that_WDT occurs_VBZ in_IN the_DT thymic_JJ cortex_NN ._.
 Negative_JJ selection_NN in_IN the_DT cortex_NN appears_VBZ to_TO be_VB a_DT suicidal_JJ inversion_NN of_IN antigen_NN responsiveness_NN :_: instead_RB of_IN turning_VBG on_IN IL-2_NN expression_NN ,_, the_DT activated_VBN cell_NN destroys_VBZ its_PRP$ own_JJ chromatin_NN ._.
 The_DT genes_NNS that_WDT need_VBP to_TO be_VB induced_VBN for_IN this_DT response_NN are_VBP not_RB yet_RB identified_VBN ,_, but_CC it_PRP is_VBZ unquestionably_RB a_DT form_NN of_IN activation_NN ._.
 It_PRP is_VBZ interesting_JJ that_IN in_IN humans_NNS and_CC rats_NNS ,_, cortical_JJ thymocytes_NNS undergoing_VBG negative_JJ selection_NN can_MD still_RB induce_VB IL-2R_NN alpha_NN expression_NN and_CC even_RB be_VB rescued_VBN in_FW vitro_FW ,_, if_IN exogenous_JJ IL-2_NN is_VBZ provided_VBN ._.
 Perhaps_RB murine_JJ thymocytes_NNS are_VBP denied_VBN this_DT form_NN of_IN rescue_NN because_IN they_PRP shut_VBD off_RP IL-2R_NN beta_NN chain_NN expression_NN at_IN an_DT earlier_JJR stage_NN or_CC because_IN they_PRP may_MD be_VB uncommonly_RB Bcl-2_NN deficient_JJ (_( cf._VBP Sentman_NNP et_FW al._FW ,_, 1991_CD ;_: Strasser_NNP et_FW al._FW ,_, 1991_CD )_) ._.
 Even_RB so_RB ,_, medullary_JJ thymocytes_NNS remain_VBP at_IN least_JJS partially_RB susceptible_JJ to_TO negative_JJ selection_NN even_RB as_IN they_PRP continue_VBP to_TO mature_VB ._.
 SRC-related_JJ proto-oncogenes_NNS and_CC transcription_NN factors_NNS in_IN primary_JJ human_JJ T_NN cells_NNS :_: modulation_NN by_IN cyclosporin_NN A_NN and_CC FK506_NN ._.
 Activation_NN of_IN T_NN lymphocytes_NNS induces_VBZ transcription_NN of_IN genes_NNS encoding_VBG for_IN lymphokines_NNS ._.
 Interleukin-2_NN (_( IL-2_NN )_) gene_NN expression_NN is_VBZ controlled_VBN transcriptionally_RB by_IN the_DT cooperative_JJ activity_NN of_IN specific_JJ trans-activating_JJ factors_NNS that_WDT bind_VBP to_TO the_DT IL-2_NN enhancer_NN ._.
 Cyclosporin_NN A_NN (_( CsA_NN )_) and_CC FK506_NN inhibit_VBP the_DT production_NN of_IN IL-2_NN in_IN T_NN lymphocytes_NNS at_IN the_DT level_NN of_IN gene_NN transcription_NN ._.
 A_DT member_NN of_IN the_DT src_NN gene_NN family_NN ,_, the_DT lymphocyte-specific_JJ protein_NN tyrosine_NN kinase_NN ,_, p56lck_NN ,_, has_VBZ been_VBN implicated_VBN in_IN IL-2_NN production_NN ._.
 CsA_NN was_VBD found_VBN not_RB to_TO inhibit_VB lck_NN gene_NN expression_NN ,_, nor_CC the_DT activity_NN of_IN the_DT lck_NN gene_NN product_NN ._.
 However_RB ,_, CsA_NN and_CC FK506_NN inhibit_VBP the_DT appearance_NN of_IN DNA_NN binding_NN activity_NN of_IN factors_NNS that_WDT bind_VBP to_TO the_DT NF-AT_NN and_CC AP-1_NN sites_NNS in_IN the_DT IL-2_NN enhancer_NN ._.
 Since_IN the_DT induction_NN of_IN NF-AT_NN and_CC AP-1_NN is_VBZ induced_VBN by_IN the_DT same_JJ stimuli_NNS that_WDT stimulate_VBP IL-2_NN production_NN ,_, these_DT results_NNS indicate_VBP that_IN the_DT immunosuppressant_JJ action_NN of_IN CsA_NN and_CC FK506_NN is_VBZ exerted_VBN at_IN the_DT level_NN of_IN these_DT trans-activating_JJ factors_NNS ._.
 TAR-independent_JJ transactivation_NN by_IN Tat_NN in_IN cells_NNS derived_VBN from_IN the_DT CNS_NN :_: a_DT novel_JJ mechanism_NN of_IN HIV-1_NN gene_NN regulation_NN ._.
 The_DT Tat_NN protein_NN of_IN human_JJ immunodeficiency_NN virus_NN type_NN 1_CD (_( HIV-1_NN )_) is_VBZ essential_JJ for_IN productive_JJ infection_NN and_CC is_VBZ a_DT potential_JJ target_NN for_IN antiviral_JJ therapy_NN ._.
 Tat_NN ,_, a_DT potent_JJ activator_NN of_IN HIV-1_NN gene_NN expression_NN ,_, serves_VBZ to_TO greatly_RB increase_VB the_DT rate_NN of_IN transcription_NN directed_VBN by_IN the_DT viral_JJ promoter_NN ._.
 This_DT induction_NN ,_, which_WDT seems_VBZ to_TO be_VB an_DT important_JJ component_NN in_IN the_DT progression_NN of_IN acquired_VBN immune_JJ deficiency_NN syndrome_NN (_( AIDS_NN )_) ,_, may_MD be_VB due_JJ to_TO increased_VBN transcriptional_JJ initiation_NN ,_, increased_VBN transcriptional_JJ elongation_NN ,_, or_CC a_DT combination_NN of_IN these_DT processes_NNS ._.
 Much_JJ attention_NN has_VBZ been_VBN focused_VBN on_IN the_DT interaction_NN of_IN Tat_NN with_IN a_DT specific_JJ RNA_NN target_NN termed_VBN TAR_NN (_( transactivation_NN responsive_NN )_) which_WDT is_VBZ present_JJ in_IN the_DT leader_NN sequence_NN of_IN all_DT HIV-1_NN mRNAs_NNS ._.
 This_DT interaction_NN is_VBZ believed_VBN to_TO be_VB an_DT important_JJ component_NN of_IN the_DT mechanism_NN of_IN transactivation_NN ._.
 In_IN this_DT report_NN we_PRP demonstrate_VBP that_IN in_IN certain_JJ CNS-derived_JJ cells_NNS Tat_NN is_VBZ capable_JJ of_IN activating_VBG HIV-1_NN through_IN a_DT TAR-independent_JJ pathway_NN ._.
 A_DT Tat-responsive_JJ element_NN is_VBZ found_VBN upstream_RB within_IN the_DT viral_JJ promoter_NN that_WDT in_IN glial-derived_JJ cell_NN lines_NNS allows_VBZ transactivation_NN in_IN the_DT absence_NN of_IN TAR_NN ._.
 Deletion_NN mapping_NN and_CC hybrid_NN promoter_NN constructs_NNS demonstrate_VBP that_IN the_DT newly_RB identified_VBN Tat-responsive_JJ element_NN corresponds_VBZ to_TO a_DT sequence_NN within_IN the_DT viral_JJ long_JJ terminal_JJ repeat_NN (_( LTR_NN )_) previously_RB identified_VBN as_IN the_DT HIV-1_NN enhancer_NN ,_, or_CC NF-kappa_NN B_NN domain_NN ._.
 DNA_NN band-shift_JJ analysis_NN reveals_VBZ NF-kappa_NN B_NN binding_NN activity_NN in_IN glial_JJ cells_NNS that_WDT differs_VBZ from_IN that_DT present_JJ in_IN T_NN lymphoid_JJ cells_NNS ._.
 Further_RB ,_, we_PRP observe_VBP that_IN TAR-deleted_JJ mutants_NNS of_IN HIV-1_NN demonstrate_VBP normal_JJ late_JJ gene_NN expression_NN in_IN glial_JJ cells_NNS as_IN evidenced_VBN by_IN syncytia_NN formation_NN and_CC production_NN of_IN viral_JJ p24_NN antigen_NN ._.
 (_( ABSTRACT_NN TRUNCATED_VBN AT_IN 250_CD WORDS_NNS )_)
 Bcl-2_NN :_: a_DT repressor_NN of_IN lymphocyte_NN death_NN ._.
 The_DT genes_NNS and_CC mechanisms_NNS that_WDT control_VBP programmed_VBN cell_NN death_NN are_VBP currently_RB the_DT subject_NN of_IN intense_JJ study_NN ._.
 The_DT bcl-2_NN gene_NN ,_, a_DT repressor_NN of_IN lymphocyte_NN death_NN ,_, is_VBZ perhaps_RB the_DT best_JJS understood_VBN of_IN the_DT programmed_VBN cell_NN death_NN associated_JJ genes_NNS ._.
 Here_RB ,_, Stanley_NNP Korsmeyer_NNP provides_VBZ a_DT brief_JJ overview_NN of_IN bcl-2_NN ,_, concentrating_VBG on_IN its_PRP$ roles_NNS in_IN B-_NN and_CC T-cell_NN development_NN and_CC in_IN oncogenesis_NN ._.
 Mitogen_NN stimulation_NN of_IN T-cells_NNS increases_VBZ c-Fos_NN and_CC c-Jun_NN protein_NN levels_NNS ,_, AP-1_NN binding_NN and_CC AP-1_NN transcriptional_JJ activity_NN ._.
 We_PRP have_VBP analysed_VBN the_DT effect_NN of_IN mitogenic_JJ lectins_NNS on_IN c-Fos_NN and_CC c-Jun_NN protein_NN levels_NNS as_RB well_RB as_IN on_IN activator_NN protein-1_NN (_( AP-1_NN )_) binding_NN and_CC enhancer_NN activity_NN in_IN Jurkat_NN T-cells_NNS ._.
 Both_CC c-Fos_NN and_CC c-Jun_NN protein_NN levels_NNS were_VBD increased_VBN after_IN Con_NN A_NN and_CC PHA_NN stimulation_NN ._.
 Since_IN T-cell_NN stimulation_NN increases_VBZ both_CC intracellular_JJ Ca2+_NN and_CC cAMP_NN levels_NNS and_CC activates_VBZ protein_NN kinase_NN C_NN (_( PKC_NN )_) ,_, the_DT possible_JJ involvement_NN of_IN these_DT intracellular_JJ messengers_NNS in_IN c-Fos_NN and_CC c-Jun_NN induction_NN was_VBD tested_VBN ._.
 PMA_NN ,_, which_WDT directly_RB activates_VBZ PKC_NN ,_, mimicked_VBD the_DT effect_NN of_IN the_DT lectins_NNS on_IN c-Fos_NN and_CC c-Jun_NN ,_, but_CC elevation_NN of_IN either_CC intracellular_JJ Ca2+_NN or_CC cAMP_NN levels_NNS had_VBD little_JJ or_CC no_DT effect_NN ._.
 The_DT mitogen-induced_JJ increase_NN of_IN c-Fos_NN and_CC c-Jun_NN immunoreactivity_NN was_VBD inhibited_VBN by_IN H-7_NN ,_, a_DT kinase_NN inhibitor_NN with_IN relatively_RB high_JJ specificity_NN for_IN PKC_NN ,_, and_CC less_RBR efficiently_RB by_IN H-8_NN ,_, a_DT structurally_RB related_JJ kinase_NN inhibitor_NN less_RBR active_JJ on_IN PKC_NN ,_, but_CC more_RBR active_JJ on_IN cyclic_JJ nucleotide-dependent_JJ kinases_NNS ._.
 Con_NN A_NN stimulation_NN was_VBD found_VBN to_TO increase_VB both_CC binding_NN of_IN AP-1_NN to_TO the_DT AP-1_NN consensus_NN sequence_NN ,_, TRE_NN ,_, and_CC AP-1_NN enhancer_NN activity_NN ,_, in_IN Jurkat_NN cells_NNS ._.
 PMA_NN was_VBD also_RB found_VBN to_TO increase_VB the_DT AP-1_NN enhancer_NN activity_NN ,_, whereas_IN elevation_NN of_IN Ca2+_NN or_CC cAMP_NN had_VBD only_RB minor_JJ effects_NNS ._.
 We_PRP conclude_VBP that_IN stimulation_NN with_IN mitogenic_JJ lectins_NNS is_VBZ sufficient_JJ to_TO increase_VB both_CC c-Fos_NN and_CC c-Jun_NN protein_NN levels_NNS ,_, AP-1_NN binding_NN and_CC AP-1_NN enhancer_NN activity_NN in_IN Jurkat_NN cells_NNS and_CC that_IN they_PRP act_VBP via_IN mechanisms_NNS that_WDT could_MD involve_VB the_DT activation_NN of_IN PKC_NN ._.
 Functional_JJ interaction_NN between_IN the_DT two_CD zinc_NN finger_NN domains_NNS of_IN the_DT v-erb_NN A_NN oncoprotein_NN ._.
 The_DT v-erb_NN A_NN oncogene_NN of_IN avian_JJ erythroblastosis_NN virus_NN is_VBZ a_DT mutated_VBN and_CC virally_RB transduced_VBN copy_NN of_IN a_DT host_NN cell_NN gene_NN encoding_VBG a_DT thyroid_NN hormone_NN receptor_NN ._.
 The_DT protein_NN expressed_VBN by_IN the_DT v-erb_NN A_NN oncogene_NN binds_VBZ to_TO DNA_NN and_CC acts_VBZ as_IN a_DT dominant_JJ negative_JJ inhibitor_NN of_IN both_CC the_DT thyroid_NN hormone_NN receptor_NN and_CC the_DT closely_RB related_JJ retinoic_JJ acid_NN receptor_NN ._.
 The_DT v-erb_NN A_NN protein_NN has_VBZ sustained_VBN two_CD amino_NN acid_NN alterations_NNS within_IN its_PRP$ DNA-binding_JJ domain_NN relative_JJ to_TO that_DT of_IN c-erb_NN A_NN ,_, one_CD of_IN which_WDT ,_, at_IN serine_NN 61_CD ,_, is_VBZ known_VBN to_TO be_VB important_JJ for_IN v-erb_NN A_NN function_NN in_IN the_DT neoplastic_JJ cell_NN ._.
 We_PRP report_VBP here_RB that_IN the_DT second_JJ alteration_NN ,_, at_IN threonine_NN 78_CD ,_, also_RB plays_VBZ an_DT important_JJ ,_, although_IN more_RBR indirect_JJ ,_, role_NN :_: alteration_NN of_IN the_DT sequence_NN at_IN threonine_NN 78_CD such_JJ that_IN it_PRP resembles_VBZ that_DT of_IN c-erb_NN A_NN can_MD act_VB as_IN an_DT intragenic_JJ suppressor_NN and_CC can_MD partially_RB restore_VB function_NN to_TO a_DT v-erb_NN A_NN protein_NN rendered_VBN defective_JJ due_JJ to_TO a_DT mutation_NN at_IN position_NN 61_CD ._.
 Threonine_NN 78_CD lies_VBZ within_IN the_DT D-box_NN of_IN the_DT v-erb_NN A_NN protein_NN ,_, a_DT region_NN thought_VBN to_TO mediate_VB receptor-receptor_JJ dimerizations_NNS ,_, and_CC is_VBZ not_RB in_IN physical_JJ proximity_NN to_TO the_DT serine_NN at_IN position_NN 61_CD ._.
 It_PRP therefore_RB appears_VBZ that_IN an_DT indirect_JJ interaction_NN occurs_VBZ between_IN these_DT two_CD sites_NNS and_CC that_IN this_DT interaction_NN is_VBZ crucial_JJ for_IN v-erb_NN A_NN function_NN ._.
 Pax-5_NN encodes_VBZ the_DT transcription_NN factor_NN BSAP_NN and_CC is_VBZ expressed_VBN in_IN B_NN lymphocytes_NNS ,_, the_DT developing_VBG CNS_NNS ,_, and_CC adult_JJ testis_NN ._.
 BSAP_NN has_VBZ been_VBN identified_VBN previously_RB as_IN a_DT transcription_NN factor_NN that_WDT is_VBZ expressed_VBN at_IN early_JJ ,_, but_CC not_RB late_JJ ,_, stages_NNS of_IN B-cell_NN differentiation_NN ._.
 Biochemical_JJ purification_NN and_CC cDNA_NN cloning_NN has_VBZ now_RB revealed_VBN that_IN BSAP_NN belongs_VBZ to_TO the_DT family_NN of_IN paired_JJ domain_NN proteins_NNS ._.
 BSAP_NN is_VBZ encoded_VBN by_IN the_DT Pax-5_NN gene_NN and_CC has_VBZ been_VBN highly_RB conserved_VBN between_IN human_JJ and_CC mouse_NN ._.
 An_DT intact_JJ paired_JJ domain_NN was_VBD shown_VBN to_TO be_VB both_CC necessary_JJ and_CC sufficient_JJ for_IN DNA_NN binding_NN of_IN BSAP_NN ._.
 Binding_VBG studies_NNS with_IN several_JJ BSAP_NN recognition_NN sequences_NNS demonstrated_VBD that_IN the_DT sequence_NN specificity_NN of_IN BSAP_NN differs_VBZ from_IN that_DT of_IN the_DT distantly_RB related_JJ paired_JJ domain_NN protein_NN Pax-1_NN ._.
 During_IN embryogenesis_NN ,_, the_DT BSAP_NN gene_NN is_VBZ transiently_RB expressed_VBN in_IN the_DT mesencephalon_NN and_CC spinal_JJ cord_NN with_IN a_DT spatial_JJ and_CC temporal_JJ expression_NN pattern_NN that_WDT is_VBZ distinct_JJ from_IN that_DT of_IN other_JJ Pax_NN genes_NNS in_IN the_DT developing_VBG central_JJ nervous_JJ system_NN (_( CNS_NN )_) ._.
 Later_RB ,_, the_DT expression_NN of_IN the_DT BSAP_NN gene_NN shifts_VBZ to_TO the_DT fetal_JJ liver_NN where_WRB it_PRP correlates_VBZ with_IN the_DT onset_NN of_IN B_NN lymphopoiesis_NN ._.
 BSAP_NN expression_NN persists_VBZ in_IN B_NN lymphocytes_NNS and_CC is_VBZ also_RB seen_VBN in_IN the_DT testis_NN of_IN the_DT adult_JJ mouse_NN ._.
 All_DT of_IN this_DT evidence_NN indicates_VBZ that_IN the_DT transcription_NN factor_NN BSAP_NN may_MD not_RB only_RB play_VB an_DT important_JJ role_NN in_IN B-cell_NN differentiation_NN but_CC also_RB in_IN neural_JJ development_NN and_CC spermatogenesis_NN ._.
 Okadaic_JJ acid_NN is_VBZ a_DT potent_JJ inducer_NN of_IN AP-1_NN ,_, NF-kappa_NN B_NN ,_, and_CC tumor_NN necrosis_NN factor-alpha_NN in_IN human_JJ B_NN lymphocytes_NNS ._.
 Treatment_NN of_IN human_JJ B_NN lymphocytes_NNS with_IN an_DT optimal_JJ concentration_NN of_IN okadaic_JJ acid_NN ,_, an_DT inhibitor_NN of_IN phosphatases_NNS 1_CD and_CC 2A_NN ,_, resulted_VBD in_IN the_DT induction_NN of_IN the_DT transcription_NN factor_NN ,_, AP-1_NN and_CC a_DT marked_JJ increase_NN in_IN NF-kappa_NN B_NN levels_NNS ._.
 In_IN contrast_NN ,_, no_DT effect_NN on_IN the_DT levels_NNS of_IN the_DT octamer_NN binding_NN proteins_NNS ,_, Oct-1_NN or_CC Oct-2_NN ,_, were_VBD found_VBN ._.
 Since_IN both_CC AP-1_NN and_CC NF-kappa_NN B_NN have_VBP been_VBN reported_VBN to_TO be_VB important_JJ in_IN the_DT induction_NN of_IN the_DT tumor_NN necrosis_NN factor-alpha_NN (_( TNF-alpha_NN )_) gene_NN we_PRP examined_VBD the_DT effects_NNS of_IN okadaic_JJ acid_NN on_IN TNF-alpha_NN mRNA_NN levels_NNS ._.
 Treatment_NN with_IN okadaic_JJ acid_NN resulted_VBD in_IN a_DT striking_JJ increase_NN in_IN TNF-alpha_NN mRNA_NN transcripts_NNS within_IN 1_CD h_NN of_IN stimulation_NN and_CC large_JJ amounts_NNS of_IN TNF-alpha_NN were_VBD released_VBN into_IN the_DT culture_NN media_NNS ._.
 Although_IN okadaic_JJ acid_NN provides_VBZ a_DT potent_JJ inductive_JJ signal_NN for_IN AP-1_NN and_CC NF-kappa_NN B_NN it_PRP did_VBD not_RB induce_VB either_CC B_NN cell_NN proliferation_NN or_CC immunoglobulin_NN secretion_NN ._.
 A_DT novel_JJ Ets-related_JJ transcription_NN factor_NN ,_, Elf-1_NN ,_, binds_VBZ to_TO human_JJ immunodeficiency_NN virus_NN type_NN 2_CD regulatory_JJ elements_NNS that_WDT are_VBP required_VBN for_IN inducible_JJ trans_JJ activation_NN in_IN T_NN cells_NNS ._.
 Human_JJ immunodeficiency_NN virus_NN type_NN 1_CD (_( HIV-1_NN )_) and_CC HIV-2_NN are_VBP structurally_RB related_JJ retroviruses_NNS which_WDT both_DT cause_VBP AIDS_NN in_IN humans_NNS ._.
 Although_IN both_DT viruses_NNS establish_VBP latency_NN in_IN quiescent_JJ human-peripheral-blood_JJ T_NN cells_NNS ,_, the_DT asymptomatic_JJ phase_NN of_IN HIV-2_NN infection_NN may_MD be_VB more_JJR prolonged_JJ than_IN that_DT of_IN HIV-1_NN ._.
 The_DT latent_JJ phases_NNS of_IN both_CC HIV-1_NN and_CC HIV-2_NN infection_NN have_VBP been_VBN shown_VBN to_TO be_VB disrupted_VBN by_IN T-cell_NN activation_NN ,_, a_DT process_NN that_WDT requires_VBZ host_NN cell_NN transcription_NN factors_NNS ._.
 In_IN the_DT case_NN of_IN HIV-1_NN ,_, the_DT transcription_NN factor_NN NF-kappa_NN B_NN is_VBZ sufficient_JJ for_IN inducible_JJ transcriptional_JJ activation_NN ._.
 In_IN contrast_NN ,_, factors_NNS in_IN addition_NN to_TO NF-kappa_NN B_NN are_VBP required_VBN to_TO activate_VB HIV-2_NN transcription_NN in_IN infected_JJ T_NN cells_NNS ._.
 In_IN this_DT report_NN ,_, we_PRP demonstrate_VBP that_IN a_DT novel_JJ Ets-related_JJ transcription_NN factor_NN ,_, Elf-1_NN ,_, binds_VBZ specifically_RB to_TO two_CD purine-rich_JJ motifs_NNS in_IN the_DT HIV-2_NN enhancer_NN ._.
 Mutagenesis_NN experiments_NNS demonstrated_VBD that_IN these_DT Elf-1_NN binding_NN sites_NNS are_VBP required_VBN for_IN induction_NN of_IN HIV-2_NN transcription_NN following_VBG T-cell-receptor-mediated_JJ T-cell_NN activation_NN ._.
 Moreover_RB ,_, Elf-1_NN is_VBZ the_DT only_JJ factor_NN present_JJ in_IN activated_VBN T-cell_NN nuclear_JJ extracts_NNS that_WDT binds_VBZ to_TO these_DT sites_NNS in_IN electrophoretic_JJ mobility_NN shift_NN assays_NNS ._.
 Thus_RB ,_, Elf-1_NN is_VBZ a_DT novel_JJ transcription_NN factor_NN that_WDT appears_VBZ to_TO be_VB required_VBN for_IN the_DT T-cell-receptor-mediated_JJ trans_JJ activation_NN of_IN HIV-2_NN gene_NN expression_NN ._.
 These_DT results_NNS may_MD explain_VB differences_NNS in_IN the_DT clinical_JJ spectra_NNS of_IN diseases_NNS caused_VBN by_IN HIV-1_NN and_CC HIV-2_NN and_CC may_MD also_RB have_VB implications_NNS for_IN the_DT design_NN of_IN therapeutic_JJ approaches_NNS to_TO HIV-2_NN infection_NN ._.
 Human_JJ immunodeficiency_NN virus_NN type_NN 1_CD Nef_NN protein_NN inhibits_VBZ NF-kappa_NN B_NN induction_NN in_IN human_JJ T_NN cells_NNS ._.
 Human_JJ immunodeficiency_NN virus_NN type_NN 1_CD (_( HIV-1_NN )_) can_MD establish_VB a_DT persistent_JJ and_CC latent_JJ infection_NN in_IN CD4+_JJ T_NN lymphocytes_NNS (_( W.C.Greene_NNP ,_, N.Engl.J._NNP Med.324_NNP :_: 308-317_CD ,_, 1991_CD ;_: S.M.Schnittman_NNP ,_, M.C.Psallidopoulos_NNP ,_, H.C._NNP Lane_NNP ,_, L.Thompson_NNP ,_, M.Baseler_NNP ,_, F.Massari_NNP ,_, C.H.Fox_NNP ,_, N.P.Salzman_NNP ,_, and_CC A.S.Fauci_NNP ,_, Science_NNP 245_CD :_: 305-308_CD ,_, 1989_CD )_) ._.
 Production_NN of_IN HIV-1_NN from_IN latently_RB infected_JJ cells_NNS requires_VBZ host_NN cell_NN activation_NN by_IN T-cell_NN mitogens_NNS (_( T.Folks_NNP ,_, D.M.Powell_NNP ,_, M.M.Lightfoote_NNP ,_, S.Benn_NNP ,_, M.A._NNP Martin_NNP ,_, and_CC A.S.Fauci_NNP ,_, Science_NNP 231_CD :_: 600-602_CD ,_, 1986_CD ;_: D.Zagury_NNP ,_, J._NNP Bernard_NNP ,_, R.Leonard_NNP ,_, R.Cheynier_NNP ,_, M.Feldman_NNP ,_, P.S.Sarin_NNP ,_, and_CC R.C._NNP Gallo_NNP ,_, Science_NNP 231_CD :_: 850-853_CD ,_, 1986_CD )_) ._.
 This_DT activation_NN is_VBZ mediated_VBN by_IN the_DT host_NN transcription_NN factor_NN NF-kappa_NN B_NN (_( G.Nabel_NNP and_CC D.Baltimore_NNP ,_, Nature_NNP (_( London_NNP )_) 326_CD :_: 711-717_CD ,_, 1987_CD )_) ._.
 We_PRP report_VBP here_RB that_IN the_DT HIV-1-encoded_JJ Nef_NN protein_NN inhibits_VBZ the_DT induction_NN of_IN NF-kappa_NN B_NN DNA-binding_JJ activity_NN by_IN T-cell_NN mitogens_NNS ._.
 However_RB ,_, Nef_NN does_VBZ not_RB affect_VB the_DT DNA-binding_JJ activity_NN of_IN other_JJ transcription_NN factors_NNS implicated_VBN in_IN HIV-1_NN regulation_NN ,_, including_VBG SP-1_NN ,_, USF_NN ,_, URS_NN ,_, and_CC NF-AT_NN ._.
 Additionally_RB ,_, Nef_NN inhibits_VBZ the_DT induction_NN of_IN HIV-1-_NN and_CC interleukin_NN 2-directed_JJ gene_NN expression_NN ,_, and_CC the_DT effect_NN on_IN HIV-1_NN transcription_NN depends_VBZ on_IN an_DT intact_JJ NF-kappa_NN B-binding_JJ site_NN ._.
 These_DT results_NNS indicate_VBP that_IN defective_JJ recruitment_NN of_IN NF-kappa_NN B_NN may_MD underlie_VB Nef_NN 's_POS negative_JJ transcriptional_JJ effects_NNS on_IN the_DT HIV-1_NN and_CC interleukin_NN 2_CD promoters_NNS ._.
 Further_JJ evidence_NN suggests_VBZ that_IN Nef_NN inhibits_VBZ NF-kappa_NN B_NN induction_NN by_IN interfering_VBG with_IN a_DT signal_NN derived_VBN from_IN the_DT T-cell_NN receptor_NN complex_NN ._.
 (_( Effect_NN of_IN antihypertensive_JJ therapy_NN with_IN captopril_NN on_IN gluco-_JJ and_CC mineralocorticoid_NN receptors_NNS of_IN peripheral_JJ blood_NN lymphocytes_NNS in_IN hypertensive_JJ patients_NNS of_IN various_JJ age_NN )_)
 Binding_NN of_IN 3H-dexamethasone_NN and_CC 3H-aldosterone_NN by_IN peripheral_JJ lymphocyte_NN receptors_NNS was_VBD investigated_VBN in_IN healthy_JJ persons_NNS and_CC hypertensive_JJ patients_NNS before_IN and_CC after_IN 2-week_JJ captopril_NN treatment_NN ._.
 The_DT number_NN of_IN glucocorticoid_NN and_CC mineralocorticoid_NN binding_NN sites_NNS was_VBD increased_VBN in_IN hypertensives_NNS vs_CC normotensives_NNS ._.
 The_DT treatment_NN with_IN the_DT ACE_NN inhibitor_NN captopril_NN led_VBD to_TO activation_NN of_IN hormone-receptor_NN interactions_NNS ._.
 There_EX was_VBD a_DT more_RBR marked_JJ rise_NN of_IN the_DT number_NN of_IN receptors_NNS in_IN middle-aged_JJ (_( 44-55_CD years_NNS )_) hypertensives_NNS vs_CC elderly_JJ (_( 61-80_CD years_NNS )_) subjects_NNS after_IN captopril_NN treatment_NN ._.
 Leukotriene_NN B4_NN transcriptionally_RB activates_VBZ interleukin-6_NN expression_NN involving_VBG NK-chi_NN B_NN and_CC NF-IL6_NN ._.
 Leukotriene_NN B4_NN (_( LTB4_NN )_) is_VBZ a_DT notable_JJ participant_NN in_IN inflammation_NN and_CC chemotaxis_NN ._.
 It_PRP is_VBZ ,_, however_RB ,_, still_RB unclear_JJ whether_IN LTB4_NN acts_VBZ in_IN this_DT regard_NN directly_RB or_CC indirectly_RB by_IN stimulating_VBG the_DT release_NN of_IN chemotactic_JJ and_CC inflammatory_JJ cytokines_NNS ._.
 Here_RB we_PRP report_VBP that_IN LTB4_NN induces_VBZ synthesis_NN of_IN interleukin_NN (_( IL_NN )_) -6_CD by_IN human_JJ blood_NN monocytes_NNS through_IN transcriptional_JJ activation_NN of_IN the_DT IL-6_NN gene_NN ._.
 We_PRP furthermore_RB demonstrate_VBP that_IN this_DT process_NN involves_VBZ activation_NN of_IN the_DT transcription_NN factor_NN NF-chi_NN B_NN and_CC ,_, to_TO a_DT lesser_JJR extent_NN ,_, of_IN NF-IL6_NN ,_, while_IN the_DT activity_NN of_IN the_DT transcription_NN factor_NN AP-1_NN ,_, shown_VBN to_TO otherwise_RB confer_VB IL-6_NN inducibility_NN ,_, appeared_VBD to_TO be_VB unaffected_JJ by_IN LTB4_NN ._.
 Involvement_NN of_IN NF-chi_NN B_NN and_CC NF-IL6_NN in_IN induction_NN of_IN IL-6_NN transcription_NN by_IN monocytes_NNS was_VBD demonstrated_VBN using_VBG deleted_JJ forms_NNS of_IN the_DT IL-6_NN promoter_NN ._.
 Activation_NN of_IN the_DT IL-6_NN promoter_NN by_IN LTB4_NN was_VBD not_RB only_RB associated_VBN with_IN accumulation_NN of_IN the_DT respective_JJ transcripts_NNS but_CC resulted_VBD in_IN synthesis_NN of_IN functional_JJ IL-6_NN protein_NN as_RB well_RB ._.
 In_IN addition_NN ,_, LTB4_NN mediated_VBD transactivation_NN of_IN a_DT heterologous_JJ promoter_NN construct_NN containing_VBG the_DT NF-chi_NN B_NN or_CC the_DT NF-IL6_NN enhancer_NN ,_, but_CC not_RB the_DT AP-1_NN enhancer_NN ._.
 The_DT signaling_NN events_NNS mediating_VBG this_DT effect_NN appeared_VBD to_TO involve_VB the_DT release_NN of_IN H2O2_NN ,_, since_IN LTB4_NN failed_VBD to_TO induce_VB NF-chi_NN B_NN or_CC NF-IL6_NN in_IN the_DT presence_NN of_IN the_DT scavenger_NN of_IN H2O2_NN ,_, N-acetyl-L-cysteine_NN ._.
 Estrogen_NN binding_NN sites_NNS in_IN peripheral_JJ blood_NN monocytes_NNS and_CC effects_NNS of_IN danazol_NN on_IN their_PRP$ sites_NNS in_FW vitro_FW ._.
 1_LS ._. This_DT study_NN was_VBD designed_VBN to_TO investigate_VB the_DT presence_NN of_IN estrogen_NN type_NN I_CD (_( high_JJ affinity_NN ,_, low_JJ capacity_NN )_) and_CC type_NN II_CD (_( low_JJ affinity_NN ,_, high_JJ capacity_NN )_) binding_NN sites_NNS in_IN human_JJ peripheral_JJ blood_NN monocytes_NNS and_CC the_DT effects_NNS of_IN danazol_NN on_IN these_DT sites_NNS ._.
 2_LS ._. These_DT two_CD types_NNS of_IN estrogen_NN binding_NN sites_NNS existed_VBD in_IN human_JJ peripheral_JJ blood_NN monocytes_NNS ._.
 3_LS ._. Danazol_NN bound_VBD to_TO these_DT sites_NNS in_IN high_JJ concentration_NN (_( 10(-6)_CD M_NN ,_, clinical_JJ serum_NN concentration_NN during_IN danazol_NN therapy_NN )_) and_CC decreased_VBD the_DT number_NN of_IN both_DT sites_NNS ._.
 4_LS ._. It_PRP is_VBZ suggested_VBN that_IN danazol_NN has_VBZ an_DT anti-estrogenic_JJ action_NN to_TO the_DT monocytes_NNS through_IN the_DT competition_NN and_CC suppression_NN of_IN estrogen_NN binding_NN sites_NNS as_IN seen_VBN in_IN the_DT estrogen_NN target_NN organ_NN ._.
 (_( Mechanism_NN of_IN action_NN of_IN steroid_NN hormones_NNS ._. I_LS ._. Estrogens_NNS )_)
 The_DT steroid_NN hormone_NN are_VBP very_RB versatile_JJ molecules_NNS :_: although_IN they_PRP are_VBP related_JJ among_IN them_PRP by_IN their_PRP$ chemical_JJ structure_NN ,_, they_PRP have_VBP very_RB diverse_JJ functions_NNS and_CC including_VBG antagonic_JJ ._.
 Their_PRP$ action_NN mechanism_NN is_VBZ not_RB completely_RB cleared_VBN ._.
 The_DT estrogens_NNS participate_VBP in_IN the_DT regulation_NN of_IN practically_RB all_PDT the_DT reproductive_JJ and_CC sexual_JJ events_NNS of_IN the_DT female_NN ,_, although_IN the_DT intracellular_JJ actions_NNS by_IN which_WDT they_PRP take_VBP place_NN are_VBP not_RB well_RB known_VBN and_CC the_DT proposed_JJ models_NNS do_VBP not_RB adequately_RB satisfy_VB the_DT questions_NNS ._.
 Currently_RB it_PRP is_VBZ accepted_VBN the_DT existence_NN of_IN a_DT cytoplasmic_JJ and/or_CC nuclear_JJ receptor_NN ,_, without_IN explaining_VBG satisfactorily_RB how_WRB the_DT hormones_NNS come_VBN to_TO the_DT nucleus_NN ._.
 The_DT endocrine_JJ events_NNS that_WDT are_VBP rapidly_RB expressed_VBN (_( seconds_NNS )_) are_VBP due_JJ to_TO a_DT possible_JJ interaction_NN with_IN cellular_JJ membrane_NN ._.
 The_DT purpose_NN of_IN this_DT review_NN is_VBZ to_TO analyze_VB and_CC concilliate_VB the_DT reported_VBN data_NNS on_IN the_DT mechanism_NN of_IN action_NN of_IN estrogens_NNS ._.
 Stable_JJ expression_NN of_IN transdominant_JJ Rev_NN protein_NN in_IN human_JJ T_NN cells_NNS inhibits_VBZ human_JJ immunodeficiency_NN virus_NN replication_NN ._.
 The_DT human_JJ immunodeficiency_NN virus_NN (_( HIV_NN )_) Rev_NN protein_NN is_VBZ essential_JJ for_IN viral_JJ structural_JJ protein_NN expression_NN (_( Gag_NN ,_, Pol_NN ,_, and_CC Env_NN )_) and_CC ,_, hence_RB ,_, for_IN viral_JJ replication_NN ._.
 In_IN transient_JJ transfection_NN assays_NNS ,_, mutant_JJ forms_NNS of_IN Rev_NN have_VBP been_VBN identified_VBN that_WDT inhibit_VBP wild-type_JJ Rev_NN activity_NN and_CC therefore_RB suppress_VBP viral_JJ replication_NN ._.
 To_TO determine_VB whether_IN such_JJ transdominant_JJ Rev_NN proteins_NNS could_MD provide_VB long-term_JJ protection_NN against_IN HIV_NN infection_NN without_IN affecting_VBG T_NN cell_NN function_NN ,_, T_NN leukemia_NN cell_NN lines_NNS were_VBD stably_RB transduced_VBN with_IN a_DT retroviral_JJ vector_NN encoding_VBG a_DT transdominant_JJ mutant_NN of_IN the_DT Rev_NN protein_NN ,_, M10_NN ._.
 While_IN all_PDT the_DT M10-expressing_JJ cell_NN lines_NNS remained_VBD infectable_JJ by_IN HIV-1_NN ,_, these_DT same_JJ cells_NNS failed_VBD to_TO support_VB a_DT productive_JJ replication_NN cycle_NN when_WRB infected_VBN with_IN a_DT cloned_VBN isolate_NN of_IN HIV-1_NN ._.
 In_IN addition_NN ,_, two_CD out_IN of_IN three_CD M10-expressing_JJ CEM_NN clones_NNS were_VBD also_RB resistant_JJ to_TO highly_RB productive_JJ infection_NN by_IN a_DT heterogeneous_JJ HIV-1_NN pool_NN ._.
 Expression_NN of_IN M10_NN did_VBD not_RB affect_VB induction_NN of_IN HIV_NN transcription_NN mediated_VBN by_IN the_DT kappa_NN B_NN regulatory_JJ element_NN or_CC Tat_NN ._.
 Importantly_RB ,_, constitutive_JJ expression_NN of_IN Rev_NN M10_NN did_VBD not_RB alter_VB the_DT secretion_NN of_IN interleukin_NN 2_CD in_IN response_NN to_TO mitogen_NN stimulation_NN of_IN EL-4_NN and_CC Jurkat_NN cells_NNS ._.
 The_DT inhibition_NN of_IN HIV_NN infection_NN in_IN cells_NNS stably_RB expressing_VBG a_DT transdominant_JJ Rev_NN protein_NN ,_, in_IN the_DT absence_NN of_IN any_DT deleterious_JJ effect_NN on_IN T_NN cell_NN function_NN ,_, suggests_VBZ that_IN such_PDT a_DT strategy_NN could_MD provide_VB a_DT therapeutic_JJ effect_NN in_IN the_DT T_NN lymphocytes_NNS of_IN acquired_VBN immunodeficiency_NN syndrome_NN patients_NNS ._.
 Glucocorticoid_NN receptor_NN in_IN patients_NNS with_IN lupus_NN nephritis_NN :_: relationship_NN between_IN receptor_NN levels_NNS in_IN mononuclear_JJ leukocytes_NNS and_CC effect_NN of_IN glucocorticoid_NN therapy_NN ._.
 We_PRP investigated_VBD the_DT clinical_JJ significance_NN of_IN glucocorticoid_NN receptor_NN determination_NN in_IN 20_CD patients_NNS with_IN systemic_JJ lupus_NN erythematosus_NN (_( SLE_NN )_) who_WP afterwards_RB developed_VBD nephrotic_JJ syndrome_NN ._.
 Glucocorticoid_NN receptor_NN concentrations_NNS in_IN mononuclear_JJ leukocytes_NNS (_( MNL_NNS )_) in_IN these_DT patients_NNS were_VBD comparable_JJ with_IN those_DT in_IN both_CC other_JJ patients_NNS with_IN SLE_NN and_CC healthy_JJ persons_NNS ._.
 Improvement_NN in_IN urinary_JJ protein_NN excretion_NN and_CC in_IN disease_NN activity_NN ,_, which_WDT was_VBD scored_VBN according_VBG to_TO the_DT SLE_NNP Disease_NNP Activity_NNP Index_NNP system_NN of_IN the_DT University_NNP of_IN Toronto_NNP ,_, closely_RB related_JJ to_TO the_DT glucocorticoid_NN receptor_NN concentrations_NNS in_IN MNL_NN isolated_VBN from_IN the_DT corresponding_JJ patients_NNS ._.
 In_IN summary_NN ,_, glucocorticoid_NN receptor_NN determination_NN in_IN patients_NNS with_IN lupus_NN nephritis_NN may_MD be_VB a_DT predictive_JJ clue_NN for_IN assessing_VBG responsiveness_NN to_TO glucocorticoid_NN therapy_NN ._.
 Selection_NN of_IN optimal_JJ kappa_NN B/Rel_NN DNA-binding_JJ motifs_NNS :_: interaction_NN of_IN both_DT subunits_NNS of_IN NF-kappa_NN B_NN with_IN DNA_NN is_VBZ required_VBN for_IN transcriptional_JJ activation_NN ._.
 Analysis_NN of_IN the_DT p50_NN and_CC p65_NN subunits_NNS of_IN the_DT NF-kappa_NN B_NN transcription_NN factor_NN complex_NN has_VBZ revealed_VBN that_IN both_DT proteins_NNS can_MD interact_VB with_IN related_JJ DNA_NN sequences_NNS through_IN either_CC homo-_JJ or_CC heterodimer_NN formation_NN ._.
 In_IN addition_NN ,_, the_DT product_NN of_IN the_DT proto-oncogene_NN c-rel_NN can_MD bind_VB to_TO similar_JJ DNA_NN motifs_NNS by_IN itself_PRP or_CC as_IN a_DT heterodimer_NN with_IN p50_NN or_CC p65_NN ._.
 However_RB ,_, these_DT studies_NNS have_VBP used_VBN a_DT limited_JJ number_NN of_IN known_JJ kappa_NN B_NN DNA_NN motifs_NNS ,_, and_CC the_DT question_NN of_IN the_DT optimal_JJ DNA_NN sequences_NNS preferred_VBN by_IN each_DT homodimer_NN has_VBZ not_RB been_VBN addressed_VBN ._.
 Using_VBG purified_VBN recombinant_JJ p50_NN ,_, p65_NN ,_, and_CC c-Rel_NN proteins_NNS ,_, optimal_JJ DNA-binding_JJ motifs_NNS were_VBD selected_VBN from_IN a_DT pool_NN of_IN random_JJ oligonucleotides_NNS ._.
 Alignment_NN of_IN the_DT selected_VBN sequences_NNS allowed_VBD us_PRP to_TO predict_VB a_DT consensus_NN sequence_NN for_IN binding_NN of_IN the_DT individual_JJ homodimeric_JJ Rel-related_JJ proteins_NNS ,_, and_CC DNA-protein_NN binding_NN analysis_NN of_IN the_DT selected_VBN DNA_NN sequences_VBZ revealed_VBD sequence_NN specificity_NN of_IN the_DT proteins_NNS ._.
 Contrary_JJ to_TO previous_JJ assumptions_NNS ,_, we_PRP observed_VBD that_IN p65_NN homodimers_NNS can_MD interact_VB with_IN a_DT subset_NN of_IN DNA_NN sequences_VBZ not_RB recognized_VBN by_IN p50_NN homodimers_NNS ._.
 Differential_JJ binding_NN affinities_NNS were_VBD also_RB obtained_VBN with_IN p50-_NN and_CC c-Rel-selected_JJ sequences_NNS ._.
 Using_VBG either_CC a_DT p50-_NN or_CC p65-selected_JJ kappa_NN B_NN motif_NN ,_, which_WDT displayed_VBD differential_JJ binding_NN with_IN respect_NN to_TO the_DT other_JJ protein_NN ,_, little_JJ to_TO no_DT binding_NN was_VBD observed_VBN with_IN the_DT heterodimeric_JJ NF-kappa_NN B_NN complex_NN ._.
 Similarly_RB ,_, in_IN transfection_NN experiments_NNS in_IN which_WDT the_DT selective_JJ kappa_NN B_NN binding_NN sites_NNS were_VBD used_VBN to_TO drive_VB the_DT expression_NN of_IN a_DT chloramphenicol_NN acetyltransferase_NN reporter_NN construct_NN ,_, the_DT p65-_NN and_CC p50-selected_JJ motifs_NNS were_VBD activated_VBN only_RB in_IN the_DT presence_NN of_IN p65_NN and_CC p50/65_NN (_( a_DT chimeric_JJ protein_NN with_IN the_DT p50_NN DNA_NN binding_NN domain_NN and_CC p65_NN activation_NN domain_NN )_) expression_NN vectors_NNS ,_, respectively_RB ,_, and_CC neither_DT demonstrated_VBD a_DT significant_JJ response_NN to_TO stimuli_NNS that_WDT induce_VBP NF-kappa_NN B_NN activity_NN ._.
 These_DT findings_NNS demonstrate_VBP that_IN interaction_NN of_IN both_DT subunits_NNS of_IN the_DT heterodimeric_JJ NF-kappa_NN B_NN complex_NN with_IN DNA_NN is_VBZ required_VBN for_IN DNA_NN binding_NN and_CC transcriptional_JJ activation_NN and_CC suggest_VBP that_IN transcriptional_JJ activation_NN mediated_VBN by_IN the_DT individual_JJ rel-related_JJ proteins_NNS will_MD differ_VB dramatically_RB ,_, depending_VBG on_IN the_DT specific_JJ kappa_NN B_NN motifs_NNS present_JJ ._.
 Characterization_NN of_IN a_DT new_JJ tissue-specific_JJ transcription_NN factor_NN binding_VBG to_TO the_DT simian_JJ virus_NN 40_CD enhancer_NN TC-II_NN (_( NF-kappa_NN B_NN )_) element_NN ._.
 We_PRP have_VBP biochemically_RB and_CC functionally_RB characterized_VBN a_DT new_JJ transcription_NN factor_NN ,_, NP-TCII_NN ,_, which_WDT is_VBZ present_JJ in_IN nuclei_NNS from_IN unstimulated_JJ T_NN and_CC B_NN lymphocytes_NNS but_CC is_VBZ not_RB found_VBN in_IN nonhematopoietic_JJ cells_NNS ._.
 This_DT factor_NN has_VBZ a_DT DNA-binding_JJ specificity_NN similar_JJ to_TO that_DT of_IN NF-kappa_NN B_NN but_CC is_VBZ unrelated_JJ to_TO this_DT or_CC other_JJ Rel_NN proteins_NNS by_IN functional_JJ and_CC biochemical_JJ criteria_NNS ._.
 It_PRP can_MD also_RB be_VB distinguished_VBN from_IN other_JJ previously_RB described_VBN lymphocyte-specific_JJ DNA-binding_JJ proteins_NNS ._.
 The_DT candidate_NN oncoprotein_NN Bcl-3_NN is_VBZ an_DT antagonist_NN of_IN p50/NF-kappa_NN B-mediated_JJ inhibition_NN ._.
 The_DT candidate_NN oncogene_NN bcl-3_NN was_VBD discovered_VBN as_IN a_DT translocation_NN into_IN the_DT immunoglobulin_NN alpha-locus_NN in_IN some_DT cases_NNS of_IN B-cell_NN chronic_JJ lymphocytic_JJ leukaemias_NNS ._.
 The_DT protein_NN Bcl-3_NN contains_VBZ seven_CD so-called_JJ ankyrin_NN repeats_NNS ._.
 Similar_JJ repeat_NN motifs_NNS are_VBP found_VBN in_IN a_DT number_NN of_IN diverse_JJ regulatory_JJ proteins_NNS but_CC the_DT motifs_NNS of_IN Bcl-3_NN are_VBP most_RBS closely_RB related_JJ to_TO those_DT found_VBN in_IN I_NN kappa_NN B_NN proteins_NNS in_IN which_WDT the_DT ankyrin_NN repeat_NN domain_NN is_VBZ thought_VBN to_TO be_VB directly_RB involved_VBN in_IN inhibition_NN of_IN NF-kappa_NN B_NN activity_NN ._.
 No_DT biological_JJ function_NN has_VBZ yet_RB been_VBN described_VBN for_IN Bcl-3_NN ,_, but_CC it_PRP was_VBD noted_VBN recently_RB that_IN Bcl-3_NN interferes_VBZ with_IN DNA-binding_NN of_IN the_DT p50_NN subunit_NN of_IN NF-kappa_NN B_NN in_FW vitro_FW ._.
 Here_RB we_PRP demonstrate_VBP that_IN Bcl-3_NN can_MD aid_VB kappa_NN B_NN site-dependent_JJ transcription_NN in_FW vivo_FW by_IN counteracting_VBG the_DT inhibitory_JJ effects_NNS of_IN p50/NF-kappa_NN B_NN homodimers_NNS ._.
 Bcl-3_NN may_MD therefore_RB aid_VB activation_NN of_IN select_JJ NF-kappa_NN B-regulated_JJ genes_NNS ,_, including_VBG those_DT of_IN the_DT human_JJ immunodeficiency_NN virus_NN ._.
 A_DT microtitre_NN assay_NN system_NN for_IN glucocorticoid_NN receptors_NNS :_: decreased_VBN receptor_NN concentration_NN in_IN myocardial_JJ infarction_NN ._.
 A_DT major_JJ difficulty_NN in_IN determination_NN of_IN glucocorticoid_NN receptor_NN sites_NNS is_VBZ the_DT very_RB complicated_JJ assay_NN procedure_NN ._.
 Therefore_RB ,_, we_PRP describe_VBP a_DT microtitre_NN assay_NN system_NN for_IN glucocorticoid_NN receptors_NNS which_WDT is_VBZ a_DT whole-cell_JJ competitive_JJ binding_NN radioassay_NN using_VBG (3H)-dexamethasone_NN as_IN radioligand_NN ._.
 This_DT modification_NN of_IN a_DT previously_RB described_VBN protocol_NN simplifies_VBZ and_CC reduces_VBZ laboratory_NN work_NN and_CC allows_VBZ assay_NN reproducibility_NN to_TO be_VB controlled_VBN more_RBR reliably_RB ._.
 Thus_RB enabled_VBN to_TO perform_VB the_DT test_NN on_IN multiple_JJ blood_NN samples_NNS in_IN parallel_NN ,_, we_PRP investigated_VBD cardiac_JJ infarction_NN patients_NNS over_IN a_DT 12-day_JJ period_NN to_TO test_VB if_IN glucocorticoid_NN receptor_NN binding_NN is_VBZ altered_VBN in_IN this_DT '_[[DQS]] stressful_JJ '_[[DQE]] disease_NN ._.
 On_IN the_DT first_JJ day_NN of_IN the_DT disease_NN ,_, glucocorticoid_NN receptor_NN capacity_NN was_VBD significantly_RB decreased_VBN without_IN alteration_NN of_IN the_DT receptor-ligand_JJ affinity_NN ,_, whereas_IN on_IN days_NNS 4_CD and_CC 12_CD the_DT number_NN of_IN receptor_NN sites_NNS was_VBD normal_JJ again_RB ._.
 This_DT result_NN fits_VBZ well_RB into_IN the_DT general_JJ observation_NN of_IN stress-induced_JJ down-regulation_NN of_IN immune_JJ responses_NNS ._.
 Regulation_NN of_IN c-jun_NN expression_NN during_IN induction_NN of_IN monocytic_JJ differentiation_NN by_IN okadaic_JJ acid_NN ._.
 The_DT present_JJ work_NN has_VBZ examined_VBN the_DT effects_NNS of_IN okadaic_JJ acid_NN ,_, an_DT inhibitor_NN of_IN type_NN 1_CD and_CC 2A_NN protein_NN phosphatases_NNS ,_, on_IN the_DT regulation_NN of_IN c-jun_NN expression_NN during_IN monocytic_JJ differentiation_NN of_IN U-937_NN leukemia_NN cells_NNS ._.
 The_DT results_NNS demonstrate_VBP that_IN okadaic_JJ acid_NN treatment_NN is_VBZ associated_VBN with_IN induction_NN of_IN a_DT differentiated_VBN monocyte_NN phenotype_NN characterized_VBN by_IN :_: (_( a_LS )_) growth_NN arrest_NN ;_: (_( b_LS )_) increases_NNS in_IN Mac-1_NN cell_NN surface_NN antigen_NN expression_NN ;_: (_( c_LS )_) down-regulation_NN of_IN c-myc_NN transcripts_NNS ;_: and_CC (_( d_LS )_) induction_NN of_IN tumor_NN necrosis_NN factor_NN gene_NN expression_NN ._.
 This_DT induction_NN of_IN monocytic_JJ differentiation_NN was_VBD associated_VBN with_IN transient_JJ increases_NNS in_IN c-jun_NN mRNA_NN levels_NNS ,_, which_WDT were_VBD maximal_JJ at_IN 6_CD h_NN ._.
 Similar_JJ effects_NNS were_VBD obtained_VBN for_IN the_DT c-fos_NN gene_NN ._.
 Run-on_JJ analysis_NN demonstrated_VBD detectable_JJ levels_NNS of_IN c-jun_NN transcription_NN in_IN U-937_NN cells_NNS and_CC that_IN this_DT rate_NN is_VBZ increased_VBN approximately_RB 40-fold_RB following_VBG okadaic_JJ acid_NN exposure_NN ._.
 c-jun_NN mRNA_NN levels_NNS were_VBD superinduced_VBN in_IN cells_NNS treated_VBN with_IN both_CC okadaic_JJ acid_NN and_CC cycloheximide_NN ,_, whereas_IN inhibition_NN of_IN protein_NN synthesis_NN had_VBD little_JJ ,_, if_IN any_DT ,_, effect_NN on_IN okadaic_JJ acid-induced_JJ c-jun_NN transcription_NN ._.
 The_DT half-life_NN of_IN c-jun_NN mRNA_NN was_VBD similar_JJ (_( 45-50_CD min_NN )_) in_IN both_CC untreated_JJ and_CC okadaic_JJ acid-induced_JJ cells_NNS ._.
 In_IN contrast_NN ,_, treatment_NN with_IN both_DT okadaic_JJ acid_NN and_CC cycloheximide_NN was_VBD associated_VBN with_IN stabilization_NN (_( t_NN 1/2_CD =_JJ 90_CD min_NN )_) of_IN c-jun_NN transcripts_NNS ._.
 Taken_VBN together_RB ,_, these_DT findings_NNS indicate_VBP that_IN the_DT induction_NN of_IN c-jun_NN transcription_NN by_IN okadaic_JJ acid_NN is_VBZ controlled_VBN primarily_RB by_IN a_DT transcriptional_JJ mechanism_NN ._.
 Since_IN previous_JJ studies_NNS have_VBP demonstrated_VBN that_IN the_DT c-jun_NN gene_NN is_VBZ autoinduced_VBN by_IN Jun/AP-1_NN ,_, we_PRP also_RB studied_VBD transcription_NN of_IN c-jun_NN promoter_NN (_( positions_NNS -132/+170_CD )_) -reporter_JJ gene_NN constructs_NNS with_IN and_CC without_IN a_DT mutated_VBN AP-1_NN element_NN ._.
 (_( ABSTRACT_NN TRUNCATED_VBN AT_IN 250_CD WORDS_NNS )_)
 Activation_NN of_IN NF-kappa_NN B_NN by_IN interleukin_NN 2_CD in_IN human_JJ blood_NN monocytes_NNS ._.
 We_PRP report_VBP here_RB that_IN interleukin_NN 2_CD (_( IL-2_NN )_) acts_VBZ on_IN human_JJ blood_NN monocytes_NNS by_IN enhancing_VBG binding_NN activity_NN of_IN the_DT transcription_NN factor_NN NF-kappa_NN B_NN to_TO its_PRP$ consensus_NN sequence_NN in_IN the_DT 5'_JJ regulatory_JJ enhancer_NN region_NN of_IN the_DT IL-2_NN receptor_NN alpha_NN chain_NN (_( p55_NN )_) ._.
 Similarly_RB ,_, IL-2_NN activates_VBZ NF-kappa_NN B_NN in_IN the_DT human_JJ monocytic_JJ cell_NN line_NN U_NN 937_CD ,_, but_CC not_RB in_IN resting_VBG human_JJ T-cells_NNS ._.
 This_DT effect_NN is_VBZ detectable_JJ within_IN 15_CD min_NN and_CC peaks_VBZ 1_CD h_NN after_IN exposure_NN to_TO IL-2_NN ._.
 Enhanced_VBN NF-kappa_NN B_NN binding_NN activity_NN is_VBZ followed_VBN by_IN functional_JJ activation_NN in_IN that_IN inducibility_NN of_IN the_DT IL-2_NN receptor_NN alpha_NN chain_NN is_VBZ mediated_VBN by_IN enhanced_VBN NF-kappa_NN B_NN binding_NN and_CC that_IN a_DT heterologous_JJ promoter_NN containing_VBG the_DT NF-kappa_NN B_NN consensus_NN sequence_NN (_( -291_CD to_TO -245_CD )_) of_IN the_DT IL-2_NN receptor_NN alpha_NN chain_NN gene_NN is_VBZ activated_VBN ._.
 In_IN addition_NN ,_, IL-2_NN is_VBZ capable_JJ of_IN increasing_VBG transcript_NN levels_NNS of_IN the_DT p50_NN gene_NN coding_VBG for_IN the_DT p50_NN subunit_NN of_IN the_DT NF-kappa_NN B_NN transcription_NN factor_NN ,_, whereas_IN mRNA_NN levels_NNS of_IN the_DT p65_NN NF-kappa_NN B_NN gene_NN remained_VBD unchanged_JJ ._.
 Single_JJ point_NN estimation_NN of_IN glucocorticoid_NN receptors_NNS in_IN lymphocytes_NNS of_IN normal_JJ subjects_NNS and_CC of_IN children_NNS under_IN long_JJ term_NN glucocorticoid_NN treatment_NN ._.
 A_DT single_JJ point_NN assay_NN of_IN glucocorticoid_NN receptors_NNS (_( GR_NN )_) in_IN human_JJ lymphocytes_NNS based_VBN on_IN the_DT measurement_NN of_IN specific_JJ dexamethasone_NN binding_NN has_VBZ been_VBN developed_VBN and_CC compared_VBN with_IN a_DT common_JJ multi-point_JJ Scatchard_NN analysis_NN ._.
 The_DT assay_NN conditions_NN -_: concentration_NN of_IN the_DT ligand_NN 20_CD nmol/l_NN ,_, incubation_NN time_NN 2_CD h_NN and_CC the_DT cell_NN count_NN 2-6_CD mil._CD cells/tube_NNS in_IN the_DT assay_NN volume_NN 0.25_CD ml_NN were_VBD found_VBN to_TO be_VB optimal_JJ ._.
 An_DT attempt_NN was_VBD also_RB undertaken_VBN to_TO use_VB a_DT cell_NN harvester_NN for_IN the_DT separation_NN of_IN cells_NNS from_IN unbound_JJ ligand_NN ._.
 Though_IN specifically_RB bound_VBN dexamethasone_NN measured_VBN by_IN whole-cell_JJ assay_NN and_CC that_DT using_VBG cell_NN harvester_NN correlated_VBD well_RB ,_, almost_RB by_IN one_CD order_NN lower_JJR values_NNS obtained_VBN with_IN the_DT latter_JJ method_NN render_VBP it_PRP non-applicable_JJ for_IN receptor_NN quantitation_NN ._.
 The_DT results_NNS from_IN 9_CD healthy_JJ volunteers_NNS (_( average_JJ GR_NN concentration_NN 7131_CD +/-_CC 1256_CD sites/cell_NNS )_) correlated_VBD excellently_RB with_IN those_DT obtained_VBN by_IN the_DT Scatchard_NN analysis_NN ._.
 The_DT single_JJ point_NN assay_NN has_VBZ been_VBN also_RB applied_VBN for_IN determination_NN of_IN GH_NN in_IN 10_CD children_NNS treated_VBN with_IN large_JJ doses_NNS of_IN prednisone_NN ._.
 The_DT average_JJ values_NNS from_IN healthy_JJ volunteers_NNS did_VBD not_RB differ_VB significantly_RB from_IN those_DT found_VBN in_IN these_DT children_NNS ,_, though_RB much_RB broader_JJR range_NN was_VBD found_VBN in_IN patients_NNS ._.
 A_DT novel_JJ B_NN cell-derived_JJ coactivator_NN potentiates_VBZ the_DT activation_NN of_IN immunoglobulin_NN promoters_NNS by_IN octamer-binding_JJ transcription_NN factors_NNS ._.
 A_DT novel_JJ B_NN cell-restricted_JJ activity_NN ,_, required_VBN for_IN high_JJ levels_NNS of_IN octamer/Oct-dependent_JJ transcription_NN from_IN an_DT immunoglobulin_NN heavy_JJ chain_NN (_( IgH_NN )_) promoter_NN ,_, was_VBD detected_VBN in_IN an_DT in_FW vitro_FW system_NN consisting_VBG of_IN HeLa_NN cell-derived_JJ extracts_NNS complemented_VBN with_IN fractionated_VBN B_NN cell_NN nuclear_JJ proteins_NNS ._.
 The_DT factor_NN responsible_JJ for_IN this_DT activity_NN was_VBD designated_VBN Oct_NN coactivator_NN from_IN B_NN cells_NNS (_( OCA-B_NN )_) ._.
 OCA-B_NN stimulates_VBZ the_DT transcription_NN from_IN an_DT IgH_NN promoter_NN in_IN conjunction_NN with_IN either_CC Oct-1_NN or_CC Oct-2_NN but_CC shows_VBZ no_DT significant_JJ effect_NN on_IN the_DT octamer/Oct-dependent_JJ transcription_NN of_IN the_DT ubiquitously_RB expressed_VBN histone_NN H2B_NN promoter_NN and_CC the_DT transcription_NN of_IN USF-_NN and_CC Sp1-regulated_JJ promoters_NNS ._.
 Taken_VBN together_RB ,_, our_PRP$ results_NNS suggest_VBP that_IN OCA-B_NN is_VBZ a_DT tissue-_NN ,_, promoter-_NN ,_, and_CC factor-specific_JJ coactivator_NN and_CC that_IN OCA-B_NN may_MD be_VB a_DT major_JJ determinant_NN for_IN B_NN cell-specific_JJ activation_NN of_IN immunoglobulin_NN promoters_NNS ._.
 In_IN light_NN of_IN the_DT evidence_NN showing_VBG physical_JJ and_CC functional_JJ interactions_NNS between_IN Oct_NN factors_NNS and_CC OCA-B_NN ,_, we_PRP propose_VBP a_DT mechanism_NN of_IN action_NN for_IN OCA-B_NN and_CC discuss_VBP the_DT implications_NNS of_IN OCA-B_NN for_IN the_DT transcriptional_JJ regulation_NN of_IN other_JJ tissue-specific_JJ promoters_NNS ._.
 The_DT regulation_NN of_IN the_DT human_JJ tumor_NN necrosis_NN factor_NN alpha_NN promoter_NN region_NN in_IN macrophage_NN ,_, T_NN cell_NN ,_, and_CC B_NN cell_NN lines_NNS ._.
 The_DT 1311-base_JJ pair_NN human_JJ tumor_NN necrosis_NN factor_NN (_( TNF_NN )_) alpha_NN promoter_NN region_NN was_VBD fused_VBN to_TO the_DT luciferase_NN (_( Luc_NN )_) reporter_NN gene_NN and_CC studied_VBN in_IN a_DT transient_JJ transfection_NN system_NN in_IN three_CD TNF_NN producing_NN cell_NN lines_NNS ,_, the_DT U937_NN macrophage_NN cell_NN line_NN ,_, the_DT MLA_NN 144_CD T_NN cell_NN line_NN ,_, and_CC the_DT 729-6_CD B_NN cell_NN line_NN ._.
 This_DT full_JJ length_NN promoter_NN construct_NN can_MD be_VB induced_VBN by_IN phorbol_NN 13-myristate_NN acetate_NN (_( PMA_NN )_) in_IN each_DT of_IN these_DT cell_NN types_NNS ._.
 Analysis_NN of_IN a_DT series_NN of_IN 5'-truncations_NNS showed_VBD several_JJ peaks_NNS of_IN basal_JJ and_CC PMA_NN induced_JJ activity_NN suggesting_VBG the_DT presence_NN of_IN several_JJ positive_JJ and_CC negative_JJ regulatory_JJ elements_NNS ._.
 A_DT PMA_NN responsive_JJ element_NN was_VBD localized_JJ to_TO a_DT region_NN between_IN -95_CD and_CC -36_CD bp_NN relative_JJ to_TO the_DT transcription_NN start_NN site_NN ._.
 Within_IN this_DT region_NN ,_, single_JJ AP-2-_NN and_CC AP-1-like_JJ consensus_NN sequences_NNS were_VBD noted_VBN ._.
 These_DT AP-2_NN and_CC AP-1_NN sites_NNS were_VBD each_DT modified_VBN with_IN a_DT double_JJ point_NN mutation_NN ._.
 A_DT modest_JJ (_( 20-50_CD %_NN )_) reduction_NN in_IN TNF_NN promoter_NN activity_NN was_VBD observed_VBN with_IN the_DT AP-2_NN site_NN mutation_NN ._.
 However_RB ,_, mutation_NN of_IN the_DT AP-1_NN site_NN markedly_RB diminished_VBD both_CC the_DT basal_JJ and_CC PMA-activated_JJ promoter_NN activity_NN ._.
 Also_RB co-transfections_NNS of_IN the_DT wild-type_JJ promoter_NN construct_NN with_IN an_DT AP-1/c-jun_NN expression_NN vector_NN resulted_VBD in_IN augmented_JJ basal_JJ and_CC PMA-induced_JJ promoter_NN activity_NN ._.
 Redox_NN status_NN of_IN cells_NNS influences_VBZ constitutive_JJ or_CC induced_VBN NF-kappa_NN B_NN translocation_NN and_CC HIV_NN long_JJ terminal_JJ repeat_NN activity_NN in_IN human_JJ T_NN and_CC monocytic_JJ cell_NN lines_NNS ._.
 We_PRP have_VBP tested_VBN the_DT hypothesis_NN that_IN cellular_JJ activation_NN events_NNS occurring_VBG in_IN T_NN lymphocytes_NNS and_CC monocytes_NNS and_CC mediated_VBN through_IN translocation_NN of_IN the_DT transcription_NN factor_NN NF-kappa_NN B_NN are_VBP dependent_JJ upon_IN the_DT constitutive_JJ redox_NN status_NN of_IN these_DT cells_NNS ._.
 We_PRP used_VBD phenolic_JJ ,_, lipid-soluble_JJ ,_, chain-breaking_JJ antioxidants_NNS (_( butylated_VBN hydroxyanisole_NN (_( BHA_NN )_) ,_, nordihydroquairetic_JJ acid_NN ,_, or_CC alpha-tocopherol_NN (_( vitamin_NN E_NN )_) to_TO show_VB that_IN peroxyl_JJ radical_JJ scavenging_NN in_IN unstimulated_JJ and_CC PMA-_NN or_CC TNF-stimulated_JJ cells_NNS blocks_VBZ the_DT functions_NNS depending_VBG on_IN NF-kappa_NN B_NN activation_NN ._.
 BHA_NN was_VBD found_VBN to_TO suppress_VB not_RB only_RB PMA-_NN or_CC TNF-induced_JJ ,_, but_CC also_RB constitutive_JJ ,_, HIV-enhancer_JJ activity_NN concomitant_JJ to_TO an_DT inhibition_NN of_IN NF-kappa_NN B_NN binding_NN activity_NN in_IN both_CC lymphoblastoid_JJ T_NN (_( J.Jhan_NN )_) and_CC monocytic_JJ (_( U937_NN )_) cell_NN lines_NNS ._.
 This_DT was_VBD also_RB true_JJ for_IN KBF_NN (_( p50_NN homodimer_NN )_) binding_NN activity_NN in_IN U937_NN cells_NNS ._.
 Secretion_NN of_IN TNF_NN ,_, the_DT product_NN of_IN another_DT NF-kappa_NN B-dependent_JJ gene_NN ,_, was_VBD abolished_VBN by_IN BHA_NN in_IN PMA-stimulated_JJ U937_NN cells_NNS ._.
 The_DT anti-oxidative_JJ effect_NN of_IN BHA_NN was_VBD accompanied_VBN by_IN an_DT increase_NN in_IN thiol_NN ,_, but_CC not_RB glutathione_NN ,_, content_NN in_IN stimulated_VBN and_CC unstimulated_JJ T_NN cell_NN ,_, whereas_IN TNF_NN stimulation_NN itself_PRP barely_RB modified_VBD the_DT cellular_JJ thiol_NN level_NN ._.
 Oxidative_JJ stress_NN obtained_VBN by_IN the_DT addition_NN of_IN H2O2_NN to_TO the_DT culture_NN medium_NN of_IN J.Jhan_NN or_CC U937_NN cells_NNS could_MD not_RB by_IN itself_PRP induce_VB NF-kappa_NN B_NN activation_NN ._.
 These_DT observations_NNS suggest_VBP that_IN TNF_NN and_CC PMA_NN do_VBP not_RB lead_VB to_TO NF-kappa_NN B_NN activation_NN through_IN induction_NN of_IN changes_NNS in_IN the_DT cell_NN redox_NN status_NN ._.
 Rather_RB ,_, TNF_NN and_CC PMA_NN can_MD exert_VB their_PRP$ effect_NN only_RB if_IN cells_NNS are_VBP in_IN an_DT appropriate_JJ redox_NN status_NN ,_, because_IN prior_JJ modification_NN toward_IN reduction_NN with_IN BHA_NN treatment_NN prevents_VBZ this_DT activation_NN ._.
 It_PRP appears_VBZ that_IN a_DT basal_JJ redox_NN equilibrium_NN tending_VBG toward_IN oxidation_NN is_VBZ a_DT prerequisite_NN for_IN full_JJ activation_NN of_IN transduction_NN pathways_NNS regulating_VBG the_DT activity_NN of_IN NF-kappa_NN B-dependent_JJ genes_NNS ._.
 Expression_NN of_IN c-fos_NN ,_, c-jun_NN and_CC jun_NN B_NN in_IN peripheral_JJ blood_NN lymphocytes_NNS from_IN young_JJ and_CC elderly_JJ adults_NNS ._.
 The_DT expression_NN of_IN c-fos_NN ,_, c-jun_NN and_CC jun_NN B_NN proto-oncogenes_NNS was_VBD studied_VBN in_IN phytohemagglutinin_NN (_( PHA_NN )_) activated_VBN peripheral_JJ blood_NN lymphocytes_NNS (_( PBL_NN )_) from_IN young_JJ and_CC aged_JJ humans_NNS ._.
 Specific_JJ mRNAs_NNS for_IN c-fos_NN and_CC c-jun_NN were_VBD detectable_JJ within_IN 30_CD min_NN after_IN cell_NN activation_NN and_CC reached_VBD maximal_JJ levels_NNS within_IN 2_CD h_NN ._.
 Both_CC c-fos_NN and_CC jun_NN B_NN mRNAs_NNS decreased_VBD to_TO pre-activation_NN levels_NNS within_IN 6_CD h_NN ,_, while_IN c-jun_NN mRNA_NN remained_VBD elevated_JJ ._.
 In_IN PHA-activated_JJ PBL_NN ,_, no_DT age-related_JJ differences_NNS were_VBD observed_VBN in_IN c-fos_NN or_CC jun_NN B_NN mRNA_NN expression_NN ._.
 However_RB ,_, c-jun_NN mRNA_NN levels_NNS decreased_VBD significantly_RB (_( 1.73_CD +/-_CC 0.08_CD vs._CC 1.16_CD +/-_CC 0.09_CD arbitrary_JJ units_NNS ,_, P_NN &lt[[SEMICOLON]]_JJR 0.01_CD ,_, young_JJ vs._CC old_JJ )_) in_IN PBL_NN from_IN elderly_JJ individuals_NNS activated_VBN with_IN PHA_NN ._.
 Because_IN previous_JJ work_NN has_VBZ demonstrated_VBN that_IN T_NN cells_NNS from_IN elderly_JJ individuals_NNS may_MD display_VB normal_JJ proliferative_JJ responses_NNS when_WRB activated_VBN via_IN the_DT anti-CD2_JJ pathway_NN ,_, c-jun_NN and_CC jun_NN B_NN mRNA_NN expression_NN was_VBD also_RB studied_VBN in_IN anti-CD2-activated_JJ purified_VBN T_NN cells_NNS ._.
 No_DT age-related_JJ differences_NNS were_VBD found_VBN in_IN the_DT expression_NN of_IN either_DT of_IN these_DT two_CD proto-oncogenes_NNS by_IN anti-CD2_NN activated_JJ T_NN cells_NNS ._.
 These_DT results_NNS suggest_VBP that_IN the_DT decreased_VBN IL-2_NN production_NN and_CC proliferative_JJ response_NN displayed_VBN by_IN PHA-activated_JJ PBL_NN from_IN elderly_JJ adults_NNS may_MD be_VB related_JJ to_TO age-related_JJ changes_NNS in_IN c-jun_NN mRNA_NN expression_NN and_CC in_IN the_DT ratio_NN of_IN c-fos_NN to_TO c-jun_NN mRNA_NN ._.
 Characterization_NN of_IN a_DT novel_JJ T_NN lymphocyte_NN protein_NN which_WDT binds_VBZ to_TO a_DT site_NN related_JJ to_TO steroid/thyroid_JJ hormone_NN receptor_NN response_NN elements_NNS in_IN the_DT negative_JJ regulatory_JJ sequence_NN of_IN the_DT human_JJ immunodeficiency_NN virus_NN long_JJ terminal_JJ repeat_NN ._.
 We_PRP have_VBP previously_RB identified_VBN a_DT T_NN lymphocyte_NN protein_NN which_WDT binds_VBZ to_TO a_DT site_NN within_IN the_DT LTR_NN of_IN the_DT human_JJ immunodeficiency_NN virus_NN type_NN 1_CD (_( HIV-1_NN )_) and_CC exerts_VBZ an_DT inhibitory_JJ effect_NN on_IN virus_NN gene_NN expression_NN ._.
 The_DT palindromic_JJ site_NN (_( site_NN B_NN )_) recognized_VBN by_IN this_DT protein_NN is_VBZ related_JJ to_TO the_DT palindromic_JJ binding_VBG sites_NNS of_IN members_NNS of_IN the_DT steroid/thyroid_JJ hormone_NN receptor_NN family_NN ._.
 Here_RB we_PRP characterize_VBP the_DT T_NN cell_NN protein_NN binding_VBG to_TO this_DT site_NN as_IN a_DT 100_CD kD_NN protein_NN which_WDT is_VBZ most_RBS abundant_JJ in_IN T_NN cells_NNS and_CC which_WDT binds_VBZ to_TO site_NN B_NN as_IN a_DT 200_CD kD_NN complex_NN ._.
 This_DT protein_NN is_VBZ distinct_JJ from_IN other_JJ members_NNS of_IN the_DT steroid/thyroid_JJ hormone_NN receptor_NN family_NN including_VBG the_DT COUP_NN protein_NN which_WDT has_VBZ a_DT closely_RB related_JJ DNA_NN binding_NN specificity_NN ._.
 A_DT mechanism_NN for_IN the_DT antiinflammatory_JJ effects_NNS of_IN corticosteroids_NNS :_: the_DT glucocorticoid_NN receptor_NN regulates_VBZ leukocyte_NN adhesion_NN to_TO endothelial_JJ cells_NNS and_CC expression_NN of_IN endothelial-leukocyte_JJ adhesion_NN molecule_NN 1_CD and_CC intercellular_JJ adhesion_NN molecule_NN 1_CD ._.
 Corticosteroids_NNS are_VBP the_DT preeminent_JJ antiinflammatory_JJ agents_NNS although_IN the_DT molecular_JJ mechanisms_NNS that_WDT impart_VBP their_PRP$ efficacy_NN have_VBP not_RB been_VBN defined_VBN ._.
 The_DT endothelium_NN plays_VBZ a_DT critical_JJ role_NN in_IN inflammation_NN by_IN directing_VBG circulating_VBG leukocytes_NNS into_IN extravascular_JJ tissues_NNS by_IN expressing_VBG adhesive_JJ molecules_NNS for_IN leukocytes_NNS (_( e.g._FW ,_, endothelial-leukocyte_JJ adhesion_NN molecule_NN 1_CD (_( ELAM-1_NN )_) and_CC intercellular_JJ adhesion_NN molecule_NN 1_CD (_( ICAM-1_NN )_) ._.
 We_PRP therefore_RB determined_VBD whether_IN corticosteroids_NNS suppress_VBP inflammation_NN by_IN inhibiting_VBG endothelial_JJ expression_NN of_IN adhesion_NN molecules_NNS for_IN neutrophils_NNS (_( polymorphonuclear_JJ leukocytes_NNS )_) ._.
 Preincubation_NN of_IN endothelial_JJ cells_NNS with_IN endotoxin_NN (_( lipopolysaccharide_NN (_( LPS_NN )_) ,_, 1_CD microgram/ml_NN )_) led_VBD to_TO a_DT 4-fold_JJ increase_NN in_IN subsequent_JJ adherence_NN of_IN polymorphonuclear_JJ leukocytes_NNS (_( P_NN <_JJR 0.0001_CD ,_, n_NN =_JJ 10_CD )_) to_TO endothelial_JJ cells_NNS ,_, an_DT increase_NN that_WDT was_VBD markedly_RB attenuated_VBN when_WRB endothelial_JJ cells_NNS were_VBD treated_VBN with_IN dexamethasone_NN (_( IC50_NN <_JJR 1_CD nM_NN ,_, P_NN <_JJR 0.0001_CD ,_, n_NN =_JJ 6_CD or_CC 7_CD )_) during_IN preincubation_NN with_IN LPS_NN ._.
 Moreover_RB ,_, the_DT steroid_NN receptor_NN agonist_NN cortisol_NN (_( 10_CD microM_NN )_) ,_, but_CC not_RB its_PRP$ inactive_JJ metabolite_NN tetrahydrocortisol_NN (_( 10_CD microM_NN )_) ,_, diminished_VBD LPS-induced_JJ endothelial_JJ cell_NN adhesiveness_NN ._.
 Further_JJ evidence_NN that_IN the_DT action_NN of_IN dexamethasone_NN was_VBD mediated_VBN through_IN ligation_NN of_IN corticosteroid_NN receptors_NNS (_( human_JJ glucocorticoid_NN receptors_NNS (_( hGRs_NNS )_) )_) was_VBD provided_VBN by_IN experiments_NNS utilizing_VBG the_DT steroid_NN antagonist_NN RU-486_NN ._.
 RU-486_NN (_( 10_CD microM_NN )_) ,_, which_WDT prevents_VBZ translocation_NN of_IN ligated_VBN hGR_NN to_TO the_DT nucleus_NN by_IN inhibiting_VBG dissociation_NN of_IN hGR_NN from_IN heat_NN shock_NN protein_NN 90_CD ,_, completely_RB aborted_VBD the_DT effect_NN of_IN dexamethasone_NN on_IN adhesiveness_NN of_IN endothelial_JJ cells_NNS (_( P_NN <_JJR 0.0005_CD ,_, n_NN =_JJ 3_CD )_) ._.
 Treatment_NN of_IN endothelial_JJ cells_NNS with_IN LPS_NN (_( 1_CD microgram/ml_NN )_) stimulated_VBD transcription_NN of_IN ELAM-1_NN ,_, as_IN shown_VBN by_IN Northern_NN blot_NN analysis_NN ,_, and_CC expression_NN of_IN membrane-associated_JJ ELAM-1_NN and_CC ICAM-1_NN ,_, as_IN shown_VBN by_IN quantitative_JJ immunofluorescence_NN (_( both_DT P_NN <_JJR 0.001_CD ,_, n_NN =_JJ 9_CD )_) ._.
 Dexamethasone_NN markedly_RB inhibited_VBD LPS-stimulated_JJ accumulation_NN of_IN mRNA_NN for_IN ELAM-1_NN and_CC expression_NN of_IN ELAM-1_NN and_CC ICAM-1_NN (_( IC50_NN <_JJR 10_CD nM_NN ,_, both_DT P_NN <_JJR 0.001_CD ,_, n_NN =_JJ 4-9_CD )_) ;_: inhibition_NN of_IN expression_NN by_IN dexamethasone_NN was_VBD reversed_VBN by_IN RU-486_NN (_( both_DT P_NN <_JJR 0.005_CD ,_, n_NN =_JJ 4-6_CD )_) ._.
 As_IN in_IN the_DT adhesion_NN studies_NNS ,_, cortisol_NN but_CC not_RB tetrahydrocortisol_NN inhibited_VBD expression_NN of_IN ELAM-1_NN and_CC ICAM-1_NN (_( both_DT P_NN <_JJR 0.005_CD ,_, n_NN =_JJ 3_CD or_CC 4_CD )_) ._.
 In_IN contrast_NN ,_, sodium_NN salicylate_NN (_( 1_CD mM_NN )_) inhibited_VBD neither_CC adhesion_NN nor_CC expression_NN of_IN these_DT adhesion_NN molecules_NNS ._.
 These_DT studies_NNS suggest_VBP that_IN antagonism_NN by_IN dexamethasone_NN of_IN endotoxin-induced_JJ inflammation_NN is_VBZ a_DT specific_JJ instance_NN of_IN the_DT general_JJ biological_JJ principle_NN that_IN the_DT glucocorticoid_NN receptor_NN is_VBZ a_DT hormone-dependent_JJ regulator_NN of_IN transcription_NN ._.
 Membrane_NN receptors_NNS for_IN aldosterone_NN :_: a_DT novel_JJ pathway_NN for_IN mineralocorticoid_NN action_NN ._.
 Rapid_JJ nongenomic_JJ in_FW vitro_FW effects_NNS of_IN aldosterone_NN on_IN intracellular_JJ electrolytes_NNS ,_, cell_NN volume_NN ,_, and_CC Na(+)-H+_JJ antiport_NN have_VBP been_VBN found_VBN in_IN human_JJ mononuclear_JJ leukocytes_NNS (_( HML_NN )_) ._.
 Binding_NN of_IN 125I-labeled_JJ aldosterone_NN to_TO plasma_NN membranes_NNS of_IN HML_NN shares_VBZ important_JJ features_NNS with_IN these_DT functional_JJ data_NNS ._.
 This_DT includes_VBZ a_DT very_RB low_JJ apparent_JJ dissociation_NN constant_NN (_( Kd_NN )_) of_IN 0.1_CD nM_NN for_IN both_CC aldosterone_NN and_CC the_DT effect_NN on_IN the_DT Na(+)-H(+)-antiport_NN ,_, a_DT high_JJ turnover_NN rate_NN ,_, and_CC the_DT almost_RB exclusive_JJ binding_NN selectivity_NN for_IN aldosterone_NN ._.
 Dexamethasone_NN ,_, RU_NN 26988_CD ,_, corticosterone_NN ,_, ouabain_NN ,_, amiloride_NN ,_, and_CC 18-hydroxyprogesterone_NN were_VBD inactive_JJ as_IN ligands_NNS ._.
 Deoxycorticosterone_NN acetate_NN had_VBD an_DT intermediate_JJ activity_NN with_IN an_DT apparent_JJ Kd_NN of_IN 100_CD nM_NN ._.
 These_DT findings_NNS are_VBP the_DT first_JJ to_TO demonstrate_VB membrane_NN binding_NN of_IN aldosterone_NN being_VBG compatible_JJ with_IN major_JJ aspects_NNS of_IN its_PRP$ nongenomic_JJ effects_NNS ._.
 Reticuloendotheliosis_NN virus_NN long_JJ terminal_JJ repeat_NN elements_NNS are_VBP efficient_JJ promoters_NNS in_IN cells_NNS of_IN various_JJ species_NNS and_CC tissue_NN origin_NN ,_, including_VBG human_JJ lymphoid_JJ cells_NNS ._.
 Promiscuous_JJ transcriptional_JJ activity_NN of_IN the_DT reticuloendotheliosis_NN virus_NN (_( REV_NN )_) long_JJ terminal_JJ repeat_NN (_( LTR_NN )_) was_VBD detected_VBN in_IN transient_JJ expression_NN assays_NNS using_VBG LTR-chloramphenicol_NN acetyltransferase-encoding_JJ gene_NN chimeras_NNS ,_, and_CC cells_NNS of_IN diverse_JJ species_NNS and_CC tissue_NN type_NN ;_: levels_NNS of_IN expression_NN from_IN two_CD different_JJ REV_NN LTRs_NNS correlate_VBP with_IN reports_NNS of_IN pathogenicity_NN of_IN the_DT respective_JJ viruses_NNS in_FW vivo_FW ._.
 REVs_NNS do_VBP not_RB encode_VB a_DT transactivator_NN targeted_VBN to_TO the_DT viral_JJ LTR_NN ,_, and_CC cells_NNS infected_VBN with_IN Marek_NN 's_POS disease_NN virus_NN ,_, a_DT herpesvirus_NN with_IN an_DT overlapping_VBG host_NN range_NN ,_, do_VBP not_RB express_VB factors_NNS that_WDT preferentially_RB enhance_VBP expression_NN from_IN REV_NN or_CC avian_JJ sarcoma/leukemia_NN virus_NN LTRs_NNS ._.
 REV_NN LTRs_NNS work_VBP efficiently_RB in_IN human_JJ lymphoid_JJ cells_NNS ,_, and_CC are_VBP viable_JJ alternatives_NNS to_TO promoters_NNS commonly_RB used_VBN for_IN expression_NN of_IN cloned_VBN genes_NNS ._.
 They_PRP may_MD also_RB prove_VB useful_JJ in_IN the_DT identification_NN of_IN new_JJ ,_, ubiquitous_JJ cellular_JJ transcription_NN factors_NNS ._.
 Natural_JJ variants_NNS of_IN the_DT HIV-1_NN long_JJ terminal_JJ repeat_NN :_: analysis_NN of_IN promoters_NNS with_IN duplicated_JJ DNA_NN regulatory_JJ motifs_NNS ._.
 Sequence_NN variation_NN in_IN the_DT long_JJ terminal_JJ repeat_NN (_( LTR_NN )_) region_NN of_IN HIV-1_NN was_VBD analyzed_VBN in_IN viral_JJ isolates_NNS of_IN 17_CD infected_JJ individuals_NNS ._.
 Two_CD classes_NNS of_IN LTR_NN size_NN variants_NNS were_VBD found_VBN ._.
 One_CD HIV-1_NN variant_NN was_VBD detected_VBN containing_VBG an_DT additional_JJ binding_VBG site_NN for_IN the_DT transcription_NN factor_NN Sp1_NN ._.
 Another_DT LTR_NN size_NN variation_NN was_VBD observed_VBN in_IN four_CD patients_NNS in_IN a_DT region_NN just_RB upstream_JJ of_IN the_DT NF-kappa_NN B_NN enhancer_NN ._.
 This_DT variation_NN was_VBD the_DT result_NN of_IN a_DT duplication_NN of_IN a_DT short_JJ DNA_NN sequence_NN (_( CTG-motif_NN )_) ._.
 Cell_NN culture_NN experiments_NNS demonstrated_VBD that_IN the_DT natural_JJ variant_NN with_IN four_CD Sp1_NN sites_NNS had_VBD a_DT slightly_RB higher_JJR promoter_NN activity_NN and_CC viral_JJ replication_NN rate_NN than_IN the_DT isogenic_JJ control_NN LTR_NN with_IN three_CD Sp1_NN sites_NNS ._.
 No_DT positive_JJ effect_NN of_IN the_DT duplicated_JJ CTG-motif_NN could_MD be_VB detected_VBN ._.
 In_IN order_NN to_TO measure_VB small_JJ differences_NNS in_IN virus_NN production_NN more_RBR accurately_RB ,_, equal_JJ amounts_NNS of_IN a_DT size_NN variant_NN and_CC the_DT wild-type_JJ plasmid_NN were_VBD cotransfected_VBN into_IN T-cells_NNS ._.
 The_DT virus_NN with_IN four_CD Sp1_NN sites_NNS did_VBD outgrow_VB the_DT three_CD Sp1_NN virus_NN in_IN 35_CD days_NNS of_IN culture_NN and_CC CTG-monomer_NN virus_NN outcompeted_VBD the_DT CTG-dimer_NN virus_NN in_IN 42_CD days_NNS ._.
 Based_VBN on_IN these_DT results_NNS we_PRP estimate_VBP a_DT 5-10_CD %_NN difference_NN in_IN virus_NN production_NN of_IN the_DT LTR_NN variants_NNS when_WRB compared_VBN to_TO that_DT of_IN wild-type_NN ._.
 SCL_NN and_CC related_JJ hemopoietic_JJ helix-loop-helix_JJ transcription_NN factors_NNS ._.
 The_DT helix-loop-helix_JJ (_( HLH_JJ )_) proteins_NNS are_VBP a_DT family_NN of_IN transcription_NN factors_NNS that_WDT include_VBP proteins_NNS critical_JJ to_TO differentiation_NN and_CC development_NN in_IN species_NNS ranging_VBG from_IN plants_NNS to_TO mammals_NNS ._.
 Five_CD members_NNS of_IN this_DT family_NN (_( MYC_NN ,_, SCL_NN ,_, TAL-2_NN ,_, LYL-1_NN and_CC E2A_NN )_) are_VBP implicated_VBN in_IN oncogenic_JJ events_NNS in_IN human_JJ lymphoid_JJ tumors_NNS because_IN of_IN their_PRP$ consistent_JJ involvement_NN in_IN chromosomal_JJ translocations_NNS ._.
 Although_IN activated_VBN in_IN T_NN cell_NN leukemias_NNS ,_, expression_NN of_IN SCL_NN and_CC LYL-1_NN is_VBZ low_JJ or_CC undetectable_JJ in_IN normal_JJ T_NN cell_NN populations_NNS ._.
 SCL_NN is_VBZ expressed_VBN in_IN erythroid_JJ ,_, megakaryocyte_NN and_CC mast_NN cell_NN populations_NNS (_( the_DT same_JJ cell_NN lineages_NNS as_IN GATA-1_NN ,_, a_DT zinc-finger_NN transcription_NN factor_NN )_) ._.
 In_IN addition_NN ,_, both_CC SCL_NN and_CC GATA-1_NN undergo_VBP coordinate_JJ modulation_NN during_IN chemically_RB induced_VBN erythroid_JJ differentiation_NN of_IN mouse_NN erythroleukemia_NN cells_NNS and_CC are_VBP down-modulated_VBN during_IN myeloid_JJ differentiation_NN of_IN human_JJ K562_NN cells_NNS ,_, thus_RB implying_VBG a_DT role_NN for_IN SCL_NN in_IN erythroid_JJ differentiation_NN events_NNS ._.
 However_RB ,_, in_IN contrast_NN to_TO GATA-1_NN ,_, SCL_NN is_VBZ expressed_VBN in_IN the_DT developing_VBG brain_NN ._.
 Studies_NNS of_IN the_DT function_NN of_IN SCL_NN suggest_VBP it_PRP is_VBZ also_RB important_JJ in_IN proliferation_NN and_CC self-renewal_JJ events_NNS in_IN erythroid_JJ cells_NNS ._.
 Transcription_NN of_IN the_DT hypersensitive_JJ site_NN HS2_NN enhancer_NN in_IN erythroid_JJ cells_NNS ._.
 In_IN the_DT human_JJ genome_NN ,_, the_DT erythroid-specific_JJ hypersensitive_JJ site_NN HS2_NN enhancer_NN regulates_VBZ the_DT transcription_NN of_IN the_DT downstream_JJ beta-like_JJ globin_NN genes_NNS 10-50_CD kilobases_NNS away_RB ._.
 The_DT mechanism_NN of_IN HS2_NN enhancer_NN function_NN is_VBZ not_RB known_VBN ._.
 The_DT present_JJ study_NN employs_VBZ RNA_NN protection_NN assays_NNS to_TO analyze_VB the_DT transcriptional_JJ status_NN of_IN the_DT HS2_NN enhancer_NN in_IN transfected_VBN recombinant_JJ chloramphenicol_NN acetyltransferase_NN (_( CAT_NN )_) plasmids_NNS ._.
 In_IN erythroid_JJ K562_NN cells_NNS in_IN which_WDT the_DT HS2_NN enhancer_NN is_VBZ active_JJ ,_, the_DT HS2_NN sequence_NN directs_VBZ the_DT synthesis_NN of_IN long_JJ enhancer_NN transcripts_NNS that_WDT are_VBP initiated_VBN apparently_RB from_IN within_IN the_DT enhancer_NN and_CC elongated_VBN through_IN the_DT intervening_VBG DNA_NN into_IN the_DT cis-linked_JJ CAT_NN gene_NN ._.
 In_IN nonerythroid_JJ HL-60_NN cells_NNS in_IN which_WDT the_DT HS2_NN enhancer_NN is_VBZ inactive_JJ ,_, long_JJ enhancer_NN transcripts_NNS are_VBP not_RB detectable_JJ ._.
 Splitting_VBG the_DT HS2_NN enhancer_NN between_IN two_CD tandem_JJ Ap1_NN sites_NNS abolishes_VBZ the_DT synthesis_NN of_IN a_DT group_NN of_IN long_JJ enhancer_NN transcripts_NNS and_CC results_VBZ in_IN loss_NN of_IN enhancer_NN function_NN and_CC transcriptional_JJ silencing_NN of_IN the_DT cis-linked_JJ CAT_NN gene_NN ._.
 In_IN directing_VBG the_DT synthesis_NN of_IN RNA_NN through_IN the_DT intervening_VBG DNA_NN and_CC the_DT gene_NN by_IN a_DT tracking_NN and_CC transcription_NN mechanism_NN ,_, the_DT HS2_NN enhancer_NN may_MD (_( i_LS )_) open_VB up_RP the_DT chromatin_NN structure_NN of_IN a_DT gene_NN domain_NN and_CC (_( ii_LS )_) deliver_VB enhancer_NN binding_NN proteins_NNS to_TO the_DT promoter_NN sequence_NN where_WRB they_PRP may_MD stimulate_VB the_DT transcription_NN of_IN the_DT gene_NN at_IN
 Phorbol_NN ester_NN reduces_VBZ constitutive_JJ nuclear_JJ NF_NN kappa_NN B_NN and_CC inhibits_VBZ HIV-1_NN production_NN in_IN mature_JJ human_JJ monocytic_JJ cells_NNS ._.
 NF_NN kappa_NN B_NN is_VBZ a_DT potent_JJ mediator_NN of_IN specific_JJ gene_NN expression_NN in_IN human_JJ monocytes_NNS and_CC has_VBZ been_VBN shown_VBN to_TO play_VB a_DT role_NN in_IN transcription_NN of_IN the_DT HIV-1_NN genome_NN in_IN promonocytic_JJ leukemias_NNS ._.
 There_EX is_VBZ little_JJ information_NN available_JJ on_IN the_DT response_NN of_IN NF_NN kappa_NN B_NN to_TO cytokines_NNS in_IN normal_JJ human_JJ monocytes_NNS ._.
 We_PRP have_VBP used_VBN a_DT 32P-labeled_JJ oligonucleotide_NN derived_VBN from_IN human_JJ immunodeficiency_NN virus_NN (_( HIV-1_NN )_) long_JJ terminal_JJ repeat_NN ,_, which_WDT contains_VBZ a_DT tandem_JJ repeat_NN of_IN the_DT NF_NN kappa_NN B_NN binding_NN sequence_NN ,_, as_IN a_DT probe_NN in_IN a_DT gel_NN retardation_NN assay_NN to_TO study_VB this_DT transcription_NN factor_NN ._.
 Using_VBG this_DT assay_NN ,_, we_PRP have_VBP detected_VBN NF_NN kappa_NN B_NN in_IN extracts_NNS of_IN nuclei_NNS from_IN normal_JJ human_JJ monocytes_NNS ._.
 Treatment_NN of_IN normal_JJ monocytes_NNS with_IN 12-0-tetradecanoyl_JJ phorbol-13-acetate_NN (_( TPA_NN )_) for_IN 4-24_CD h_NN caused_VBD the_DT complete_JJ disappearance_NN of_IN NF_NN kappa_NN B_NN from_IN nuclear_JJ extracts_NNS of_IN monocytes_NNS ._.
 A_DT similar_JJ result_NN was_VBD obtained_VBN with_IN the_DT mature_JJ monocytic_JJ leukemia_NN cell_NN line_NN THP-1_NN ._.
 The_DT constitutive_JJ transcription_NN factor_NN SP1_NN was_VBD unaffected_JJ by_IN addition_NN of_IN TPA_NN ._.
 The_DT disappearance_NN of_IN NF_NN kappa_NN B_NN from_IN the_DT nucleus_NN was_VBD concentration_NN dependent_JJ between_IN 10_CD and_CC 50_CD ng/ml_NN of_IN phorbol_NN ester_NN ._.
 In_IN THP-1_NN cells_NNS ,_, TPA_NN also_RB induced_VBD a_DT new_JJ ,_, faster-migrating_JJ NF_NN kappa_NN B_NN species_NNS not_RB induced_VBN in_IN monocytes_NNS ._.
 Protein_NN kinase_NN C_NN inhibitor_NN staurosporine_NN ,_, but_CC not_RB cyclic_JJ nucleotide-dependent_JJ protein_NN kinase_NN inhibitor_NN HA-1004_NN ,_, also_RB dramatically_RB reduced_VBD constitutive_JJ levels_NNS of_IN nuclear_JJ NF_NN kappa_NN B_NN ._.
 Finally_RB ,_, TPA_NN addition_NN to_TO monocytes_NNS infected_VBN with_IN HIV-1_NN inhibited_VBD HIV-1_NN replication_NN ,_, as_IN determined_VBN by_IN reverse_JJ transcriptase_NN assays_NNS ,_, in_IN a_DT concentration-dependent_JJ manner_NN ._.
 These_DT results_NNS are_VBP in_IN striking_JJ contrast_NN to_TO the_DT increase_NN in_IN nuclear_JJ NF_NN kappa_NN B_NN and_CC HIV-1_NN replication_NN induced_VBN by_IN phorbol_NN esters_NNS in_IN promonocytic_JJ leukemia_NN cells_NNS U937_NN and_CC HL-60_NN ,_, and_CC emphasize_VBP the_DT importance_NN of_IN studying_VBG cytokine_NN regulation_NN of_IN HIV-1_NN in_IN normal_JJ monocytes_NNS ._.
 Ablation_NN of_IN transplanted_VBN HTLV-I_NN Tax-transformed_JJ tumors_NNS in_IN mice_NNS by_IN antisense_JJ inhibition_NN of_IN NF-kappa_NN B_NN (_( published_VBN erratum_NN appears_VBZ in_IN Science_NNP 1993_CD Mar_NNP 12_CD ;_: 259_CD (_( 5101_CD )_) :_: 1523_CD )_)
 Mice_NNS transgenic_JJ for_IN the_DT human_JJ T_NN cell_NN leukemia_NN virus_NN (_( HTLV-I_NN )_) Tax_NN gene_NN develop_VBP fibroblastic_JJ tumors_NNS that_WDT express_VBP NF-kappa_NN B-inducible_JJ early_JJ genes_NNS ._.
 In_FW vitro_FW inhibition_NN of_IN NF-kappa_NN B_NN expression_NN by_IN antisense_JJ oligodeoxynucleotides_NNS (_( ODNs_NNS )_) inhibited_VBD growth_NN of_IN these_DT culture-adapted_JJ Tax-transformed_JJ fibroblasts_NNS as_RB well_RB as_IN an_DT HTLV-I-transformed_JJ human_JJ lymphocyte_NN line_NN ._.
 In_IN contrast_NN ,_, antisense_JJ inhibition_NN of_IN Tax_NN itself_PRP had_VBD no_DT apparent_JJ effect_NN on_IN cell_NN growth_NN ._.
 Mice_NNS treated_VBN with_IN antisense_NN to_TO NF-kappa_NN B_NN ODNs_NNS showed_VBD rapid_JJ regression_NN of_IN transplanted_VBN fibrosarcomas_NNS ._.
 This_DT suggests_VBZ that_IN NF-kappa_NN B_NN expression_NN may_MD be_VB necessary_JJ for_IN the_DT maintenance_NN of_IN the_DT malignant_JJ phenotype_NN and_CC provides_VBZ a_DT therapeutic_JJ approach_NN for_IN HTLV-I-associated_JJ disease_NN ._.
 Inhibition_NN of_IN anti-CD3_JJ monoclonal_JJ antibody-induced_JJ T-cell_NN proliferation_NN by_IN dexamethasone_NN ,_, isoproterenol_NN ,_, or_CC prostaglandin_NN E2_NN either_CC alone_RB or_CC in_IN combination_NN ._.
 1_LS ._. The_DT purpose_NN of_IN these_DT studies_NNS was_VBD to_TO investigate_VB the_DT modulation_NN of_IN the_DT proliferation_NN of_IN human_JJ T_NN cells_NNS obtained_VBN from_IN peripheral_JJ blood_NN by_IN dexamethasone_NN (_( DEX_NN )_) ,_, isoproterenol_NN (_( ISO_NN )_) ,_, and_CC prostaglandin_NN E2_NN (_( PGE2_NN )_) ._.
 The_DT former_JJ two_CD substances_NNS interact_VBP with_IN T_NN cells_NNS via_IN the_DT glucocorticoid_NN and_CC beta-adrenergic_JJ receptors_NNS respectively_RB ._.
 When_WRB occupied_VBN by_IN their_PRP$ natural_JJ ligands_NNS ,_, glucocorticosteroids_NNS and_CC catecholamines_NNS ,_, these_DT receptors_NNS have_VBP a_DT role_NN in_IN modulating_VBG T-cell_NN function_NN during_IN stress_NN ._.
 During_IN the_DT inflammatory_JJ response_NN increased_VBN levels_NNS of_IN PGE2_NN bind_VBP to_TO their_PRP$ receptors_NNS on_IN T_NN cells_NNS and_CC thus_RB alter_VBP responsiveness_NN ._.
 Proliferation_NN of_IN T_NN cells_NNS was_VBD induced_VBN by_IN immobilized_VBN anti-CD3_JJ monoclonal_JJ antibody_NN (_( mAb_NN )_) in_IN the_DT presence_NN or_CC absence_NN of_IN an_DT additional_JJ costimulatory_JJ signal_NN delivered_VBN by_IN anti-CD28_JJ mAb_NN ._.
 2_LS ._. Various_JJ physiologic_JJ concentrations_NNS of_IN DEX_NN ,_, ISO_NN ,_, or_CC PGE2_NN were_VBD added_VBN at_IN the_DT time_NN of_IN initiation_NN of_IN the_DT cultures_NNS and_CC subsequent_JJ proliferation_NN of_IN the_DT unstimulated_JJ T_NN cells_NNS was_VBD determined_VBN ._.
 The_DT results_NNS demonstrate_VBP that_IN physiologic_JJ concentrations_NNS of_IN all_DT three_CD of_IN these_DT agents_NNS inhibit_VBP the_DT anti-CD3_JJ mAb-induced_JJ proliferation_NN of_IN T_NN cells_NNS ._.
 3_LS ._. Although_IN DEX_NN and_CC PGE2_NN were_VBD equipotent_JJ in_IN suppressing_JJ T-cell_NN proliferation_NN ,_, ISO_NN was_VBD much_RB less_RBR effective_JJ ._.
 4_LS ._. Because_IN concomitant_JJ elevations_NNS in_IN the_DT peripheral_JJ levels_NNS of_IN these_DT substances_NNS may_MD occur_VB ,_, experiments_NNS were_VBD performed_VBN to_TO determine_VB the_DT T-cell_NN inhibitory_JJ effects_NNS of_IN DEX_NN together_RB with_IN either_CC PGE2_NN or_CC ISO_NN ._.
 Synergistic_JJ suppression_NN of_IN T-cell_NN proliferation_NN was_VBD observed_VBN when_WRB various_JJ concentrations_NNS of_IN DEX_NN and_CC PGE2_NN ,_, but_CC not_RB DEX_NN and_CC ISO_NN ,_, were_VBD added_VBN to_TO cultures_NNS ._.
 This_DT synergistic_JJ suppression_NN could_MD not_RB be_VB explained_VBN by_IN an_DT increase_NN in_IN cAMP_NN accumulation_NN in_IN T_NN cells_NNS stimulated_VBN with_IN DEX_NN and_CC PGE2_NN ._.
 5_LS ._. Finally_RB ,_, the_DT addition_NN of_IN anti-CD28_JJ mAb_NN to_TO anti-CD3_JJ mAb-stimulated_JJ T_NN cells_NNS overcame_VBD much_JJ of_IN the_DT suppression_NN of_IN proliferation_NN induced_VBN by_IN PGE2_NN or_CC ISO_NN but_CC less_RBR so_RB than_IN that_DT induced_VBN by_IN DEX_NN ._.
 Targeted_VBN degradation_NN of_IN c-Fos_NN ,_, but_CC not_RB v-Fos_NN ,_, by_IN a_DT phosphorylation-dependent_JJ signal_NN on_IN c-Jun_NN ._.
 The_DT proto-oncogene_NN products_NNS c-Fos_NN and_CC c-Jun_NN heterodimerize_VBP through_IN their_PRP$ leucine_NN zippers_NNS to_TO form_VB the_DT AP-1_NN transcription_NN factor_NN ._.
 The_DT transcriptional_JJ activity_NN of_IN the_DT heterodimer_NN is_VBZ regulated_VBN by_IN signal-dependent_JJ phosphorylation_NN and_CC dephosphorylation_NN events_NNS ._.
 The_DT stability_NN of_IN c-Fos_NN was_VBD found_VBN to_TO also_RB be_VB controlled_VBN by_IN intracellular_JJ signal_NN transduction_NN ._.
 In_IN transient_JJ expression_NN and_CC in_FW vitro_FW degradation_NN experiments_NNS ,_, the_DT stability_NN of_IN c-Fos_NN was_VBD decreased_VBN when_WRB the_DT protein_NN was_VBD dimerized_JJ with_IN phosphorylated_VBN c-Jun_NN ._.
 c-Jun_NN protein_NN isolated_VBN from_IN phorbol_NN ester-induced_JJ cells_NNS did_VBD not_RB target_VB c-Fos_NN for_IN degradation_NN ,_, which_WDT suggests_VBZ that_IN c-Fos_NN is_VBZ transiently_RB stabilized_VBN after_IN stimulation_NN of_IN cell_NN growth_NN ._.
 v-Fos_NN protein_NN ,_, the_DT retroviral_JJ counterpart_NN of_IN c-Fos_NN ,_, was_VBD not_RB susceptible_JJ to_TO degradation_NN targeted_VBN by_IN c-Jun_NN ._.
 Mutations_NNS in_IN the_DT Pit-1_NN gene_NN in_IN children_NNS with_IN combined_JJ pituitary_JJ hormone_NN deficiency_NN ._.
 Pit-1_NN is_VBZ a_DT pituitary-specific_JJ transcription_NN factor_NN that_WDT binds_VBZ to_TO and_CC transactivates_VBZ promoters_NNS of_IN growth_NN hormone_NN and_CC prolactin_NN genes_NNS ._.
 In_IN three_CD unrelated_JJ Japanese_JJ children_NNS with_IN combined_JJ pituitary_JJ hormone_NN deficiency_NN ,_, we_PRP identified_VBD three_CD point_NN mutations_NNS in_IN the_DT Pit-1_NN gene_NN ,_, Pro24Leu_NN ,_, Arg143Gln_NN ,_, and_CC Arg271Trp_NN ,_, located_JJ on_IN the_DT major_JJ transactivation_NN region_NN ,_, POU-specific_JJ domain_NN ,_, and_CC POU-homeodomain_NN ,_, respectively_RB ._.
 Calcitriol_NN :_: a_DT hematolymphopoietrope_NN ?_. (_( editorial_NN )_)
 A_DT MEDLINE_NN search_NN of_IN the_DT English-language_JJ literature_NN was_VBD conducted_VBN using_VBG the_DT indexing_NN terms_NNS '_[[DQS]] immunology_NN ,_, calcitriol_NN and_CC vitamin_NN D_NN '_[[DQE]] to_TO identify_VB studies_NNS indicating_VBG a_DT role_NN for_IN calcitriol_NN as_IN a_DT primary_JJ immunomodulator_NN ._.
 Sixty-six_CD papers_NNS published_VBN between_IN January_NNP 1956_CD and_CC June_NNP 1991_CD were_VBD identified_VBN ._.
 Forty-five_CD of_IN these_DT reports_NNS are_VBP cited_VBN in_IN this_DT review_NN ._.
 The_DT data_NNS strongly_RB suggest_VBP an_DT endocrine_NN ,_, autocrine_NN and/or_CC paracrine_NN role_NN for_IN calcitriol_NN in_IN immune_JJ regulation_NN ._.
 No_DT unifying_JJ hypothesis_NN has_VBZ yet_RB emerged_VBN explaining_VBG this_DT collection_NN of_IN data_NNS ._.
 This_DT paper_NN provides_VBZ a_DT brief_JJ review_NN of_IN immune_JJ properties_NNS currently_RB attributed_VBN to_TO calcitriol_NN ._.
 Activation_NN of_IN protein_NN kinase_NN C_NN and_CC elevation_NN of_IN cAMP_NN interact_VBP synergistically_RB to_TO raise_VB c-Fos_NN and_CC AP-1_NN activity_NN in_IN Jurkat_NN cells_NNS ._.
 We_PRP have_VBP earlier_RBR found_VBN that_IN in_IN Jurkat_NN cells_NNS activation_NN of_IN protein_NN kinase_NN C_NN (_( PKC_NN )_) enhances_VBZ the_DT cyclic_JJ adenosine_NN monophosphate_NN (_( cAMP_NN )_) accumulation_NN induced_VBN by_IN adenosine_NN receptor_NN stimulation_NN or_CC activation_NN of_IN Gs_NN ._.
 Here_RB we_PRP have_VBP therefore_RB examined_VBN the_DT effect_NN of_IN the_DT phorbol_NN ester_NN PMA_NN (_( phorbol_NN 12-myristate_NN 13-acetate_NN )_) which_WDT stimulates_VBZ PKC_NN and_CC a_DT combination_NN of_IN the_DT adenosine_NN receptor_NN agonist_NN NECA_NN (_( 5'-(N-ethyl)-carboxamido_JJ|NN adenosine_NN )_) and_CC forskolin_NN to_TO raise_VB cAMP_NN ,_, on_IN the_DT levels_NNS of_IN c-Fos_NN and_CC Jun_NN and_CC on_IN the_DT binding_VBG and_CC transcriptional_JJ activity_NN of_IN the_DT transcription_NN factor_NN ,_, activator_NN protein-1_NN (_( AP-1_NN )_) ._.
 PMA_NN treatment_NN caused_VBD a_DT concentration-_NN and_CC time-dependent_JJ increase_NN in_IN both_CC c-Fos_NN and_CC Jun_NN immunoreactivity_NN in_IN contrast_NN to_TO cAMP_NN elevation_NN that_WDT had_VBD only_RB a_DT slight_JJ effect_NN ._.
 Both_CC PMA_NN and_CC the_DT combination_NN of_IN NECA_NN and_CC forskolin_NN acted_VBD together_RB either_CC to_TO increase_VB (_( c-Fos_NN )_) or_CC decrease_VB (_( Jun_NN )_) protein_NN levels_NNS as_RB well_RB as_IN increasing_VBG AP-1_NN binding_NN ,_, as_IN judged_VBN by_IN gel-shift_NN assay_NN ,_, and_CC AP-1_NN transcriptional_JJ activity_NN ._.
 Furthermore_RB there_EX was_VBD a_DT clear-cut_JJ synergy_NN between_IN the_DT PKC_NN stimulator_NN and_CC the_DT cAMP_NN elevating_NN agents_NNS ._.
 The_DT results_NNS demonstrate_VBP that_IN the_DT simultaneous_JJ activation_NN of_IN PKC_NN and_CC elevation_NN of_IN cAMP_NN leads_VBZ to_TO an_DT enhanced_VBN AP-1_NN transcriptional_JJ activity_NN in_IN a_DT T-leukemia_NN cell_NN line_NN ,_, suggesting_VBG that_IN the_DT previously_RB observed_VBN interaction_NN between_IN the_DT parallel_JJ signal_NN transduction_NN pathways_NNS may_MD have_VB functional_JJ consequences_NNS at_IN the_DT level_NN of_IN gene_NN transcription_NN ._.
 The_DT use_NN of_IN interferon-gamma-treated_JJ U937_NN cells_NNS in_IN chemiluminescence_NN assays_NNS to_TO detect_VB red_JJ cell_NN ,_, platelet_NN and_CC granulocyte_NN antibodies_NNS of_IN potential_JJ clinical_JJ significance_NN ._.
 The_DT chemiluminescent_JJ (_( CL_JJ )_) response_NN of_IN interferon-gamma-treated_JJ U937_NN (_( IFN-U937_NN )_) cells_NNS to_TO sensitized_VBN target_NN cells_NNS has_VBZ been_VBN used_VBN to_TO detect_VB red_JJ cell_NN ,_, platelet_NN and_CC granulocyte_NN antibodies_NNS ._.
 A_DT clone_NN of_IN U937_NN cells_NNS was_VBD selected_VBN which_WDT expressed_VBD Fc_NN receptor_NN I_NN (_( Fc_NN gamma_NN RI_NN )_) and_CC which_WDT ,_, after_IN incubation_NN with_IN IFN-gamma_NN for_IN 72_CD h_NN ,_, was_VBD capable_JJ of_IN generating_VBG high_JJ levels_NNS of_IN lucigenin-enhanced_JJ CL_NN ._.
 The_DT CL_NN responses_NNS of_IN IFN-U937_NN cells_NNS and_CC peripheral_JJ blood_NN human_JJ monocytes_NNS to_TO sensitized_VBN red_JJ cells_NNS ,_, platelets_NNS or_CC granulocytes_NNS were_VBD then_RB compared_VBN ._.
 Assays_NNS using_VBG monocytes_NNS or_CC IFN-U937_NN cells_NNS were_VBD of_IN comparable_JJ sensitivity_NN for_IN detection_NN of_IN antibodies_NNS against_IN all_DT three_CD types_NNS of_IN target_NN cell_NN ._.
 In_IN addition_NN ,_, the_DT use_NN of_IN IFN-U937_NN cells_NNS reduced_VBD interassay_JJ variation_NN and_CC simplified_VBD|VBN assay_NN performance_NN ._.
 The_DT potential_JJ clinical_JJ usefulness_NN of_IN these_DT CL_NN assays_NNS was_VBD suggested_VBN by_IN the_DT ability_NN of_IN both_CC monocytes_NNS and_CC IFN-U937_NN cells_NNS to_TO respond_VB to_TO red_JJ cells_NNS ,_, platelets_NNS or_CC granulocytes_NNS sensitized_VBN with_IN sera_NN from_IN pregnant_JJ women_NNS whose_WP$ babies_NNS had_VBD either_CC haemolytic_JJ disease_NN of_IN the_DT newborn_JJ (_( HDN_NN )_) ,_, alloimmune_JJ thrombocytopenia_NN or_CC alloimmune_JJ neutropenia_NN respectively_RB ._.
 In_IN addition_NN ,_, monocytes_NNS and_CC IFN-U937_NN cells_NNS both_DT responded_VBD to_TO red_JJ cells_NNS sensitized_VBN with_IN antibodies_NNS against_IN a_DT variety_NN of_IN specificities_NNS of_IN assumed_VBN (_( although_IN not_RB documented_VBN )_) clinical_JJ significance_NN for_IN blood_NN transfusion_NN recipients_NNS ._.
 In_IN contrast_NN ,_, monocytes_NNS and_CC IFN-U937_NN cells_NNS responded_VBD only_RB weakly_RB to_TO red_JJ cells_NNS sensitized_VBN with_IN either_CC anti-D_JJ in_IN sera_NN from_IN mothers_NNS of_IN babies_NNS unaffected_JJ by_IN HDN_NN ,_, or_CC with_IN antisera_NNS containing_VBG high_JJ titre_NN antibodies_NNS with_IN specificities_NNS not_RB normally_RB associated_VBN with_IN significantly_RB reduced_VBN red_JJ cell_NN survival_NN ._.
 Photoaffinity_NN labeling_NN of_IN plasma_NN membrane_NN receptors_NNS for_IN aldosterone_NN from_IN human_JJ mononuclear_JJ leukocytes_NNS ._.
 Non-genomic_JJ effects_NNS of_IN aldosterone_NN on_IN the_DT sodium-proton-antiport_NN have_VBP been_VBN shown_VBN in_IN human_JJ mononuclear_JJ leukocytes_NNS which_WDT could_MD be_VB related_JJ to_TO a_DT new_JJ aldosterone_NN membrane_NN receptor_NN ._.
 In_IN the_DT present_JJ paper_NN plasma_NN membranes_NNS from_IN human_JJ mononuclear_JJ leukocytes_NNS were_VBD covalently_RB photolabeled_VBN with_IN a_DT (125I)-aldosterone_NN derivative_NN ._.
 Sodium_NN dodecyl_NN sulfate-polyacrylamide_JJ gel_NN electrophoresis_NN showed_VBD significant_JJ aldosterone_NN binding_NN at_IN a_DT molecular_JJ weight_NN of_IN approximately_RB 50000_CD Dalton_NN which_WDT was_VBD absent_JJ with_IN 1_CD microM_NN cold_JJ aldosterone_NN ,_, but_CC not_RB cortisol_NN in_IN the_DT binding_VBG media_NNS ._.
 The_DT presence_NN of_IN the_DT sulfhydryl_NN agent_NN dithiothreitol_NN did_VBD not_RB affect_VB results_NNS suggesting_VBG the_DT absence_NN of_IN disulfide_NN bridges_NNS in_IN the_DT steroid_NN binding_NN domain_NN of_IN the_DT receptor_NN ._.
 These_DT data_NNS are_VBP the_DT first_JJ to_TO define_VB the_DT molecular_JJ weight_NN of_IN the_DT membrane_NN receptor_NN for_IN aldosterone_NN ._.
 Alpha-lipoic_JJ acid_NN is_VBZ a_DT potent_JJ inhibitor_NN of_IN NF-kappa_NN B_NN activation_NN in_IN human_JJ T_NN cells_NNS ._.
 Acquired_VBN immunodeficiency_NN syndrome_NN (_( AIDS_NN )_) results_VBZ from_IN infection_NN with_IN a_DT human_JJ immunodeficiency_NN virus_NN (_( HIV_NN )_) ._.
 The_DT long_JJ terminal_JJ repeat_NN (_( LTR_NN )_) region_NN of_IN HIV_NN proviral_JJ DNA_NN contains_VBZ binding_VBG sites_NNS for_IN nuclear_JJ factor_NN kappa_NN B_NN (_( NF-kappa_NN B_NN )_) ,_, and_CC this_DT transcriptional_JJ activator_NN appears_VBZ to_TO regulate_VB HIV_NN activation_NN ._.
 Recent_JJ findings_NNS suggest_VBP an_DT involvement_NN of_IN reactive_JJ oxygen_NN species_NNS (_( ROS_NN )_) in_IN signal_NN transduction_NN pathways_NNS leading_VBG to_TO NF-kappa_NN B_NN activation_NN ._.
 The_DT present_JJ study_NN was_VBD based_VBN on_IN reports_NNS that_IN antioxidants_NNS which_WDT eliminate_VBP ROS_NN should_MD block_VB the_DT activation_NN of_IN NF-kappa_NN B_NN and_CC subsequently_RB HIV_NN transcription_NN ,_, and_CC thus_RB antioxidants_NNS can_MD be_VB used_VBN as_IN therapeutic_JJ agents_NNS for_IN AIDS_NN ._.
 Incubation_NN of_IN Jurkat_NN T_NN cells_NNS (_( 1_CD x_CC 10(6)_CD cells/ml_NNS )_) with_IN a_DT natural_JJ thiol_NN antioxidant_NN ,_, alpha-lipoic_JJ acid_NN ,_, prior_JJ to_TO the_DT stimulation_NN of_IN cells_NNS was_VBD found_VBN to_TO inhibit_VB NF-kappa_NN B_NN activation_NN induced_VBN by_IN tumor_NN necrosis_NN factor-alpha_NN (_( 25_CD ng/ml_NN )_) or_CC by_IN phorbol_NN 12-myristate_NN 13-acetate_NN (_( 50_CD ng/ml_NN )_) ._.
 The_DT inhibitory_JJ action_NN of_IN alpha-lipoic_JJ acid_NN was_VBD found_VBN to_TO be_VB very_RB potent_JJ as_IN only_RB 4_CD mM_NN was_VBD needed_VBN for_IN a_DT complete_JJ inhibition_NN ,_, whereas_IN 20_CD mM_NN was_VBD required_VBN for_IN N-acetylcysteine_NN ._.
 These_DT results_NNS indicate_VBP that_IN alpha-lipoic_JJ acid_NN may_MD be_VB effective_JJ in_IN AIDS_NN therapeutics_NNS ._.
 Activation_NN of_IN lymphokine_NN genes_NNS in_IN T_NN cells_NNS :_: role_NN of_IN cis-acting_JJ DNA_NN elements_NNS that_WDT respond_VBP to_TO T_NN cell_NN activation_NN signals_NNS ._.
 Activation_NN of_IN T_NN cells_NNS is_VBZ initiated_VBN by_IN the_DT recognition_NN of_IN antigen_NN on_IN antigen_NN presenting_NN cells_NNS to_TO exert_VB the_DT effector_NN functions_NNS in_IN immune_JJ and_CC inflammatory_JJ responses_NNS ._.
 Two_CD types_NNS of_IN helper_NN T_NN cell_NN (_( Th_NN )_) clones_NNS (_( Th1_NN and_CC Th2_NN )_) are_VBP defined_VBN on_IN the_DT basis_NN of_IN different_JJ patterns_NNS of_IN cytokine_NN (_( lymphokine_NN )_) secretion_NN ._.
 They_PRP determine_VBP the_DT outcome_NN of_IN an_DT antigenic_JJ response_NN toward_IN humoral_JJ or_CC cell-mediated_JJ immunity_NN ._.
 Although_IN lymphokine_NN genes_NNS are_VBP coordinately_RB regulated_VBN upon_IN antigen_NN stimulation_NN ,_, they_PRP are_VBP regulated_VBN by_IN the_DT mechanisms_NNS common_JJ to_TO all_DT as_RB well_RB as_IN those_DT which_WDT are_VBP unique_JJ to_TO each_DT gene_NN ._.
 For_IN most_JJS lymphokine_NN genes_NNS ,_, a_DT combination_NN of_IN phorbol_NN esters_NNS (_( phorbol_NN 12-myristate_NN 13_CD acetate_NN ,_, PMA_NN )_) and_CC calcium_NN ionophores_NNS (_( A23187_NN )_) is_VBZ required_VBN for_IN their_PRP$ maximal_JJ induction_NN ._.
 Yet_RB phorbol_NN ester_NN alone_RB or_CC calcium_NN ionophore_NN alone_RB produce_VBP several_JJ lymphokines_NNS ._.
 The_DT production_NN of_IN the_DT granulocyte-macrophage_JJ colony_NN stimulating_NN factor_NN (_( GM-CSF_NN )_) is_VBZ completely_RB dependent_JJ on_IN the_DT two_CD signals_NNS ._.
 We_PRP have_VBP previously_RB found_VBN a_DT cis-acting_JJ region_NN spanning_VBG the_DT GM-CSF_NN promoter_NN region_NN (_( positions_NNS -95_CD to_TO +27_CD )_) that_WDT confers_VBZ inducibility_NN to_TO reporter_NN genes_NNS in_IN transient_JJ transfection_NN assays_NNS ._.
 Further_JJ analysis_NN identified_VBD three_CD elements_NNS required_VBN for_IN efficient_JJ induction_NN ,_, referred_VBN to_TO as_IN GM2_NN ,_, GC-box_NN and_CC conserved_VBN lymphokine_NN element_NN (_( CLE0_NN )_) ._.
 GM2_NN defines_VBZ a_DT binding_VBG site_NN for_IN protein_NN (_( s_NNS )_) whose_WP$ binding_NN is_VBZ inducible_JJ by_IN PMA_NN ._.
 One_CD protein_NN ,_, NF-GM2_NN is_VBZ similar_JJ to_TO the_DT transcription_NN factor_NN NF-kB_NN ._.
 GC-box_NN is_VBZ a_DT binding_VBG site_NN for_IN constitutively_RB bound_VBN proteins_NNS ._.
 CLEO_NN defines_VBZ a_DT binding_VBG site_NN for_IN protein_NN (_( s_NNS )_) whose_WP$ optimum_NN binding_NN is_VBZ stimulated_VBN by_IN PMA_NN and_CC A23187_NN ._.
 Viral_JJ trans-activators_NNS such_JJ as_IN Tax_NN (_( human_JJ T_NN cell_NN leukemia_NN virus-1_NN ,_, HTLV-1_NN )_) and_CC E2_NN (_( bovine_JJ papilloma_NN virus_NN ,_, BPV_NN )_) proteins_NNS are_VBP other_JJ agents_NNS which_WDT activate_VBP lymphokine_NN gene_NN expression_NN by_IN bypassing_VBG T_NN cell_NN receptor_NN (_( TCR_NN )_) mediated_JJ signaling_NN ._.
 The_DT trans-activation_NN domain_NN of_IN E2_NN and_CC Tax_NN is_VBZ interchangeable_JJ although_IN they_PRP have_VBP no_DT obvious_JJ sequence_NN homology_NN between_IN them_PRP ._.
 The_DT viral_JJ trans-activators_NNS appear_VBP to_TO target_VB specific_JJ DNA_NN binding_NN protein_NN such_JJ as_IN NF-kB_NN and_CC Sp1_NN to_TO cis-acting_JJ DNA_NN site_NN and_CC promote_VB lymphokine_NN gene_NN expression_NN without_IN TCR-mediated_JJ stimulation_NN ._.
 I_NN kappa_NN B/MAD-3_NN masks_VBZ the_DT nuclear_JJ localization_NN signal_NN of_IN NF-kappa_NN B_NN p65_NN and_CC requires_VBZ the_DT transactivation_NN domain_NN to_TO inhibit_VB NF-kappa_NN B_NN p65_NN DNA_NN binding_NN ._.
 The_DT active_JJ nuclear_JJ form_NN of_IN the_DT NF-kappa_NN B_NN transcription_NN factor_NN complex_NN is_VBZ composed_VBN of_IN two_CD DNA_NN binding_NN subunits_NNS ,_, NF-kappa_NN B_NN p65_NN and_CC NF-kappa_NN B_NN p50_NN ,_, both_DT of_IN which_WDT share_VBP extensive_JJ N-terminal_JJ sequence_NN homology_NN with_IN the_DT v-rel_NN oncogene_NN product_NN ._.
 The_DT NF-kappa_NN B_NN p65_NN subunit_NN provides_VBZ the_DT transactivation_NN activity_NN in_IN this_DT complex_JJ and_CC serves_VBZ as_IN an_DT intracellular_JJ receptor_NN for_IN a_DT cytoplasmic_JJ inhibitor_NN of_IN NF-kappa_NN B_NN ,_, termed_VBN I_NN kappa_NN B_NN ._.
 In_IN contrast_NN ,_, NF-kappa_NN B_NN p50_NN alone_RB fails_VBZ to_TO stimulate_VB kappa_NN B-directed_JJ transcription_NN ,_, and_CC based_VBN on_IN prior_JJ in_FW vitro_FW studies_NNS ,_, is_VBZ not_RB directly_RB regulated_VBN by_IN I_NN kappa_NN B_NN ._.
 To_TO investigate_VB the_DT molecular_JJ basis_NN for_IN the_DT critical_JJ regulatory_JJ interaction_NN between_IN NF-kappa_NN B_NN and_CC I_NN kappa_NN B/MAD-3_NN ,_, a_DT series_NN of_IN human_JJ NF-kappa_NN B_NN p65_NN mutants_NNS was_VBD identified_VBN that_WDT functionally_RB segregated_VBD DNA_NN binding_NN ,_, I_NN kappa_NN B-mediated_JJ inhibition_NN ,_, and_CC I_NN kappa_NN B-induced_JJ nuclear_JJ exclusion_NN of_IN this_DT transcription_NN factor_NN ._.
 Results_NNS from_IN in_FW vivo_FW expression_NN studies_NNS performed_VBN with_IN these_DT NF-kappa_NN B_NN p65_NN mutants_NNS revealed_VBD the_DT following_NN :_: 1_LS )_) I_NN kappa_NN B/MAD-3_NN completely_RB inhibits_VBZ NF-kappa_NN B_NN p65-dependent_JJ transcriptional_JJ activation_NN mediated_VBN through_IN the_DT human_JJ immunodeficiency_NN virus_NN type_NN 1_CD kappa_NN B_NN enhancer_NN in_IN human_JJ T_NN lymphocytes_NNS ,_, 2_LS )_) the_DT binding_NN of_IN I_NN kappa_NN B/MAD-3_NN to_TO NF-kappa_NN B_NN p65_NN is_VBZ sufficient_JJ to_TO retarget_VB NF-kappa_NN B_NN p65_NN from_IN the_DT nucleus_NN to_TO the_DT cytoplasm_NN ,_, 3_LS )_) selective_JJ deletion_NN of_IN the_DT functional_JJ nuclear_JJ localization_NN signal_NN present_JJ in_IN the_DT Rel_NN homology_NN domain_NN of_IN NF-kappa_NN B_NN p65_NN disrupts_VBZ its_PRP$ ability_NN to_TO engage_VB I_NN kappa_NN B/MAD-3_NN ,_, and_CC 4_LS )_) the_DT unique_JJ C-terminus_NN of_IN NF-kappa_NN B_NN p65_NN attenuates_VBZ its_PRP$ own_JJ nuclear_JJ localization_NN and_CC contains_VBZ sequences_NNS that_WDT are_VBP required_VBN for_IN I_NN kappa_NN B-mediated_JJ inhibition_NN of_IN NF-kappa_NN B_NN p65_NN DNA_NN binding_NN activity_NN ._.
 Together_RB ,_, these_DT findings_NNS suggest_VBP that_IN the_DT nuclear_JJ localization_NN signal_NN and_CC transactivation_NN domain_NN of_IN NF-kappa_NN B_NN p65_NN constitute_VBP a_DT bipartite_JJ system_NN that_WDT is_VBZ critically_RB involved_VBN in_IN the_DT inhibitory_JJ function_NN of_IN I_NN kappa_NN B/MAD-3_NN ._.
 Unexpectedly_RB ,_, our_PRP$ in_FW vivo_FW studies_NNS also_RB demonstrate_VBP that_IN I_NN kappa_NN B/MAD-3_NN binds_VBZ directly_RB to_TO NF-kappa_NN B_NN p50_NN ._.
 This_DT interaction_NN is_VBZ functional_JJ as_IN it_PRP leads_VBZ to_TO retargeting_NN of_IN NF-kappa_NN B_NN p50_NN from_IN the_DT nucleus_NN to_TO the_DT cytoplasm_NN ._.
 However_RB ,_, no_DT loss_NN of_IN DNA_NN binding_NN activity_NN is_VBZ observed_VBN ,_, presumably_RB reflecting_VBG the_DT unique_JJ C-terminal_JJ domain_NN that_WDT is_VBZ distinct_JJ from_IN that_DT present_JJ in_IN NF-kappa_NN B_NN p65_NN ._.
 Surrogate_NN thyroglobulin_NN receptors_NNS and_CC T_NN cell_NN proliferation_NN in_IN Hashimoto_NN 's_POS thyroiditis_NN ._.
 Immunoglobulin_NN molecules_NNS on_IN the_DT surface_NN of_IN a_DT B_NN lymphocyte_NN are_VBP the_DT endogenous_JJ "_[[DQS]] receptors_NNS "_[[DQE]] to_TO which_WDT specific_JJ antigens_NNS bind_VBP ._.
 Studies_NNS in_IN mice_NNS have_VBP shown_VBN that_IN a_DT monoclonal_JJ antibody_NN ,_, conjugated_VBN with_IN palmitate_NN to_TO provide_VB a_DT lipid_NN tail_NN ,_, can_MD be_VB inserted_VBN into_IN the_DT cell_NN membrane_NN to_TO provide_VB a_DT "_[[DQS]] surrogate_JJ "_[[DQE]] antigen_NN receptor_NN ._.
 We_PRP have_VBP investigated_VBN whether_IN a_DT palmitate_JJ conjugate_NN of_IN a_DT human_JJ monoclonal_JJ antibody_NN specific_JJ for_IN thyroglobulin_NN (_( TG_NN )_) could_MD function_VB as_IN a_DT surrogate_JJ TG_NN receptor_NN on_IN blood_NN mononuclear_JJ cells_NNS separated_VBN into_IN fractions_NNS enriched_VBN for_IN T_NN cells_NNS or_CC depleted_VBN of_IN T_NN cells_NNS (_( non-T_JJ cells_NNS )_) ._.
 Using_VBG flow_NN cytometry_NN ,_, we_PRP detected_VBD surrogate_JJ TG_NN receptors_NNS on_IN non-T_JJ (_( but_CC not_RB on_IN T_NN )_) cells_NNS from_IN 11_CD of_IN 11_CD individuals_NNS studied_VBN (_( 5_CD Hashimoto_NN patients_NNS and_CC 6_CD control_NN donors_NNS )_) ._.
 In_IN contrast_NN ,_, endogenous_JJ TG_NN receptors_NNS could_MD only_RB be_VB detected_VBN on_IN non-T_JJ cells_NNS from_IN 1_CD of_IN 3_CD Hashimoto_NN patients_NNS and_CC from_IN 0_CD of_IN 4_CD control_NN donors_NNS ._.
 Because_IN of_IN the_DT efficient_JJ binding_NN of_IN TG_NN by_IN surrogate_JJ receptors_NNS on_IN non-T_JJ cells_NNS ,_, we_PRP assessed_VBD the_DT ability_NN of_IN such_JJ cells_NNS to_TO present_VB TG_NN to_TO T_NN cells_NNS ._.
 Proliferation_NN in_IN response_NN to_TO TG_NN was_VBD observed_VBN in_IN T_NN cells_NNS from_IN only_RB 1_CD of_IN 5_CD Hashimoto_NN patients_NNS ._.
 This_DT low_JJ frequency_NN of_IN response_NN was_VBD no_RB different_JJ from_IN that_DT previously_RB detected_VBN using_VBG cultures_NNS of_IN T_NN cells_NNS and_CC autologous_JJ dendritic_JJ cells_NNS ._.
 Therefore_RB ,_, the_DT successful_JJ generation_NN of_IN surrogate_JJ receptors_NNS on_IN non-T_JJ cells_NNS is_VBZ not_RB associated_VBN with_IN more_RBR efficient_JJ TG_NN presentation_NN of_IN T_NN cells_NNS ._.
 Furthermore_RB ,_, the_DT significance_NN of_IN the_DT present_JJ study_NN is_VBZ that_IN the_DT T_NN cells_NNS ,_, not_RB the_DT antigen-presenting_JJ cells_NNS ,_, are_VBP likely_JJ to_TO be_VB the_DT limiting_VBG element_NN in_IN the_DT T_NN cell_NN proliferative_JJ response_NN to_TO TG_NN and_CC other_JJ thyroid_NN autoantigens_NNS ._.
 Aldosterone-specific_JJ membrane_NN receptors_NNS and_CC rapid_JJ non-genomic_JJ actions_NNS of_IN mineralocorticoids_NNS ._.
 Functional_JJ studies_NNS in_IN extrarenal_JJ ,_, non-epithelial_JJ cells_NNS such_JJ as_IN smooth_JJ muscle_NN cells_NNS and_CC more_RBR recently_RB circulating_VBG human_JJ lymphocytes_NNS have_VBP provided_VBN increasing_VBG evidence_NN that_IN aldosterone_NN produces_VBZ not_RB only_RB classical_JJ genomic_JJ effects_NNS ,_, but_CC also_RB rapid_JJ ,_, non-genomic_JJ effects_NNS on_IN transmembrane_NN electrolyte_NN movements_NNS ._.
 These_DT involve_VBP activation_NN of_IN the_DT sodium/proton_NN exchanger_NN of_IN the_DT cell_NN membrane_NN at_IN very_RB low_JJ ,_, physiological_JJ concentrations_NNS of_IN aldosterone_NN with_IN an_DT acute_JJ onset_NN within_IN 1-2_CD min_NN ._.
 A_DT second_JJ messenger_NN cascade_NN involved_VBN is_VBZ the_DT inositol_NN 1,4,5-trisphosphate/calcium_NN pathway_NN which_WDT responds_VBZ over_IN the_DT same_JJ rapid_JJ time_NN course_NN ._.
 Such_JJ changes_NNS clearly_RB can_MD not_RB be_VB explained_VBN by_IN genomic_JJ mechanisms_NNS ,_, which_WDT are_VBP responsible_JJ for_IN later_JJ effects_NNS than_IN the_DT membrane_NN related_JJ rapid_JJ responses_NNS ._.
 The_DT mechanisms_NNS underlying_VBG these_DT rapid_JJ effects_NNS of_IN aldosterone_NN on_IN electrolytes_NNS have_VBP been_VBN extensively_RB studied_VBN in_IN human_JJ lymphocytes_NNS ,_, which_WDT thus_RB may_MD represent_VB valuable_JJ tools_NNS in_IN the_DT delineation_NN of_IN the_DT receptor-effector_JJ mechanisms_NNS involved_VBN ._.
 The_DT unique_JJ characteristics_NNS of_IN this_DT new_JJ pathway_NN for_IN steroid_NN action_NN include_VBP its_PRP$ rapid_JJ time_NN course_NN ,_, 10,000-fold_JJ selectivity_NN for_IN aldosterone_NN over_IN cortisol_NN and_CC the_DT ineffectiveness_NN of_IN spironolactones_NNS ,_, classical_JJ mineralocorticoid_NN antagonists_NNS ,_, as_IN antagonists_NNS of_IN the_DT response_NN ._.
 Cellular_JJ immune_JJ and_CC cytokine_NN pathways_NNS resulting_VBG in_IN tissue_NN factor_NN expression_NN and_CC relevance_NN to_TO septic_JJ shock_NN ._.
 Cells_NNS of_IN monocyte_NN lineage_NN serve_VBP as_IN effector_NN cells_NNS in_IN the_DT cellular_JJ immune_JJ response_NN ._.
 In_IN addition_NN ,_, they_PRP respond_VBP to_TO LPS_NN and_CC cytokines_NNS with_IN activation_NN and_CC expression_NN of_IN inflammatory_JJ effector_NN gene_NN products_NNS similar_JJ to_TO those_DT elicited_VBN by_IN the_DT antigen_NN driven_JJ response_NN ._.
 The_DT response_NN to_TO antigen_NN proceeds_VBZ at_IN the_DT T_NN helper_NN cell_NN level_NN through_IN two_CD independent_JJ forms_NNS of_IN cellular_JJ collaboration_NN ,_, contact_NN and_CC lymphokine_NN ._.
 We_PRP review_VBP the_DT control_NN of_IN expression_NN of_IN the_DT Tissue_NN Factor_NN (_( TF_NN )_) gene_NN and_CC the_DT function_NN of_IN the_DT TF_NN protein_NN ._.
 The_DT enhanced_VBN initiation_NN of_IN transcription_NN of_IN the_DT TF_NN gene_NN appears_VBZ to_TO require_VB engagement_NN of_IN a_DT 56_CD bp_NN LPS_NN Response_NN Element_NN ,_, an_DT enhancer_NN that_WDT is_VBZ engaged_VBN by_IN both_DT AP-1_NN type_NN heterodimeric_JJ complexes_NNS as_RB well_RB as_IN NF_NN kappa_NN B_NN like_IN heterodimeric_JJ complexes_NNS ._.
 Dissociation_NN of_IN NF_NN kappa_NN B_NN from_IN Ig_NN kappa_NN B_NN by_IN cytokine_NN and_CC LPS_NN stimulation_NN ,_, and_CC possibly_RB activated_VBN T_NN cells_NNS ,_, may_MD represent_VB a_DT common_JJ pathway_NN to_TO induction_NN of_IN the_DT TF_NN and_CC other_JJ inflammatory_JJ genes_NNS ._.
 Enhancement_NN of_IN expression_NN of_IN TF_NN is_VBZ observed_VBN upon_IN adhesion_NN of_IN Mo_NN to_TO endothelial_JJ cells_NNS and_CC extracellular_JJ matrix_JJ proteins_NNS ,_, as_RB well_RB as_IN upon_IN engagement_NN of_IN leukocyte_NN integrins_NNS ._.
 The_DT biological_JJ effects_NNS that_WDT follow_VBP from_IN expression_NN of_IN TF_NN by_IN vascular_JJ cells_NNS have_VBP been_VBN resolved_VBN by_IN analysis_NN of_IN function_NN aided_VBN by_IN the_DT use_NN of_IN recombinant_JJ full_JJ length_NN TF_NN and_CC truncated_VBN surface_NN domain_NN of_IN TF_NN ._.
 The_DT rules_NNS of_IN assembly_NN of_IN the_DT cognate_JJ ligands_NNS of_IN TF_NN ,_, namely_RB the_DT zymogen_NN plasma_NN factors_NNS VII_NN and_CC the_DT serine_NN protease_NN factor_NN VIIa_NN ,_, with_IN the_DT soluble_JJ surface_NN domain_NN of_IN TF_NN in_IN free_JJ solution_NN ,_, in_IN the_DT presence_NN of_IN phospholipid_JJ surfaces_NNS and_CC cell_NN surface_NN and_CC of_IN the_DT anchored_VBN TF_NN molecule_NN have_VBP been_VBN described_VBN ._.
 It_PRP is_VBZ evident_JJ that_IN assembly_NN of_IN the_DT surface_NN domain_NN of_IN TF_NN with_IN VIIa_NN to_TO form_VB the_DT binary_JJ TF.VIIa_NN complex_NN induces_VBZ a_DT significant_JJ increase_NN in_IN the_DT Kcat_NN of_IN the_DT catalytic_JJ domain_NN of_IN VIIa_NN for_IN small_JJ peptidyl_JJ substrates_NNS and_CC more_JJR profoundly_RB for_IN protein_NN substrate_NN ._.
 This_DT provides_VBZ substantial_JJ evidence_NN for_IN an_DT allosteric_JJ effect_NN on_IN the_DT catalytic_JJ cleft_NN of_IN VIIa_NN that_WDT is_VBZ imparted_VBN by_IN binding_VBG to_TO TF_NN ,_, its_PRP$ cognate_JJ catalytic_JJ cofactor_NN ._.
 It_PRP is_VBZ also_RB evident_JJ that_IN the_DT TF.VIIa_NN complex_NN is_VBZ proteolytically_RB active_JJ and_CC can_MD activate_VB the_DT zymogen_NN plasma_NN factor_NN X_NN to_TO the_DT serine_NN protease_NN Xa_NN in_IN free_JJ solution_NN ,_, inferring_VBG that_IN extended_VBN substrate_NN recognition_NN by_IN induced_VBN structural_JJ loci_NNS of_IN the_DT TF.VIIa_NN complex_NN are_VBP created_VBN from_IN either_DT or_CC both_DT proteins_NNS to_TO constitute_VB a_DT new_JJ recognition_NN structure_NN ._.
 It_PRP is_VBZ also_RB evident_JJ that_IN association_NN of_IN X_NN with_IN charged_JJ phospholipid_JJ surfaces_NNS enhances_VBZ the_DT proteolytic_JJ activation_NN of_IN this_DT zymogen_NN by_IN increasing_VBG recognition_NN and_CC susceptibility_NN of_IN the_DT sessile_NN peptide_NN bond_NN deduced_VBN from_IN the_DT markedly_RB decreased_VBN Km_NN and_CC increased_VBN Kcat_NN ._.